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Abstract 
Abstract 
Parasitic diseases, particularly prevalent in tropics, impact severely on public health. 
This thesis presents a metabolism-driven top-down systems biology approach to 
characterise metabolic changes in mice resulting from parasitic infections, specifically 
Plasmodium berghei and Schistosoma mansoni. A metabolic profiling approach has 
been applied to characterise dynamic metabolic changes induced by parasitic infections 
and to examine changes associated with therapeutic intervention for the infection. The 
strategy consists of 3 steps: (1) development of animal models: where biofluid samples 
were collected at different experimental time points and tissues were obtained at the end 
point of experiments. Randomised housing of mice, consistent environmental conditions 
and strict sampling time were adhered to in order to minimise the environment, stress 
and diurnal variation which can cause bias in metabolic profiles; (2) sample acquisition: 
where all biofluid samples were analysed by high-resolution 1H nuclear magnetic 
resonance (NMR) spectroscopy and tissue samples were analysed by 1H magic angle 
spinning NMR spectroscopy. Two-dimensional NMR experiments such as correlation 
spectroscopy and total correlation spectroscopy were carried out on selected samples to 
aid the identification of metabolites; (3) multivariate data analyses including both 
unsupervised (principal component analysis) and supervised (orthogonal-projection to 
latent structures-discriminant analysis) methods. Various multivariate statistical 
strategies were used to characterise infection-related changes in metabolism at the 
system level across multiple biofluids and tissues. 
For both S. mansoni and P. berghei infections the metabolic response included changes 
in energy metabolism, inflammatory responses and gut microbiota metabolites. The 
effect of treatment with vancomycin was also assessed in order to further explore the 
gut microbiota changes. Time-course changes in mouse gut microbial community after 
vancomycin treatment were monitored using 16S rRNA gene polymerase chain 
reaction-denaturing gradient gel electrophoresis (PCR-DGGE) analysis of the faeces. 
The integration of the microbial and DGGE data helped to promote understanding of the 
microbial-mammalian metabolic axis. 
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Chapter 1 Introduction 
1.1 Aims and objectives 
The overall aim of this thesis is to characterise dynamic responses of mammalian hosts 
to parasitic diseases and associated drug interventions using 1H nuclear magnetic 
resonance (NMR) spectroscopy-based metabolic profiling methods combined with 
multivariate data analyses. The general structure of the thesis is shown in Figure 1-1. 
Briefly the results chapters are structured as follow: 
(1) Investigation of metabolic consequences of Plasmodium berghei infection in the 
mouse (Chapter 3). 
• Identification of the metabolic responses of a mouse model to a single infection 
with P. berghei in biofluids (urine and plasma) using 1H NMR spectroscopy 
combined with multivariate data analyses. 
(2) Characterisation of the global metabolic response of mice to a Schistosoma mansoni 
infection. 
• Assessment of the dynamics of biological responses of S. mansoni-infected mice 
in biofluids (urine, plasma and faecal extracts) using II-I NMR spectroscopy 
coupled with multivariate data analyses (Chapter 4). 
• Investigation of organ and tissue pathology caused by a S. mansoni infection at 
the molecular level using 1 H magic angle spinning (MAS) NMR spectroscopy 
together with multivariate data analyses (Chapter 5). 
(3) Evaluation of the biological consequences of vancomycin administration in mice 
with a view to establishing a baseline for exploring microbial changes in parasitic 
diseases (Chapter 6). 
• Assessment of the effect of vancomycin treatment on the metabolite profile in 
the uninfected control mice. 
• Monitoring of the disturbance of bacterial species in faeces by the vancomycin 
treatment using the polymerase chain reaction-denaturing gradient gel 
electrophoresis (PCR-DGGE) technique. 
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1.2 Introduction to metabonomics 
Systems biology is an interdisciplinary study based on a number of integrated 
disciplines, which focus on complex biological interactions at a systems level using 
integrated approaches such as genomics (identification of the entire genome of an 
organism), transcriptomics (gene expression measurements in a cell or tissue), 
proteomics (complete identification of proteins and protein expression patterns of a cell 
or tissue), metabonomics (complete identification and measurements of metabolites in 
biofluids or tissues), glycomics (measurements of all carbohydrates in a cell or tissue), 
etc. Genomics, proteomics and metabonomics have been developed to accommodate the 
drive to express an organism's behaviour at a global systems biology level. In particular, 
metabonomics, in detail defined as 'the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or 
genetic modification' (Nicholson et al., 1999; Lindon et al., 2000; Nicholson et al., 
2002), provides an endpoint metric of metabolic perturbation in an organism. Its 
application will form the basis of this thesis. Metabonomics not only provides a means 
for characterising the metabolic response of an organism to a physiological or 
pathological stimulus but can also complement or be used to direct and interpret results 
obtained from genomics and proteomics (Nicholson et al., 1999). Metabolic signatures 
can reflect the physiological or pathological condition of an organism and indicate 
imbalances in the homeostatic regulation of tissues and extracellular fluids. It has 
become a well-established analytical tool for studying the metabolic consequences in 
many scientific areas such as basic physiology (Lindon et al., 2004; Bollard et al., 2005), 
nutritional biochemistry (Gibney et al., 2005; Solanky et al., 2005; Wang et al., 2005b; 
Kussmann et al., 2006), parasitology (Wang et al., 2004; Wang et al., 2006), drug 
toxicity (Nicholls et al., 2000; Nicholson et al., 2002). Metabonomics involves the 
analysis of sample compositions (usually via high-resolution spectroscopy), metabolite 
identification and multivariate data analysis for classification and biomarker extraction. 
Analysis of sample composition: High-resolution III nuclear magnetic resonance (NMR) 
spectroscopy, liquid chromatography (LC)-mass spectrometry (MS), gas 
chromatography (GC)-MS and capillary electrophoresis (CE) are common techniques 
for investigating metabolic compositions of biological materials. Depending upon the 
concentration and the nature of samples, one or more appropriate techniques are 
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selected for generating metabolic profiles and for subsequent biomarker identification. 
In this thesis, high-resolution 1H NMR spectroscopy was applied as the main analytical 
tool as (1) it can simultaneously detect a wide range of metabolites in a sample within a 
short time period (5-15 mins); (2) it does not require much sample preparation; (3) it 
provides excellent reproducibility and relatively good sensitivity and (4) it can be 
applied to many types of samples such as urine (Waters et al., 2001; Wang et al., 2004), 
plasma (Solanky et al., 2003; Lenz et al., 2003), faecal extracts (Saric et al., 2008a), 
tissue extracts (Waters et al., 2002) and plant extracts (Krishnan et al., 2005). For intact 
tissues, high-resolution magic angle spinning (MAS) 1H NMR spectroscopy can be 
utilised to detect the metabolic composition and to explore compartmentalisation of 
molecules (Cheng et al., 1997; Tomlins et al., 1998). The basic principles of NMR 
spectroscopy will be described in Section 1.5 
Metabolite identification: 1-dimensional (1-D) 1H NMR spectra of biofluids are heavily 
overlapped, particularly in the region containing sugar resonances (51H 3.2-4), thus, this 
can make metabolite identification difficult. 2-D NMR spectroscopy methods including 
1H-1H correlation spectroscopy (COSY) and 1H-1H total correlation spectroscopy 
(TOCSY), providing bond connectivity information between protons in the same 
molecule, are routinely used to assign complex spectra. Alternatively, the recently 
developed statistical total correlation spectroscopy (STOCSY) analysis method can be 
applied not only to aid the identification of a metabolite, but also to indicate the positive 
and even negative correlation of metabolites involved in the same pathway (Cloarec et 
al., 2005). The principles of STOCSY will be described in Section 1.6.6. Other useful 
tools in metabolite identification include Amix-Viewer software and various database 
websites including the Human Metabolome Database, which can give an initial idea of 
the identity of a potential biomarker. For some metabolites that are present in low 
concentrations in a particular complex, separation methods such as solid phase 
extraction (SPE) and HPLC are typically employed to isolate these unknown 
compounds from the complex biological fluid in order to perform further identification. 
Spiking of an authentic candidate compound is used to further confirm the identity of a 
given metabolite. 
Multivariate data analysis: `Omics' techniques generate large multi-dimensional 
complex datasets, which require statistical mathematics and computing approaches to 
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extract valuable information from the data (Lindon et al., 2001; Trygg et al., 2007). 
Thus, multivariate data analysis strategies are typically used to interpret large datasets 
by reducing the data size, constructing models and visualising results. These 
multivariate statistical analysis methods include principal component analysis (PCA), 
projection to latent structure-discriminant analysis (PLS-DA), orthogonal signal 
corrected-PLS-DA (O-PLS-DA), O-PLS, hierarchical PCA (H-PCA) and H-PLS-DA, 
which will all be detailed in Section 1.6. 
1.3 Introduction to parasitology 
Parasitology is the study of parasites and their relationship with their hosts. The most 
fundamental stage of parasitology is the diagnosis of a parasitic infection either by 
direct or indirect diagnostic approaches. Once the infection has been identified, research 
on its life cycle, related diseases, its control and prevention, diagnosis, chemotherapy 
and vaccines will follow. Thus, many other sciences including phylogenetics, ecology, 
morphology, physiology, chemotherapeutics, nutrition, microbiology, immunology, cell 
biology, molecular biology and biochemistry, can be recruited to aid parasitological 
research (Thomas, 1986; Roberts and Janovy, 1996). This thesis focuses on the 
biochemical aspect of parasitology and specifically on the metabolic consequences of 
parasitic infections in the mammalian host. 
1.3.1 Concepts of parasite and host 
"Any animal, plant, or protist that spends a portion or all of its life intimately associated 
with another organism of a different species is considered to be a symbiont or symbiote, 
and the relationship is designated as symbiosis." (Thomas, 1986) There are four types of 
symbiotic relationship, namely, (i) phoresis, (ii) commensalism, (iii) parasitism and (iv) 
mutualism (Thomas, 1986; Roberts and Janovy, 1996; John and Petri, 2006). 
Phoresis is simply a transportation relationship between parasites and their hosts 
without any metabolic interactions. For example, some bacteria can travel by attaching 
themselves on the legs of flies. 
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Commensalism is characterised by the host sharing food with the invading organisms 
and providing shelter without any detrimental effect to the host. 
Parasitism is an intimate and obligatory relationship between a parasite and host, where 
the parasite is metabolically dependent on the host and usually causes mechanical 
damage to the host. 
Mutualism is a metabolically beneficial relationship for both parasites and hosts. 
Taking an example of algae and fungi, the alga synthesises certain organic compounds, 
which are used by the fungus, and in return, the fungus offers water and minerals to the 
alga. 
In parasitism, there are four types of host: (i) a definitive host where the parasite 
completes the sexual maturity (e.g. humans for the disease schistosomiasis); (ii) an 
intermediate host where the parasite temporarily stays as a part of its life cycle (e.g. 
aquatic snails for the disease schistosomiasis); (iii) a transport host where the parasite 
does not experience any development but remains infective to other hosts and (iv) a 
reservoir host, an infected animal, from where other animals can be infected via a 
vector (Thomas, 1986; Roberts and Janovy, 1996). 
1.3.2 Parasites and parasitic diseases 
1.3.2.1 Introduction to parasitic protozoa 
There are more than 45,000 protozoan species recorded, most of which are parasitising 
to vertebrates (Cox, 1993). Protozoa are unicellular and intermediate between the 
prokaryotic and higher eukaryotic organisms containing a nucleus, nuclear membrane, 
chromosomes, endoplasmic reticulum, mitochondria, Golgi apparatus, ribosomes, 
plasma membrane, etc. They are reproductive and have a relative short generation time. 
Parasitic protozoa generally cause immunological responses in the host and initiate 
strong adaptation reactions so that they can survive in their hosts (Cox, 1993). 
Additionally, protozoa evolve metabolism and interact with their hosts by absorbing and 
secreting substances. 
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Classification: Protozoa can be classified into four types in terms of their manner of 
locomotion: (i) the flagellates, which move by flagella (e.g. Leishmania spp., 
Trypanosoma spp.); (ii) the amoebae, by amoeboid motion (e.g. Entamoeba spp.); (iii) 
the ciliates, by cilia (e.g. Paramecium spp.) and (iv) protozoa which have no obvious 
mode of locomotion (e.g. Balantidium spp.) (Cox, 1993; Bush et al., 2001). 
Protozoan infection-related diseases: The protozoa provoke a number of severe 
parasitic diseases such as malaria caused by Plasmodium spp., human African 
trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei spp., Chagas 
disease caused by Trypanosoma cruzi spp. and leishmaniasis by Leishmania spp.. 
Malaria, in particular, is a major concern as 40% of the global population are at risk and 
that it exerts a huge impact on public welfare. 
The investigation of malaria in a rodent model is one of the main objectives of this 
thesis and will be discussed in Chapter 3, where the life cycle of the Plasmodium spp., 
prevalence, diagnosis and treatment of malaria will be introduced. 
1.3.2.2 Introduction to parasitic helminths 
Helminths or parasitic worms include cestodes, nematodes and trematodes, which are 
significantly variable in terms of their structure, physiology and behaviour. Thus the life 
cycle and metabolism of helminths are diverse. In the current thesis, the focus is on 
trematodes. Adult trematodes are commonly seen in a flat or cylindrical shape and most 
of them inhabit the gut, bile duct or lung. Most trematodes possess a pair of suckers 
including a ventral acetabulum and an oral sucker around the anterior mouth. Both 
suckers are used for the adherence to internal walls within the host and the latter is also 
used for feeding. The digestive system of trematodes is incomplete, and consists of 
mouth, pharynx, oesophagus and caeca, and the excretory system is usually operated by 
diffusion through the surface of intestinal caeca to the outside. The life cycles of 
trematodes tend to be complex, involving several developmental stages and hosts (Cox, 
1993; Bush et al., 2001). 
Helminthic infection-related diseases: Helminthic infections cause a number of 
debilitating and life-threatening diseases in human and livestock populations all over the 
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world, particularly in tropical and subtropical regions where there is a lack of hygiene 
conditions. There are some human cestode diseases, such as echinococcosis (hydatid 
disease) caused by Echinococcus spp.. Schistosomiasis, caused by a trematode of the 
genus Schistosoma, is endemic in Africa, South America and the Far East. Nematode 
infections exert a considerable impact on human health, such as ascariasis caused by the 
roundworm Ascaris lumbricoides, ancylostomiasis and necatoriasis caused by the 
hookworms Ancylostoma duodenale and Necator americanus respectively, 
strongyloidiasis caused by the threadworm Strongyloides stercoralis, trichuriasis caused 
by the whipworm Trichuris trichiura and entrobiasis by the pinworm Enterobius 
vermicularis (Bethony et al., 2006). 
Characterisation of schistosomiasis in a rodent model is one of the main objectives of 
this thesis and will be discussed in Chapters 4 and 5, where the life cycle of 
schistosomiasis, prevalence, diagnosis and treatment of the disease will be introduced. 
1.4 Overview of current research on malaria and schistosomiasis 
The increasing threat of parasitic diseases to humans and animals has driven numerous 
research studies carried out in the parasitic infection-related areas, with many of these 
studies focussing on host responses to the infections. Traditionally the exploration of 
host-parasite interactions has been undertaken in vitro or at the level of a single tissue or 
an isolated metabolic pathway, but these fail to provide integrated metabolic 
information and lack the ability to consider effects from other organisms or metabolic 
pathways in a complex biological system. Therefore, modern research has taken this 
into account and currently proposes to acquire `omit' data and employ mathematical 
methods to analyse multivariate data in order to extract valuable information. Detailed 
overviews of current studies on malaria and schistosomiasis will be discussed in 
Chapters 3 and 4, respectively, thus here several histological and metabonomic research 
strategies are briefly presented in the following sections. 
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1.4.1 Histopathological examination on parasitic diseased tissue 
Histopathology is a microscopy technique used to examine disease-related pathological 
changes in tissues, which is of key importance in anatomical pathology. 
Histopathological examination can provide direct visualisation of the structural 
alterations caused by diseases, thus, it has become a useful diagnostic tool for 
aetiological diagnosis. However, its use is limited as a diagnostic tool for human 
populations, since obtaining biopsies from patients is invasive and examination requires 
expertise, is labour-intensive and often unethical. 
Many parasitic infections can lead to direct damage and/or inflammatory lesions in 
tissues, thus microscopy becomes a direct technique with which to observe these tissue 
alterations. For example, histopathological studies have been extensively carried out on 
schistosomiasis to observe egg-induced granulomous inflammatory (De Jonge et al., 
2003a). 
1.4.2 Metabonomic studies on parasite-host interactions 
Metabolic profiling or metabonomic strategies based on high-resolution NMR 
spectroscopy in combination of multivariate data analysis were initially employed to 
generate comprehensive metabolic signatures of urine samples obtained from 
Schistosoma mansoni-infected mice (Wang et al., 2004). This study demonstrated the 
application of NMR-based metabolic profiling in investigation of host responses to a 
parasitic infection in vivo. Several subsequent studies on schistosomiasis (S. japonicum 
in hamsters) (Wang et al., 2006), echinostomiasis (E. caproni in mice) (Saric et al., 
2008b) and trypanosomiasis (T. brucei brucei in mice) (Wang et al., 2008a) have been 
published to produce complementary metabolic information on the global parasite-host 
interplay, which has aided the identification of new mechanisms of pathology by 
generating integrated signatures of biofluids. 
This thesis extends the preliminary published work with the aim of investigating in vivo 
dynamic responses of mice to selected parasitic infections (e.g. malaria and 
schistosomiasis) using 1H high-resolution NMR spectroscopy-based metabonomic 
techniques, coupled with multivariate data analysis. These investigations will enhance 
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the current understanding of parasite-host interactions and also aim to provide a novel 
paradigm for disease diagnosis and surveillance. It may also generate meaningful 
information for drug and vaccine development. 
1.5 Nuclear magnetic resonance spectroscopy 
NMR spectroscopy is a powerful and versatile technique, which has been successfully 
applied in analytical chemistry, biochemistry, physiology and medicine. NMR dates 
back to 1938 when Isidor Rabi first described the NMR phenomenon in molecular 
beams and in 1946 the Felix Bloch and Edward Purcell groups independently 
demonstrated the effect in both liquids and solids, for which they were awarded the 
Nobel Prize in physics in 1952. Since then enormous progress in the understanding of 
the theory and in the technical implementation has meant that NMR techniques can now 
be used to analyse liquids, solids, semi-solids, liquid-crystal and gas states for their 
chemical composition, molecular structures, reactions and dynamics. This section was 
constructed from several NMR textbooks including "Basic one- and two-dimensional 
NMR spectroscopy" and "Nuclear magnetic resonance" (Hore, 1995; Friebolin, 2005). 
1.5.1 The basic theory of liquid-state NMR 
Many atoms such as 1H, 13C, 31P, 15N, 19F, which have an overall spin property and have 
a nuclear magnetic moment, can manifest the nuclear magnetic resonance phenomenon 
in a magnetic field. This overall spin can be represented by the nuclear spin quantum 
number I which is determined by the number of both neutrons and protons (Table 14). 
Table 1-1 Spin quantum number (/) of different nuclei. 
The number of 
protons 
The number of 
neutrons Spin mode Example (1) 
even 
odd 
even 
odd 
even 
even 
odd 
odd 
no overall spin 
half-integer spin 
half-integer spin 
integer spin 
12c (0), 160 (0)  
1H (1/2), 23Na (3/2) 
13C (1/2), 170 (5/2) 
2H (1), 10B (3) 
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Figure 1-2 Energy levels for a proton in an external magnetic field (Bo ). AE represents the 
energy difference between the two energy levels. 
A spin I nucleus has 2/+1 energy levels (m,=/, 1-1,...-I, ni, is the magnetic quantum 
number). When it is placed into an external magnetic field Bo, the 2/+1 energy levels 
will have different energies in the direction of Bo. The simplest example is hydrogen 
with 1=1/2 that has two possibilities (2x1/2+1=2) of states, with the higher energy level 
considered to be opposed to Bo and lower energy level aligned with Bo as shown in 
Figure 1-2. The energy state parallel to Bo is the lower energy level and is often denoted 
a (m,=+1/2), while the magnetic moment anti-parallel with Bo is the higher energy level 
referred as 1 (m,=-1/2). 
The distribution of nuclei in the low energy state (Na ) and in the high energy state (NI] ) 
can be described by the Boltzmann distribution. 
Na = e AEI kT 
N fi 
where k is the Boltzmann constant (k=1.3805 x 10-23 J/Kelvin) and T is the Kelvin 
temperature ([°C] = [K] — 273.15). 
The energy difference between these two energy levels, AE, is proportional to the 
external magnetic field. Spins at the lower energy level can be excited to the high 
energy level by absorbing the radio frequency (RF) radiation. 
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AE = hv 
Nevertheless, only when the frequency of the electromagnetic radiation, v, and the 
strength of the external magnetic field Bo meet the condition described as below, will 
resonance occur. 
v= 
2r 
Here, v represents the Larmor frequency, y is a constant unique to each type of nucleus 
(magnetogyric ratio) and h is Planck's constant (6.626 x 10 34 J•S) 
Therefore, the energy difference relates both to the external magnetic field and to the 
selected nucleus. This net population difference between the states gives rise to an 
equilibrium magnetisation (M0 ) parallel to Bo. To generate a NMR signal, this 
population difference is perturbed by the application of radiofrequency energy at the 
correct frequency given by the following equation: 
AE = hv =
hyB° 
 
2r 
This energy is delivered to the sample by a short intensive radiofrequency pulse. As the 
spin level population returns to equilibrium by a process known as relaxation, an 
oscillating RF signal is generated in a detector coil. This is called a free induction decay 
(FID). It takes several seconds for acquisition, following a few microseconds long pulse 
(approximately 10 ils). The spectrum signal-to-noise ratio can be then improved by 
adding multiple scans. 
Figure 1-3 illustrates the effect of an RF pulse on Mo using a rotating coordinate system 
(x', y' and z) which rotates with the same frequency as the radio frequency. Figure 1-3A 
illustrates the equilibrium magnetisation (M0 ) and a 90 degree pulse (B1 ), defined by the 
length of the time and the power of the field necessary to rotate the magnetisation 
through 90 degree, applied on the —x' axis and this flips the net magnetisation (M0 ) 
along the y' axis (Figure 1-3B). This then dephases in the x'y' plane (Figure 1-3C) and 
M0 gradually spirals back to thermal equilibrium (Figure 1-3A). Thus the receiver coil 
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along the y' axis detects the time-domain signal (HD) (Figure 1-3 D) as an oscillating 
decaying voltage. 
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Figure 1-3 Schematic representation of the NMR effect. Equilibrium magnetisation (M0 ) in 
a rotating coordinate system (x', y' and z) and a 90 degree pulse field (BI ) which is applied 
along the —x' axis (A) and flips the magnetisation along the y' axis (B). Magnetisation 
dephases in the x'y' plane (C) and eventually return to the z axis (A). The receiver coil 
along they' axis detects the time-domain signal which is known as a FID (D). 
The time domain expression of the spectrum (Figure 1-4 A) can not be interpreted easily. 
Consequently, the time domain data are usually converted into the more familiar 
frequency domain spectrum (Figure 1-4 B) using Fourier transformation (FT). The 
Cooley-Tukey algorithm is a very efficient FT algorithm and extensively used in data 
transformation. 
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Figure 1-4 Effect of Fourier transformation on the free induction decay. 
The basic principle of NMR discussed above is based on the simple situation of a single 
nucleus, whereas the practical situation, however, is more complex as there are many 
magnetic nuclei surrounded by different chemical and molecular electronic 
environments in a molecule. Therefore, two important parameters (chemical shift and 
spin-spin coupling) in the typical NMR spectra are now introduced. 
1.5.1.1 Chemical shift 
The circulation of electrons around a nucleus will produce another minor magnetic field, 
B', shielding the nucleus from the actual value of B0 and causing a change in its Larmor 
frequency. In an atom, the direction of B' is opposite to Bo, thus the nucleus is shielded 
from the external field by its surrounding electrons and the "real" field strength such a 
nucleus experiences is slightly smaller as B=Bo —B'=B0(1--6), where 6 is called the 
shielding constant. So, the resonance condition becomes 
v = gi
o (1— a) 
2R- 
In a molecule, the situation becomes more complex because B' may either decrease or 
increase the external field depending on the environment of a nucleus. For example, in 
the [18]-annulene (C18I-118) the six inner hydrogen atoms are positively shielded thus 
with a lower resonance frequency whilst the twelve outer ones are negatively shielded 
thus with a higher resonance frequency. In order to make quantitative shielding constant 
independent of the magnetic field strength, the concept of the chemical shift was 
introduced. This is given the symbol S with the relative unit of ppm (parts per million). 
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Commonly, 8, or the difference of resonance frequencies between the nucleus of interest, 
v, and a reference nucleus, vr, is defined to represent the chemical shift. For this reason, 
the chemical shift is an extremely useful parameter in structural characterisation. 
=106 (v - vr ) 
v,. 
106-  a) 
••• 	= 	r 	106 (Crr a) 
1-6r 
Commonly, an extremely shielded nucleus, e.g. the methyl group hydrogens in sodium 
3-(trimethylsilyl)-propionate-2,2,3,3-d4 (TSP) giving a sharp single peak at a very low 
chemical shift away from most other resonances, is used as reference frequency, and is 
defined at 8IH 0. Consequently, a batch of 'H NMR spectra can be calibrated with this 
reference frequency in order to perform comparisons between spectra. 
1.5.1.2 Spin-spin coupling 
An additional useful parameter that can be obtained from NMR spectra is the spin-spin 
coupling resulting from the through-bond magnetic interactions between nuclei. Hence 
a given nucleus HA coupled to another nucleus HB will experience both spin states of HB 
and the HA resonance will be split into a 1:1 doublet since the population for HB are 
almost equal. The splitting, which is the strength of the interaction is called the spin—
spin coupling, given the symbol J and is measured in Hertz (Hz). Considering the more 
complex situation where these are two equivalent neighbouring nuclei spin system 
(CHA-CHx2 spin system) as an example and assuming 1=1/2 for all spins, each X 
nucleus generates a minor magnetic field (B ") and nucleus A can thus experience the 
strength of external fields with three possibilities (Table 1-2). 
Table 1-2 Spin-spin coupling in an AX2 spin system. 
Applied external field Magnetic field generated by X 
Resulting external 
field (B) Spin mode 
Bo 
Bo 
Bo 
Bo 
B" 
B" 
B" 
B" 
B0+2B" 
Bo+B"-B" 
Bo+B"-B" 
B0-2B" 
TT 
TI 
IT 
11 
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Therefore, the A resonance will be split to give a "triplet" centred at the chemical shift 
of A with relative intensities of 1:2:1 with identical frequency differences between the 
signals (Figure 1-5). The spin coupling patterns can become very complex for many 
interacting nuclei. In general for a spin 1/2 nucleus coupled to n equivalent spin 1/2 
nuclei, the splitting patterns and peak intensities are given by Pascal's triangle. The 
simple model given above does not apply where the chemical shift differences between 
coupled nuclei approach the J values or when the spin system has symmetry. 
Figure 1-5 NMR spectrum of nucleus A in an AX2 spin system with the coupling constant 
JAX• 
1.5.2 The basic theory of 2-dimensional NMR spectroscopy 
It is clear that one-dimensional 11-1 NMR is often insufficient to determine the structures 
of complex compounds because of the complexity and heavy overlapping of resonances. 
The use of 2-D NMR correlation techniques such as 1H-1H COSY and 1H-1H TOCSY, 
can represent a better possibility for the structural elucidation of analytes. 
A simple 2-D NMR experiment is characterised by three time intervals: preparation, 
evolution (ti) and detection (t2 ) periods. A typical 2-D NMR experimental data consists 
of a number of 1-D NMR spectra collected for a period t2 whilst the value of ti is 
incremented a systematic fashion. This can be described as a matrix X containing two 
axes: ti and t2 (Figure 1-6 A). The first Fourier transformation is performed with respect 
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to t2 and the resulting matrix (X (ti, F2 )) (Figure 1-6 B) will be a series of 1-D spectra as 
a function of ti. Then the second Fourier transformation is carried out with respect to ti 
and the matrix X (Fi, F2 ) obtained is a 2-D NMR spectrum which can be displayed as a 
stack plot (Figure 1-6 C). In the interest of simple interpretation, it is then changed into 
a contour plot (Figure 1-7). For most homonuclear 2-D experiments that correlate one 
spin with another (e.g. COSY), the diagonal is the 1-D NMR spectrum and off diagonal 
peaks identify the chemical structure of mutually coupled protons. There are many types 
of 2-D experiments, homonuclear correlation, heteronuclear correlation, J-resolved, etc., 
and these NMR principles are discussed in more detail in several books (Croasmun, 
1987; Sanders and Hunter, 1993). 
Figure 1-6 Schematic representation of the general 2-D NMR experiment (Source: 
Guillermo Moyna, internet access, NMR lecture on 28/2/1999). 
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ppm 
Figure 1-7 A contour plot of a 2-D 1H-1H NMR TOCSY spectrum (Source: Guillermo 
Moyna, internet access, NMR lecture on 28/2/1999). The diagonal and cross peaks joined 
by a dashed square represent protons with mutual J couplings. 
1.5.3 The basic theory of magic angle spinning (MAS) NMR spectroscopy 
MAS NMR spectroscopy as a technique has been known for many years and was first 
used to acquire high-resolution spectra of solids. More recently with the development of 
NMR probes with a deuterium lock facility, MAS NMR spectroscopy has been applied 
to semi-solid biological tissues and cell samples, as it has the ability to average out 
multiple line-broadening mechanisms. In tissues and for Ill NMR spectra these are 
mainly caused by dipolar coupling and magnetic susceptibility effects. 
1.5.3.1 Dipolar coupling 
The mutual dipolar coupling, D, is the most obvious interaction between two adjacent 
nuclei. It is the mutual effect of one another's dipolar magnetic fields, which is 
dependent on their internuclear distance and respective orientation to Bo. Dipolar 
coupling between two neighbouring nuclei A and B can be described as follows: 
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Y AY B  
DAB = (3 cos 2 eAB -1)  
rAB 
Where 7A and 7B are the magnetogyric moments of A and B, r is the internuclear 
distance and BAB is the angle between the internuclear vector and the external magnetic 
field, Bo. In solution, molecules tumble freely and rapidly, and the orientational average 
value of the angular factor is zero, thus this anisotropic interaction averages to zero, but 
at any moment the value of D will not be zero. In solids, due to the restriction of the 
molecular motion, the value of D is not zero and can dominate the spectra of solids 
(being several kHz). If the sample is spun at an angle II to Bo this introduces another 
angular factor of the same form (3cos2/i-1). If II is chosen to be 54.7°, the so-called 
magic angle, then this term goes to zero irrespective of the value of the other angular 
factor, (3cos20-1), and hence the effect is to cause the D value to average to zero. 
1.5.3.2 Magnetic susceptibility 
Tissue samples contain water, free tumbling molecules in cytosol, lipids, and proteins 
and so on, which are located in different compartments. These various parts of a 
heterogeneous sample can have different magnetic susceptibilities resulting in a range 
of shifts and hence line broadening. In addition, such susceptibility effects can be 
anisotropic. This distribution results in anisotropic magnetic susceptibility. Anisotropic 
magnetic susceptibility also has the angular dependence as dipolar coupling and thus 
spinning a sample at the magic angle can remove this broadening. It does not remove 
any isotropic effects due to regions of different susceptibility and hence different 
isotropic chemical effects can be observed for different tissue compartments for 
example, a useful effect for studying localisation of metabolites. 
1.5.3.3 Magic angle spinning NMR in practice 
Practically, in order to conquer these line-broadening factors, the tissue sample is tightly 
packed in a well-sealed zirconium oxide rotor (Figure 1-8 A). Then the rotor is placed 
inside of the magnet and spun at an angle of 54.7° relative to Bo, driven by nitrogen gas 
(Figure 1-8 B). The spinning rate must be fast enough to overcome the anisotropic line 
broadening so that a high-resolution spectrum can be achieved (Figure 1-9). Sample 
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packing can also affect the quality of the spectrum. The small spherical sample shape 
produces higher quality of spectra than a larger cylindrical sample (Waters et al., 2000). 
An increase in sample temperature caused by the high speed sample spinning cannot 
only accelerate sample degradation, but also lead to poor quality spectra (Nicholls and 
Mortishire-Smith, 2001b), so this is eliminated by cooling the spinning gas to a desired 
temperature. 
Although MAS NMR experiments are time-consuming due to the lengthier sample 
preparation and shimming time in comparison with conventional NMR spectroscopy of 
fluids, they provide valuable information on intact tissue and/or cell biochemical 
composition. 
A 
	
B  
 
54.7° 
Rotor cap 
Teflon grub screw 
Zirconia case 
Teflon spacer 
Tissue sample 
Teflon spacer 
Figure 1-8 Illustration of the structure of a zirconium oxide rotor (A) and sample spinning 
status and the angle (B) (Source: Mehta, 2004). 
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Figure 1-9 600 MHz 'H CPMG NMR spectra of rat liver, (a) spinning at the magic angle, 
(b) non-spinning (Bollard et al., 2000). 
1.6 Introduction to multivariate data analysis 
Since NMR spectra of biofluids are very complicated due to the heavy overlap of 
metabolite signals and the complex nature of the mixture of biochemicals, it is desirable 
to employ computer-based analytical tools for the purpose of data analysis. Multivariate 
data analysis methods, also referred to as pattern recognition (PR) or chemometrics, 
have been developed in order to extract significant information from huge multivariate 
data sets. PR can simplify huge data sets and provides easy visualisation of the 
similarities and differences between the different observations (e.g. samples or spectra) 
(Holmes et al., 1994; Eriksson et al., 2006; Trygg et al., 2007). 
There are two commonly used types of pattern recognition methods (Jain et al., 2000). 
One is unsupervised multivariate techniques, such as principal component analysis 
(PCA) and hierarchical cluster analysis (Hansch et al., 1973), which are employed to 
establish a model without a priori knowledge of class membership, thereby showing the 
intrinsic differences within a dataset. The other type is supervised multivariate 
techniques, such as projection to latent structure (PLS) and projections to latent 
structures-discriminant analysis (PLS-DA) which require prior knowledge of class 
membership. Here the knowledge of class membership is used to optimise the 
43 
Chapter 1-Introduction 
separation between different classes and requires subsequent validation via prediction of 
an independent test set to prevent overfitting of the data. 
1.6.1 Data reduction and pre-processing NMR spectra 
Data reduction: Prior to performing multivariate data analysis, NMR spectra require a 
series of processing steps including Fourier transformation, phasing, baseline correction 
and calibration. The entire spectra (olli 0-10) will be imported into MATLAB 
environment and digitised by integrating over small segments of a spectrum, typically 
0.0005 ppm wide. Spectral regions containing only noise or the residual water peak can 
be removed as they would introduce bias to the classification. 
Normalisation: Normalisation to total area of the remaining spectral data is performed 
in some cases where it is necessary, in order to maximise the sensitivity of the analysis 
and to minimise effects of variations which are not related to classification and which 
may be unavoidable during the sampling process, such as variations in concentrations of 
urine from individual to individual and in weights of tissue samples. 
Mean-centring: The resulting spectral data are typically mean centred, which means the 
average value of each variable is calculated and then subtracted from the data. This step 
aligns the variables and improves the interpretability of models, but without further 
scaling it highlights big variables such as signals from metabolites present in high 
concentrations. 
Scaling methods: A variable with a large numerical range can have a large variance, and 
vice versa. Some unsupervised analysis methods such as PCA are more likely to express 
a variable with a large variance in the model than that with a small variance. Thus 
scaling is an essential step of pre-processing in the analysis of spectral data in order to 
optimise information recovery. There are several scaling methods that are commonly 
used, such as scaling to unit variance also called auto scaling, and Pareto scaling. In unit 
variance scaling, each variable is divided by its standard deviation, such that the weight 
of a variable with large variance will shrink while a small variance of a variable will be 
stretched. Hence, all the variables have equal variance and no variable can dominate 
another, so that small variations in the levels of low concentration signals in the spectra 
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will be detected. Unit variance scaling is useful when variables have a broad range of 
variance and are not directly comparable. However, scaling to unit variance can make 
the model prone to artefacts introduced by noise. With Pareto scaling, each variable is 
divided by the square root of its standard deviation. This scaling method is in between 
no scaling and unit variance scaling. There are many other forms of scaling such as 
logarithmic transform, etc., but these are not often applied in NMR data analysis. 
1.6.2 Principal component analysis (PCA) 
PCA is one of the most widely used unsupervised methods for overviewing large data 
sets. It is a way of reducing data complexity, identifying patterns in data and expressing 
the data to highlight their intrinsic similarities and differences. 
Basically, a data set defined as an X matrix contains N rows (e.g. each row is one NMR 
spectrum) and K variables (e.g. integrals of a small width of chemical shift region or 
individual data point). PCA finds points, lines, planes and hyperplanes in a K 
dimensional space; however, since patterns in data can be hard to find in data of high 
dimensionality, PCA compresses a large dataset by reducing the dimensionality without 
much loss of information. For this reason, PCA defines an axis of the first component 
which goes through the mean centre of the data and minimises the square of the distance 
of each point to that axis, which is also called the coordinate value or scores, 
represented by tb where b is the number of the component. In other words, the first 
principal component (PC1) covers the maximum variation in the data. The second 
principal component (PC2) must meet three conditions: it must (i) pass through the 
centre point; (ii) be orthogonal to the first component and (iii) best describe the dataset 
using the remaining variables. Subsequent components obey the same rules being 
orthogonal to all other components. Thus generally the components occur in order of 
significance. In most cases the first 2 or 3 components can be selected to explain the 
dominant variance in a dataset. If a 2-D plane is defined by PC1 and PC2, all data points 
representing all observations are projected onto this plane, the resulting diagram is 
called a scores plot where the points within the same cluster share a high similarity and 
ones belonging to the separated clusters are biochemically different (Figure 1-10). The 
corresponding loadings (pb where b is the number of the component) plot displays the 
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variables which dominate the score plot, hence, revealing information on the 
relationship between the patterns of similarity/difference in the scores plot. 
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Figure 1-10 Representation of multidimensional space mapping of spectral data through 
pattern recognition-based techniques. A total of 12 typical partial NMR spectra (A) are 
digitised and mapped in a scores (t) plot (B) where each point represents one observation 
(e.g. a NMR spectrum). The corresponding loadings (p) plot (C) shows the variables (e.g. 
chemical shift) contributing most to the separation of observations. 
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1.6.3 Projection to latent structures (PLS) and orthogonal signal correction-PLS 
(O-PLS) 
PLS is extensively used for regression modelling. PLS comprises an X matrix (e.g. 
NMR spectra), but also a Y matrix representing quantitative values, usually of some sort 
of measure of response (e.g. concentrations of metabolites, worm burden). PLS, as a 
regression extension of PCA, is used to calculate a quantitative relationship between X 
and Y. A PLS model indicates the linear link between dataset X and corresponding 
response Y, thus explaining how the data matrix X correlates with the response matrix Y. 
However, any systematic variations in the X matrix which are not linked to the Y matrix 
will introduce some pitfalls and can compromise the strong correlation between two 
matrices, possibly obscuring the metabolite biomarkers which are potentially important 
to the data interpretation. 
O-PLS (PLS with an inbuilt orthogonal signal correction filter) is an optimised method 
based on PLS. It applies a data filtering algorithm to the data before PLS analysis is 
performed. Orthogonal signal correction (OSC), as a mathematical tool, can remove or 
suppress the systematic variations from the X or Y matrices which are non-relevant to 
the X or Y matrix correlations (Trygg and Wold, 2002). The advantage of O-PLS is in 
separating the systematic variation in X matrix into a linear correlation to Y and a non-
correlation to Y by adding orthogonal components. The resulting model solely focuses 
on the linear correlation between the datasets. 
1.6.4 Projection to latent structures-discriminant analysis (PLS-DA) and 0- PLS-
DA 
PLS-DA is similar to PLS but addresses the discrimination between classes by use of a 
class membership indicator in the Y matrix. Here, the Y matrix, contains qualitative 
values and is used to define two or more classes, encoded in discrete fashion, e.g. by 1 
or 0 on the basis of prior knowledge of observation class membership. The PLS-DA 
method provides a maximum separation of observations in the X matrix according to the 
classification information in the Y matrix. 
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O-PLS-DA is an extension of the PLS-DA method. As explained in O-PLS, the 
resulting multivariate models of O-PLS-DA with orthogonal components will only be 
focused on class discrimination since variation not correlated to the biological response 
has been removed or suppressed. 
1.6.5 Hierarchical-PCA (H-PCA) and H-PLS-DA 
Hierarchical PCA or H-PLS-DA is a method for comparing several blocks (e.g. several 
PCA models) derived from the same object (e.g. animal) in order to improve the 
interpretability of the model. This method is ideally used for analysing variable-rich 
datasets (Westerhuis et al., 1998). The basic principle is to divide the data into several 
meaningful blocks, for example upon the type of samples (e.g. urine, plasma and faecal 
water), A, B and C, as shown in Figure 1-11. A PCA model is constructed for each block 
and scores (tb) from each PCA model are combined, forming a super block, T. Then 
PCA and PLS-DA methods are employed on T with scores denoted as variables and 
sample identities denoted as observations. The resulting super scores (tT) plot shows the 
relationship between observations and the super loadings (p T ) plot indicates which sub-
level scores are most influential on the H-PCA/H-PLS-DA models, and hence facilitate 
visualisation of differences/similarities of the data in multiple blocks. 
1.6.6 Statistical total correlation spectroscopy (STOCSY) 
STOCSY operates on the premise that the intensities of signals in a set of variable 
spectra (e.g. NMR spectra) are multi-co-linear to generate a 2-D NMR spectrum, similar 
to a TOCSY spectrum, showing the correlation of different peaks within a sample 
(Cloarec et al., 2005). Theoretically, different signal intensities from the same molecule 
will have the same ratio across samples. With perfect experimental conditions, this ratio 
will be totally correlated with a correlation coefficient value (r) of 1. However, due to 
the heavy overlap of complex biofluid spectra and spectral noise, r is always less than 1. 
Therefore, within a set of spectra, the concentrations of the same molecule differ among 
the samples, which enhance the correlation between the resonance variables since these 
resonance intensities from the same molecule share the identical increase or decrease 
ratio among the samples (Cloarec et al., 2005). 
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STOCSY is not restricted to the identification of a single molecule, but also can provide 
correlation information on other molecules which are involved in the same biological 
pathway as the initial molecule, as these molecules may share similar behaviour to a 
stimulus. But the con-elation coefficients for pairs of signals within the same molecule 
will generally be stronger than other correlations between signals from different 
molecules involved in the same pathway (Cloarec et al., 2005). This method provides 
correlation information in a sample and can aid metabolite identification. It has been 
applied to study drug metabolism, molecular epidemiology data and also been utilised 
for heteronuclear correlation analysis (Holmes et al., 2006; Holmes et al., 2007; Coen et 
al., 2007; Wang et al., 2008h). 
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Figure 1-11 Schematic representation of the basic principles of H-PCA and H-PLS-DA (A, 
B and C are data blocks). 
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1.7 Introduction to polymerase chain reaction and denaturing gradient gel 
electrophoresis (PCR-DGGE) 
1.7.1 Introduction to polymerase chain reaction (PCR) 
PCR was first described by Kjell Kleppe in 1971, whose work demonstrated the 
synthesis of small DNA molecules using two primers and DNA polymerase (Kleppe et 
al., 1971). Significant improvement was made by Kary Mullis to drive the PCR 
technique towards the modem technology (Mullis et al., 1994). The successful 
application of thermally stable polymerase (Taq), isolated from the bacteria Thermus 
aquaticus, was published (Saiki et al., 1988), which accelerated the use of PCR in 
molecular biology research. Because of this, Kary Mullis was awarded the Nobel Prize 
for Chemistry in 1993. 
A standard PCR procedure is represented in Figure 1-12. There are five indispensable 
agents for the PCR experiment, namely, target DNA template, oligonucleotide primers, 
DNA polymerase, deoxynucleoside triphosphate (dNTPs) and reaction buffer 
(containing MgC12). 
DNA template: This is the target DNA to be amplified. Its quality, quantity and purity 
are influential to the PCR. 
Oligonucleotide primers: The PCR procedure requires forward and reverse 
oligonucleotide primers to start with and they are responsible for the specificity of the 
reaction. 
dNTPs: This class of molecules includes deoxyadenosine triphosphate (dATP), 
deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP) and 
deoxythymidine triphosphate (dTTP). These dNTPs covalently attach to the free 
hydroxyl group of the primer. 
DNA polymerase: The function of DNA polymerase is to catalyse the synthesis of new 
complementary strands by binding free monomeric dNTPs based on one of the parental 
DNA strands. The most extensively-used DNA polymerase for PCR is thermostable 
Taq polymerase from Thermus aquaticus, which is a thermophilic bacterium. 
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Reaction buffer: This is commercially available and it provides an appropriate chemical 
environment for optimising the activity and stability of the DNA polymerase. It contains 
MgC12, the concentration of which can be adjusted. Additionally, several organic 
additives such as glycerol and betaine solution (0.8-1.6 M) can improve specificity of 
the reaction. 
A PCR cycle consists of three steps including denaturation of the DNA template, 
oligonucleotide primer annealing, and DNA polymerase extension (Figure 1-12). 
Denaturation of the DNA template: This step involves separation of DNA strands in 
order to allow the binding of oligonucleotide primers to the target DNA strands. The 
initial denaturation takes several minutes to activate the Taq polymerase, but for the rest 
of the reaction cycles, denaturation only takes about 30 seconds at a temperature of 92 
°C (Figure 1-12 a). 
Oligonucleotide primer annealing: The next step is to attach the primers onto the target 
DNA strands and it lasts approximately 40 seconds and is carried out at a temperature of 
55 °C. However, for different primers, this temperature can vary according to the base 
composition of the primers (Figure 1-12 b). 
DNA polymerase extension: This step allows the dNTPs to pair with the target DNA 
strands and synthesise the complementary DNA strands. It generally lasts 1 minute at 72 
°C (Figure 1-12 c). 
This PCR product increases exponentially based on 2", where n is the number of cycles. 
It is generally repeated 20-40 times to ensure that a sufficient amount of PCR product is 
amplified without introducing any background product. The PCR product needs to be 
visualised on agarose gel to check the quality and purity of the product. However, the 
PCR product of environmental or biological DNA generally contains many similar-
sized DNA molecules from different microbial organisms and agarose gel 
electrophoresis fails to separate them. Thus a molecular fingerprinting method, DGGE, 
needs to be employed to further study different DNA molecules. 
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Figure 1-12 Schematic illustration of a basic PCR procedure. There are five required 
agents (DNA template, primers, DNA polymerase, nucleotides and reaction buffer) and 
three major steps: denaturation where DNA strands separate (a), annealing where 
primers adhere to each strand (b) and extension where nucleotides attach to the DNA 
strands with the aid of polymerase enzyme (c). Repeating this cycle (a, b, c) results in an 
exponential increase in the amount of the DNAs. 
Pictures of the DNA template, Eppendorf and the PCR machine were adapted from the following websites: 
http://www.stern.deLcontent/50/44/504448/dna_500.jpg; http://www.daigger.com/assets/product_images/23565a.jpg;  
http://www.ssilink.org/images/stories/PCR_machine_2jpg,  
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1.7.2 Introduction to denaturing gradient gel electrophoresis (DGGE) 
The DGGE technique takes advantage of the different melting properties of DNA in 
solution to separate DNA molecules with the precision of one base variation by raising 
temperature or denaturant concentration of the gel. The DNA melting point 
predominantly depends on the composition of DNA molecules; even a single base 
. change can change the melting point by 1.5 °C. In practice, a primer with a 40-50 base 
pair (bp) GC-clamp is used to amplify the PCR product prior to the DGGE since the 
GC-clamp will help the melted DNA firmly stay in the gel. Under a consistent 
temperature environment, DNA fragments loaded on the top of a linear-gradient 
polyacrylamide gel can be electrophoresed down to the bottom of the gel, which 
contains higher DNA denaturant concentration. The double-stranded PCR products can 
denature when they reach their threshold denaturant concentrations (Figure 1-13) 
(Erlich, 1989; Hughes and Moody, 2007). Theoretically, each single band represents a 
microbial organism but in practice this is not always the case. 
11> 	  
'OF)FPI FFPEN  
GC-clamp 
FlPFil FFPC1 
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Figure 1-13 Schematic representation of DGGE using GC-clamped DNA products from 
PCR. 
The background of the current study and basic principles of techniques and statistical 
methods employed in the thesis have been described in this chapter and the following 
chapter will introduce the methods which were applied in the current study. 
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Chapter 2 Methodology 
This chapter describes standard procedures for sample collection and preparation for 1I-1 
NMR spectroscopy analysis, together with general parameters adopted in multivariate 
data analysis of spectroscopic data. Where appropriate, detailed and specific methods 
will be described in the methods and materials section of each chapter. 
2.1 Chemicals 
HPLC grade water, D20 (99.9% of D), NaC1, NaH2PO4, Na2HPO4, pipecolic acid, 3-
(trimethylsily1)-propionate-2,2,3,3-d4, Na-azide (NaN3), vancomycin, Tween 80 and 
formalin phosphate buffer were purchased from Aldrich (Poole, UK). 
2.2 Animal husbandry 
Two mouse-parasite models and one mouse-drug intervention model were carried out at 
the animal care facilities of the Swiss Tropical Institute (Basel, Switzerland). The 
animal living environment and all manipulation on animals including sample collection, 
infection and dissection strictly adhered to the requirements of the relevant national 
legislation and local guidelines (permission no. 2081). This animal care facility at STI 
maintains animals under consistent environmental conditions with a temperature of 
—22°C, a relative humidity of —70% at day/night cycle of 12/12 hours. Female out-bred 
NMRI strain mice, purchased from RCC (Fiillinsdorf, Switzerland) were used for all 
animal experimental models and fed on food pellets (PAB45 — NAFAG 9009, Provimi 
Kliba; Kaiseraugst, Switzerland) and provided with free access to water. 
Mice were labelled with distinct marks as shown in Figure 2-1, in order to distinguish 
and trace the individual. 
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Figure 2-1 Schematic demonstration of the mouse labelling. 
2.3 Experimental design of a mouse-parasite and mouse-vancomycin treatment 
model 
Three of the result chapters adopted the complex animal experimental design below 
(Figure 2-2). Methodological details of the remaining result chapter relating to P. 
berghei will be described in Chapter 3. 
Mice and Parasites: In order to reduce the animal cost and adhere to the animal 
legation, which requires usage of as few animals as possible, models of mouse-S. 
mansoni and mouse-vancomycin treatment were combined to share the same control 
group, as shown in Figure 2-2. A total of 30 NMRI female mice were randomly divided 
in to 3 groups, which were an uninfected control group (10 mice); S. mansoni-infected 
group (10 mice) and vancomycin-treated group (10 mice), and kept in 6 macrolonTm 
cages with 5 mice per cage. Animals were acclimatised for 14 days prior to the study 
under the controlled environmental conditions described in Section 2.2. Animals were 
approximately 5-weeks old and their weights were between 19.7 and 24.9 g (mean= 
22.9 g, SD= 1.9 g) at the outset of the experiment. 
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The S. mansoni life cycle was kept at Swiss Tropical Institute in a Biomphalaria 
glabrata strain of intermediate host snails and hamsters as a mammalian host. A 
Liberian strain of S. mansoni cercariae was obtained following an artificial light 
exposure to the infected B. glabrata snails for approximately 4 hours. 
Infection and drug treatment: On day 0 (Do), 10 mice belonging to S. mansoni-infected 
group were infected intraperitonealy with 80 S. mansoni cercariae. 
At 54 days post-infection, mice (at 13 weeks old) belonging to both uninfected control 
and S. mansoni-infected groups orally received 2 doses (100 mg/kg) of drug vehicle 
(7% Tween 80 and 3% ethanol), while mice from the vancomycin-treated group were 
administered 2 doses (8am and 8pm) of 100 mg/kg of vancomycin with drug vehicle at 
day 62 (14 weeks old). The time difference of the treatment was due to the time overlap 
of several ongoing animal models and lack of manpower. However, this one-week 
difference in age can be ignored since mice at this age are completely mature and their 
microbial community would thus be fully established. 
Sample collection (urine, plasma and faeces) was performed at 1 day pre-infection (D..1) 
and on a weekly basis until 53 days post-infection (D6, D14, D20, D27, D34, D41, D48 and 
D53). After the treatment on D54, sampling was carried out more frequently (D55, D57, 
D59, D61, D67 and D73) in order to monitor the short-term effect induced by the treatment 
of vancomycin. For the purpose of distinguishing the two models, in the mouse-S. 
mansoni model (Chapters 4 and 5), the D„ symbol was used to indicate the time point, 
while in the mouse-vancomycin model (Chapter 6), TR. represents the time point after 
the treatment. On day 74 and 83, all mice were killed by spinal dislocation. Tissues 
including jejunum, ileum, colon, liver, spleen and kidney were collected for NMR 
analysis, and the spleen and kidney were obtained for histological examination. Detailed 
procedures will be described in Section 2.4. 
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Tissues: jejunum, ileum, colon, liver, spleen, kidney 
Figure 2-2 Schematic demonstration of combined models of mouse-S. mansoni and mouse-
vancomycin. 
2.4 Standard procedures of sample collection, measurement of other parameters 
2.4.1 Sample collection procedures 
Urine and faeces (for NMR analysis): For the purpose of minimising the diurnal 
variation in biofluid compositions, sample collection was carried out between 08:00 and 
11:00 on each collection day. At least 25 it of urine and 2 pellets of faeces from each 
mouse were collected into a Petri dish, which was achieved by gently stretching the 
mice or rubbing their abdomen. Those mice that failed to generate sufficient quantities 
of urine or faeces were placed individually into empty plastic cages (thoroughly washed 
before with distilled water) and observed carefully until they provided sufficient amount 
of samples. Urine and faecal samples were immediately transferred into separate 
Eppendorf tubes with unique identification numbers (e.g. UrD6T1, StD_1C5), kept on dry 
ice until animals give sufficient amount (>25 pl of urine, 2 pellets of faeces) of samples 
and then stored in a -40°C freezer. 
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Plasma (for NMR analysis): Blood samples were collected from the tail of the mouse 
after cutting off its tip using a pair of scissors. Approximately 45 Ill of blood were 
collected into a haematocrit tube with a sodium heparin-coat. Tubes were centrifuged at 
4,000 g for 5 mins, which allows plasma to separate from erythrocytes. Plasma samples 
were transferred into Eppendorf tubes with unique identity labels (e.g. P1D48T1) and 
stored at -40°C. 
Faeces (for microbiological analysis): More than 2 faecal pellets from each mouse 
were collected onto a Petri dish and transferred into 15 ml Falcon tubes containing 0.5 
ml of 4% formalin solution for fixing faecal samples. Once fixed, 9.5 ml of 70% ethanol 
(Vethano1:VH20,-.7:3) was added and stored the tubes at -20°C. The samples were shipped 
at ambient temperature by FedEx to University College Cork. 
Tissues (for NMR analysis): Various tissues were harvested from each mouse at the 
end of the experiment. A small portion (-15 mg) of the liver (Li) was transferred into a 
small cryo-tube, labelled with a unique identification number (e.g. LiC1, LiT10), and 
immediately immersed in liquid nitrogen for subsequent NMR analysis. The same 
procedure was followed for the left kidney (e.g. KiC1), the distal part (-5 mm) of the 
spleen (e.g. SpC1). Small portions at three different locations of the intestine were 
collected, namely colon, jejunum and ileum. The criteria for sampling jejunum and 
ileum were as follows: the first 12 cm of intestine from stomach was considered as 
duodenum and the rest of intestine was divided into three sections, the first 2/3 were 
designated as jejunum and remaining 1/3 as ileum. The colon was taken from the site of 
the 3-4 cm off the anus. Samples (-0.5 cm long) were taken in the middle of each 
section to avoid variation due to possible differences in the length of sections. The 
tissues were washed with phosphate buffer saline and then transferred into small cryo-
tubes, labelled with unique identification numbers (e.g. Co1C1, JejCi, IleCI) and 
immediately immersed in liquid nitrogen for subsequent NMR analysis. During these 
procedures, water was used to clean the blade and tweezers instead of alcohol and other 
antiseptic solution, in order to avoid introducing contaminating signals into the NMR 
spectra. 
Tissues (for histological analysis): For histological investigations, the right kidney and 
a small portion of the spleen were obtained and transferred into a 30 ml bottle filled 
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with 25m1 of 4% formalin phosphate buffer. The samples were delivered at ambient 
temperature to the Institute of Pathology, University Hospital Basel for subsequent 
histological analyses. 
Tissue samples were cut, stained with haematoxylin and eosin and then examined under 
a light microscope. The results from tissue samples obtained from S. mansoni-infected 
mice were compared with those recovered from non-infected control animals. 
2.4.2 Measurement of body weight 
Animals were weighed after urine/faecal sample collection at each sampling day, using 
a Mettler balance with an accuracy of 0.1 g (Im Langacher, Switzerland). 
2.4.3 Measurement of parasitaemia 
Parasitaemia, defined by the percentage of infected cells, was determined with a 
FACScan (Becton Dickinson; Basel, Switzerland) by counting 100,000 red blood cells 
(Franke-Fayard et al., 2004). 
2.4.4 Measurement of packed cell volume (PCV) 
After removal of the haematocrit tubes from the centrifuge, the lengths of "whole 
blood" and "red blood cells" were measured using a ruler with the accuracy of 1 
millimetre and its ratio (e.g. "red blood cells" to "whole blood" (v/v)) was calculated. 
This measure determines the PCV, which is a good aggregate measure for anaemia and 
thus estimating the pathophysiological stage of a host animal. 
2.4.5 Worm count 
The S. mansoni worm burden was quantified in the infected mice by examination of the 
liver and the mesenteric veins surrounding the intestine at the end of the study. The 
liver was placed into a transparent plastic folder (20x20 cm) and gently pressed between 
2 glass plates until it became a flat and thin layer so that the microscopist can easily 
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detect worms. The layer was examined under a microscope with x10 magnification. The 
entire intestine with mesenteric veins around, placed in a Petri dish, was examined using 
the same microscopy and all worms were taken out and placed into a Petri dish 
containing some water. After removing all worms, the number and sex of each worm 
was monitored (Utzinger et al., 2002). 
2.5 Sample preparation, 1H high-resolution NMR spectroscopy and metabolite 
identification 
2.5.1 Urine sample preparation and 111 high-resolution NMR spectroscopy 
A total of 30 ill of a mouse urine sample mixed with 25 ml of phosphate buffer 
(D20:H20, v/v, 9:1; pH=7.4), consisting of 0.01% TSP for the chemical shift reference 
and 3 mM sodium-azide, was transferred into a 1.7 mm internal diameter microtube. 1H 
NMR spectra were acquired using a Bruker DRX 600 MHz spectrometer (Rheinstetten, 
Germany) with a 5 mm TXI probe operating at 600.13 MHz. The field was locked to the 
2H resonance of the D20 solvent. In order to suppress the large water signal, a standard 
1-D NMR pulse (RD-90°-ti-90°-6-90°-acquire FID) was employed for the acquisition 
of all spectra. The water peak was suppressed by selective irradiation during RD of 2 s 
and mixing time (tn,) of 100 ms. t1 was fixed to 3 vs. The 90° pulse length was adjusted 
to approximately 10 vs. A total of 256 scans were recorded into 32 k data points with a 
spectral width of 20 ppm. An exponential function was applied to FID prior to the 
Fourier transformation which broadened a line by 0.3 Hz. 
Only for the mouse-P. berghei model, 20 ill of a mouse urine sample was mixed with 20 
ill of phosphate buffer (D20:H20, v/v, 1:1; pH=7.4), consisting of 0.05% TSP for the 
chemical shift reference and 3 mM Na-azide, was transferred into a 1.7 mm inner 
diameter microtube. Other parameters matched those described above except for the 
number of scans which were sixty four. 
Additionally, 2-D NMR experiments (1H-1H COSY and 1H-1H TOCSY), to assist 
metabolite identification, were also carried out with selected urine samples. A total of 
128 increments with 80 scans were accumulated into 2 k data points with a spectral 
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width of 10 ppm for each dimension. The 1H-1H TOCSY NMR spectra were acquired 
by using the MLEV-17 sequence for the spin-lock with a spin-lock power of 6 kHz. 
2.5.2 Faecal sample preparation and 1H high-resolution NMR spectroscopy 
Two pellets of faecal samples from each animal at each time point were manually 
smashed in 700 gl of the same phosphate buffer (D20:H20=9:1) as mentioned in 
Section 2.5.1 in 2 ml Eppendorfs. Homogenates were sonicated at room temperature for 
30 min in order to fully dissolve the water-soluble components and also reduce the 
effect of micro-organisms on the samples. The centrifugation was carried out at 11,000 
g for 10 min and 550 1.11 supernatant was transferred into a 5 mm glass tube for NMR 
analysis. The NMR spectra were acquired using the same parameters to those of urine 
as detailed in Section 2.5.1, but with 256 scans. 
2.5.3 Plasma sample preparation and 111 high resolution NMR spectroscopy 
For the mouse-S. mansoni model, 25 gl of plasma samples were mixed with 25 gl of 
saline (D20:H20, v/v, 9:1, 0.9% (w/v) NaC1). For the mouse-P. berghei model, plasma 
samples were prepared by mixing 20 gl of blood plasma with 20 pi of saline (D20:H20, 
v/v, 1:1, 0.9% (w:v, g/ml, NaC1), subsequently placing them into 1.7 mm inner diameter 
microtubes. 
Two 1-D NMR experiments, 1H standard and Carr-Purcell-Meiboom-Gill (CPMG) 
spectra were acquired for each sample on a Bruker DRX 600 MHz spectrometer 
(Rheinstetten, Germany). Both 1H standard NMR and CPMG spectra were obtained 
using the same parameters described in Section 2.5.1 with 256 scans except that the 
CPMG spectra were acquired using a spin-echo pulse sequence: [RD-90°-(T-180°-t)„-
acquire FID]. For the CPMG experiment, a spin relaxation delay (2nT) of 160 ms was 
used. The water suppression was achieved as described in the previous Section 2.5.1. 
A diffusion-edited 1H NMR spectrum with water suppression was acquired for selected 
samples using the bipolar-pair-longitudinal-eddy-current pulse sequence: [RD-90°-Gi-t- 
180°- (-G1)-T-90°-G2-T-A1-90°-G -T-180°-(-Gi)-T-90°-G2-T-A2-90°-acquire FID], where 
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G1 is a pulsed-field gradient (G1=2.5 ms) and G2 is a spoil gradient (G2=2 ms), ti is the 
time between bipolar gradients (T=0.4 ms). The diffusion time, A, equals 0.1 s which is 
the period (90°-G1-T-180°-(-G1)-T-90°-G2-T-A1) and a short delay, Te, equals 5 ms which 
is the period (G2-ti-A2). A total of 256 scans were recorded into 16 k data points with a 
spectral width of 20 ppm. This experiment was applied so as to observe the large 
molecules present in blood plasma such as lipids. Due to the NMR time constraints, this 
type of the experiment was only applied to samples from selected time points. 
2.5.4 Tissue sample preparation and 11-1 high-resolution MAS NMR spectroscopy 
Kidneys were separated into renal cortex and papilla tissue and —15 mg was taken from 
each region. Each sample was isolated and packed into a 4 mm outer diameter 
zirconium oxide rotor (Bruker Analytische GmbH; Rheinstetten, Germany) with 0.9% 
saline D20 as field lock, and 1H NMR spectra were acquired on a 600 MHz Bruker 
DRX spectrometer (Rheinstetten, Germany) operating at 600.13 MHz, equipped with a 
triple-resonance MAS probe. The spin rate was regulated at 5000 Hz at a temperature of 
283 K. Three 1H NMR spectra were acquired from each sample with 1-D standard, 
CPMG and diffusion-edited pulse sequences. For the CPMG experiment, a spin 
relaxation delay (2nt) of 200 ms was used. The 90° pulse length of 10 tts was used. The 
spectral width was 20 ppm and 128 transients were collected into 32 k data points. An 
exponential function was applied to the FID prior to Fourier transformation with a line 
broadening factor of 0.3 Hz. The liver, spleen and intestinal tissues (jejunum, ileum and 
colon) were measured following the same procedures as described above. 
2-D 1H-1H COSY and 1H-1H TOCSY NMR spectra were acquired from selected 
samples for structural assignment of metabolites. A total of 80 transients and 256 
increments were collected into 2 k data points with a spectral width of 10 ppm. The 1H-
1H TOCSY NMR spectra were acquired by using the MLEV-17 sequence for the spin-
lock with a spin-lock power of 6 kHz. 2-D 1H-1H COSY and 1H-1H TOCSY NMR data 
were multiplied by an unshifted sine-bell and a shifted sine-bell apodisation function 
respectively prior to Fourier transformation. 
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2.5.5 Metabolite identification 
2-D NMR spectra such as 1H-1H COSY and 1H-1H TOCSY are usually used for 
metabolite identification. Additionally, STOCSY, as a computing and statistical 
analysis aid, is commonly used to seek the signals derived from the same molecule in a 
series of complex NMR spectra, particularly when the sample is not available for 2-D 
experimental acquisition. To confirm the identity of a metabolite, spiking with an 
authentic standard is a necessary step. The detailed steps are as follows: (1) acquire 
spectra of the original sample and the candidate standard separately; (2) add in an 
appropriate amount of candidate standard calculated to be approximately the same 
concentration as the metabolite present in the sample and acquire a spectrum of the 
resulting sample. 
2.6 Data reduction and multivariate data analysis 
1H NMR spectra obtained from urine, faecal extract and plasma samples were 
automatically phased, baseline-corrected and referenced using a MATLAB script 
elaborated by Tim Ebbels at Imperial College. 1H MAS-NMR spectra obtained from 
tissues were manually phased and corrected for baseline distortions. Urine and faecal 
extract spectra were referenced using TSP resonance of 61H 0.00, whereas plasma and 
tissue spectra were referenced using the anomeric proton from a-glucose at 61H 5.223. 
Further analysis will be discussed in the methods and materials section of each result 
chapter as the process is variable for each type of samples since the scaling and 
preprocessing parameters were independently optimised for each model. 
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Chapter 3 Global metabolic responses of NMRI mice to an 
experimental Plasmodium berghei infection 
3.1 Aim 
The global aim of this study was to evaluate the metabolic response of out-bred NMRI 
mice to an experimental infection with Plasmodium berghei using II-I NMR 
spectroscopy in biofluids (urine and plasma) combined with multivariate data analyses, 
with a view to identifying candidate biomarkers of the presence and severity of the 
infection. 
3.2 Introduction to malaria 
Malaria is one of the world's 'big three' infectious diseases — together with human 
immunodeficiency virus (HIV) and tuberculosis — and is widespread throughout the 
tropics and subtropics including Asia, Africa and South America. It places 
approximately 40% of the world's population at risk. Plasmodium falciparum malaria 
accounted for more than 500 million clinical cases in 2002 (Snow et al., 2005) and more 
than 1 million deaths were attributed to malaria in 2001 (Lopez et al., 2006). Malaria is 
particularly rampant in sub-Saharan Africa, with children under the age of 5 years and 
pregnant women at highest risk of disease-related morbidity and mortality (Breman, 
2001; Tuteja, 2007). The global burden of malaria is currently estimated at 
approximately 40 million disability-adjusted life years (DALYs) (Lopez et al., 2006). 
Due to the increased number of travellers and immigrants from endemic regions, 
imported malaria incidence in the developed world has escalated with about 10,000 to 
30,000 travellers returning from developing countries each year who had contracted 
malaria (Kain and Keystone, 1998b). Delays in diagnosis, lack of knowledge by 
clinicians regards malaria and lack of treatment options readily available might raise 
morbidity and mortality in those patients with imported malaria (Kain et al., 1998a). A 
further challenge is that global warming and climate variability is predicted to enhance 
malaria transmission (Patz et al., 1996). 
Malaria is caused by an infection by protozoa of the genus Plasmodium. Human malaria 
is caused by four types of Plasmodium, namely, P. falciparium, P. vivax, P. ovale and P. 
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malariae (Tuteja, 2007). The most serious grade of the disease is caused by P. 
falciparium. Apart from these four human malaria parasites, there are more than 100 
species of Plasmodium infecting other animals. P. berghei, P. chabaudi, P. vinckei and 
P. yoelii are the common rodent malaria parasites, which are often used as disease 
models for studying mechanism or response to therapeutic intervention and so forth 
(Cox, 1993). 
3.2.1 Life cycle of malaria 
Figure 3-1 shows the life cycle of malaria. It consists of two main phases, the first 
occurring in a vertebrate host (e.g. human) and the second in an insect vector (e.g. 
mosquito). Out of the 30-40 of the approximately 400 known species of Anopheles 
mosquito, only female mosquitoes can transmit malaria as male mosquitoes do not feed 
on blood. The sporozoites from the mosquito salivary gland are injected into the human 
via a bite from an infected mosquito. Once residing in human blood vessels, the 
sporozoites infect the liver and invade hepatocytes, where they divide asexually and 
generate merozoites. The merozoites are released and subsequently penetrate 
erythrocytes where they produce either merozoites or microgametocytes (male) and 
macrogametocytes (female). Most of the merozoites reinvade red blood cells and form a 
cycle in the blood, which causes pathology such as severe anaemia and damage of 
essential organs of the host including the kidney, liver and spleen (Miller et al., 2002). 
A small portion of merozoites develop into microgametocytes and macrogametocytes, 
which flow into the gut of another mosquito via a blood meal completing the host-stage. 
In the vector stage, macrogametocytes are fertilised following the occurrence of 
exflagellation of microgametocytes in the gut. The resulting ookinete passes through the 
wall of a cell in the midgut to form a static oocyst. A large number of sporozoites are 
produced by sporogeny within the oocyst. When the oocyst ruptures, sporozoites escape 
into the haemocoele and migrate to salivary gland cells where they remain in vacuoles 
for up to 59 days to develop their infective ability prior to infecting another host. 
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Figure 3-1 The life cycle of the Plasmodium (copyright © Pearson Education, Inc., 
publishing, Benjamin Cummings). 
3.2.2 Clinical symptoms and diagnosis of malaria 
The clinical symptoms of malaria are mainly caused by parasitic invasion of 
erythrocytes (Trampuz et al., 2003). The infection initially manifests flu-like symptoms 
such as fever, chills and headaches. Recurrent episodes of fever usually occur every 
second day in P. falciparum, P. vivax and P. ovale infections, and once every third day 
for P. malariae (Cox, 1993). Other symptoms include abdominal pain, diaphoresis, 
nausea, vomiting, mild diarrhoea, haemolysis-derived anaemia, haemoglobinuria, 
convulsions, malaise, dizziness and dry cough. Hepatomegaly and splenomegaly also 
typically develop (Trampuz et al., 2003). In more severe forms of the disease, the major 
complications include cerebral malaria, that is, malaria infection of central neurological 
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system, acute renal failure, severe anaemia, bleeding, pulmonary oedema, acidosis and 
hypoglycaemia, which can occur in combination leading to rapid disease progression 
and death within a few hours or days (Beales et al., 2000). 
In clinical diagnosis, apart from the observation of these symptoms mentioned above, 
microscopic detection of parasites in thick and thin stained blood films remains the 
`gold standard' and is the most widely used diagnostic test in malaria-endemic settings 
(Moody and Chiodini, 2000). Thick blood films are more sensitive than thin films, 
while thin films are superior to thick ones in species identification (Moody and Chiodini, 
2000). This microscopic approach allows determination of the level of infection 
(parasitaemia) at relatively low cost, but requires experienced microscopists, and 
intensive labour work due to long preparation time (up to 60 min). Additionally, the 
sensitivity of this method is relatively low, particularly at low levels of parasitaemia. A 
number of rapid malaria diagnostic tests have been developed over the past decade. 
They are based on immunochromatographic dipstick assays and increasingly applied for 
self-diagnosis, but they are expensive and have imperfect sensitivity, particularly in the 
case of low parasitaemia (Moody, 2002; Wongsrichanalai et al., 2007). Several PCR 
assays based on Plasmodium nucleic acid sequences appear to be the laboratory 
standard for diagnosis of malaria. This PCR-based technique is characterised by high 
sensitivity for detection of low parasitaemia; however, it requires complicated pre-
process of samples including DNA extraction and selection of primers, which may give 
rise to variations in the result (Moody and Chiodini, 2000). 
A particularly vexing problem is the large number of asymptomatic patients (Njama-
Meya et al., 2004; Coura et al., 2006) for whom detection of parasitaemia using 
conventional methods is difficult. Therefore, discovering, developing and deploying 
novel tools and strategies for malaria-specific biological marker discovery is needed in 
order to aid diagnosis, interventions and integrated control packages. The long-term aim 
of this study is to explore a potential diagnostic tool, which can ultimately be used for 
individual diagnosis of malaria and for monitoring disease control programmes at the 
population level. 
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3.2.3 Chemotherapy and resistance on malaria 
Chloroquine is a cheap drug that has been widely used against malaria; however, 
resistance to this compound has spread in most parts of the endemic areas. Sulfadoxine-
pyrimethamine (SP) is used to replace chloroquine, but resistance to it has also occurred. 
To mitigate the problem of malaria parasite resistance to antimalarial drugs, 
combination therapy with drugs exhibiting different mechanisms of actions has been 
introduced to the clinical antimalaria treatment. Artemisinin-based combination 
therapies are more widely used. The combination of dihydroartemisinin and piperaquine 
is popular in Asian and African markets due to its low price and favourable efficacy 
(Greenwood et al., 2005). 
Bacterial infections such as aspiration pneumonia and sepsis often occur in patients with 
severe malaria. Thus antimicrobial therapy should be also taken into account (Trampuz 
et al., 2003). However, bacterial infections may not be diagnosed initially, so seeking 
methods for robust and comprehensive diagnosis is essential. 
3.2.4 Studies of malaria on human and animals 
There is a huge body of research on malaria, including parasite biology, drug 
development, metabolism and resistance, vaccine development and assessment, immune 
responses of hosts and vector controls (Greenwood et al., 2005). Only a brief discussion 
of genomic, transcriptomic, proteomic and metabonomic studies on the interactions 
between the mammalian host and the Plasmodium parasite is given. Investigation into 
the genome sequence of Plasmodium spp. is in progress and the genome sequence of P. 
falciparum which comprises 14 chromosomes and about 5,300 genes is completed 
(Gardner et al., 2002; Hoffman et al., 2002). Transcriptomics has been utilised to 
characterise malaria infections in human caused by P. falciparum (Daily et al., 2007). 
Daily and colleagues (2007) reported an in vivo expression profile which was 
represented by three distinct physiological stages consisting of the upregulation of 
glycolysis, respiration and metabolism of carbon sources, and an environmental stress 
response such as heat shock, oxidative stress and osmotic stress. Genomic sequence data 
allows the identification and characterisation of the Duffy-binding-like domain-
containing, the rhoptry (Preiser et al., 1999) and reticulocyte (Triglia et al., 2001) 
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binding protein families, which are important for parasite invasion of erythrocytes and 
the pathogenesis of malaria. 
Proteomic studies on different stages of the P. falciparum life cycle including 
sporozoites (the infectious stage injected from the mosquito), merozoites (the invasive 
form to erythrocytes), trophozoites (the stage within erythrocytes) and gametocytes (the 
sexual stage) have been carried out using high-resolution liquid chromatography and 
tandem mass spectrometry techniques (Florens et al., 2002). An extensive description of 
the protein interaction network has been reported by LaCount et al. (2005), where they 
identified 2,846 unique interactions and characterised the correlation of P. falciparum 
proteins involved in the same pathway or parasite process (LaCount et al., 2005). These 
Plasmodium proteins involved in mechanism of pathogenesis are considered to be 
potential vaccine targets. Metabolic profiling strategies have begun to be applied in 
investigating the metabolic behaviour of Plasmodium. Pelczer et al. and colleagues at 
Princeton University have examined the erythrocyte culture media of the synchronised 
P. falciparum for 48 hours in situ, using NMR spectroscopy. Their study provided a set 
of informative data which reflects the potential metabolic pathway and process in a 
certain period of the Plasmodium life cycle (Istvan Pelczer, unpublished data). 
Although these previously mentioned studies performed either in vitro on P. falciparum 
or in vivo on blood samples from P. falciparum-infected humans offered comprehensive 
information on genes, proteins and metabolites of the parasite, these models fail to 
benefit research on immunology, pathology and therapeutic interventions as they can 
only be used to address in vivo models. Due to the complicated life cycle of malaria, the 
specificity of P. falciparum to the human host and the substantial diversity of parasite 
strains, it is difficult to establish P. falciparum in rodent models (Moreno et al., 2007). 
However, due to the high cost and ethical concern alternative models were sought for 
the investigation of malaria (Fraunholz, 2005; Hall et al., 2005). The molecular 
mechanisms of infection and response to therapeutic interventions have been studied 
extensively in rodent models using murine malaria parasites, such as P. berghei, 
P. chabaudi, P. vinckei, and P. yoelii (Kruckeberg et al., 1981; Chen et al., 1994; 
Staines and Kirk, 1998; Min-Oo et al., 2003), but the question as to transferability of the 
results to human malaria still remains given differences between both host and parasite 
species. Alternatively, recently a P. falciparum infection has been established in 
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immunocompromised mice and it is expected to enhance the understanding of malaria 
and drug efficacy in humans, compared with other rodent-Plasmodium models (Moreno 
et al., 2007). 
With the increasing body of research achieved on laboratory models with respect to 
drug efficacy evaluation, biomarker investigation for diagnosis and vaccine target 
exploration, the transferability of these outcomes from the laboratory to the field has 
become a particularly prominent issue. There are several obstacles that confound the 
direct translation of laboratory studies to human populations, such as genetic and 
environmental factors (e.g. life styles, diet, stress, etc.), which introduce much variation 
and dilute the focus of the study. On the other hand, although different hosts and 
parasite species can result in different experimental outcomes, as a preliminary study 
these animal models can allow researchers to identify and extract potential candidate 
markers that will aid further more complex studies in humans. 
In this thesis, an experimental malarial infection (P. berghei) in mice was characterised 
by applying a metabolism-driven top-down systems biology strategy that has proved 
effective in studying transgenomic interactions in mammalian symbiotic systems, e.g. 
the gut microflora (Martin et al., 2007; Martin et al., 2008). Similar approaches have 
also been successfully applied to characterising the systemic metabolic fingerprints of 
Schistosoma spp. and Trypanosoma brucei brucei infections in rodent models (Wang et 
al., 2004; Wang et al., 2006; Wang et al., 2008a). In order to characterise the dynamic 
metabolic consequences of a P. berghei infection in the mouse, urinary and plasma 
metabolite profiles from host animals prior to the infection and profiles obtained from 
biofluids collected 1-4 days post-infection were compared. The long-term goal of this 
study is to enhance the understanding of the metabolic response to a malaria parasite 
infection and to investigate potential candidate biomarkers which may be transferable to 
diagnosis and prognosis in human populations. 
3.3 Materials and methods 
Animal maintenance, sample collection and preparation for 1H NMR spectroscopy 
analysis have been described in Chapter 2, thus the following section will specify the 
experimental design and related parameters for spectroscopic data analyses only. 
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3.3.1 Experimental design of a mouse-P. berghei model 
A total of 24 female (age: -3 weeks; weight: 20-25 g) outbred NMRI strain mice were 
randomly housed in six macrolonTm cages with four mice per cage, and acclimatised for 
7 days prior to the study under controlled environmental conditions as described in 
Section 2.2. The mice were approximately 4-week-old and their weights were between 
22.7 and 26.5 g at outset of the experiment. These 24 mice were divided into 2 groups 
of 12 mice each. One group was left as the uninfected control group while the other 
group was infected with P. berghei (Figure 3-2). 
Figure 3-2 Schematic experimental design of the mouse-P. berghei model. 
The green fluorescent protein (GFP) ANKA strain of the P. berghei parasite (Franke-
Fayard et al., 2004) was used for the infection. In brief, heparinised blood is taken from 
a donor mouse that has a high parasitaemia (- 30%), and is diluted in physiological 
saline to 108 parasitised erythrocytes per ml. In this experiment, an aliquot of 0.2 ml of 
this suspension (e.g. containing 2 x 107 parasitised erythrocytes) was injected 
intravenously (i.v.) into each mouse belonging to the infected group, which was carried 
out by the senior laboratory technologist Josefina Santo Tomas (Vennerstrom et al., 
2004). 
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Samples of urine and blood plasma were collected daily from the day before the 
infection until 4 days after the infection: 	D1, D2, D3 and D4. In addition, the body 
weight, parasitaemia and packed cell volume (PCV) ratio of each mouse were measured 
and recorded at each time point. On day 4, all mice were killed using the CO2 method 
and tissues, including liver, kidney and spleen, were collected for histological 
examination. The detailed procedures pertaining to these measurements have been 
previously described in Section 2.4. 
3.3.2 Data reduction and multivariate data analyses 
1H NMR spectra obtained from urine and plasma were automatically phased and 
baseline-corrected, using an in-house developed MATLAB script (Dr. Ebbels, Imperial 
College London). Urine spectra were referenced to the TSP resonance at 61H 0.00, 
whereas plasma spectra were referenced to the anomeric proton signal from a-glucose at 
51H 5.22. Each complete spectrum (51H 0-10.0) was each digitised into 40,000 data 
points using another in-house developed MATLAB script (Dr. Cloarec, Imperial 
College London). The regions between 5 1H 4.20 and 6.24 in urine spectra, and between 
5 1H 4.50 and 5.10 in plasma spectra were removed in order to minimise the effect of the 
remaining baseline distortion caused by imperfect water suppression. In addition, the 
regions 61H 0.0-0.85 and 51H 8.5-10.0 in urine spectra, and the regions 5 1H 0.0-0.8 and 
5 1 H 8.5-10.0 in plasma spectra containing only noise were also removed. 
For each spectrum, normalisation to the entire remaining spectrum was performed prior 
to conducting multivariate data analyses. PCA was employed to gain an overview of the 
1H NMR spectral data operating in the SIMCA-P-1-11.5 software, followed by an 0-
PLS-DA in a MATLAB environment using in-house developed scripts. This latter 
method employed back-scaled transformation of the variables to the covariance matrix 
in order to facilitate interpretation of the results. 
3.4 Results 
There are two ways to express the results of this study. One is via horizontal comparison 
that is to compare P. berghei-infected mice with non-infected ones (parallel controls) at 
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the same sampling time point. The other method is a vertical comparison, which is to 
compare the same mice post-infection with pre-infection, i.e. each mouse acts as its own 
control. This mouse-P. berghei model was performed on adult mice and only lasted 4 
days, thus aging-induced variation can be ignored. Here, all results shown below are 
from the latter comparison strategy using each individual as its own control. 
3.4.1 Physiological responses of mice to a P. berghei infection 
Table 3-1 shows the mean of PCV ratios, parasitaemia and body weights of 12 female 
NMRI out-bred mice 4-6 hours prior to, and at 1, 2, 3 and 4 days after an infection of 
-20 million P. berghei-infected erythrocytes each. The average value of PCV ratios 
decreased from 55% prior to infection to 33% on day 4 post-infection. Using a t-test 
allowing for unequal variance revealed that the difference between the average PCV 
values pre-infection and post-infection was significant at day 1 post-infection (p < 0.05) 
and became more significant at day 3 and 4 post-infection (p < 0.01). Parasitaemia 
increased significantly from day 1 to day 4 post-infection, reaching a mean value of 
34.4% at the final observation data point, 4 days post-infection. The mean body weight 
of mice remained constant over the whole course of the experiment. 
Table 3-1 Mean PCV, parasitaemia and body weight of 12 female NMRI out-bred mice 
prior to, and at 1, 2, 3 and 4 days after the infection with approximately 20 million P. 
berghei-infected erythrocytes. * indicates p<0.05; ** indicates p<0.01 
Time Mean (SD) point 
PCV in % Parasitaemia in % Body weight in g 
4 to 6-h pre-infection 55 (4) — 23.8 (1.2) 
day 1 post-infection 49 (3)* 0.4 (0.1) 23.5 (1.5) 
day 2 post-infection 47 (4)* 4.1 (0.2) 23.9 (1.6) 
day 3 post-infection 44 (4)** 16.3 (2.0) 23.9 (1.7) 
day 4 post-infection 33 (3)** 34.4 (5.2) 23.9 (1.6) 
3.4.2 Histological interpretation of tissue samples from infected animals 
Histological examination of the spleen obtained from P. berghei-infected mice on day 4 
post-infection showed signs of a response to a systemic infection. In particular, there 
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was an impressive reactive follicular hyperplasia of white pulp nodules that was 
accompanied by red pulp congestion with abundant haemozoin in cordal macrophages 
in all infected animals (Figure 3-3). Cellular architecture in both liver and kidney 
appeared normal, although there was a tendency towards a higher quantity of tubular 
cell damage in the kidney in comparison with the control. 
Figure 3-3 Section of a spleen obtained from a P. berghei-infected mouse 4 days post-
infection showing a marked reactive follicular hyperplasia with large, nearly confluent 
germinal centres consisting of centroblasts and immunoblasts (A, arrow-a). In addition, 
there was red pulp congestion with abundant haemozoin in cordal macrophages (A, 
arrow-b). For comparison, a section of a spleen from a healthy control mouse (same strain, 
age- and sex-matched) is shown in B. Note the small non-stimulated primary follicle and 
the lack of malarial haemozoin pigment. All tissue samples were stained with 
haematoxylin and eosin; and magnifications for images A and B were 100x and 200x, 
respectively. 
3.4.3 1H NMR spectroscopy of mouse urine 
Typical 'H NMR spectra of urine obtained from mice 4-6 hours pre-infection, and 4 
days post-infection with P. berghei are shown in Figures 3-4 A and B, respectively. 
Metabolites identified from urine of both pre- and post-infected mice included 3-
methyl-2-oxovalerate, 2-oxoisocaproate, 3-carboxy-2-methyl-3-oxopropanamine, 2-
oxoisovalerate, lactate, lysine, acetate, 3-ureidopropionate, citrate, succinate, 
dimethylamine, trimethylamine, 2-oxoglutarate, creatine, creatinine, trimethylamine-N-
oxide (TMAO), taurine, cytosine, phenylacetylglycine (PAG), pyruvate, p-cresol 
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glucuronide and formate. Metabolite identification was assisted by our in-house 
database, together with the aid of 2-D 1H-1H COSY and 1H-1H TOCSY experiments 
(Figure 3-5). The identified metabolite resonances together with the chemical shift and 
multiplicity are summarised in Table 3-2. 
In addition to the metabolites observed in the spectra obtained both the pre- and post-
infection, pipecolic acid was identified only in urine samples derived from mice at later 
stage (e.g. 3 and 4 days post-infection) of infection with P. berghei. Resonances of 
pipecolic acid occur in the aliphatic regions and overlap with signals from many other 
metabolites, such as triplet signal of lysine at 81H 3.03 and multiplets from 2-isovalerate 
at 61H 3.02. However, the 2-D 1H-1H TOCSY spectrum shown in Figure 3-5 presents 
obvious cross peaks of pipecolic acid. The 1-D STOCSY method was also used to 
establish the correlated peaks from pipecolic acid and the signal at 81H 1.66 was chosen 
as a driver peak on which to perform STOCSY (Figure 3-6 A). Peaks at 81H 1.86, 3.03, 
and 3.6 showed a relatively strong correlation with the driver peak, but due to the heavy 
overlapping and the low intensity of signals, resonances at 81H 2.2 and 3.4 (Figure 3-6 
A*) did not present a significant correlation with the driver peak. To further confirm the 
identity of this metabolite, a 1H NMR spectrum was acquired from the standard 
pipecolic acid purchased from SIGMA (Figure 3-6 B) and the standard pipecolic acid-
spiked urine sample obtained at 4 days post-infection (Figure 3-6 C red). In Figure 3-6 
C, the blue spectrum was obtained from the urine sample before spiking and the red one 
was derived after spiking. It is obvious that the intensity of all resonances from 
pipecolic acid increased and the patterns of these peaks are matched, thereby confirming 
the presence of pipecolic acid in the urine of infected mice. 
In order to focus on the dynamic metabolite changes as the infection progressed, an 0-
PLS-DA strategy was applied to these urinary spectra to extract further potential 
biomarkers of the infection. 
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a urine sample of an infected mouse. Key: CMOPA: 3-carboxy-2-methyl-3-
oxopropanamine; DMA: dimethylamine; Lys: lysine; MOV: 3-methyl-2-oxovalerate; OGT: 
2-oxoglutarate; OIC: 2-oxoisocaproate; OIV: 2-oxoisovalerate; PA: pipecolic acid; PAG: 
phenylacetylglycine; Tau: taurine; Thr: threonine; UPA: 3-ureidopropionate. 
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Figure 3-6 Identification of pipecolic acid using 1-D STOCSY (A) where the arrowed 
signal at 81H 1.66 played as a driver peak and spiking (C) where the 1H NMR spectrum in 
blue was obtained from a pre-spiked urine sample and the one in red was from the same 
sample post-spiking. (B) is the standard pipecolic acid spectrum. * Due to heavy overlap in 
some spectra, these peaks did not show the correlation. 
78 
Chapter 3- Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection 
Table 3-2 Identified metabolites in 'H NMR spectra of urine (u) and plasma (p) 
obtained from mice pre- and post-infection of P. berghei, together with the respective 
chemical shifts and signal multiplicities. *s: singlet; d: doublet; t: triplet; m: multiplet; 
q: quadruplet; dd: double doublet; td: triple doublet; ddd: double double doublet; bs: 
broad signal. 
Metabolites H group 114 (multiplicity*) Biofluids 
2-oxoglutarate 13-CH2; le-CH2 3.01(t); 2.45(t) u 
2-oxoisocaproate 13-CH2; y-CH; 2x CH3  2.61(d); 2.09(m); 0.94(d) u 
2-oxoisovalerate 13-CH; 2x CH3  3.02(m); 1.13(d) 
3-carboxy-2-methyl-3- 
oxopropanamine 13-CH; CH3; le-CH2 
2.49(m); 1.08(d); 3.19(m), 
3.56(m), 3.72(m) 
(3-CH; p-CH3; 7-0-12(i); 2.93(m); 1.1(d); 1.7(m); 
3-methyl-2-oxovalerate y-CH2(ii); y-CH3  1.46(m); 0.9(t) u 
acetate CH3  1.93(s) u/p 
alanine CH; CH3  3.77(q); 1.47(d) p 
a-CH; 13-CH2; 7-CH2; 3.76(t); 1.92(m); 1.65(m); 
arginine 8-CH2 3 24(t) p 
choline N-(CH3)3; a-CH2; 13-CH2 3.20(s); 4.07(m); 3.52(m) p 
citrate CH2(i); CH2(ii) 2.66(d); 2.54(d) u/p 
creatine N-CH3; CH2 3.03(s); 3.92(s) u/p 
creatinine N-CH3; CH2 3.03(s); 4.05(s) 
cytosine 5-CH; 6-CH 6.01(d); 7.50(d) 
a-CH2(i); a-CH2(ii); 2.41(dd); 2.31(dd); 4.16(m); 
D-3-hydroxybutyrate 13-CH; CH3  1.2(d) 
dimethylamine 2x CH3  2.71(s) 
formate CH 8.46(s) 
glycerophosphoryl N-(CH3)3; a-CH2; (3-CH2; 3.22(s); 4.32(t); 3.68(t); 
choline a'-CH2; 13'-CH; 7'-CH2 3.61(dd); 3.90(m); 3.72(dd) p 
a-CH; 13-CH; 13-CH3; 3.68(d); 1.98(m); 
y-CH2(i); y-CH2(ii); 1.02(d);1.25(m),1.47(m); 
isoleucine y-CH3  0.94(t) p 
lactate a-CH; 13-CH3  4.11(q);1.32(d) u/p 
a-CH; 13-CH2; y-CH; 3.72(t); 1.74(m); 1.70(m); 
leucine 2x CH3  0.96(t) p 
lipid fraction CH2CH2C=O 1.57(bs) p 
lipid fraction CH2C=C 2.0(bs) p 
lipid fraction CH2C=O 2.22(bs) p 
lipid fraction C=CCH2C=C 2.75(bs) p 
lipid fraction CH=CH 5.30(bs) p 
lipid fraction CH3(CH2). 0.83(bs) p 
lipid fraction (CH2)11 1.22(bs) p 
a-CH; 13-CH2; 7-CH2; 3.78(t); 1.92(m); 1.72(m); 
lysine 8-CH2; c-CH2 1.47(m); 3.03(t) 
p-cresol glucuronide 2,6-CH; 3,5-CH; CH3; 7.06(d); 7.23(d); 2.3(s) u 
p-hydroxyphenylacetate 2,6-CH; 3,5-CH; CH2; 7.16(d); 6.89(d); 3.45(s) u 
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continue Table 3-2 
p-hydroxyphenyllactate 
phenylacetylglycine 
pipecolic acid 
pyruvate 
succinate 
taurine 
trimethylamine 
trimethylamine N-oxide 
3-ureidopropionic acid 
valine 
a-glucose 
13-glucose 
unknown 1 
unknown 2 
unknown 3  
2,6-CH; 3,5-CH; CH; 
CH2(i); CH2(ii) 
3,5-CH; 2,4,6-CH; 
Ar-CH2; N-CH2 
2-CH; 6-CH; 3-CH; 
5-CH; 4,5-CH; 3,4,5-CH 
CH3  
2x CH2 
N-CH2; S03-CH2 
3x CH3  
3x CH3  
a-CH2; 13-CH2 
a-CH; I3-CH; y-CH3; 
y'-CH3  
1-H; 2-H; 341; 4-H; 5-H; 
CH2(i); CH2(ii) 
1-H; 2-H; 3-H; 4-H; 5-H; 
CH2(i); CH2(ii) 
7.18(d); 6.87(d); 4.21(q); 
2.81(dd);3.02(dd) 
7.43 (m); 7.37 (m); 3.75 (d); 
3.68 (s) 
3.57(dd); 3.40(d); 2.21(m); 
3.02(td); 1.86(m); 1.63(m) 
2.36(s) 
2.41(s) 
3.43(t); 3.27(t) 
2.89(s) 
3.28(s) 
2.38(t); 3.31(t) 
3.62(d); 2.28(m); 0.99(d); 
1.04(d) 
5.22(d); 3.54(dd); 3.71(t); 
3.42(t); 3.83(ddd); 3.84(m); 
3.76(m) 
4.65(d); 3.24(dd); 3.48(t); 
3.40(t); 3.47(ddd); 3.72(dd); 
3.90(dd) 
1.20(d), 3.67, 4.05, 
1.26 (d), 3.81 
6.27(d), 6.30(d) 
u 
u/p 
u 
u 
u 
3.4.4 Multivariate statistical analyses of 1H NMR spectra of mouse urine 
In order to distinguish the metabolic features separating the post-infected group from 
the pre-infected control group, an O-PLS-DA method was applied to build models using 
NMR spectral data as the X matrix and class information (e.g., pre- or post-infection) as 
the dummy Y matrix. For each sample collection time point, an O-PLS-DA model was 
constructed based on the unit variance-scaled spectral data using one PLS component 
and one orthogonal component (Figure 3-7). The colour of the variables or signals in the 
O-PLS -DA coefficient plots indicates significance of metabolites contributing to the 
class separation, for example, between pre- and post-infection time points. The 
significance level increases from blue (no correlation with class) to red (highly 
correlated with discrimination between classes), which is shown in the colour bar on the 
right-hand side of the O-PLS-DA coefficient plots (Figure 3-7). The orientation of 
peaks in the plot reflects the trend of changes in metabolites; upward orientation 
representing a relatively higher level of metabolite at the post-infection time point 
compared with the pre-infection and vice versa. 
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Table 3-3 lists the main metabolites contributing to the separation of urinary 1H NMR 
spectra of pre-infected mice from the post-infected ones, and R2X (goodness of fit) and 
Q2Y (goodness of prediction) values of models are given for each post-infection 
collection time point. The increasing strength of the Q2Y model values over time from 
days 2 to 4 post-infection corresponds to an increase in severity of infection, 
underscored by the declining PCV, and the elevated parasitaemia levels. During the first 
2 days of the infection, concentrations of urinary 2-oxoisocaproate, 2-oxoisovalerate, 3-
methyl-2-oxovalerate, phenylacetylglycine, creatinine, acetate and formate showed 
higher levels in the post-infected mice in comparison to the pre-infection time point. 
Additionally, increased levels of phenylacetylglycine and dimethylamine and decreased 
levels of trimethylamine-N-oxide and taurine were observed in urine collected from 
P. berghei-infected mice at later time points (e.g. on day 3 and 4), when compared with 
pre-infection. Pipecolic acid was found to be one of the most discriminatory metabolite 
and was only present at detectable levels in the P. berghei-infected urine samples on 
days 3 and 4 post-infection. 
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Figure 3-7 O-PLS-DA coefficient plots derived from 'H NMR spectra of urine individually 
collected from mice prior to a P. berghei infection and 1 (A), 2 (B), 3 (C) and 4 (D) days 
post-infection, illustrating the metabolic discrimination between the pre- and post-
infection stages. Key: DMA: dimethylamine; MOV: 3-methyl-2-oxovalerate; OIV: 2-
oxoisovalerate; PA: pipecolic acid; PAG: phenylacetylglycine; Tau: taurine; TMAO: 
trimethylamine-N-oxide; UN: unknown. 
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Table 3-3 Discriminatory metabolites observed in O-PLS-DA models derived from urine 
samples of mice at different time points after infection with P. berghei, compared with 
pre-infection time point. `+' represents increased concentrations of metabolites in the 
post-infected mice, whilst `-' represents decreased concentrations of metabolites in the 
post-infected mice. 'I' represents no change observed. 
Importance of contribution at different time points post-infection 
Metabolite Day 1 Day 2 Day 3 Day 4 
(Q2Y=0.25; (Q2Y =0.23; (Q2Y =0.45; (Q2Y =0.57; 
R2X=0.27) R2X=0.22) R2X=0.31) R2X=0.35) 
2-oxoisocaproate +0.565 / / / 
2-oxoisovalerate +0.679 / / 
3-methyl-2-oxovalerate +0.671 / / / 
creatinine +0.580 / +0.663 / 
acetate +0.616 +0.564 / / 
dimethylamine / / +0.652 +0.583 
trimethylamine-N-oxide / / -0.705 -0.576 
phenylacetylglycine +0.696 / / +0.661 
taurine / / / -0.576 
formate +0.637 / / / 
pipecolic acid / / +0.766 +0.783 
unknown 1 / / +0.904 +0.850 
unknown 2 / / +0.916 +0.759 
unknown 3 / / +0.941 +0.901 
3.4.5 Standard 1-D 11-1 NMR spectroscopy of mouse plasma 
Two typical 1-D standard 1H NMR spectra from a mouse at pre-infection and 4 days 
post a P. berghei infection are shown in Figures 3-8 A and B. Glucose, lactate, choline, 
glycerophosphorylcholine (GPC) and a rage of amino acids including alanine, leucine, 
isoleucine, together with lipid fractions were assigned based on an in-house database 
and literature (Nicholson et al., 1995). All the resonances detected including the 
chemical shift and multiplicity are summarised in Table 3-2. 
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Figure 3-8 Standard 1-D 600 MHz 1H NMR spectra of plasma samples collected from a 
mouse at pre-infection (A) and 4 days after a P. berghei infection (B). Key: Ala: alanine; 
Arg: arginine; GPC: glycerophosphorylcholine; HB: D-3-hydroxybutyrate; Hem isoleucine; 
Leu: leucine; Lys: lysine; Val: valine. 
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3.4.6 Multivariate statistical analyses of standard 1-D 1H NMR spectroscopy of 
mouse plasma 
The standard 1-D 1H NMR spectra of blood plasma were first modelled by PCA using 
mean-centred data using SIMCA software. A total of two components were calculated 
for each model and percentages of variance explained by the model are listed in Table 
3-4. The PCA scores plots (Figure 3-9) demonstrated that the separations between the 
pre-infected and post-infected groups were more evident as the infection progressed as 
expected. One outlier was detected in each of these plots (Figure 3-9: 1A, 2A and 2B) 
and was found to be from the same sample (D4T1), which contained more lactate than 
other samples from pre-infected mice. All the model parameters of PCA scores plots are 
listed in Table 3-4. Following PCA, a PLS-DA calculation was performed on the mean-
centred data set and one PLS component and one orthogonal component were calculated. 
The separation between the uninfected and infected classes was clearer than that 
observed with PCA. As with the models of the urine data, the predictivity (Q2Y) values 
generated from day 3 and day 4 post-infection were much higher than those generated 
from day 1 and day 2 post-infection. Levels of glucose and lipids were decreased in the 
infected class whilst levels of lactate appeared to increase compared with the uninfected 
class according to loading plots. These changes in metabolite concentration exerted the 
strongest influence on the clustering of the two classes as seen in the both the PCA and 
PLS-DA scores plots. 
Table 3-4. The corresponding values of evaluation parameters in PCA and PLS-DA plots 
of standard 1-D NMR spectra of plasma. *PC1: the first principal component. 
Figure PCA Figure PLS-DA 
R2X(PC1*) R2X(PC2) Q2X R2X(PC1) R2X(PC2) Q2Y 
1(A) 60.9% 13.5% 53% 1(B) 45.9% 25.3% 34% 
2(A) 55.2% 21.0% 68% 2(B) 49.1% 24.0% 36% 
3(A) 71.3% 16.3% 85% 3(B) 71.3% 3.8% 63% 
4(A) 49.8% 31.4% 72.9% 4(B) 49.5% 21.3% 66.8% 
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Figure 3-9 1(A), 2(A), 3(A) and 4(A) illustrated PCA scores plots derived from standard 
1H NMR spectra of plasma collected from pre-infected (black) and 1 (blue), 2 (green), 3 
(orange), 4 (red) days post-infected mice, respectively. 1(B), 2(B), 3(B) and 4(B) are the 
corresponding PLS-DA scores plots. 
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3.4.7 1-D 1H NMR CPMG spectra of mouse plasma 
Selected 1-D 1H NMR CPMG spectra of plasma samples obtained from mice 4 to 6-h 
before and 4 days after infection with P. berghei are shown in Figure 3-10. This 
experiment results in the attenuation of signals from fast relaxing protons from 
macromolecules and motionally constrained metabolites due to protein binding 
(Nicholson and Wilson, 1989). A number of low molecular weight metabolites, such as 
leucine, valine, lactate, alanine, acetate, pyruvate, citrate, creatine, choline, 
glycerophosphorylcholine, lysine, arginine and glucose were identified in these plasma 
spectra and are summarised in Table 3-2. 
3.4.8 Multivariate statistical analyses of 111 NMR CPMG spectra of mouse plasma 
PCA and PLS-DA analyses were performed on 1H NMR CPMG spectra of mouse 
plasma and they showed the same class separation as 1H standard spectra. Hence, in 
order to prevent redundancy of information, this section mainly demonstrates O-PLS-
DA analysis. O-PLS-DA models were constructed based on one PLS component and 
one orthogonal component using mean centred data with unit variance scaling applied to 
the 1H NMR CPMG plasma spectra. Resonances pointing upwards indicate the 
increased concentration of metabolites in the infected mice. The discrimination between 
mouse plasma samples obtained pre- and post- P. berghei infection was evident, 
especially on days 3 and 4 post-infection with Q2Y values of 0.76 and 0.64, respectively 
(Figure 3-11). The coefficient plots showed that the increase of the relative 
concentration of lactate became more significant from day 2 after P. berghei infection 
onwards, whereas glucose levels decreased at days 3 and 4 post-infection, together with 
decreased levels of creatine and glycerophosphorylcholine. Plasma metabolites that 
significantly contributed to class discrimination between pre- and post-infection time 
points are summarised in Table 3-5. 
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A 	 glucose 
Figure 3-10 Typical 600 MHz 'H CPMG NMR spectra of plasma samples collected from a 
mouse at pre-infection (A) and 4 days after a P. berghei infection (B). Key: Ala: alanine; 
Arg: arginine; GPC: glycerophosphorylcholine; HB: D-3-hydroxybutyrate; Hem isoleucine; 
Leu: leucine; Lys: lysine; Val: valine. 
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4.0 	3.5 	3.0 	2.5 	2.0 	1.5 	1.0 81H 
Figure 3-11 O-PLS-DA coefficient plots derived from 'H NMR CPMG spectra of plasma 
obtained 4-6 hours pre-infection and at days 1 (A), 2 (B), 3 (C) and 4 (D) post-infection 
reflecting the metabolic fingerprint of a P. berghei infection and changes over time as the 
disease progressed. Key: GPC: glycerophosphorylcholine. 
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Table 3-5 Changes in metabolite levels observed in plasma obtained from mice at 
different time points after infection with P. berghei, compared with pre-infection time 
point. `+' represents increased concentrations of metabolites in the infected mice, whilst 
`—' represents decreased concentrations of metabolites in the infected mice. '/' represents 
no change observed. 
Importance of contribution at different time points post-infection 
Metabolite (key) Day 1 Day 2 Day 3 Day 4 
(Q2Y=0.45; (Q2Y =0.35; ( Q2Y =0.76; ( Q2Y =0.64; 
R2X=0.24) R2X=0.29) R2X=0.33) R2X=0.31) 
acetate -0.661 -0.622 -0.550 -0.654 
creatine 
glycerophosphoryl 
choline 
-0.619 
+0.718 
I 
-0.613 
-0.686 
-0.758 
-0.733 
-0.795 
lactate I +0.728 +0.738 +0.706 
pyruvate I +0.682 +0.772 +0.853 
citrate I +0.651 
a-glucose -0.724 -0.674 
3.5 Discussion 
This study demonstrated the application of 1H NMR spectroscopy-based metabolic 
profiling in characterisation of the host response to a protozoan infection, P. berghei. A 
range of systematic metabolic perturbations in the urine and plasma of the mouse 
infected with P. berghei were detected as early as 1 day post-infection and these 
changes were enhanced by the progressive infection severity. The metabolic changes 
observed in both urine and plasma samples will be discussed according to the following 
four aspects of metabolism: physiological variation, host energy metabolism, pipecolic 
acid metabolism and host microbial metabolism. 
3.5.1 Effects of physiological variations on metabolic profiles 
Physiological variations due to environmental factors such as age, diet and stress can 
give rise to the biochemical perturbation in biofluid composition, thus investigations 
into drug intervention and disease should take these factors into account. In the current 
study, all animals were acclimatised for a week in order to minimise the environment-
induced variation. At the beginning of the experiment, all mice were relatively mature 
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(— 4 weeks old) and were expected to have relatively stable metabolic status. Since the 
entire rodent model experiment only lasted 6 days, it is highly unlikely that aging 
exerted a major impact on metabolic profiles, even though all pairwise comparisons 
were performed based on pre- and post-infection. Additionally, there was no metabolic 
difference observed in urine and plasma from the non-infected control group between a 
1 and D4. During the course of the experiment, food was kept consistent and the weight 
of both control and infected animals was maintained over the duration of the study. 
Animal manipulation and the infection of P. berghei by injecting erythrocytes per se 
could cause stress. However, due to ethical consideration, the control animals were not 
given a sham injection of non-infected erythrocytes. With regard to previous studies on 
acute stress (Teague et al., 2007; Wang et al., 2007b), the metabolic changes observed 
in this study were not consistent with their findings that increased levels of glucose and 
ketone bodies including D-3-hydroxybutyrate and acetone, and decreased levels of 
lactate, leucine, alanine, acetate and isoleucine in the plasma samples following acute 
stress. Therefore, the findings of the current study are almost certainly associated with a 
direct metabolic response of mice to the P. berghei infection rather than being indicative 
of general stress. 
3.5.2 Effects of P. berghei infection on host energy metabolism 
Glycolysis is believed to be an important energy-generating pathway for the mammalian 
malaria parasite (Homewood, 1977). In this study, a decrease in the concentration of 
glucose and an increase in lactate and pyruvate levels on days 2-4 post-infection were 
observed in the plasma samples when compared with the pre-infection time point, 
which indicates an upregulation of glycolysis. This is consistent with previous in vitro 
studies where it was found that P. berghei- or P. falciparum-parasitised erythrocytes 
consume higher amounts of glucose compared to normal erythrocytes (Kruckeberg et al., 
1981; Roth et al., 1988). Kruckeberg et al. reported that the higher glycolytic enzyme 
activities in the P. berghei-infected erythrocytes of mice were observed and the unique 
electrophoretic forms of these glycolysis-related enzymes including phosphoglycerate 
mutase, enolase, aldolase and pyruvate kinase only appear in the parasite-infected 
erythrocytes rather than in control erythrocytes, which indicates that these enzymes are 
derived from the parasite and the parasite could synthesise several enzymes for its own 
benefit (Kruckeberg et al., 1981). Moreover, P. falciparum ATP levels were found 
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greatly dependent on glucose transport but not on mitochondrial activity, together with 
increased turnover of glucose in the infected erythrocytes observed in vitro and in vivo, 
which suggests that malaria parasites require glucose from the host and produce energy 
primarily via anaerobic glycolysis at the intraerythrocytic asexual stage (Lang-Unnasch 
et al., 1998; Mehta et al., 2005). Another in vitro study using [2-13C] glucose labelling 
and NMR spectroscopy also described that the P. falciparum-infected erythrocytes 
inhibit glucose utilisation of uninfected erythrocytes (Mehta et al., 2005). In a recent 
study, Daily et al. characterised significant changes of the expression profiles of malaria 
parasites obtained from the blood of humans infected with P. falciparum (Daily et al., 
2007). Three distinct transcriptional states of the parasite were discussed, namely (i) 
growth with glycolysis-provided energy, (ii) a starvation response of the parasite, and 
(iii) an environmental stress response. Observation of the first stage conforms to the 
perturbations of energy-related metabolites observed in the current study. Anaerobic 
glycolysis results in the accumulation of pyruvate and lactate. Pyruvate is metabolised 
from phosphoenolpyruvate under the catalysis of pyruvate kinase (PK), releasing ATP. 
PK deficiency was found to protect against malaria in a mouse model of an infection 
with P. chabaudi and in humans infected with P. falciparum, even though the 
mechanisms of effect of PK deficiency on Plasmodium replication capability remain 
unknown (Min-Oo et al., 2003; Ayi et al., 2008). High levels of lactate observed in P. 
berghei-infected mice could lead to lactic acidosis, which has been identified as a 
significant biochemical predictor of death in patients with severe P. falciparum malaria 
(Krishna et al., 1994; Agbenyega et al., 2000; Ehrhardt et al., 2005). 
The concentration of glycerophosphorylcholine in plasma was found to be lower in 
P. berghei-infected mice at days 2-4 post-infection than at pre-infection. A report 
showed that GPC in the adult filarial parasite Brugia malayi is important for nutrient 
acquisition (Shukla-Dave et al., 1999). GPC is a precursor of free choline and it could 
break down to provide free choline to Plasmodium parasites since choline, as a 
phospholipid precursor, can be transported into Plasmodium parasite through its plasma 
membrane, phosphorylated by choline kinase and kept within the parasite (Kirk et al., 
1994; Lehane et al., 2004). It has been previously reported that P. vinckei vinckei-
infected erythrocytes from mice and P. falciparum-infected erythrocytes from human 
take up higher amount of free choline than uninfected erythrocytes do and that this 
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uptake of choline is of importance in the synthesis of phosphatidylcholine (Staines and 
Kirk, 1998; Lehane et al., 2004). A depletion of plasma creatine was observed in post-
infected mice and this finding might be related to the elevated concentration of serum 
creatine phosphokinase, which is one of the biological indications of severe malaria 
(Saissy et al., 1994). 
3.5.3 Pipecolic acid in urine from P. berghei-infected mice 
The elevated concentration of pipecolic acid in urine from P. berghei-infected mice was 
detected, for the first time, in a parasitic infection using a metabolic profiling strategy. 
Pipecolic acid originates from either a pipecolic acid-containing diet such as beans 
(43.81 mg/kg) and broccoli (13.56 mg/kg) where most of the pipecolic acid is present as 
the L-isomer, or via catabolism of lysine by intestinal microbiota as depicted in Figure 
3-12. With regard to the origin of pipecolic acid in mammalian urine and plasma, Fujita 
et al. found that pipecolic acid is mainly derived from lysine degradation rather than 
food intake, especially the D-isomer (Fujita et al., 1999). In the current study, all 
animals were fed on the same diet and maintained under the same environmental 
conditions, and thus food intake seems unlikely to be linked to the increased level of 
pipecolic acid. 
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Figure 3-12 Biosynthesis of pipecolic acid from lysine. 
Increased levels of pipecolic acid in plasma, urine and/or cerebrospinal fluid have also 
been recorded in patients with pyridoxine-dependent epilepsy, Dyggve-Melchior-
Clausen syndrome, chronic liver disease, and Zellweger syndrome (Danks et al., 1975; 
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Kawasaki et al., 1988; Roesel et al., 1991; Matsuda et al., 2000; Plecko et al., 2000). 
Pipecolic acid is known to act as a neuromodulator in the central nervous system, since 
it has been found to inhibit the initial uptake of gamma-aminobutyric acid (GABA), an 
inhibitory neurotransmitter, and to increase a high K+-induced release of GABA 
(Nomura et al., 1981). The biological function of the elevated level of pipecolic acid in 
mouse urine with a P. berghei infection remains unclear due to the fact that disturbance 
of the intestinal microbial community, liver dysfunction and neurological damage are all 
consequences of the malaria infection. 
3.5.4 Effects of P. berghei infection on microbial metabolism 
Altered concentrations of dimethylamine and trimethylamine-N-oxide (TMAO) were 
found in the urine samples of infected mice at days 3 and 4 post-infection. The 
increased dimethylamine and TMAO in urine from methanol intoxicated patients were 
believed to indicate moderate renal cortical damage (Janus et al., 2005). As severe 
malaria is known to cause renal failure (Day et al., 1999) and disturbed levels of 
dimethylamine and TMAO were observed at days 3 and 4 post-infection, it may suggest 
renal dysfunction in the P. berghei-infected mice. However, histological examination of 
kidney collected from P. berghei-infected mice on termination of the experiment 
presented no clear evidence of pathological damage. Thus it is more likely that altered 
excretion of dimethylamine and TMAO, which derive from choline metabolism, 
indicate a disturbance of the gut microbiota (Dumas et al., 2006). In addition, 
phenylacetylglycine and acetate showed marked increases in urine samples obtained 
from post-infected mice. These metabolites are also known to be associated with gut 
microbiota (Wang et al., 2004). Therefore, the varied excretion of phenylacetylglycine, 
acetate, dimethylamine and TMAO observed in the current study may have been caused 
by the disturbance of microbial activities by the P. berghei infection. One of the clinical 
symptoms of malaria is high fever, which may be responsible for the change of gut 
microbiota. However, little is known about the association between body temperature 
and gut flora composition and/or activities. Kluger et al. reported the gut flora in itself 
has an effect on body temperature of rats and mice but also showed that decreased body 
temperature in germ-free mice was not correlated with microbial activities (Kluger et al., 
1990). However, it is still not clear whether high body temperature alters disturbance of 
the gut microbial ecosystem. 
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Figure 3-13 Schematic representation of the putative interpretation of metabolic 
observations in the plasma and urine from P. berghei-infected mice. Key: CPK: creatine 
phosphokinase; DMA: dimethylamine; PAG: phenylacetylglycine; TMA: trimethylamine; 
TMAO: trimethylamine-N-oxide. 
3.5.5 Comparisons of P. berghei with other protozoan infections 
Changes in the urinary and plasma metabolic profiles of mice infected with a P. berghei 
infection were characterised and reflect a global change in metabolic regulation and 
homeostasis (Figure 3-13). 
This NMR-based metabolic profiling approach has been employed to investigate the 
dynamic responses of female NMRI mice to a single Trypanosoma brucei brucei 
infection (Wang et al., 2008a) and T. brucei brucei 2 strains co-infection (urinary 
spectral data available but unpublished). The changes in energy metabolism-related 
metabolites indicating induced by T brucei brucei an upregulation of glycol ysis were 
found to be similar to those observed with P. berghei. However, the perturbations of 
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observed amino acids in plasma were different with an increased level of creatine in 
T. brucei brucei, and a decreased level in P. berghei. Although both Plasmodium and 
Trypanosoma are protozoan parasites, Plasmodium is intracellular while Trypanosoma 
is intercellular, which could explain the different pattern in the perturbation of amino 
acids observed in plasma. Elevated levels of O-acetylglycoprotein fragments were 
found in the plasma from T. brucei brucei-infected mice, which are believed to be 
associated with immunological or inflammatory responses. All perturbed urinary 
changes observed in these 3 protozoan parasite-mouse models are summarised in Table 
3-6. It is clearly noted that the pattern of host metabolic changes characteristic of a P. 
berghei infection is discriminated from that of a T. brucei brucei infection and co-
infection, particularly by pipecolic acid, which is unique to the P. berghei infection. 
Several urinary changes in T. brucei brucei infection and the 2-strain co-infection model 
are highly similar except for 4-hydroxyphenylpyruvate and phenylpyruvate which were 
only found in the latter T. brucei brucei experiment. These two metabolites are known 
to be derived from the parasite; however, due to the parasitaemia and the strains of the 
parasites were different, it is difficult to conclude that these observations could be 
related to the strains of the parasite and/or parasitaemia. Although disturbance of 
microbiota-related metabolites was induced in both protozoan infections, these 
metabolites are different. For example, DMA, PAG and TMAO were found in the P. 
berghei-mouse model, while 4-hydroxyphenylacetic acid, hippurate and TMA were 
observed in the T. brucei brucei-mouse model. Although the mice used in all models 
were mature, strain and sex matched, and from the same source, the urinary metabolite 
profiles of control animals varied greatly according to batch. For example, there was no 
hippurate detected in urine from mice involved in the P. berghei infection model. Hence, 
due to the diversity of metabolic signatures in this out-bred strain of NMRI mice it is 
inappropriate to compare these microbiota-associated metabolites across the models and 
the natural batch to batch variation in urinary metabolites requires further attention 
beyond the scope of this current thesis. Pipecolic acid was only observed in the P. 
berghei-infected mice, which appears to be unique to the infection but further work is 
required to characterise its origin. 
Integrating the findings in these different mouse-protozoa models, although they share 
some similarities such as energy metabolism, each protozoan infection also holds its 
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unique metabolic fingerprint. Hopefully these specific patterns of metabolic changes 
can be used as potential biomarkers in disease diagnosis. 
Table 3-6 Summary of urinary metabolite perturbation observed in P. berghei-mouse, T. 
brucei brucei-mouse (Wang et al., 2008a), T. brucei brucei 2 strains (R and G) co-
infection (Appendix IX)-mouse models. T  represents a higher concentration of the 
metabolite in infected animals and represents a lower concentration of the metabolite 
in infected animals. 
Models 
Metabolite 
P. berghei- 
mouse 
T. brucei 
brucei- 
mouse 
T. brucei brucei 2 strains-mouse 
Pre- 
infection vs. 
4 days post- 
infection 
Control vs. 
28 days 
post- 
infection 
Control 	Control 	Control 	Control 
vs. G 	vs. R 	vs. vs. 
strain 	strain 	R7G5 	R7G7 
RX =0.35 
Q2Y =0.57 
RX =0.90 
Q2Y =0.86 
RX 	RX 	RX 	R2X 
=0.78 	=0.80 	=0.83 	=0.75 
Q2y Q2y Q2y Q2y 
=0.87 	=0.95 	=0.95 	=0.95 
3-methyl-2-oxovalerate 
methylcrotonate 
hippurate 
4-h ydroxyphenylp yruvate 
phenylpyruvate 
4-hydroxyphenylacetate 
3-carboxy-2-methyl-3- 
oxopropanamine 
2-oxoisovalerate 
2-oxoglutarate 
N-methylnicotinamide 
D-3-hydroxybutyrate 
lactate 
pyruvate 
trimethylamine 
tryptophan 
dimethylamine 
trimethylamine-N-oxide 
phenylacetylglycine 
pipecolic acid 
taurine 
_ 
- 
_ 
- 
- 
- 
- 
- 
- 
- 
- 
T 
l. 
T 
T 
l. 
T 
l. 
I 
- 
T 
T 
T 
- 
_ 
T 
T 
- 
T 
T 
- 
- 
- 
- 
- 
- 	T 	T 
- 	l. 	l. 
I 	l. 	l. 
T 	1' 	T 	T 
T 	T 	T 	T 
T 	T 	1' 	T 
T 	T 
T 
- 	 _ 
_ 
_ 	 T 
- 	- 
- _ 	_ 
- 	 _ 
- 
- 	- 	- 	_ 
- 	- 	- 	_ 
_ 	- 	- 
- 	- _ 
- 	- 	- 	- 
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3.6 Summary 
This study has presented the extensive metabolic cross-talk among the host (e.g. NMRI 
mouse), the parasite (e.g. P. berghei ANKA strain) and microbial colonisation in vivo 
and demonstrated the potential of a 1H NMR spectroscopy-based metabolic profiling 
strategy in combination with multivariate data analysis. Pipecolic acid was found for the 
first time in the parasitic infection, but its urinary level is relatively low, thus further 
study will explore the potential of mass spectrometry and target other metabolites 
related with pipecolic acid. This NMR-based metabolic profiling strategy holds promise 
for extraction of biomarker information and presents the potential capability to the 
development of a novel, rapid, and non-invasive diagnostic method. Of particular note 
is the observation of pipecolic acid excretion in the infected mice, which thus far (after 
comparison of 7 host-parasite models) is unique to P. berghei. 
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Chapter 4 Chemometric analysis of biofluids from mice 
infected with Schistosoma mansoni 
4.1 Aim 
To characterise S. mansoni infection-induced dynamic changes in the biochemical 
composition of biofluids (urine, plasma and faeces) of the host (NMRI strain mouse) 
using 1H NMR spectroscopy and multivariate data analyses with a view to identifying 
potential biological markers of S. mansoni infection. 
4.2 Introduction to schistosomiasis 
Schistosomiasis, also known as bilharzias, is one of the main neglected tropical diseases 
in the tropics. It affects over 250 million people and is of considerable public health 
significance. Schistosomiasis is caused by blood-dwelling fluke worms of the genus 
Schistosoma, commonly occurring species including S. mansoni, S. japonicum, S. 
haematobium, S. intercalatum and S. mekongi. The former three have the widest 
geographical distributions, and are of particular public health and economic impact 
(Utzinger and Keiser, 2004; King et al., 2005; Steinmann et al., 2006; Gryseels et al., 
2006). An estimated 779 million people are at risk of the infection, and 207 million 
manifest the infection. Schistosomiasis-induced morbidity affects approximately 120 
million people and annual mortality ranges from 15,000 to 280,000, with higher 
infection rates in children than in adults. The annual loss of between 1.7 and 4.5 million 
DALYs is caused by schistosomiasis (Utzinger and Keiser, 2004; King et al., 2005; 
Steinmann et al., 2006; Gryseels et al., 2006). 
4.2.1 Life cycle of Schistosoma spp. 
The life cycle of Schistosoma spp. is shown in Figure 4-1. The cycle starts from the 
fork-tailed cercaria penetrating the skin of the human host, and shedding its tail after the 
penetration, transforming into a schistosomula. The schistosomula burrows into the 
dermis and remains there for several days for further development before migrating to 
lung and liver via the blood vessels. The schistosomula grows into an adult worm in 4-6 
weeks in the portal vein and mates. The adult worms are threadlike, with 10-30 mm in 
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length and 0.2-1.0 mm in diameter (Figure 4-1, 10) and have an anterior and ventral 
sucker, which aid attachment to the vascular wall and movement. The female worm 
permanently stays in the ventral groove of the male worm during the entire lifespan, 
which is typically about 3-5 years but also can live as long as 30 years. Paired worms 
travel, via the portal circulation, to the mesenteric veins of the intestine (Figure 4-1, B) 
where the female lays about 300 eggs per day. These eggs with unique lateral spines 
either travel along with the blood vessel to other sites (e.g. liver, intestine, lung or 
cerebrospinal system) of the host, which cause the inflammatory and granulomatous 
reactions when the eggs are trapped in the tissues, or traverse the endothelium and 
basement membrane of the vessel, the connective tissue and the wall of the small 
intestine using proteases secreted by eggs. However, some studies reported that this 
process could involve an immunological component (Pearce and MacDonald, 2002). 
Eggs reaching the lumen of the small intestine are excreted with faeces by the host, 
which can continue the other phase of the Schistosoma life cycle when the eggs are 
deposited in fresh water containing the appropriate intermediate host, freshwater snails. 
The egg releases the miracidium which swims and seeks the snail host by photo- and 
chemotactic stimuli. When the miracidium penetrates the snail and reaches the 
hepatopancreas, it multiplies asexually into the mother generation of sporocysts and 
then further multiplies into the daughter generation of sporocysts, which hatch a large 
number of cercariae with bifurcated tails. It takes about 4-6 weeks from infection to the 
release of cercaria. The cercaria swims towards the surface of the water and light sites, 
and searches for the skin of the host, where the life cycle completes. The cercaria will 
die if it fails to do so within 72 hours (Despommier and Karapelou, 1987; Gryseels et al., 
2006). 
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Figure 4-1 The life cycle of Schistosoma spp.. 
(Source: http://lamarck.unl.edu/zoo/lifecycles/Schistosoma.gif)  
4.2.2 Clinical symptoms and diagnosis of schistosomiasis 
Schistosomal eggs and not worms are thought to be responsible for the main symptom 
of the disease. The common clinical symptoms of this infection are abdominal pain, 
diarrhoea with or without blood, fever, and fatigue. Eggs deposited in the presinusoidal 
periportal region of the liver can cause inflammatory hepatic schistosomiasis, leading to 
hepatomegaly. In chronic cases, bowel (the lower colon and rectum) and hepatic fibrosis 
can be seen, which result in occlusion of the portal veins, portal hypertension, 
splenomegaly and gastrointestinal varices. In fatal cases, bleeding from gastro-
oesophageal varices is the most serious form (Ross et al., 2001; Gryseels et al., 2006). 
Diagnosis of schistosomiasis is essential for screening a global or individual picture of 
schistosomal infection, monitoring the efficacy of drug treatment at both population and 
individual levels, and evaluating the results of control strategies. For this purpose, 
101 
Chapter 4-Chemometric analysis of biofluids from mice infected with Schistosoma mansoni 
diagnostic methods are required to be robust, sensitive, specific and applicable. In 
general, there are three types of diagnostic methods available: (1) parasitological 
examination of urine, faeces or rectal mucosa to detect schistosome eggs; (2) 
immunological tests to evaluate the levels of parasite/eggs-derived antigens and 
immunological responses to the parasite antigens in urine and blood; (3) measurement 
of pathological damage of organs using radiography, computed tomography, 
myelography and magnetic resonance imaging (Ross et al., 2001). 
The microscopic examination of urine or faeces is a traditional approach to detect 
schistosome eggs, and remains the gold standard for the diagnosis of schistosomiasis 
(Feldmeier and Poggensee, 1993). This method is simple and specific, but less sensitive 
in mild or light infection. Quantitative approaches, such as urine filtration and the Kato-
Katz thick smear examination have been extensively applied to evaluate faecal egg 
counts in field surveys (Ross et al., 2001). However, intra-individual and day-to-day 
variation of egg excretion is considerable, especially in the case of mild and light 
infection, thus it is ideal to have multiple stool examinations, which is, nevertheless, 
impractical at the population level since it requires a lot of time and labour-intensive 
work (Ross et al., 2001; Booth et al., 2003). 
Nucleic acid-based assays such as DNA probes and PCR have been developed as a 
diagnostic tool for use in parasitic diseases for more than two decades (Weiss, 1995). 
DNA probe detection involves capturing specific parasite DNA or RNA in the target 
specimen using a reporter DNA molecule which can consist of an oligonucleotide, a 
DNA fragment, single-stranded DNA, or plasmid DNA (Weiss, 1995). PCR amplifies 
target sequences in the specimen and then the resulting product is detected by a DNA 
probe or gel electrophoresis (Weiss, 1995; Sandoval et al., 2006). Although PCR is 
highly sensitive and specific, it involves multiple steps and is time consuming and 
labour intensive, thus, not suitable for global screening. In addition, PCR can give false 
positive and false negative results due to contamination during the sample process or 
carryover for the former, and the presence of PCR inhibitor in the DNA extraction for 
the latter (Weiss, 1995). 
Immunological diagnosis of schistosomiasis has been widely studied and applied to the 
assessment of the infection at the community level. Most commonly used antibody- 
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based assays involve the measurement of immunoglobulin G (IgG), IgM, or IgE levels, 
indirect haemagglutination, or immunofluorescence (Gryseels et al., 2006). These 
techniques demonstrate good sensitivity but poor specificity; they can react to other 
helminthic infections and cannot reflect the active infection, thus, are not feasible under 
complex field conditions (Feldmeier and Poggensee, 1993). Moreover, they fail to 
reflect the infection intensity (Doenhoff et al., 2004). Although antibody-based assays 
are not capable of being applied to global assessment, this method can be useful for 
diagnosis in travelers, migrants and well-controlled/low-transmission areas (prevalence 
< 3% according to parasitological examination) (Ross et al., 2001; Gryseels et al., 2006). 
Detection and quantification of somatic schistosome antigens, including the gut-derived 
circulating anodic antigen (CAA) and circulating cathodic antigen (CCA), could 
overcome the major disadvantages of antibody-based assays because, first of all, the 
levels of schistosome-derived antigens are highly related to the intensity of 
schistosomiasis infection (Feldmeier and Poggensee, 1993), secondly, both CAA and 
CCA are detectable in urine, the collection of which is less invasive than blood. Antigen 
detection in serum is not as sensitive as in urine, but for screening at population levels, 
less specific urine-based antigen detection assays (e.g. reagent strip) is more applicable 
in urinary schistosomiasis as it is cheap, easy and effective. 
However, these approaches mentioned above are less satisfactory for the diagnosis of 
intestinal and hepatosplenic diseases. To surmount this problem, a number of imaging 
techniques have been applied to characterise schistosomal pathology such as visualising 
organ lesions, portal-vein distension and gastro-oesophageal varices. These techniques 
include ultrasonography, X-rays, computed tomography (CT), cystoscopy, endoscopy 
and magnetic resonance imaging (MRI), which need to be done in a hospital, with the 
exception of ultrasonography (Hatz, 2001). Thus, ultrasonography, as a safe and easy-
access tool, has been employed to examine hepatosplenic schistosomal disease in 
epidemic fields according to WHO protocols as an additional tool for clinical 
examination (Hatz et al., 1992; Richter et al., 2003). MRI can provide a detailed image, 
which is preferable in diagnosis of neuroschistosomiasis (Lambertucci et al., 2000). 
Biopsy techniques can characterise histological alteration of tissues and visualising the 
granulomatous inflammation and fibrosis, but it is difficult to obtain tissue samples 
from patients (Ross et al., 2001). 
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Summarising the advantages and disadvantages of common diagnostic methods for 
schistosomiasis in Table 4-1, it is clear that there is no absolute "gold standard" tool 
available for both individual examination and population screening, especially with the 
case of low-intensity infections. Therefore, this chapter aimed to generate a 
comprehensive picture of metabolic profiles of 3 different biofluids in a mouse-S. 
mansoni model and to extract biological markers for the infection using a metabolic 
profiling strategy which could be potentially used for diagnosis. 
Table 4-1 Comparison of diagnostic methods in schistosomiasis infection 
Method Sample Advantage Disadvantage 
Parasitological 
examination 
DNA probe 
PCR 
Immunological 
detection 
imaging 
biopsies 
urine 
faeces 
urine 
faeces 
urine 
serum 
patient 
tissues 
Simple 
Direct examination 
High specificity 
High specificity and 
sensitivity (PCR) 
Direct examination 
Simple 
Fast 
Applicable for screening 
under certain circumstance 
Visualisation of organ 
lesions 
Direct 
Visualisation of 
pathological changes 
Slow 
Heavy labour work 
Low sensitivity 
Low specificity and sensitivity 
(DNA probe) 
Multi steps 
Carryover contamination (false-
positive) 
PCR inhibitor contamination (false-
negative) 
Low specificity 
Require standardised reagents 
Expensive 
Requires expertise 
Invasive 
4.2.3 Drug treatment and resistance on Schistosoma 
The treatment and control of schistosomiasis virtually relies on a single drug, 
praziquantel, which has been heavily and regularly prescribed due to lack of alternative 
choices. A commercial tablet usually contain 600 mg effective component, however the 
quality varies depending on companies and batches (Appendix II). Since treatment 
relies on a single therapeutic drug, the long-term consequence of the development of 
resistance to praziquantel is of serious concern (Doenhoff, 1998; Shadan, 2008). S. 
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mansoni resistance to praziquantel in some areas is looming (Doenhoff, 1998; Shadan, 
2008), which underlines the importance of understanding the mechanism of action of 
the drug, particularly with respect to the immunological and metabolic response of the 
host to the treatment. Due to little or no effect of praziquantel on premature worms or 
eggs, artemisnin derivatives are used to treat the premature worms of S. japonicum and 
S. mansoni mainly, but it is not recommended as a routine treatment in malaria-endemic 
areas since it could raise the artemisnin resistance to malaria parasites (the primary 
target of artemisnin-used therapeutics). Schistosomal worms have been shown to be 
resistant to hycanthone and oxamniquine in both laboratory animal and field studies 
(Gryseels et al., 2006). 
4.2.4 Studies of schistosomiasis on human and animals 
In order to control schistosomiasis and investigate potential drug and vaccine targets, 
numerous studies have been performed, particularly, more recent genomic, proteomic 
and metabolic research, which permit insights into further understanding of the disease 
mechanism. In 2003, the transcriptomes of S. mansoni and S. japonicum were 
simultaneously published in Nature Genetics, which enriched the genomic information 
on schistosome. Approximately 45,000 expressed-sequence tags (ESTs) were found in 
adult S. japonicum and eggs, while 125,000 ESTs were obtained from 6 different stages 
in the life cycle of S. mansoni. Although many of ESTs remain unassigned, encoded 
ones were believed to be involved in schistosome maturation, development, host-
parasite immunological interplay, nutrient acquisition and metabolism (Verjovski-
Almeida et al., 2003; Hu et al., 2003). 
Proteomic studies on schistosomal tegument have demonstrated several proteins which 
are associated with metabolite transport, signaling and membrane structure, together 
with some previously unknown proteins potentially involved in host-parasite 
interactions (Braschi et al., 2006). 
In addition, a large number of protein- and lipid-linked glycans detected at different 
stages of schistosoma have been reported and it has also been found that the 
glycosylation products are gender-specific (Khoo et al., 1997a; Khoo et al., 1997b; 
Wuhrer et al., 2006). These glycoproteins and glycolipids play an important role in the 
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immunoregulation of the parasite (Hokke et al., 2007). These studies are sometimes 
referred to as `glycomics' (Hokke et al., 2007). 
Previous studies have also demonstrated the application of 1H NMR-based 
metabonomics approach in S. mansoni and S. japonicum infections in mouse and 
hamster, respectively (Wang et al., 2004; Wang et al., 2006). In these studies, stimulated 
glycolysis with increased levels of pyruvate, and an inhibition of the tricarboxylic acid 
(TCA) cycle, manifested by decreased concentrations of citrate, succinate and 2-
oxoglutarate were reported. A range of amino acids were also found to alter with 
infections. In addition, microbiota-related metabolites, such as acetate, butyrate, 
hippurate, p-cresol glucuronide and phenylacetylglycine indicated cross-talk among 
parasite, host and more interestingly host microbiota. 
The current study represents an extension of the previous S. mansoni-mouse model 
investigating the infection-induced metabolic effects across a wider range of biological 
fluids (urine, plasma and faecal extracts), and allowed the examination of the metabolic 
perturbation across time up to 73-day post infection, in order to overview the dynamic 
changes of metabolic profiles to develop a deeper understanding of the mechanisms of 
infection and to establish robust biomarkers for diagnostic purposes. 
4.3 Materials and methods 
Animal maintenance, experimental design, sample collection and preparation for 11-1 
NMR spectroscopy analyses have been described in Chapter 2. Briefly biofluids (urine, 
plasma and faeces) were collected from the S. mansoni-infected (n=10) and non-
infected (n=9) mice over a 73-day time course. 
Data reduction and multivariate data analyses: Pre-processing of spectra consisted of 
5 steps: (1) 11-1 NMR spectra of urine, faecal water and plasma were automatically 
phased and baseline-corrected using an in-house developed MATLAB script (Dr. 
Ebbels, Imperial College London). (2) Urine and faecal water spectra were calibrated to 
the TSP resonance at 5111 0.00, whereas plasma spectra were calibrated to the signal of 
anomeric proton from a-glucose at 6'H 5.22. (3) The resulting spectra (6'H 0-10.0) 
were digitised into 20,000 data points with the segment width of 0.0005 ppm and 
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imported into MATLAB using another in-house developed MATLAB script (Dr. 
Cloarec, Imperial College London). (4) To reduce the effects of the distortion in 
suppression of the water peak on modelling, the water regions (51H 4.6-5.05 in urinary 
spectra, 51H 4.7-4.9 in faecal water spectra and 51H 4.4-5.15 in plasma spectra) were 
removed. Moreover, these regions (51H 0-0.35 and 51H 9.6-10.0 in urine spectra, 51H 0-
0.3 and 51H 9.1-10.0 in faecal extract spectra, and the regions 51H 0-0.7 and 51H 5.4-
10.0 in plasma spectra) containing only noise, were also removed. For urinary spectra, 
regions of 51H 5.16-6.35 were also removed due to the variations of the intensity of urea 
signal caused by chemical exchange with the water. A further region at 51H 3.34-3.38 in 
urinary spectra and 51H 3.33-3.36 in CPMG plasma spectra, arising from contamination 
of the buffer with methanol, has been removed. (5) To avoid concentration variation in 
different samples, for each spectrum, normalisation to total spectral area was carried out 
prior to employing multivariate data analysis methods including PCA and 0-PIS-DA. 
Two urinary metabolites, namely, hippurate and phenylacetylglycine, were found to be 
most highly correlated with the S. mansoni infection, thus O-PLS regression analysis 
was performed using pre-processed faecal extract spectral data as X matrix and the 
integrated hippurate resonance (51H 7.815-7.858) or the integrated phenylacetylglycine 
resonance (51H 7.4-7.446) as Y matrix. Although 2-oxoadipate was also highly 
correlated with the infection, it was not integrated for PLS analysis due to substantial 
peak overlap and its low intensity, which would lead to inaccuracy in the calculation. 
4.4 Results 
4.4.1 Physiological observation of S. mansoni infection in mice 
Packed cell volume (PCV, refer to Chapter 2 for the definition) ratios were visualised in 
Figure 4-2. The average PCV of the control group remained consistent during the entire 
period of the experiment, whereas that of the infected group dropped from —50% to 
46.6% at day 48 post infection and continued to decrease to 33.7% on day 73. Day 48 
onward post infection is defined as the later stage of the infection, while day 1 to day 41 
post-infection was classed as the early stage. Worm burden in infected mice was 
assessed at day 74 post-infection after mice were killed and dissected. The mean worm 
burden was 36 with a standard deviation of ±7. Hence, on average 45% (range 33-58%) 
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of S. mansoni cercariae had developed into adult worms, which is consistent with 
number reported in a previous study (Wang et al., 2004). There was no body weight 
difference between control and the infected mice during the entire course of the 
experiment. 
55 
50 
45 
--40— control 
30 - infected 
a 40 
35 
N '` 	 C;\ C) 0N 	 0 c 0 	0 0 0 
time point 
Figure 4-2 The PCV ratio of control and infected groups across all the experimental time 
points. Error bars are standard deviation. 
4.4.2 Metabolic profiling on mouse urine 
4.4.2.1 11-I NMR spectroscopy of mouse urine 
Two typical 1 H NMR spectra of urine obtained from an uninfected control and S. 
mansoni-infected mice at 53 days post infection are shown in Figure 4-3. All 
assignments were carried out with the aid of 2-D spectra including Ifi- IH COSY (Figure 
4-4) and 111-1 H TOCSY, and with the extant literature (Wang et al., 2004; Wang et al., 
2008a). Lactate, lysine, citrate, 2-oxoglutarate, succinate, 3-ureidopropionic acid, 
acetate, trimethylamine, creatine, creatinine, taurine, trimethylamine-N-oxide, alanine, 
arginine, hippurate, scyllo-inositol, glycine, 2-oxoadipate, 2-oxoisocaproate, 3-methyl-
2-oxovalerate, phenylacetylglycine and 2-oxoisovalerate have been identified in the 
control urinary spectra, whereas p-cresol glucuronide was only found in the infected 
mice at later stage of the infection from day 48 post infection onward. Chemical shifts 
and multiplicities of signals are summarised in Table 4-2. 
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Figure 4-4 A typical 600 MHz NMR 1H-1H COSY spectrum of the aliphatic region from a 
urine sample of an infected mouse. Key: Ala: alanine; CMOPA: 3-carboxy-2-methyl-3-
oxopropanamine; Gly: glycine; MOV: 3-methyl-2-oxovalerate; OAP: 2-oxoadipate; OGT: 
2-oxoglutarate; OIC: 2-oxoisocaproate; OIV: 2-oxoisovalerate; PAG: phenylacetylglycine; 
Tau: taurine; TMA: trimethylamine; UPA: 3-ureidopropionate. 
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Table 4-2 Identified metabolites in 11I NMR spectra of urine (u), plasma (p) and faecal 
water (f) obtained from mice with or without an infection of S. mansoni, together with the 
respective chemical shifts and signal multiplicities. *s: singlet; d: doublet; t: triplet; m: 
multiplet; q: quadruplet; dd: double doublet; ddd: double double doublet; bs: broad 
signal. 
Metabolites H group 111 (multiplicity*) Biofluids 
2-oxoadipate y-CH2; 5-CH2 2.77(t); 1.82(m); 2.22(t) u 
2-oxoglutarate 13-CH2; y-CH2 3.01(t); 2.45(t) u 
2-oxoisocaproate y-CH; 2x CH3  2.61(d); 2.1(m); 0.94(d) u 
2-oxoisovalerate (3-CH; 2x CH3  3.02(m); 1.13(d) u/f 
3-carboxy-2-methy1-3-
oxopropanamine P-CH; CH3; y-CH2  
2.49(m); 1.08(d); 3.19(m), 
3.56(m), 3.72(m) 
13-CH; i3-CH3; y-CH2(i); 2.93(m); 1.1(d); 1.7(m); 
3-methyl-2-oxovalerate y-CH2(ii); 1.46(m); 0.9(t) u/f 
a-CH2; 	y-CH2; 2.24(t); 1.64(m); 1.66(m); 
5-aminovalerate 5-CH2 3.02(t) 
acetate CH3  1.93(s) u/p/f 
alanine CH; CH3  3.77(q); 1.47(d) p/f 
a-CH; 0-CH2; y-CH2; 3.78(t); 1.92(m); 1.65(m); 
arginine 5-CH2 3.20(t) u/ f 
asparagine a-CH; i3-CH2 4.01(dd); 2.87(dd),2.95(dd) 
aspartate a-CH; [3-CH2 3.89(dd); 2.69(dd),2.80(dd) 
butyrate a-CH2; ii-CH2; CH3  2.16(t); 1.56(m); 0.9(t) 
choline N-(CH3)3; a-CH2; 3.20(s); 4.07(m); 3.52(m) p/f 
citrate CH2(i); CH2(ii) 2.66(d); 2.54(d) u/p 
creatine N-CH3; CH2 3.03(s); 3.92(s) u/p 
creatinine N-CH3; CH2 3.03(s); 4.05(s) 
cytidine 5-CH; 6-CH 6.10(d); 7.85(d) f 
cytosine 5-CH; 6-CH 5.98(d); 7.51(d) f 
dimethylamine 2x CH3  2.72(s) 
a-CH2(i); a-CH2(ii); 2.41(dd); 2.31(dd); 4.16(m); 
D-3-hydroxybutyrate (3-CH; CH3  1.2(d) p 
glutamine a-CH; i3-CH2; y-CH2 3.78(t); 2.12(m); 2.43(m) p/f 
glutamate a-CH; i3-CH2; y-CH2 3.76(t); 2.07(m); 2.34(m) f 
glyceryl of lipids CH2OCOR 4.28(m) 
glycine CH 3.55(s) f 
N-acetylglycoprotein 
fraction NHCOCH3  2.06(s) u/f 
N-(CH3)3; Ct-CH2; 0-CH2; 3.22(s); 4.32(t); 3.68(t); 
glycerophosphorylcholine a'-CH2; ii'-CH; y'-CH2 3.61(dd); 3.90(m); 3.72(dd) 
CH2; 2,6-CH; 3,5-CH; 3.97(d); 7.84(d); 7.55(t); 
hippurate 4-CH 7.64 (t) 
UN 4.11(bs); 3.75(m); 3.65(m) p 
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a-CH; P-CH;13-CH3; 
y-CH2(i); 7-CH2(ii); 
3.68(d); 1.98(m); 
1.02(d);1.25(m),1.47(m); 
isoleucine CH3  0.94(t) p/f 
lactate a-CH; (3-CH3  4.11(q);1.32(d) u/p/f 
a-CH; (3-CH2; y-CH; 3.72(t); 1.74(m), 1.70(m); 
I eucine 2x CH3  0.96(t) p/f 
lipid fraction CH2C=C 2.0(bs) p 
lipid fraction CH2C=0 2.22(bs) p 
lipid fraction C=CCH2C=C 2.75(bs) p 
lipid fraction CH=CH 5.30(bs) p 
lipid fraction CH3(CH2)n 0.83(bs) p 
lipid fraction (CHA 1.22(bs) p 
lipid fraction CH3CH2CH2C= 0.87(bs) p 
lipid fraction CH2CH2CO 1.57(bs) p 
a-CH; (3-CH2; 7-CH2; 3.78(t); 1.92(m); 1.72(m); 
lysine 8-CH2; c-CH2 1.47(m); 3.03(t) u/p/f 
a-CH; (3-CH2; 7-CH2; 3.87(t); 2.14(m); 2.63(t); 
methionine S-CH3  2.13(s) f 
2-CH; 6-CH; 4-CH; 8.92(s); 8.70(d); 8.24(d); 
nicotinurate 5-CH; CH2 7.60(dd); 3.99(s) 
p-cresol glucuronide 2,6-CH; 3,5-CH; CH3  7.06(d); 7.23(d); 2.3(s) 
3,5-CH; 2,4,6-CH; 7.43 (m); 7.37 (m); 3.75 (d); 
phenylacetylglycine Ar-CH2; N-CH2 3.68 (s) 
2,6-CH; 3,5-CH; 4-CH; 
half Ar-CH2; 7.33(d); 7.43(m); 7.36(m); 
phenylalanine half Ar-CH2; N-CH 3.17(dd),3.30(dd); 3.99(dd) 
a-CH; half p-CH2; half J3- 4.13(dd); 2.08(m), 2.37(m); 
proline CH2; 7-CH2; 8-CH2 2.01(m); 3.38(m) 
propionate CH2; CH3  2.19(m); 1.06(t) f 
pyruvate CH3  2.36(s) u/p 
scyllo-inositol 6x CH 3.33(s) u/f 
succinate 2x CH2 2.41(s) u/f 
taurine N-CH2; S03-CH2 3.43(t); 3.27(t) u/f 
threonine a-CH; (3-CH; CH3  3.59(d); 4.27(m); 1.32(d) f 
trimethylamine 3x CH3  2.89(s) u/f 
trimethylamine N-oxide 3x CH3  3.28(s) u 
2,6-CH; 3,5-CH 7.18(d); 6.88(d) 
tyrosine a-CH; P-CH2 3.94(dd); 3.20(dd), 3.10(dd) f 
uracil 5-CH; 6-CH 5.80(d); 7.52(d) f 
3-ureidopropionic acid a-CH2; p-CH2 2.38(t); 3.31(t) u 
a-CH; 13-CH; y-CH3; 3.62(d); 2.28(m); 0.99(d); 
valine y'-CH3  1.04(d) p/f 
5.22(d); 3.54(dd); 3.71(t); 
1-H; 2-H; 3-H; 4-H; 5-H; 3.42(t); 3.83(ddd); 3.84(m); 
a-glucose CH2(i); CH2(ii) 3.76(m) p/f 
4.65(d); 3.24(dd); 3.48(t); 
1-H; 2-H; 3-H; 4-H; 5-H; 3.40(t); 3.47(ddd); 3.72(dd); 
(3-glucose CH2(i); CH2(ii) 3.90(dd) p/f 
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4.4.2.2 Time-related principal component analysis on urinary spectra 
An unsupervised PCA method was carried out on the normalised NMR spectral data 
acquired from urine samples of both control and infected groups at all data points using 
unit variance-scaled data. A total of 3 principal components were calculated to construct 
the model and these 3 PCs explained 38.1% of the total variance. A 3-dimensional PCA 
scores plot was derived and is shown in Figure 4-5 A. It is evident that (1) control mice 
occupy a smaller space than the S. mansoni-infected mice in this metabolic space and (2) 
mice at early stage (5 41-day-old infection) of the infection of S. mansoni remain with 
the control samples; however, from day 48 of the infection, these infected mice deviated 
from the control cluster along PC1 and formed a separated cluster. The corresponding 
loadings plot indicated that phenylacetylglycine was the dominant metabolite 
influencing the separation between control/early stage of the infected mice and mice at 
late stage of the infection. 
4.4.2.3 O-PLS-DA analysis on urinary spectra 
Having overviewed the entire NMR dataset using an unsupervised method (PCA), a 
supervised O-PLS-DA strategy was subsequently employed to the NMR spectral data of 
the infected and control mice at individual time points to optimally discriminate these 
two classes. There was no difference between early-stage-infected and uninfected 
control mice as shown in the PCA scores plot (Figure 4-5). However, metabolic 
disturbances were observed in the infected mice from 41 days post infection. Selected 
O-PLS-DA coefficient plots (day 41, 48, 61 and 73) are shown in Figure 4-6 and the 
dominant metabolite changes are summarised in Figure 4-7. In these O-PLS-DA plots, 
the upward orientation of peaks represents increased concentrations of metabolites in 
the infected mice and vice versa. The colour of peaks codes the significance of peaks in 
discriminating the classes in the model, with increased importance ranging from blue 
(little or no correlation with infection) to red (strong correlation with infection). 
Decreased levels of hippurate, and increased concentrations of creatine and 3-
ureidopropionate were found in the infected mice at day 41 post infection. As the S. 
mansoni infection progressed, hippurate levels continued to decrease, together with 2-
oxoadipate, 2-oxoisovalerate, 2-oxoisocaproate and taurine in the infected mice. 
Phenylacetylglycine, p-cresol glucuronide, trimethylamine and pyruvate levels were 
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elevated in the infected mice at the later stage of the infection. Over the entire course of 
the observation, hippurate, phenylacetylglycine, 2-oxoadipate and trimethylamine were 
found to be consistently different between the infected and control groups. 
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Figure 4-5 A 3-D PCA trajectory scores plot (A) derived from urinary spectra of both 
control (black), S. mansoni-infected mice at early stage (13-41 days post infection, blue) 
and these infected mice at the late stage (48-73 days post infection, red). B and C represent 
2-D PCA scores plots constructed from and 2nd principal components (B), and Ft and 
3rd (C) principal components, respectively. 
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phenylacetylglycine; p-CG: p-cresol glucuronide; Tau: taurine; TMA: trimethylamine; UPA: 3-ureidopropionate. 
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4.4.3 Metabolic profiling on mouse plasma 
4.4.3.1 111 NMR spectroscopy of mouse plasma 
Figure 4-8 displays three typical 1H NMR spectra of plasma from a control mouse 
acquired using standard 1-D (A), CPMG (B), diffusion-edited (C) pulse sequences, 
separately. Standard 1-D 1H NMR spectra of plasma contain a wide range of resonances 
from small molecules, proteins and lipids, which results in complexity and heavy 
overlap of the spectra. In contrast, the CPMG edited spectra of plasma are less complex 
and signals of low molecular weight metabolites are clearer since the broader 
resonances are attenuated at the expense of the macromolecular components, although 
some lipid residual resonances are still visible in the spectra. D-3-hydroxybutyrate, 
lysine, citrate and glutamine can be easily observed in the CPMG spectrum of plasma 
(Figure 4-8 B). The diffusion-edited spectrum (Figure 4-8 C) provides a picture of lipid 
signals with low molecular weight components being edited out. Several lipid signals 
such as CH3, (CH2)n, CH=CH, CH2C=C, CH2CO, =CH-CH2-CH= and N(CH3)3 were 
identified. All assignments were carried out based on literature and 2-D 1H-1H COSY 
spectra (Figure 4-9). The previous table 4-2 summarises all resonances identified in 
plasma spectra. 
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Figure 4-8 Typical 1-D 1H NMR spectra of control mice acquired using standard (A), 
CPMG (B) and diffusion-edited (C) pulse sequences. Key: Ala: alanine; Gin: glutamine; 
GPC: glycerophosphorylcholine; HB: D-3-hydroxybutyrate; lleu: isoleucine; Leu: leucine; 
Lys: lysine; Val: valine. 
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glucose & amino acids 
Figure 4-9 Typical 2-D 11-1-111 COSY spectrum of plasma from a control mouse. Key: Ala: 
alanine; Gln: glutamine; GPC: glycerophosphorylcholine; HB: D-3-hydroxybutyrate; 
isoleucine; Leu: leucine; Lys: lysine; Val: valine. 
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4.4.3.2 Time-related principal component analysis on plasma spectra 
 
An unsupervised PCA model was calculated based on the normalised 'H standard 
(Figures 4-10 A and C) and CPMG (Figures 4-10 B and D) NMR spectral data, 
respectively, derived from plasma samples of both control and infected groups at the 
early infection stage (e.g. days 13, 27, 34 and 41 post infection) and at the later stage 
(e.g. 48, 53, 57, 61, 67 and 73 days post infection) using pareto variance-scaled data. A 
total of 3 principal components were calculated to construct the models and 73.7% and 
48.1% of the total variance were explained by these 3 PCs in each model. 
Figure 4-10 PCA scores plots derived from 'H standard (A) and CPMG (B) NMR spectral 
data (black: control, blue: S. mansoni-infected mice at the early stage of the infection, red: 
these mice at later stage of the infection) and their corresponding loading plots are shown 
in C and D. 
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Both of the scores plots (Figures 4-10 A and B) represent a separation of the later stage 
infected-mice from the cluster of the control and early stage infected-mice with a clearer 
differentiation in 114 standard spectral data. Their corresponding loadings plots (Figures 
4-10 C and D) showed similar information on the dominant variables, that is, higher 
levels of lactate and lower levels of N-(CH3)3-containing compounds, possibly choline, 
glycerophosphorylcholine and phosphorylcholine, which were found in the infected 
mice at the later stage of the infection compared with the control and early infection. 
4.4.3.3 O-PLS-DA analysis on mouse plasma spectra 
In order to extract biological markers of the S. mansoni infection, an O-PLS-DA method 
was used to analyse 1-D 1H standard, CPMG and diffusion-edited (only on two time 
points: D48 and D53) NMR spectral data to compare the control with S. mansoni-infected 
mice at each sampling point (e.g. D13, D27, D34, D41, D48, D53, D61, D67 and D73). 
Spectral data were normalised to total area and unit variance-scaling was used to 
construct models using an appropriate number of components. The parameters 
indicating goodness of fit (R2X) and predictability (Q2Y), and the number of components 
are listed in Table 4-3. The S. mansoni-induced effects on plasma composition were 
observed from 41 days post infection onwards. Strong models were obtained from 
standard 1H NMR spectra of plasma from 48 days post infection with QY > 90%. 
However models derived from CPMG spectral data showed lower values of QY 
compared with corresponding O-PLS-DA models of standard spectral data except at D41. 
Q2Y values of O-PLS-DA models of diffusion-edited spectra on D48 and D53 were 
similar to those models of the standard spectra at the matching time points. 
O-PLS-DA models derived from standard 11-1 NMR spectra, CPMG and diffusion-edited 
spectra on day 53 post-infection are selected for demonstration purpose in Figure 4-11, 
where upward peaks represent higher levels of metabolites in the infected group and 
vice versa. A range of lipid fractions such as CH3CH2CH2C=, (CH2)n, CH2CH2CO, 
CH2C=C, CH2CO, C=CCH2C=C, CH2OCOR and —CH=CH-, were found to be 
increased in the S. mansoni-infected mice, while lipid signals (e.g. CH3(CF12)n, 
CH3CH2CH2) and phosphatidylcholine, confirmed by STOCSY, were decreased. Lower 
levels of several low molecular weight metabolites including D-3-hydroxybutyrate, 
acetate, creatine and were observed in both standard and CPMG II-1 NMR spectra of the 
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infected plasma samples in comparison with these of control at day 53 post infection. 
Decreased levels of glucose and citrate were observed in the CPMG spectral data of the 
infected mice. The diffusion-edited spectra showed similar trends of macromolecular 
changes to the standard 1H spectrum, and contained an unknown macromolecule at 
resonances 4.12 (broad singlet), 3.61 (multiplets) and 3.76 (multiplets). All the 
metabolite changes observed at other sampling time points are summarised in Figure 4-
7. It is noticeable that metabolic perturbations caused by the S. mansoni infection were 
stronger at days 48, 53 and 73 than the rest sampling time points in terms of the number 
of altered metabolites. 
Table 4-3 Parameters of all O-PLS-DA models derived from plasma spectral data of 
control and the S. mansoni-infected mice on days 41, 48, 53, 61, 67 and 73 post-infection. 
Models Explained variation (R2X) 
Predictive 
ability (Q2y) 
Number of predictive components + 
number of orthogonal components 
D41 standard 77% 53% 1+3 
D41_CPMG 47% 55% 1+2 
D48_standard 86% 91% 1+3 
D48_CPMG 72% 76% 1+5 
D48_diffusion 76% 90% 1+5 
D53_standard 79% 94% 1+2 
D53_CPMG 62% 86% 1+5 
D53_diffusion 72% 93% 1+5 
D61_standard 80% 92% 1+3 
D61_CPMG 46% 74% 1+2 
D67_standard 82% 91% 1+3 
D67_CPMG 66% 85% 1+4 
D73_standard 86% 96% 1+5 
D73_CPMG 64% 83% 1+5 
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Figure 4-11 O-PLS-DA models derived from plasma spectral data acquired using 
standard (A), CPMG (B), diffusion-edited (C) pulse sequences on 53 days post-infection. 
Key: GPC: glycerophosphorylcholine; HB: D-3-hydroxybutyrate; UN: unknown. 
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4.4.4 Metabolic profiling on mouse faecal extracts 
4.4.4.1 1H NMR spectroscopy of mouse faecal extracts 
Typical 1H NMR spectra of faecal extracts obtained from a control and a S. mansoni-
infected mouse at day 53 post infection are shown in Figure 4-12. A number of 
metabolites such as amino acids (e.g. leucine, valine, alanine, isoleucine, aspartate, 
glutamine, glutamate, lysine, arginine, glycine, methionine, phenylalanine and tyrosine), 
short chain fatty acids (e.g. butyrate, propionate and acetate), uracil, 5-aminovalerate 
(confirmed by STOCSY), nicotinurate, succinate and glucose were assigned with in-
house database, the assistance of previously published data (Saric et al., 2008a) and 2-D 
NMR spectra (Figure 4-13). 
4.4.4.2 Multivariate data analyses on faecal extract spectra 
PCA and O-PLS-DA analyses were applied to analyse all acquired spectra from faecal 
extracts. The PCA trajectory scores plot is not shown as it did not present a clear 
separation between the infected and control mice due to the large variance in the faecal 
extract metabolic profiles. O-PLS-DA models for each time point were constructed 
based on unit variance scaled faecal extract spectral data using one PLS predictive and 
two orthogonal components. The coefficient plots (Figure 4-14) showed the disturbance 
of a number of metabolites, such as increased propionate, 5-aminovalerate and N-
acetylglycoprotein fragments in the infected mice, which are summarised in Figure 4-7. 
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Figure 4-13 A 2-D 1H-1H TOCSY spectrum of the faecal extract sample from a control 
mouse. Key: Ala: alanine; Arg: arginine; Asn:asparagine; Asp: asparate; Gln: glutamine; 
Glu: glutamate; Ileu: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; MOV: 3-
methy1-2-oxovalerate; OIV: 2-oxoisovalerate; Pro: proline; Tau: taurine; Thr: threonine; 
Val: valine. 
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Figure 4-14 O-PLS-DA coefficient plots derived from 'H NMR faecal extract spectra at 
day 61 (A) and 73 (B) (Q2Y=0.86 and 0.83, R2X=49% and 70%, respectively), reflecting the 
discrimination between the S. mansoni-infected mice and control mice. Key: 5-AV: 5-
aminovalerate; Ma: alanine; N-AG: N-acetylglycoprotein fraction. 
4.4.5 O-PLS correlation of urinary hippurate and phenylacetylglycine 
concentrations with faecal metabolite profiles 
Urinary levels of hippurate and phenylacetylglycine were found to be consistently 
disturbed throughout the duration of the infection due to the S. mansoni infection from 
day 41 and day 48 onwards, respectively. In order to characterise the link between these 
two urinary metabolites and faecal extract profiles, O-PLS regression analysis was 
applied to the spectral data of faecal extracts against the relative concentration of each 
metabolite. O-PLS regression of urinary hippurate against the faecal extract profiles 
generated relatively strong models at day 48 (Q2 Y=0.58, R2X=80%) with one predictive 
component and four orthogonal components, day 53 (Q2 Y=0.57, R2X=39%) and day 73 
(Q2Y=0.58, R2X=29%) with one predictive component and one orthogonal component. 
N-acetylglycoprotein fragments and propionate were negatively correlated with the 
urinary hippurate levels, while butyrate was found to be positively correlated with 
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hippurate at day 73 post infection (Figure 4-15). No correlation between hippurate 
levels and faecal metabolites were observed at other sampling time points. 
Figure 4-15 Schematic illustration of correlations between faecal metabolites (e.g. 
propionate, aspartate, 5-aminovalerate, N-acetylglycoprotein and butyrate) and urinary 
hippurate (HP) and phenylacetylglycine (PAG) levels. A solid line represents positive 
correlation between two metabolites while a dashed line represents negative correlation. 
D„ indicates the data points at which the correlation was observed. 
O-PLS regression of urinary phenylacetylglycine against the faecal extract profiles 
generated stronger models than hippurate at all observation time points, such as day 48 
(Q2Y=0.65, R2X=79%) and day 53 (Q2Y=0.87, R2X=70%) with one predictive 
component and 4 orthogonal components, day 61 (Q2Y=0.75, R2X=41%) with one 
predictive component and two orthogonal components, day 67 (Q2Y=0.65, R2X=62%) 
with one predictive component and three orthogonal components and day 73 (Q2Y=0.85, 
R2X=76%) with one predictive and four orthogonal components. Propionate and 5-
aminovalerate were found to be highly correlated with the urinary phenylacetylglycine 
level, whilst aspartate was negatively linked to PAG at day 61 post infection (Figure 4-
15). 
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O-PLS regression was also performed on biofluid spectral data obtained at the last time 
point against worm burden, but no significant correlation was observed. 
4.5 Discussion 
4.5.1 Potential of metabolic profiling for schistosomiasis diagnosis 
This chapter has demonstrated S. mansoni infection-induced dynamic changes in the 
biofluid (e.g. urine, plasma and faeces) composition of mice using 111 NMR 
spectroscopy and multivariate data analyses and elucidated potential biological markers 
of S. mansoni infection for diagnosis. At present, Kato-Katz thick smear detection 
aforementioned in Section 4.2.2 remains the gold standard diagnostic method, but it is 
labour-intensive and demonstrates low sensitivity. Hence, one of the aims of this current 
study was to develop a potential diagnostic method. Using a NMR-based metabolic 
profiling strategy, a clear separation of the S. mansoni-infected mice from day 48 post 
infection from the control mice has been shown in PCA time trajectory plots of urinary 
and plasma spectra in Figures 4-5 and 4-10, but not in faecal extracts. This suggests that 
urine and plasma composition are more sensitive to the parasitic infection than faecal 
extract composition and that both urinary and plasma fingerprints hold potential for 
schistosomiasis diagnosis. In terms of sample analysis procedures, urine and plasma 
samples are also superior to faecal extracts as urine and plasma are straightforward for 
acquisition of the profile while faeces requires slightly longer time for extracting soluble 
components. From the practical diagnosis point of view, easily accessible samples such 
as urine are preferred as it is less invasive compared with plasma collection and more 
easily handled than faeces. Specificity and sensitivity of the biomarkers also needs to be 
taken into consideration. An ideal diagnostic biomarker is required to be robust and 
specific to the infection. In the current study, 3 urinary metabolites including hippurate, 
phenylacetylglycine and 2-oxoadipate, and a range of lipid fractions, D-3-
hydroxybutyrate and glycerophosphorylcholine in plasma repetitively manifested at 
altered levels from day 41 post infection. Altered levels of hippurate and 
phenylacetylglycine, which are gut microbe-related metabolites, have previously been 
reported in various microbiota and toxicity studies (Nicholls et al., 2000; Nicholls et al., 
2001a; Nicholls et al., 2003; Rohde et al., 2007). Plasma concentrations of D-3-
hydroxybutyrate were also observed to be abnormal when the biological system 
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suffered a disturbed fat metabolism (Martin et al., 2006). Thus, an integrated pattern of 
metabolic signatures in one or more biofluids is considered to be more beneficial to a 
specific and sensitive diagnostic tool. 
Table 4-4 The comparison of S. mansoni infection-induced mouse urinary metabolic 
changes in two batches of studies. (` • ' represents higher concentrations of metabolites 
in the infected mice, '•' represents lower concentrations of metabolites in the infected 
mice, " means no changes observed and '/' means no such metabolite identified in 
urine. 
Previous study 
Metabolite 	 (Wang et al., 2004) 	 Current 	study 
trimethylamine 	 A 	 A 
phenylacetylglycine 	 A A 
taurine 	 • 	 • 
citrate ♦ — 
acetate 	 ♦ 	 — 
creatine • • 
3-ureidopropionate 	 • 	 • 
pyruvate 	 • • 
2-oxoisocaproate 	 • 	 • 
tryptophan 	 ♦ / 
hippurate • 	 • 
butyrate 	 ♦ / 
p-cresol glucuronide 	 A 	 A 
succinate 	 ♦ — 
malonate ♦ 	 / 
propionate 	 ♦ / 
2-oxoglutarate ♦ 	 — 
alanine 	 ♦ / 
2-oxoisovalerate 	 • 	 • 
D-3-hydroxybutyrate ♦ / 
3-methyl-2-oxovalerate 	 / 	 • 
2-oxoadipate 	 / • 
4.5.2 Reproducibility of S. mansoni-induced changes in urine 
A previous study (Wang et al., 2004) on S. mansoni-infected mice has demonstrated 
metabolic changes occurred in 20 metabolites in urine at 2 time points (e.g. days 49 and 
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56 post infection), while 13 urinary metabolite alteration were observed in the current 
study (Table 4-4). Ten of them including trimethylamine, phenylacetylglycine, taurine, 
creatine, 3-ureidopropionate, pyruvate, 2-oxoisocaproate, hippurate, p-cresol 
glucuronide and 2-oxoisovalerate showed the same changes across the two studies, most 
of which had a highly significant contribution to the discrimination between the infected 
and control mice in both of the studies. This suggests that these biomarkers are robust 
and as a panel could be specific to the S. mansoni infection. However, several 
metabolites such as citrate, acetate, succinate and 2-oxoglutarate were only observed to 
be decreased in the previous study. Although succinate and 2-oxoglutarate levels 
depleted, their contributions to the class separation (e.g. infected vs. control) were not as 
significant as trimethylamine, phenylacetylglycine, pyruvate and etc. Citrate resonances 
are pH sensitive and demonstrate a heavy positional shift in urinary spectra so it can 
compromise the actual change it should have been observed. Furthermore, the entire 
spectra were digitised with a higher resolution of 0.0005 ppm, compared with 0.04 ppm 
in the previous study, providing a more precise form to monitor the overlapping signals. 
Metabolites such as tryptophan, malonate, propionate, butyrate, D-3-hydroxybutyrate, 3-
methyl-2-oxovalerate and 2-oxoadipate were only assigned in the previous study (Wang 
et al., 2004), which was possible due to the great variations between animal batches or 
low concentrations of the metabolite placing them below the detection limit. 
4.5.3 S. mansoni-induced anemia in mice 
A dramatic decrease in PCV ratio of mice harbouring 48-day-old S. mansoni infection 
reflected that these infected mice suffered from anemia which could be caused by the 
following four mechanisms: (1) iron deficiency due to the blood loss in faeces; (2) 
splenomegaly resulting in erythrocyte sequestration; (3) autoimmune haemolysis and (4) 
inflammation-related anemia (Friedman et al., 2005). Observations in the current study 
provided evidence to support mechanisms (1), (2) and (4). Blood was found in faeces 
from some of the infected mice at several time points from day 48 onwards during 
sampling, but anemia was found in all the infected mice, thus blood loss in faeces could 
be one of the mechanisms but is not likely to be the major cause. Spleen enlargement 
was observed in all the S. mansoni-infected mice on dissection, which could be caused 
by portal hypertension due to hepatic granulomas and fibrosis. This will be discussed in 
detail in Chapter 5. Additionally, an in-house unpublished satellite study showed 
131 
Chapter 4-Chemometric analysis of biofluids from mice infected with Schistosoma mansoni 
elevated levels of several cytokine such as interferon-y (IFN-y), tumour necrosis factor-
a (TNF-a), Interleukin-4 (IL-4), IL-5 and IL-12 in the plasma in response to the 
infection. Although S. mansoni-induced anemia could involve multiple mechanisms, it 
is more likely that splenomegaly and inflammation play a major role leading to host 
anemia. 
4.5.4 S. mansoni-induced energy metabolism disturbance 
Adult schistosome pairs living in the mesenteric veins are dependent on glucose taken 
up from the host to provide energy for their survival and egg production (Bueding, 
1950), which may explain the prominent finding of the lower concentration of glucose 
in plasma from the S. mansoni-infected mice. Schistosomal tegument is the apical 
double bilayer membrane which is important for glucose transportation. Glucose is 
actively taken into the parasite by facilitated diffusion with schistosome glucose 
transport proteins (SGTP), identified as SGTP1, SGTP2 and SGTP4, of which SGTP4 is 
responsible for transporting glucose from host into the tegument through the apical 
double bilayer membrane, while SGTPI aids the transport of glucose further to inner 
tissues for energy support of the parasite body (Skelly and Shoemaker, 1996; El-Ansary, 
2003). The consequent feature of glycolysis is the accumulation of lactate anions and 
[H-1, which can be released to the host, otherwise, it could lead to low intracellular pH, 
thereby, inhibiting further metabolism of the parasite. Lactic acid release to the host 
could involve several lactic acid transporters or similar proteins as Githui et al. found 
phloretin and a-cyano-4-hydroxycinnamate exerted an inhibitory effect on lactic acid 
secretion (Githui et al., 2006). This may explain increased levels of pyruvate in urine 
and lactate in plasma from infected mice observed in the present study. However, these 
observations could also be due to the stimulated glycolysis in the host since the 
activities of glycolysis-involved pyruvate kinase and phosphofructokinase in liver were 
reported to be greater in the S. mansoni-infected mice, which also supported the current 
finding (Ahmed and Gad, 1995). 
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4.5.5 S. mansoni-induced mitochondrial dysfunction 
Decreased levels of citrate and accumulation of pyruvate suggest a suppressed TCA 
cycle in host mitochondria as reported in Wang et al.'s study (Wang et al., 2004). 
Citrate is an intermediate of the TCA cycle and is formed by condensation of 
oxaloacetate with acetyl CoA with the assistance of citrate synthase. The activity of 
citrate synthase was found to be reduced in the liver of S. mansoni-infected mice 
(Ahmed and Gad, 1995), which could explain the decreased concentration of citrate in 
the plasma in the current study. Acetyl CoA can be formed from fatty acid oxidation in 
mitochondria and pyruvate with pyruvate dehydrogenase. The observed increase in 
urinary pyruvate concentration could indicate insufficient acetyl CoA formation for 
TCA cycle metabolism (Wang et al., 2004). In addition, increased levels of a broad 
range of lipid fractions in plasma from mice harbouring infection from 48 days onward 
may be indicative of a perturbation of lipid metabolism. Furthermore, D-3-
hydroxybutyrate, one of the ketone bodies, is converted from acetyl CoA, thus its 
depletion would also support deficient levels of acetyl CoA. Therefore, all these 
observations appeared to support the hypothesis that S. mansoni infection could exert a 
negative impact on mitochondrial function in mice. 
Urinary levels of 2-oxoisovalerate, 2-oxoisocaproate and 2-oxoadipate were decreased 
in the infected mice, which are consistent observations with the previous study (Wang et 
al., 2004). These three metabolites are known to originate from valine, leucine and a-
aminoadipate, and of these valine and leucine were found to be accumulated in the liver 
from S. mansoni-infected mice (see Chapter 5). Taken together all these alterations 
suggest a disturbance of amino acids metabolism, and are likely to reflect liver 
dysfunction. 
4.5.6 S. mansoni-induced disturbance of phospholipid metabolism 
Phospholipids are believed to act as important mediators in immunological modification 
and signal transduction. Schistosomes are incapable of synthesising fatty acids de novo, 
thus they must absorb and utilise exogenous lipids from the host's blood so 
incorporating them into their membrane structures in order to evade the host immune 
response (Brouwers et al., 1998). The decreased level of phospholipids such as 
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phosphatidylcholine in plasma from the S. mansoni-infected mice could be due to 
absorption of phosphatidylcholine by the parasite, or alternatively, it could provide free 
choline by its breakdown to diglycerides synthesised within schistosomes, which may 
also explain the lower levels of glycerophosphorylcholine in plasma of the infected 
mice. This finding was in agreement with Rumjanek and Simpson's previous research 
(Rumjanek and Simpson, 1980). 
4.5.7 Metabolic effects of S. mansoni eggs 
Compared with S. mansoni cercariae and adult worms, S. mansoni eggs play a major 
role in triggering a variety of host immune responses by secreting glycoproteins, 
glycolipid antigens and unconjugated oligosaccharides (Srivatsan et al., 1992a; 
Srivatsan et al., 1992b; Robijn et al., 2007). The difference in faecal extracts between 
the S. mansoni-infected and control mice was characterised by a markedly higher 
amount of N-acetylglycoprotein fragments in mice with a 67 and 73 days old infection, 
which may originate from S. mansoni eggs. In plasma, there is an unknown metabolite 
(Figure 4-11) at 81H 4.11 (broad singlet) and a couple of multiplet resonances between 
81H 3.5-4, which may be from one of egg-secreted oligosaccharides and requires further 
investigation. 
4.5.8 S. mansoni-induced microbial disturbance 
The relative concentrations of microbial and microbial-mammalian co-metabolites such 
as phenylacetylglycine, hippurate, trimethylamine and p-cresol glucuronide varied in 
urinary profiles. Hippurate is formed by conjugation of glycine with benzoate in the 
liver mitochondria (Gatley and Sherratt, 1977). Its depletion is possibly caused by the 
decreased bioavailability of benzoate and/or the decreased capability of biosynthesis of 
hippurate. Benzoate is usually formed by gut microbiota, but also can derive from the 
diet. However, since the diet for both the infected and control mice was the same and no 
difference was observed in body weight between two groups, it is more likely that a S. 
mansoni infection cause a disturbed microbial community. On the other hand, the 
decreased hippurate could indicate mitochondrial dysfunction, which may lead to the 
decreased ability of glycine conjugation, reflected by the elevated glycine observed in S. 
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mansoni-infected liver as discussed in Chapter 5. This also can be supported by 
suppressed TCA cycle mentioned in Section 4.5.5. 
Phenylacetylglycine (PAG) has been regarded as a putative biomarker of 
phospholipidosis but is also associated with microbial metabolism (Nicholls et al., 2000; 
Nicholls et al., 2003). PAG is formed via the conjugation of phenylacetyl-CoA with 
glycine (Jones, 1982). Phenylacetate, required for phenylacetyl-CoA formation, may be 
derived via two pathways, the 13-oxidation of phenyl containing fatty acids and/or the 
metabolism of phenylalanine (Nicholls et al., 2000). For the former pathway, 
bioavailability of phenyl containing fatty acids is not clear. If it derived from diet, no 
change should be observed since diet was kept the same all mice. For the latter route, 
phenylalanine can be converted to phenylacetate via either phenylpyruvate or 
phenylethylamine and phenylacetaldehyde. However, sufficient evidence to show a S. 
mansoni infection can induce production of phenyacetate was not apparent. Urinary 
PAG was reported to reach a maximum concentration in germ-free rats 24-48 hours 
after exposure to a normal animal house environment, which suggested PAG is a 
microbiota-associated metabolite (Nicholls et al., 2003). Trimethylamine (TMA) can be 
derived from dietary choline via microbial processing and eventually excreted into the 
urine after being absorbed by microvillae and circulate to the kidney via the 
bloodstream (Zeisel et al., 1983). Thus, the present observation of higher levels of PAG 
and TMA was likely caused by the S. mansoni infection-induced microbial disturbance. 
p-Cresol has been reported to potentially be correlated with colon cancer (Ling and 
Hanninen, 1992), and its production is subject to intestinal environment such as 
composition of microbiota, food intake (protein intake, particularly tyrosine) and pH of 
the intestinal tract (Smith and Macfarlane, 1996). Clostridium difficile and the 
Lactobacillus strains are known to produce p-cresol by decarboxylation of p-
hydroxyphenylacetate (Elsden et al., 1976; Yoko yama and Carlson, 1981). 
Subsequently, p-cresol is excreted as a form of p-cresol glucuronide in urine (Lesaffer et 
al., 2003). Thus, elevated urinary levels of p-cresol glucuronide observed in the infected 
mice may indicate that S. mansoni infection could activate those p-cresol-producing 
bacteria strains or somehow disrupt the microbial ecology favouring the presence of 
activity of p-cresol producing bacteria. Kawakami et al. has reported that fasting can 
increase serum and caecal p-cresol production in the rat intestinal tract due to the 
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utilisation of endogenous protein by bacteria under the circumstance of insufficient 
carbohydrate in the caecum (Kawakami et al., 2007). But it is unlikely in the present 
study as no body weight changes observed between the infected and control mice. 
5-Aminovalerate and short chain fatty acids including propionate were increased in 
faecal extract samples from the infected mice. In particular, 5-aminovalerate was 
consistently increased and stable changes during the last 3 time points. Stadtman et al. 
has previously shown that Clostridium sticklandii, a gram-positive anaerobic bacterium 
belonging to the proteolytic clostridia, can produce 5-aminovalerate from proline 
(Elsden et al., 1976). These short chain fatty acids originate from bacterial fermentation 
of non-digestible starch or oligosaccharides and the production of short chain fatty acids 
rely on the bacteria species and intestinal atmosphere (e.g. pH) (Walker et al., 2005). In 
addition, hippurate was found to be positively correlated with butyrate and negatively 
correlated with propionate and N-acetylglycoprotein, while phenylacetylglycine was 
positively correlated with propionate, which indicates that these urinary metabolites 
could be indirectly involved in the same series of microbial metabolism pathways as 
these faecal extract metabolites. Therefore, both disturbance of urinary microbiota-
related metabolites and variations in faecal extracts supported the hypothesis that S. 
mansoni infection could have a direct and/or an indirect impact on host microbial 
community. 
4.5.9 Comparison of S. mansoni and Echinostoma caproni infections in mice 
Systematic changes in the urinary, plasma and faecal extract metabolic profiles of mice 
infected with S. mansoni are illustrated in Figure 4-16, which reflects a global change in 
metabolic regulation and homeostasis. In this section, a previous study on an 
Echinostoma caproni infection in mice (Saric et al., 2008b) will be compared with S. 
mansoni infection since both of the parasites are trematodes and the same metabolic 
profiling approach was employed in these studies. Metabolic signatures of biofluids 
obtained from the infections with S. mansoni and E. caproni were similar. For example, 
microbiota-associated metabolites including trimethylamine, p-cresol glucuronide, 
hippurate, phenylacetylglycine, 5-aminovalerate and propionate were found to be 
altered in both sets of studies. The similarities in plasma profiles were reflected by 
increased concentrations of lipid fractions and decreased levels of GPC. However, 
unique signatures for each parasite were also observed, including the fluctuation of 
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formate and glucose levels and lower concentration of lactate in plasma from the E. 
caproni-infected mice, and increased lactate and decreased D-3-hydroxybutyrate and 
phosphatidylcholine in the S. mansoni-infected mice. 
Although these two parasites may exhibit similar behaviour with regard to alteration of 
the microbial environment possibly due to their residence in the host (e.g. E. caproni in 
the intestine and S. mansoni in the mesenteric veins around the intestine), each infection 
also has its specific metabolic signatures. These specific patterns of metabolic changes 
could be used as potential biomarkers in diseases diagnosis. 
4.6 Summary 
This global picture of a S. mansoni infection in mice has extended previous knowledge 
on the host-parasite interaction in the following aspects: (1) changes in urine were 
observed as early as a 41 day-old infection, which was a week earlier than previously 
reported (Wang et al., 2004) and (2) additional plasma and faecal extract profiles 
provide complementary information on the systematic perturbation induced by the S. 
mansoni infection. The NMR-based metabonomic study has again proved to be a 
powerful and robust tool to monitor the biological changes in biofluids at the molecular 
level. Compared with other host-parasite models studied previously, the metabolic 
interactions between host and parasite shared some similarities, however, each strain of 
parasite also demonstrated a unique metabolic signature, which is promising in terms of 
developing a robust diagnostic tool for both individual and population levels. 
137 
m
ansoni-infected m
ice. K
ey: TC
A
: tricarboxylic
 acid. 
Figure 4-16  S
chem
atic illustratio
n
 of  system
atic
 chang
es observed  in biofluids from
 S. 
C
hapter 4-Chem
om
etric
 analysis
 of biofluids from
 mice infected with
 Schistosom
a mansoni 
pyruvate 2-oxoisocaproate 	 
URINE 
2-oxoadipate 	 
hippurate 	trimethylamine 
a-aminoadipate 
leucine 
valine 
PLASMA 
2-oxoisovalerate 	 
p-cresol glucuronide f phenylacetyiglycine 
( 	 
FAECES 
microbiota 
t N-acetylglycoprotein 
propionate t 
5-aminovalerate 
glycolysis 
acetyl-CoA —a-3-hydroxybutyrate 
alanine fatty acids t 
0 
qi .17 phosphatidylcholine 
choline 
At 
glycerolphosphorylcholine citrate I TCA cycle 
glucose 
1 Zir 
- - pyruvate 
lactate t 
Chapter 5-Metabolic profiling of a Schistosoma mansoni infection in mouse tissues using magic angle 
spinning-nuclear magnetic resonance spectroscopy 
Chapter 5 Metabolic profiling of a Schistosoma mansoni 
infection in mouse tissues using magic angle spinning-nuclear 
magnetic resonance spectroscopy 
5.1 Aim 
To characterise metabolic signatures of a S. mansoni infection expressed as tissue 
damage in a range of organs and tissues in NMRI mice using 1H magic angle spinning 
(MAS) NMR spectroscopy coupled with multivariate data analyses. 
5.2 Introduction 
An introduction to schistosomiasis, including the life cycle, clinical symptoms, 
diagnosis and chemotherapy has been described in Chapter 4. Thus, the sections below 
will focus on egg-induced tissue damage and related histological studies, followed by 
the application of magic angle spinning NMR on intact tissues. 
5.2.1 Egg-induced tissue damage and histological studies on schistosomiasis 
The pathogenesis of schistosomiasis is largely due to inflammatory reactions cause by 
trapped schistosome eggs. An adult female S. mansoni worm, for example, produces 
—300 eggs per day (Moore and Sandground, 1956), approximately half of which are 
excreted from the host in the faeces whilst the remaining ones are trapped in various 
tissues (e.g. lung, brain and skeletal muscle etc.), mainly intestine and liver in the case 
of S. mansoni and S. japonicum, where they trigger a host immune response and 
subsequently cause granuloma formation around the eggs, which ultimately leads to 
fibrosis in these tissues (Boros, 1989; El-Garem, 1998; Ross et al., 2002; Gryseels et al., 
2006). Egg migration is believed to be associated with host immune status, which was 
supported by the reduction of egg excretion in faeces from T-cell-deficient mice and 
patients with immunodeficiency syndrome (Karanja et al., 1997). Intestinal 
schistosomiasis results from eggs trapped in the intestinal wall, provoking inflammation, 
ulceration, hyperplasia and microabscess. Hepatomegaly is caused by granuloma 
formation around the egg deposited in the presinusoidal capillary venules, which can 
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block the portal blood system and induce portal hypertension. Reticuloendothelial 
hyperplasia and blockage of the portal veins leads to splenomegaly (Boros, 1989; El-
Garem, 1998). Renal damage develops slowly and usually occurs years after 
hepatosplenic schistosomiasis, which is reflected by mesangial expansion and mesangial 
cell hyperplasia (Boros, 1989). 
Schistosomiasis-induced alterations in the intestine, liver and spleen tissues from 
experimental animals have been investigated by microscopic histology. The ileum 
obtained at 8, 12 and 16 weeks post-infection has been characterised by granulomas in 
mucosa, the submucosa and on the serosal surface contained lymphocytes, macrophages 
and eosinophilic granulocytes. A diffuse infiltrate was observed in the mucosa resulting 
in an increasing thickness of the mucosa (Bogers et al., 2000; De Man et al., 2002). In 
the liver, neovascular formation occurs in the scar tissue, and schistosome eggs and the 
granulomatous inflammation gradually obstructs portal venous flow, consequently 
leading to portal hypertension (Bloch et al., 1972). The major observations in spleen by 
a microscopic technique were the thickening of the splenic cords and enlargement of the 
venous sinuses, which are responsible for splenomegaly (Freitas et al., 1999). Although 
microscopic techniques can offer visualisation of differences between healthy and 
infected individuals, they fail to provide information at the molecular level, which might 
be important for further understanding of physiological and pathological consequences 
of the disease. 
5.2.2 Application of magic angle spinning (MAS) NMR on intact tissues 
NMR-based metabolic profiling provides a holistic platform with which to analyse 
small intact tissue samples using the magic angle spinning technique that has been 
introduced in Section 1.5.3. 1I-1 MAS NMR spectroscopy has been extensively applied 
to various types of tissue such as liver, intestine, kidney and brain in many studies in 
order to characterise the metabolic alteration induced by pathogens, physiological 
factors and toxins (Bollard et al., 2000; Garrod et al., 2001; Wang et al., 2005a). 
Additionally, MAS can provide a metabolic link between histology and metabolic 
profiling of biofluids, and can generate useful metabolic information on the metabolic 
consequences or mechanisms of external stimuli. 
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5.3 Materials and methods 
Animal maintenance, experimental design, tissue sample collection and preparation for 
1H MAS NMR spectroscopy analysis have been described in Chapter 2. 
Data reduction and multivariate data analysis: 1H MAS-NMR spectra obtained from 
intestinal tissues were manually phased and corrected for baseline distortions. The 
spectra were referenced using the signal from the anomeric a-glucose proton at 51H 
5.223. The entire spectrum (51H 0.0-10.0) was digitised into —20,000 data points with a 
resolution of 0.0005 ppm using an in-house developed MATLAB script (version 7.0). 
The region between 51H 4.70 and 5.20 was removed in order to minimise the effect of 
the imperfect baseline caused by the water suppression. In addition, regions between 
51H 0.0-0.3 and 51H 9.0-10.0 containing only noise were removed. Normalisation to the 
total area of the remaining NMR spectrum was performed prior to multivariate data 
analysis. An unsupervised multivariate data analysis tool such as PCA and a supervised 
multivariate data analysis tool such as O-PLS-DA, were applied to analyse 1H NMR 
spectral data in SIMCA and MATLAB software. 
Individual PCA models were constructed using unit-variance scaled 1H NMR spectral 
data of each type of tissues as X matrices and an appropriate number of principal 
components (as determined using the optimal goodness of prediction value, Q2Y) were 
calculated for each PCA model. 
O-PLS-DA models were constructed using NMR data as X matrices and the infection 
status (e.g. infection or control) as the Y matrix. One PLS component was calculated for 
each model with one orthogonal component using unit variance data scaling. The 
validation of each model was conducted using a 7-fold cross validation, e.g. iterative 
construction of models by repeatedly leaving out one-seventh of the samples and, 
subsequently, predicting them back into the model. 
In order to achieve a simultaneous comparison of the different tissue types and to assess 
the metabolic similarities/dissimilarities of tissues in response to S. mansoni infection, a 
multiblock H-PCA and H-PLS-DA method was employed to compare several blocks 
(e.g. several PCA models of individual tissue) derived from the same objects (e.g. 
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animals). This method is ideally used for analysing variable-rich datasets (Westerhuis et 
al., 1998; Eriksson et al., 2004). In sub-level PCA models, a total of 3 principal 
components were calculated for data obtained from jejunum and ileum and 2 principal 
components for the liver, kidney, spleen and colon using unit variance-scaled data. All 
meaningful scores (4) from these sub-level PCA models derived from 7 different types 
of tissue samples (e.g. jejunum, ileum, colon, liver, spleen, renal medulla and renal 
cortex) obtained from the same mouse were combined together with observations (e.g. 
animal identity) and formed a super block (T). Then a further PCA or PLS-DA, so 
called hierarchical PCA or hierarchical PLS-DA, was employed on T. A total of 2 
principal components were calculated based on mean-centred data for both H-PCA and 
H-PLS-DA models to facilitate visualisation of differences/similarities in the metabolic 
responses of multiple tissues or organs. 
In order to establish correlations between the metabolic alterations in different types of 
tissues and S. mansoni worm burden, an O-PLS algorithm was applied to the datasets 
using 1H MAS NMR spectra of each tissue from the S. mansoni-infected mice as X 
matrices and the worm burden, a typical parameter used to describe the infection level 
of S. mansoni, as the Y matrix. One predictive component with one orthogonal 
component was calculated for each model. 
5.4 Results 
5.4.1 Gross observation 
Two mice in the S. mansoni-infected group died at day 67 and 70 post-infection. Death 
was possibly caused by internal bleeding of oesophageal varices since a flood of blood 
was observed in the intestine of the dead mice. Additionally, upon dissection of mice, 
enlargement of the spleen and liver, thicker and rougher intestinal surface were 
observed in all S. mansoni-infected animals compared with those from the uninfected 
control mice. 
5.4.2 Histological examination 
The liver was not collected for histological examination as the entire liver, apart from 
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—15 mg taken for NMR analysis, was used to measure the worm burden. On the other 
hand, histological examination on the liver in schistosomiasis has been well documented, 
thus histological examination in the current study has been carried out on spleen and 
kidney samples obtained from uninfected control mice showed normal cellular 
architecture (Figure 5-1 A and B). Spleen samples obtained from S. mansoni-infected 
mice showed pronounced lymphofollicular hyperplasia with markedly increased 
neutrophilic granulocytes (Figure 5-1 C), including splenic microabscesses. Kidney 
samples obtained from the S. mansoni-infected mice appeared normal, with an 
exception of one animal that was characterised by a pyelonephritis, most likely due to a 
sepsis (Figure 5-1 D). 
Figure 5-1 Histology of spleen (A) and kidney (B) obtained from non-infected control mice. 
In mice infected with S. mansoni for 74 days, there was a marked lymphofollicular 
hyperplasia with prominent germinal centres with tangible body macrophages in the 
spleen (C, arrow-a), whereas no changes were observed in the kidney from S. mansoni-
infected animals with one exception (D, arrow-b) showed a pyelonephritis. All tissue 
samples were stained with haematoxylin and eosin; and magnifications for images A, B, C 
and D were 100x, 40x,100x and 400x, respectively. 
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5.4.3 Metabolite identification in 1H MAS NMR spectra of intact tissue samples 
For the purpose of metabolite identification, several 2-D 1H-1H TOCSY MAS NMR 
spectra of jejunum, ileum, colon, liver, spleen, renal cortex and medulla tissue obtained 
from selected uninfected control mice and mice infected with S. mansoni for 74 days 
were acquired. These selected 2-D spectra of jejunum, ileum, colon, liver, spleen, renal 
cortex and medulla tissues obtained from infected mice are shown in Figures 5-2 to 5-8, 
and aromatic regions of 2-D spectra of jejunum, liver, spleen and renal cortex are 
plotted in Figure 5-9. A number of metabolites, acetate, creatine, 
glycerophosphorylcholine, phosphorylcholine, choline, cytidine, uracil, glucose, 
fumarate, inosine, nicotinurate, deoxyuridine, ascorbate, formate, xanthine, glycogen, 
pyruvate, trimethylamine-N-oxide, lipid fractions, scy//o-inositol and a range of amino 
acids, such as leucine, isoleucine, proline, glutamine, glutamate, lysine, arginine, serine, 
threonine, asparagine, aspartate, methionine, glycine, alanine and valine, were identified 
based on 2-D 1H NMR spectra and the extant literature (Nicholson et al., 1995; Fan, 
1996; Wang et al., 2005a). The chemical shifts and peak multiplicities of all identified 
metabolites in the different tissue samples are listed in Table 5-1. 
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Figure 5-2 A 2-D 'H-'H TOCSY spectrum of the jejunum from a S. mansoni-infected 
mouse. Key: a-glu: a-glucose; Ala: alanine; Arg: arginine; Asn: asparagine; Asp: 
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glycine; GPC: glycerophosphorylcholine; lieu: isoleucine; Leu: leucine; Lys: lysine; Met: 
methionine; PC: phosphorylcholine; Pro: proline; tier: serine; Tau: taurine; Thr: 
threonine; Val: valine. 
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Figure 5-3 A 2-D 11-1- 1H TOCSY spectrum of the ileum from a S. mansoni-infected mouse. 
Key: Ala: alanine; Arg: arginine; Asn: asparagine; Asp: aspartate; 13-glu: 11-glucose; EA: 
ethanolamine; Gln: glutamine; Glu: glutamate; Gly: glycine; GPC: 
glycerophosphorylcholine; Ileu: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; PC: 
phosphorylcholine; Pro: proline; Ser: serine; Tau: taurine; Thr: threonine; Val: valine. 
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Figure 5-4 A 2-D 11 11-1 H TOCSY spectrum of the colon from a S. mansoni-infected mouse. 
Key: Ala: alanine; Arg: arginine; Asn: asparagine; Asp: aspartate; 	n-glucose; EA: 
ethanolamine; Gln: glutamine; Glu: glutamate; Gly: glycine; GPC: 
glycerophosphorylcholine; lieu: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; PC: 
phosphorylcholine; Pro: proline; Ser: serine; Tau: taurine; Thr: threonine; Val: valine. 
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Figure 5-5 A 2-D 'H-'H TOCSY spectrum of the liver from a S. mansoni-infected mouse. 
Key: a-glu: a-glucose; Ala: alanine; Arg: arginine; Asc: ascorbate; Asn: asparagine; Asp: 
aspartate; p-glu: a-glucose; EA: ethanolamine; Gln: glutamine; Glu: glutamate; Gly: 
glycine; GPC: glycerophosphorylcholine; lieu: isoleucine; Leu: leucine; Lys: lysine; Met: 
methionine; PC: phosphorylcholine; Tau: taurine; Thr: threonine; Val: valine. 
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Tau 
Figure 5-6 A 2-D 1H-11-1 TOCSY spectrum of the spleen from a S. mansoni-infected mouse. 
Key: a-glu: a-glucose; Ala: alanine; Arg: arginine; Asc: ascorbate; Asn: asparagine; Asp: 
aspartate; P-glu: P-glucose; EA: ethanolamine; Gln: glutamine; Glu: glutamate; Gly: 
glycine; GPC: glycerophosphorylcholine; Ileu: isoleucine; Leu: leucine; Lys: lysine; Met: 
methionine; PC: phosphorylcholine; Tau: taurine; Thr: threonine; Val: valine. 
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Figure 5-7 A 2-D 'H-'H TOCSY spectrum of the renal cortex from a S. mansoni-infected 
mouse. Key: Ala: alanine; Arg: arginine; Asn: asparagine; Asp: aspartate; p-glu: 13-
glucose; EA: ethanolamine; Gln: glutamine; Glu: glutamate; Gly: glycine; GPC: 
glycerophosphorylcholine; Ben: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; PC: 
phosphorylcholine; Pro: proline; Tau: taurine; Thr: threonine; Val: valine. 
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Figure 5-8 A 2-D 111-1 H TOCSY spectrum of the renal medulla from a S. mansoni-infected 
mouse. Key: a-glu: a-glucose; Ala: alanine; Arg: arginine; Asc: ascorbate; Asn: 
asparagine; Asp: aspartate; a-glu: a-glucose; EA: ethanolamine; Gln: glutamine; Glu: 
glutamate; Gly: glycine; GPC: glycerophosphorylcholine; Ileu: isoleucine; Leu: leucine; 
Lys: lysine; Met: methionine; PC: phosphorylcholine; Tau: taurine; Thr: threonine; Val: 
valine. 
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Table 5-1 Identified metabolites in IH MAS-NMR CPMG spectra of jejunum (J), ileum 
(I), colon (C), liver (L), spleen (S) and kidney (K) obtained from mice with or without 
an infection with S. mansoni, together with the respective chemical shifts and signal 
multiplicities. *s: singlet; bs: broad signal; d: doublet; t: triplet; q: quadruplet; m: 
multiplet; dd: double doublet. **A: all tissues. ***U: contamination from dissection. 
Metabolites H group 81H (multiplicity*) Tissues 
acetate CH3 1.91(s) A** 
alanine CH; CH3  3.77(q); 1.47(d) A 
3.76(t); 1.92(m); 1.65(m); 
arginine a-CH; P-CH2; 7-CH2; 5-CH2 3.24(t) A 
half CH2; half CH2; CHOH; 3.76(d); 3.74(d); 
ascorbate CH 4.03(ddd); 4.52(d) L/S/K 
4.01(dd); 
asparagine a-CH; p-CH2 2.87(dd),2.95(dd) A 
3.89(dd); 
aspartate a-CH; P-CH2 2.69(dd),2.80(dd) A 
choline N-(CH3)3; a-CH2; p-CH2 3.20(s); 4.07(m); 3.52(m) A 
creatine N-043; CH2 3.03(s)- 3 92(s) A 
cytidine 5-CH; 6-CH 6.09(d); 7.85(d) L/S 
deoxyuridine 5-CH; 6-CH 5.88(d); 7.86(d) L/S/K 
ethanol CH3; CH2 1.15(t); 3.65(m) U*** 
ethanolamine NH-CH2; HO-CH2 3.14(t); 3.82(t) A 
formate CH 8.45(s) 
fumarate 2x CH 6.52(s) S 
glutamate a-CH; p-a-12; 7-CH2 3.76(t); 2.07(m); 2.34(m) A 
glutamine a-CH; P-CH2; 7-CH2 3.78(t); 2.15(m); 2.45(m) A 
glycine CH 3.55(s) A 
glycogen CH 5.4(d) 
3.22(s); 4.32(t); 3.68(t); 
L 
glycerophosphoryl N-(CH3)3; a-CH2; P-CH2; 3.61(dd); 3.90(m); 
choline a'-CH2; p'-CH; 'y'-CH2  3.72(dd) 
2-CH; 6-CH; 2'-CH; 3'-CH; 8.34(s); 8.24(s); 6.10(d); 
inosine 4'-CH; 	5'-CH; CH2(i); 4.76(t); 4.44(t); 4.28(q); 
CH2(ii) 3.92(dd); 3.85(dd) 
3.68(d); 1.98(m); 
isoleucine a-CH; fl-CH; fl-CH3; 7-CH2(i); 1.02(d);1.25(m), 1.47(m); 
'y-CH2(ii); 7-CH3 0.94(t) A 
lactate a-CH; fl-CH3 4.11(q); 1.32(d) 
a-CH; fl-CH2; 7-CH; 3.72(t); 1.74(m); 1.70(m); 
A leucine 2x CH3 0.96(t) 
continued overleaf 
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continue Table 5-1 
-CH3; 0.89(bs); 
-(CH2),,-; 1.29(bs); 
CH2CH2CO; 1.59(bs); 
lipid fractions CH2CH2CO; 2.25(bs); 
CH2C=CCH2; 2.03(bs); 
=CH-CH2-CH=; 2.77(bs); 
CH=CH 5.32(bs) I/J/C/L/S 
a-CH; 13-CH2; y-CH2; 8-CH2; 3.78(t); 1.92(m); 1.72(m); 
lysine c-CH2 1.47(m); 3.03(t) A 
3.87(t); 2.14(m); 2.63(t); 
methionine a-CH; I3-CH2; y-CH2; S-CH3  2.13(s) A 
2-CH; 6-CH; 4-CH; 5-CH; 8.92(s); 8.70(d); 8.24(d); 
nicotinurate CH2 7.60(dd); 3.99(s) 1-4( 
phosphorylcholine N-(CH3)3; N-CH2; P03-CH2 3.22(s); 3.61(m); 4.25(m) A 
2,6-CH; 3,5-CH; 4-CH; 7.40(m); 7.33(m); 
phenylalanine 
half Ar-CH2; half Ar-CH2; 
N-CH 
7.35(m); 3.17(dd), 
3.30(dd); 3.99(dd) A 
4.13(dd); 
a-CH; half f3-CH2; half (3-CH2; 2.08(m),2.37(m); 
proline y-CH2; 5-CH2 2.01(m); 3.38(m) A 
pyruvate CH3  2.38(s) L/S 
scyllo-inositol 6x CH 3.33(s) J/I/C/K 
serine a-CH; 13-CH2 3.84(m); 3.96(m) A 
taurine N-CH2; S03-CH2 3.43(t); 3.27(t) A  
threonine a-CH; 13-CH; CH3  3.59(d); 4.27(m); 1.32(d) L/S/K 
trimethylamine-N-oxide 3x CH3  3.28(s) L/S/K 
7.18(d); 6.88(d); 
tyrosine 
2,6-CH; 3,5-CH 
a-CH; 13-CH2 
3.94(dd); 3.20(dd), 
3.10(dd) 
uracil 5-CH; 6-CH 5.80(d); 7.52(d) 
3.62(d); 2.28(m); 0.99(d); 
valine a-CH; I3-CH; y-CH3; y'-CH3  1.04(d) A 
xanthine CH 7.96(s) J/UC 
5.22(d), 3.56 (dd), 3.7(t), 
a-glucose 
1-CH, 2-CH, 3-CH, 4-CH, 
5-CH, half 6-CH2, half 6-CH2 
3.4(t), 3.83(m), 3.72(dd), 
3.85(m) A 
4.65(d), 3.25 (dd), 3.47(t), 
1-CH, 2-CH, 3-CH, 4-CH, 3.4(t), 3.47(ddd), 
13-glucose 5-CH, half 6-CH2, half 6-CH2 3.78(dd), 3.9(dd) A 
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5.4.4 PCA analysis of 1H MAS NMR spectra 
A PCA method was applied to analyse each type of experiments (e.g. 1-D 1H standard 
and CPMG spectra) for each type of tissue samples. PCA models constructed from 1H 
standard and CPMG spectra of each type of tissues generated similar results apart from 
lipid fractions which showed more significant changes in 1H standard spectra compared 
with CPMG spectra derived from the same tissue samples as expected since the 
macromolecular contribution is suppressed in the CPMG experiments. As CPMG 
spectra provide not only the same trend of changes in lipid fractions but also more 
detailed information on low molecular weight components, the following results will 
focus on the application of different analysis methods on CPMG spectra of each type of 
tissues. 
PCA scores plots derived from 1H CPMG spectral data of jejunum, ileum and colon 
tissues with the unit variance scaling method are shown in Figure 5-10. The mutual 
feature of these 3 plots is that uninfected control animals spread more extensively in the 
metabolic space than the S. mansoni-infected animals, especially in the PCA plot 
derived from the colon tissue. Moreover, the PCA scores plots obtained from the colon 
tissue spectra demonstrates a clearer separation than the jejunum and ileum samples as 
shown in Figure 5-10 C, where the S. mansoni-infected colon tissues differentiate from 
the uninfected control ones along the second principal component. 
The same analysis was performed on the liver, spleen, renal cortex and renal medulla 
tissues and the corresponding scores plots are shown in Figure 5-11. The separation of 
the S. mansoni-infected tissue samples from the uninfected controls is along the first 
principal component in all models with a clearer separation in PCA plots of the liver and 
spleen tissues. 
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Figure 5-10 PCA scores plots derived from 11-1 CPMG spectra of jejunum (A), ileum (B) 
and colon (C) tissues with 3, 3 and 2 principal components, respectively, which explained 
62.8%, 66.8% and 45.7% of variation for each model, reflecting separation of S. mansoni-
infected mice (red) from the uninfected control animals (blue). 
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Figure 5-11 PCA scores plots obtained from 'H CPMG spectra of liver (A), spleen (B), 
renal cortex (C) and renal medulla (D) tissues based on 2 principal components for each 
model, which explained 52.0%, 44.9%, 37.6% and 31.9% of variation for each model, 
representing separation of S. mansoni-infected mice (red) from the uninfected control 
animals (blue). 
5.4.5 O-PLS-DA analysis of 11-1 MAS NMR spectra 
In order to investigate the metabolic changes in various organs induced by S. mansoni 
infection and to further extract the biological markers related to the infection, an 0- 
PLS-DA strategy was used to compare 	CPMG NMR spectra of jejunum, ileum, 
colon, liver, spleen, renal cortex and medulla obtained from the infected mice and 
uninfected controls. The cross-validated scores plots (left hand side) and corresponding 
O-PLS-DA coefficient plots (right hand side) in Figures 5-12, 5-13 and 5-14 were 
generated from samples obtained from uninfected control and S. mansoni-infected mice 
for all tissues. The cross-validated score plots provide visualisation of the separation 
between the two groups, whereas the coefficient plots present the differences in 
metabolic profiles related to the infection. Here, upward oriented peaks in O-PLS-DA 
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coefficient plots represent a relative increase in the levels of metabolites in the infected 
group, whereas downward oriented peaks suggest a decrease in the levels of the 
metabolites. The colours shown on the plot are associated with the significance of 
metabolites in separating the two groups; red indicates a more pronounced change than 
blue indicating no change. Clear separations between the S. mansoni-infected and 
control mice and highly predictive models are observed in Figures 5-12, 5-13 and 5-14, 
which reflect the high Q217 values. The total explained variation for the X matrix for 
each tissue as indicated by the R2X value, the corresponding cross-validation parameter, 
Q2Y, indicating the predictability of the model and coefficient covariance values of 
those metabolites that were significantly correlated with S. mansoni infection are 
summarised in Table 5-2. A total of 8 mice are shown in the infected group since 2 died 
before the dissection and 9 in the control group since one animal was ill and was killed 
at day 48. 
In cross-validated scores plots, metabolic profiles of control animals are more variable 
than the S. mansoni-infected animals, as reflected by the extensive spread in the cluster 
relating to control animals and tightly clustering of infected animals in the metabolic 
space, particularly with respect to the colon and spleen tissues. In addition, the clearest 
separation was observed in the O-PLS-DA models of the colon, liver and spleen, with a 
larger distance between the uninfected control and the infected clusters compared with 
models derived from the jejunum, ileum, renal cortex and renal medulla. 
In the coefficient plots, the metabolic effects of S. mansoni infection on the jejunum and 
ileum (Figures 5-12 A and B) were similar and included higher levels of amino acids, 
such as, leucine, isoleucine, valine, lysine, arginine, methionine, glutamine, tyrosine and 
phenylalanine in the infected tissues than in the controls. In addition, lower levels of 
choline, fumarate and scyllo-inositol were observed in the jejunum of S. mansoni-
infected mice. In the ileum of infected mice, there were low levels of lipid fractions and 
high levels of alanine, taurine, glycine, creatine, inosine, glycerophosphorylcholine, 
phosphorylcholine and xanthine. A marked metabolic disturbance in the metabolite 
profiles of colon tissue (Figure 5-12 C) was also observed, including higher levels of 
GPC and PC, and a lower level of scyllo-inositol in infected mice. 
The metabolic response of these NMRI mice to a S. mansoni infection in the liver and 
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spleen (Figure 5-13) was similar, and was characterised by low levels of lipid fractions, 
and elevated levels of cytidine, uracil, fumarate, lactate and a number of amino acids, 
including lysine, arginine, methionine, glutamine, asparagine, phenylalanine, alanine, 
glycine, creatine, proline, leucine, isoleucine and valine. Moreover, relative levels of 
ascorbate and pyruvate were increased in the liver of infected mice. High levels of 
tyrosine, deoxyuridine and formate were found in the infected spleen. 
The S. mansoni infection-induced changes in the metabolic profiles of the renal medulla 
and cortex (Figure 5-14) were characterised by high levels of glutamine, lysine, 
asparagine and ascorbate, and marked lower levels of scy//o-inositol and choline. 
Additionally, low levels of ethanolamine and inosine were found in the renal cortex 
obtained from the infected mice in comparison with the non-infected group. 
Figure 5-12 Cross-validated score plots (left) and O-PLS-DA coefficient plots (right) 
derived from 'H CPMG NMR spectra of jejunum (A), ileum (B) and colon (C) from non-
infected (blue) and S. mansoni-infected mice (red). Key: Ala: alanine; Arg: arginine; Asn: 
asparagine; Gln: glutamine; Gly: glycine; GPC: glycerophosphorylcholine; lieu: 
isoleucine; Leu: leucine; Lys: lysine; Met: methionine; PC: phosphorylcholine; Phe: 
phenylalanine; s-ino: scyllo-inositol; Tau: taurine; Tyr: tyrosine; Val: valine. 
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Figure 5-13 Cross-validated score plots (left) and O-PLS-DA coefficient plots (right) 
derived from 'H CPMG NMR spectra of liver (A) and spleen (B) from non-infected (blue) 
and S. mansoni-infected mice (red). Key: Ala: alanine; Arg: arginine; Asn: asparagine; 
Asp: aspartate; Gln: glutamine; Glu: glutamate; Gly: glycine; GPC: 
glycerophosphorylcholine; Ileu: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; PC: 
phosphorylcholine; Phe: phenylalanine; Pro: proline; s-ino: scyllo-inositol; Tau: taurine; 
TMAO: trimethylamine-N-oxide; Tyr: tyrosine; Val: valine. 
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Figure 5-14 Cross-validated score plots (left) and O-PLS-DA coefficient plots (right) 
derived from 'H CPMG NMR spectra of renal cortex (A) and medulla (B) from non-
infected (blue) and S. mansoni-infected mice (red). Key: Asn: asparagine; EA: 
ethanolamine; lieu: isoleucine; Leu: leucine; Lys: lysine; s-ino: scyllo-inositol; Val: valine. 
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Table 5-2 Metabolites contributing to the discrimination between non-infected and S. mansoni-
infected mice in O-PLS-DA models derived from jejunum, ileum, colon, liver, spleen, renal 
medulla and renal cortex. Key: `+' (higher) and `-' (lower) indicate the direction of metabolite 
change in S. mansoni-infected versus non-infected control mice. '/' represents no change. 
O-PLS-DA plots 
metabolites 	jejunum 
Q2Y=0.73; 
R2X=0.45 
ileum 
Q2Y=0.72 
R2X=0.45 
colon 
; 	Q2Y=0.81 
R2X=0.44 
liver 
; 	Q2Y=0.94 ; 
R2X=0.56 
spleen 
Q2Y=0.86 ; 
R2X=0.45 
renal 
medulla 
Q2Y=0.58 
R2X=0.28 
renal 
cortex 
; 	Q2Y=0.54 ; 
R2X=0.33 
lysine 	+0.7724 +0.8380 / +0.7622 +0.7210 +0.7666 +0.6886 
methionine 	+0.6586 +0.8271 / +0.8712 +0.8688 / / 
glutamine 	+0.6732 +0.8465 / +0.8957 +0.8831 +0.7052 / 
asparagine 	+0.8994 / / +0.9084 +0.8800 +0.7673 +0.7715 
choline -0.6409 / +0.9195 +0.7839 -0.7136 -0.8041 
deoxyuridine 	+0.8551 +0.8680 / / +0.8540 / / 
fumarate 	-0.8884 / / +0.6665 +0.7914 / / 
tyrosine +0.8932 +0.8802 / / +0.9659 / +0.6245 
phenylalanine 	+0.7492 
lipid fractions 
+0.9042 +0.6299 +0.8150 +0.7173 
-CH3 -0.8297 -0.8174 -0.8531 
-(CH2)- -0.8464 -0.8350 -0.8360 
CH2CH2CO /  / CH2CH2CO -0.7687 / 
-0.7455 -0.8260 
- 
/ / 
CH2C=C CH2 -0.8473 -0.7471 -0.8434 
=CH-CH2- -0.7481 -0.5809 -0.8224 
CH=CH -0.8683 -0.7462 -0.8817 
leucine 	+0.7262 +0.8745 +0.7924 +0.7900 +0.6153 
isoleucine 	+0.7087 +0.6797 / +0.8420 +0.8033 / +0.6364 
valine +0.6719 +0.7332 / +0.8280 +0.7175 +0.6302 
alanine 	 / +0.6803 / +0.8703 +0.9501 / / 
GPC / +0.7581 +0.9009 +0.9381 +0.7338 / 
taurine 	 / +0.7754 / +0.7208 +0.7322 / 
glycine / +0.6756 / +0.9390 +0.8869 +0.6883 
creatine 	 / +0.7172 / +0.7206 +0.8970 / / 
inosine / +0.8601 / / / / -0.7320 
scyllo-inositol 	-0.7619 / -0.6670 / / -0.7815 -0.7889 
PC 	 / +0.7262 +0.8937 +0.8682 +0.8659 / / 
xanthine 	 / +0.7781 / / / / / 
TMA / / / / / +0.6525 / 
ascorbate 	/ / / +0.8634 / +0.9138 +0.7248 
lactate / / / +0.7922 +0.7999 / / 
cytidine 	 / / / +0.8665 +0.8331 / / 
uracil / / / +0.6950 +0.8563 / / 
nicotinurate 	/ / / +0.7685 / / +0.7989 
a-glucose / / / -0.6982 -0.8985 / / 
proline 	 / / / +0.9268 +0.8245 / / 
pyruvate / / / +0.7662 / / / 
TMAO 	 / / / +0.8359 +0.6864 / / 
formate / / / / +0.7710 / / 
glycogen 	/ -0.8039 / 	 / 
ethanolamine 	/ / / -0.8212 
aspartate 	/ / / / +0.8619 / / 
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5.4.6 Correlation of 11-I CPMG NMR spectra with worm burden 
An O-PLS method was employed to establish correlations between the metabolic 
changes in liver, kidney, spleen and intestinal tissues and the S. mansoni worm burden 
measured upon dissection of the mice. The O-PLS models generated from jejunal, liver 
and renal medullary tissues demonstrated strong correlations with the worm burden, and 
are shown in Figure 5-15. The metabolites in these tissues that were highly correlated 
with worm burdens, together with the quality of the models (Q2Y, R2X) are summarised 
in Table 5-3. Concentrations of amino acids such as lysine, tyrosine, alanine and 
glutamine in these tissue were positively correlated with the worm burden, whilst levels 
of glucose were positively associated with worm burden in renal medulla and jejunal 
tissues, but showed an inverse association in liver tissue. In addition, levels of glycogen 
in liver and membrane metabolites including choline and GPC in renal medulla were 
negatively related to the worm burden. 
Table 5-3 Metabolites that were correlated with worm burden and Q2Y and R2X of each 
model from jejunum, liver and renal medulla. `+' represents positive correlation to the 
worm burden whilst `—' represents negative correlation to the worm burden. '/' 
represents no correlation. 
O-PLS plots 
metabolites jejunum 
Q2Y=0.61; 
R2X=0.46 
liver 
Q2Y=0.40; 
R2X=0.41 
renal medulla 
Q2Y=0.45; 
R2X=0.35 
(3-glucose +0.8682 -0.5348 +0.6906 
lysine +0.7032 / / 
glutamine +0.6113 / +0.8531 
a-glucose +0.8598 -0.6712 / 
tyrosine +0.6140 / / 
alanine I +0.6964 
glycerophosphoryl 
choline / / -0.8074 
choline I 	 I -0.6671 
glycogen I -0.7940 I 
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Figure 5-15 O-PLS plots derived from MAS-NMR CPMG spectra of jejunum (A), liver 
(B) and renal medulla (C) from S. mansoni infected mice using worm burden as the class 
descriptor (Y matrix). Key: a-glu: a-glucose; 13-glu: 11-glucose; Ala: alanine; Gln: 
glutamine; GPC: glycerophosphorylcholine; Lys: lysine; Tyr: tyrosine. 
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5.4.7 H-PCA and H-PLS-DA on 111 NMR spectral data of multi-tissues 
H-PCA and H-PLS-DA were built based on PCA models constructed individually for 
each type of tissue as described in Section 5.4.4. A total of two principal components 
were calculated in the H-PCA model with 59% of total variance being explained. The 
H-PLS-DA model was also constructed based on 2 components with R2X of 51.4% and 
Q2Y of 94%. Both the H-PCA and H-PLS-DA scores plots (Figures 5-16 A and B) 
showed a clear separation between the S. mansoni-infected and control group along the 
first principal component, and as expected the power of the separation using the 
combined tissue matrix was greater than that of any individual tissue. The H-PLS-DA 
loadings plot (Figure 5-16 C) presents correlations between scores (tb) imported from 
the sub-level PCA models. The scores that dominate the separation of infection from 
control include Jej.t[1], Jej.t[3], Ile.t[1], Ile.t[2], Col.t[2], Liv.t[1], Spl.t[1], Med.t[1] and 
Cox.t[1] (Jej, Ile, Col, Liv, Spl, Med and Cox stand for jejunum, ileum, colon, spleen, 
renal medulla and renal cortex; the adjacent numerical value in square brackets refers to 
the principal component from which the scores were derived. Thus Jej.t[1] represents 
the first principal component for the sub-level of the PCA model derived from the 
jejunal tissue). Jej.t[1] and lle.t[2], Spl.t[1] and Liv.t[1] shared the similar changes in 
metabolic profiles post infection since certain degrees of clustering were observed in the 
H-PLS-DA loading plot. In order to investigate the key metabolic changes in each tissue, 
the corresponding loading plots (ph ) of these important scores (tb) from sub-level PCA 
models were plotted in Figures 5-16 D-L. S. mansoni infected mice showed higher 
levels of leucine, isoleucine, alanine, valine, lysine, phosphorylcholine and 
glycerophosphorylcholine in jejunum, ileum, colon and kidney tissues, whereas control 
mice manifested relatively higher concentrations of glucose and lipid fractions in ileum, 
liver and spleen tissues together with an increased concentration of hepatic glycogen. 
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Figure 5-16 H-PCA scores plot (A), H-PLS-DA scores plot (B) and H-PLS-DA loadings 
plot (C) obtained from scores of sub-level PCA models which separately derived from 7 
different tissues from the S. mansoni-infected (red) and non-infected mice (blue). Sub-level 
PCA loadings (Med.t[1], Jej.t[1], Jej.t[3], Ile.t[2], CoLt[2], Liv.t[1], Spl.t[1], Ile.t[1] and 
Cox.t[2]) contributing significant contributions to the separation are shown in panels D-L. 
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5.5 Discussion 
1H NMR MAS spectra of various intact tissue samples including jejunum, ileum, colon, 
liver, spleen, renal medulla and renal cortex provided valuable information on metabolic 
alterations induced by a 73-day old S. mansoni infection in mice. Metabolic disturbance 
of each type of the tissue was visualised by O-PLS-DA coefficient plots. Furthermore, a 
metabolic overview allowed the characterisation of similarities/differences across all 
types of tissues with the aid of multivariate data analysis methods such as H-PCA and 
H-PLS-DA. In addition, the histological image of the spleen tissue revealed 
architectural structure damage which complements the metabolic observations at the 
molecular level. 
5.5.1 Metabolic effects of a S. mansoni infection on the intestinal tissue of mice 
Intestinal tissues from the S. mansoni-infected mice appeared to have a thicker and 
rougher surface than those from non-infected control mice by visual inspection. These 
observations are consistent with previous histological studies on the ileum from mice at 
8-12 weeks post infection of S. mansoni that noted a diffuse thickening of the smooth 
muscle layers of the intestine, disturbance of the architectural structure of the myenteric 
plexus and broadening of the intestinal villi due to a patent S. mansoni infection (Bogers 
et al., 2000; De Man et al., 2002; De Jonge et al., 2003a; De Jonge et al., 2003b). 
Elevated levels of membrane phospholipid metabolites, such as GPC and PC found in 
the ileum and colon of infected mice in the current study could also be associated with 
structural changes in the intestinal architecture. These elevated levels of membrane 
phospholipid metabolites may be responsible for cellular swelling and/or a proliferation 
of smooth muscle cells, leading to the accumulation of intracytoplasmic fluids in cells 
and cellular overgrowth, as previously reported (Blennerhassett et al., 1992; Bogers et 
al., 2000). For example, a transient increase of mast cells in mucosa in mice, reaching a 
peak value at 8 weeks post-infection with S. mansoni was reported (De Jonge et al., 
2003a). Further effects on the intestinal architectural structure can be induced by the 
trapped S. mansoni eggs in the intestine, which results in the secretion of antigens that 
cause the granulomous inflammation and lead to tissue fibrosis (Lukacs et al., 1993; 
Weinstock, 1996). Intestinal fibrosis is particularly common in the distal ileum and the 
proximal colon (Weinstock, 1996), which may explain the elevated levels of GPC and 
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PC observed in the ileum and colon from S. mansoni-infected mice in the current study. 
Biochemical changes associated with inflammation triggered by the S. mansoni 
infection appeared to be similar to those caused by chronic bowel diseases. For example, 
biopsies of colon from patients with Crohn's disease contained high levels of choline-
containing compounds (e.g. GPC and PC) compared with normal parts of colon from 
the same patients (Bezabeh et al., 2001). 
Intestinal inflammation is commonly accompanied by disorders of the gastrointestinal 
tract. Investigation into the association between inflammatory response and alteration in 
intestinal muscle contractility in a Trichinella spiralis-rat model has been well 
documented (Khan and Collins, 2006). Hypercontractility can physically lead to a 
higher level of break down of proteins, facilitated by the assistance of enzymes from 
pancreas and intestinal glands, leading to high levels of amino acids in the small 
intestine (Martin et al., 2006). In the present study, the most prominent observation was 
the increased concentrations of a range of amino acids in the small intestine (jejunum 
and ileum) tissues of S. mansoni infected mice. Hypercontractility of intestinal muscle 
of the infected mice requires higher energy compared to non-infected control mice. This 
requirement for energy could be met via creatine metabolism and lipid oxidation in 
infected mice. Indeed, relatively high levels of creatine were observed in the ileum of 
mice infected with S. mansoni for 74 days when compared to non-infected mice. 
Phosphorylcreatine serves as an energy store and, together with ADP, is transferred into 
creatine and ATP in order to replenish the energy requirement. In the current study, 
levels of lipid fractions were found to be decreased in the intestine of S. mansoni-
infected mice, particularly in the ileum. Both in vitro and in vivo studies showed that the 
host response to the S. mansoni infection involves the production of reactive oxygen 
species and that oxidative processes commonly occur at the site of inflammation, which 
is used to reduce the effect of schistosomiasis (Abdallahi et al., 1999; El-Sokkary et al., 
2002). These resulting free radicals could lead to oxidation of lipids. Alternatively, 
oxidation of lipids can also provide energy for intestinal contractility. The observation 
of a significant positive relationship between worm burden and energy-related 
metabolites such as glucose, lysine, glutamine and tyrosine underscores the high energy 
requirement of hypercontractility of the small intestine of infected mice. In addition, 
elevated levels of lipid fractions were found in plasma samples from S. mansoni-
infected mice, which could also result from lipid absorption from the intestine. 
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Furthermore, taurine, which was present in higher levels in the ileum, liver and spleen 
from the infected mice, is known to be a multifunctional metabolite. It has been reported 
to have antioxidant and anti-inflammatory effects and to be involved in several Ca2+-
dependent mechanisms, such as muscular contractility, control of cell volume and tissue 
osmolality (Baumrucker et al., 1989; Huxtable, 1992; Son et al., 1998; Martin et al., 
2006; Das et al., 2008). Therefore, increased levels of taurine in the S. mansoni-infected 
mice could play protective role against free radical damage and cell expansion caused 
by inflammation. 
5.5.2 Metabolic effects of a S. mansoni infection on the liver tissue of mice 
It is widely acknowledged that a S. mansoni infection causes inflammation of the liver 
and eventually leads to liver fibrosis, a crucial feature of chronic schistosomiasis in 
humans (Gryseels et al., 2006). Liver fibrosis — regardless of its cause — is often 
associated with the deposition of extracellular matrix proteins, including collagens and a 
number of glycoproteins (Maher and Mcguire, 1990). Levels of free proline, a precursor 
of hydroxyproline, as well as glycine and alanine, which are major amino acids in the 
synthesis of collagen, were observed to be elevated in the liver from the S. mansoni-
infected mice, which might imply stimulated collagen synthesis activity. Previous in 
vitro investigations also proved that collagen synthesis by fibrotic liver slices grew as 
the concentration of free proline was increased in the medium (Dunn et al., 1977). The 
elevated level of free proline could be partially attributed to the production of 
S. mansoni eggs as shown in a previous study documenting a distinct increase in the 
proline production-involved enzyme activities of ornithine-S-transaminase and A'-
pyrroline-5-carboxylic acid reductase in S. mansoni eggs (Isseroff et al., 1983). 
Furthermore, elevated levels of ascorbate were found in the liver of infected mice. 
Ascorbate is a reducing agent and plays an important role in collagen synthesis probably 
by keeping prolyl hydroxylase in an optimal state and maintaining iron atoms in their 
ferrous state (Stryer, 1981). 
An increased ratio of glutamine and glutamate complex to lipid was reported as the 
severity of liver fibrosis progressed to the later stage (Cho et al., 2001), which is 
consistent with our results of higher levels of hepatic glutamine together with the 
relatively lower concentration of lipids in the liver from infected mice. 
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An egg granulomatous-induced liver fibrosis not only results in a structural alteration 
(Silva et al., 2000), but also causes functional alterations, such as decreased oxidative 
deamination of amino acids and a disturbance in ammonia metabolism (Daugherty et al., 
1954). Previously, a decreased expression of enzymes related to the citric acid cycle, the 
fatty acid cycle, the urea cycle and amino acid metabolism and catabolism has been 
shown in mice 8 weeks after infection with S. mansoni (Harvie et al., 2007). Here, a 
decreased level of glycogen was found in the liver of S. mansoni-infected mice, which 
might be explained by either the inhibition of glycogen synthesis or enhanced glycogen 
breakdown. However, it has been reported that glycogen phosphorylase for 
glycogenolysis was suppressed in mice due to an infection with S. mansoni (Ahmed and 
Gad, 1995). Moreover, stimulated glycolysis in S. mansoni-infected mice has been 
previously reported (Wang et al., 2004). Therefore, it is likely that the infection or 
infection-induced host responses contribute to both the inhibition of the glycogen 
synthesis and stimulation of the glycogen breakdown, resulting in the depletion of 
glycogen levels in the liver recovered from S. mansoni-infected mice. Independent 
enzymatic assays on activities of glycogen phosphorylase and uridine diphosphate 
(UDP)-glucose pyrophosphorylase would verify whether the reduction levels of 
glycogen is caused by both processes simultaneously or dominated by only one of these 
processes. 
5.5.3 Metabolic effects of a S. mansoni infection on the spleen tissue of mice 
S. mansoni-induced inflammation is also reflected in an enlargement of the spleen, 
which was confirmed in our study upon dissection of mice by gross observation and 
further underscored by histological examination. Spleen enlargement is hypothesised to 
result from passive congestion of portal hypertension and/or cellular hyperplasia (Ross 
et al., 2001). Biochemical features associated with a S. mansoni infection included 
higher concentrations of glutamine, coupled with a decrease in lipids and glucose in the 
spleen from the infected mice. Glutamine is an essential energy source in mitochondria 
and can also be utilised by lymphocytes (Klimberg and McClellan, 1996; Yaqoob and 
Calder, 1997). Therefore, an elevated level of glutamine may indicate a hyperactive 
immune system triggered by the S. mansoni eggs trapped in the tissue. Glycolysis is 
also carried out in lymphocytes and macrophages which could be used to meet the 
energy requirement of a stimulated immune system due to the infection. As a 
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consequence, depleted levels of glucose and elevated levels of lactate would be 
expected, consistent with our observations in the spleen of infected mice. 
5.5.4 Metabolic effects of a S. mansoni infection on the renal tissue of mice 
An epidemiological investigation carried out among school children in an area highly 
endemic for schistosomiasis found that renal disease was uncommon (Johansen et al., 
1994). On the other hand, although neither the adult worms nor the eggs of S. mansoni 
directly caused a pathogenic effect in the kidney of hamsters;  there was an 
immunological response 6 weeks post-infection, characterised by the deposition of 
immune complex and renal amyloidosis (Sobh et al., 1991). In our study, we found 
elevated levels of glutamine, GPC and choline in the renal medulla of S. mansoni-
infected mice, which were positively correlated with the worm burden. Glutamine and 
GPC have been reported to have osmotic function in the brain and inner kidney, 
respectively (Miller et al., 2000). These observations may indicate a counterbalance 
response and dysfunction of the kidney due to the parasitic infection. However, with the 
exception of one mouse, the cellular architecture in the kidney of the remaining 
S. mansoni-infected mice appeared normal. Perhaps longer term the infection may lead 
to structural damage. 
5.5.5 Metabolic effects of a S. mansoni infection in mice at the system level 
Informative H-PCA and H-PLS-DA models provide a better description of molecular 
consequences of the S. mansoni infection in mice at the system level. Metabolic effects 
of S. mansoni infection on the liver and spleen profiles were similar, as reflected by the 
decreased levels of lipid fractions and elevated levels of amino acids in the infected 
mice (Figures 5-16 I and J). The variations explained by the second principal 
component in the PCA models derived from the ileum and colon, separately, were 
similar, including increased concentrations of GPC and PC in the infected mice. This 
hierarchical method has demonstrated a convenient platform which allows a multiple 
compartmental comparison in a large dataset or multi-compartment study, although 
these hierarchical methods represent only one of a myriad of possibility for a systems 
level investigation. 
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5.6 Summary 
Metabolic effects were observed in various intestinal tissues, liver, spleen and kidney of 
S. mansoni-infected mice as revealed by a metabolic profiling strategy. The current 
findings indicate both localised and remote effects induced by the infection and the 
metabolic consequences of inflammation and hypercontractility of the intestine, damage 
to the liver and kidney and enlargement of the spleen caused by a S. mansoni infection. 
These findings provided a holistic approach to characterising the metabolic effects due 
to a S. mansoni infection in host organs at the molecular level and indicated a 
coordinated response across several tissues in response to this parasitic infection. 
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Chapter 6 Metabonomic and microbiological analysis of the 
dynamic effect of vancomycin-induced gut microbiota 
modification in the mouse 
Altered microbiota-related urinary metabolites induced by the parasitic infections were 
monitored in the previous studies, thus the current chapter aims to use the treatment of 
mice with vancomycin as a model in order to provide a metabolic and metagenomic 
baseline of microbial disturbance and recovery for further work on investigation of 
microbial changes in the parasite infected-host. 
6.1 Aims 
• To characterise the dynamic perturbation of urinary and faecal metabolites caused 
by treatment of conventional NMRI mice with vancomycin using 1H NMR 
spectroscopy in conjunction with multivariate data analyses. 
• To monitor time-course changes in the gut microbiota community during the course 
of the recovery from vancomycin treatment using 16S rRNA polymerase chain 
reaction-denaturing gradient gel electrophoresis (PCR-DGGE) analysis. 
• To correlate microbial changes with urinary and faecal metabolic features and to 
provide a baseline for further study on vancomycin-treated S. mansoni-infected mice. 
6.2 Introduction to microbiology 
6.2.1 Composition of microbiota 
A large number of complex and diverse microbiota (anaerobic and aerobic) live in the 
mammalian gut. The number of bacterial species in a given individual is approximately 
500-1000 and the microbial population ranges from 10 to 100 trillion (Sonnenburg et al., 
2004). Bacteria mainly reside in the large intestine with a few species in the stomach 
and small intestine (Figure 6-1). The bacterial density in the colon reaches 1011-1012 
bacterial per gram, which comprise approximately 60% of faecal solids, while in the 
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stomach and small intestine, bacteria number is only approximately 101-103 and 104-107 
bacterial per gram respectively (Guarner and Malagelada, 2003; O'Hara and Shanahan, 
2006). This is due to the inhibitory effect of the lumina] medium (e.g. acid, bile and 
pancreatic secretions) on the colonisation of bacteria in upper gastrointestinal tract, and 
the bowel propulsive activity towards the ileal end, which physically push bacteria to 
the colon (Guarner and Malagelada, 2003). It has been reported that anaerobic bacteria 
are 100-1000 times more abundant than aerobic bacteria (Guarner and Malagelada, 
2003). The predominant bacterial genera in human beings are bacteroides, 
bifidobacterium, eubacterium, clostridium, peptococcus, peptostreptococcus and 
ruminococcus, while some aerobic bacterial genera such as escherichia, enterobacter, 
enterococcus, klebsiella, lactobacillus and proteus are subdominant (Salminen et al., 
1998; Guarner and Malagelada, 2003). 
Figure 6-1 The distribution of bacteria density and the list of common anaerobic and 
aerobic genera. CFU: colony forming units. 
The intestine picture is from the link below: 
http://www.upmccancercenters.com/pdq_xml/media/CDR0000415499.jpg  
The foetal gastrointestinal tract is sterile but colonisation of bacteria starts immediately 
after birth when it is exposed to microbes of the mother and the environment (Tannock, 
2005). This initial establishment of bacteria is influenced by various factors, such as the 
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manner of delivery (passage through the birth canal vs. caesarean), the feeding mode 
(breast vs. formula), hygiene levels and chemotherapeutic interventions (Gronlund et al., 
1999; Rinne et al., 2005; Penders et al., 2006). Penders et al. (2006) have found lower 
levels of bifidobacteria and bacteroides and higher levels of C. difficile in infants born 
through caesarean section in contrast with those born naturally; E. coli, C. difficile, 
bacterioides and lactobacilli were found in greater numbers in formula-fed infants; and 
intervention of antibiotics induced a decrease in bifidobacteria and bacteroides. These 
pioneer bacteria can modulate gene expression in host epithelial cells, and create an 
optimum atmosphere in order to live and inhibit the growth of other bacteria (Hooper et 
al., 2001). Therefore, the initial colonisation of the intestine is closely associated with 
the stable composition of microbiota in adults (Guarner and Malagelada, 2003). 
Although the gut microbial composition in adults is relatively stable, it varies greatly 
between individuals and populations, which are affected by host genotype, diet, age, sex, 
diseases and medication usage (e.g. antibiotics) (Moore and Moore, 1995; Nicholson et 
al., 2005; Li et al., 2008). 
6.2.2 Functions of microbiota 
It is widely acknowledged that the presence of the gut microbiota is a key factor in gut 
development, structure and function including various metabolic activities, trophic 
effects on intestine and immune function, and protection against the invasion of other 
microbes (Barbara et al., 2005; Tannock, 2005; O'Hara and Shanahan, 2006). 
Metabolic activities of the microbiota: Metabolic activities of microbes in the host are 
very complex since the microbiota contain a diverse range of enzymes. These microbes 
often possess different metabolic pathways compared to the host. A major metabolic 
activity of microbiota is the fermentation of carbohydrates and endogenous mucus 
produced by the epithelia, which provides energy and nutrition for microbiota growth 
and reproduction. These carbohydrates include non-digestible dietary residue (e.g. 
starches, cellulose, hemicellulose and gums) and some escaping oligosaccharides from 
the enzymatic digestion in the small intestine. The main end products of the 
fermentation are short chain fatty acids (SCFAs, e.g. acetate, butyrate and propionate), 
which play an essential role in host physiology, such as vitamin synthesis, improvement 
of ion absorption and maintenance of intestinal epithelial function. The effect of 
175 
Chapter 6-Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut 
microbiota modification in the mouse 
butyrate on colonic epithelial, vascular endothelial and extracolonic cells has been 
characterised both in vivo and in vitro, where it has been shown that butyrate is a major 
energy resource for colonic epithelial cells, may have an anti-inflammatory effect, and 
could be a potential chemopreventive compound in carcinogenesis (Scheppach and 
Weiler, 2004). Propionate and acetate can be absorbed by the colon and metabolised in 
the liver and peripheral tissues (Cummings et al., 1987). In addition to SCFAs, bacteria 
also produce several toxic substances such as ammonia, amines, phenols, thiols and 
indols, via the anaerobic metabolism of peptides and proteins. 
Trophic effects of the microbiota: The resulting SCFAs from the fermentation of 
carbohydrates exert a trophic effect on differentiation and proliferation of epithelial 
cells of the intestine. For example, butyrate is considered to protect against colon cancer 
by inhibiting cell proliferation and promoting cell differentiation in colon tumour cell 
lines (Hague et al., 1995; Velazquez et al., 1996). In addition, gut microbiota are also 
closely associated with the host immune system since the intestinal mucosa is a major 
platform for the interaction between the immune system and the external environment 
(Guarner and Malagelada, 2003). 
Protective function of the microbiota: Resident microbiota provide a protective barrier 
against invasive pathogens via several mechanistic procedures. Resident microbiota 
attach themselves to the brush border of intestinal epithelial cells, which results in few 
sites being available for the adherence of exogenous microbes (Bernet et al., 1994). The 
balanced symbiotic relationship between resident microbes and the host (e.g. supply and 
demand of nutrients) can also prevent the invasion of potential pathogens (Guarner and 
Malagelada, 2003). Moreover, microbes can produce bacteriocins, or antimicrobial 
substances, to inhibit the growth of competitive intruders (Lievin et al., 2000). 
6.2.3 Microbiota-related diseases 
Bacterial translocation: Bacterial translocation is defined as the passage of viable 
indigenous bacteria from the intestinal tract through the epithelial mucosa to the 
systemic circulation via the mesenteric lymph nodes (Vanleeuwen et al., 1994). Having 
crossed the mucosa, these bacteria travel to the liver, spleen and kidney, and then 
disseminate throughout the body, hence potentially causing sepsis, multisystem organ 
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failure and shock. An overgrowth of enteric bacteria, increased permeability of the 
intestinal mucosal barrier, and the disturbed host immune system are the main 
mechanisms promoting bacterial translocation (Berg, 1999). 
Inflammatory bowel diseases, Irritable bowel syndrome and Colon cancer: Intestinal 
microbiota may also play a major role in the aetiology of many gut disorders, such as 
inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and colon cancer 
(Sokol et al., 2006; Thompson-Chagoyan et al., 2007). IBDs including Crohn's disease 
(CD) and ulcerative colitis (UC) are considered to be linked to both faecal and mucosa-
associated microbiota. Faecal microbiota from patients with IBDs hold a different 
pattern of microbes compared with healthy individuals, such as reduced concentrations 
of Clostridium coccoides and C. leptum groups in faeces from UC and CD patients 
(Sokol et al., 2006). Furthermore, a larger amount of bacteria from diverse genera were 
found attached to the epithelial surfaces in patients with IBD or IBS than in healthy 
subjects and some of them (e.g. bacteroides) are identified in the epithelial layer 
(Swidsinski et al., 1999; Thompson-Chagoyan et al., 2007). Although the 
pathophysiological functions of these altered bacteria remain unknown, the intestinal 
inflammatory responses could be activated by these bacteria and can play a role in the 
aetiology of these diseases. 
Fat-rich diets and high consumption of red meat are known to be related to the initiation 
of colon cancer since this diet exerts an impact on the metabolic activities and 
composition of microbiota, and subsequently these influenced intestinal microbiota may 
promote the production of carcinogens, cocarcinogens, or procarcinogens (Guarner 
Malagelada, 2003). A study on human faecal microbiota showed that Bacteroides 
vulgatus and B. stercoris were associated with high risk of colon cancer while 
Lactobacillus acidiphilus, L. S06 and Eubacterium aerofaciens were associated with 
low risk (Moore and Moore, 1995). 
Obesity: The microbial genomes, or so-called microbiome, has recently been reported to 
vary significantly between obese individuals (human and animals) and normal 
individuals, and it is known to provide refined control mechanisms on energy recovery 
through catabolism of otherwise poorly digestible nutrients, e.g., resistant starch and 
other polysaccharides (Turnbaugh et al., 2006; Thompson-Chagoyan et al., 2007; 
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Backhed et al., 2007). The main differences in gut microbiota of obese subjects were a 
reduced level of Bacteroidetes and an increased level of Firmicutes (Tumbaugh et al., 
2006). Since the microbiota are extremely metabolically active and co-metabolise many 
endogenous and xenobiotic compounds, they clearly have the potential to affect the 
biochemical composition of the tissues and biofluids of the host (Phipps et al., 1998; 
Nicholls et al., 2003). 
Microbial association in parasitic diseases: Urinary fingerprints derived from mice 
with a S. mansoni infection have shown changes in the concentration of hippurate, 
phenylacetylglycine, SCFAs and p-cresol glucuronide, which are known to be products 
of microbial metabolism (Wang et al., 2004). In particular, cresol metabolites are known 
to be antimicrobial products of Clostridium difficile (Selmer et al., 2001). Altered 
hippurate levels have also been observed in T. brucei brucei-infected mice (Wang et al., 
2008a). Thus, these diseases clearly result in a disruption of the intestinal microbial 
community, which can also be reflected by the biochemical composition of biofluids. 
6.2.4 Antibiotics and vancomycin 
Antibiotics are commonly used to treat infection-induced diseases but little attention is 
paid to their effect on the intestinal microbiota. Clinical research has reported a decrease 
in anaerobes, aerobes and Gram-negative bacilli and an increase in yeast, E. coli and C. 
difficile post antibiotic treatment. Antibiotic-induced overgrowth of C. difficile can 
cause diarrhoea and pseudomembranous colitis and its outbreak leads to a high rate of 
mortality in both adult patients and paediatric populations (McFarland et al., 2000; 
Thompson-Chagoyan et al., 2007). 
Vancomycin (C66H75C12N9024, M=1449.3, Figure 6-2), a glycopeptide antibiotic, is 
produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis. It 
is commonly used in the treatment of serious Gram-positive bacteria-induced infections 
by interfering with proper cell wall synthesis in Gram-positive bacteria. Due to its large 
molecular weight, vancomycin is not absorbed orally and is generally given 
intravenously. 
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Figure 6-2 Chemical structure of vancomycin (picture source: Wikipedia). 
6.2.5 Molecular biology methods in microbial studies 
Culturing techniques have been used for several decades in microbiologic studies; 
however, only 1% or less of bacteria in the environment can be cultured in the 
laboratory since a complicated symbiotic relationship exists between the bacteria 
themselves and their environment (Amann et al., 1995). Hence, these culture-dependent 
studies fail to provide comprehensive information regarding bacteria in a complex 
mixture or community as found in the biosphere. Modern molecular biology methods, 
such as metagenomics (the genomic analysis of uncultured microorganisms), allow us to 
investigate the complex composition of microbial community in situ (Amann et al., 
1995; Schloss and Handelsman, 2003; Riesenfeld et al., 2004; Handelsman, 2004; 
Tringe et al., 2005; Wilmes et al., 2006). 
The culture-independent technique based on 16S rRNA PCR and DNA sequencing has 
been applied to the investigation of microbial composition in healthy/diseased human 
gut. Several recent publications have demonstrated the potential of this metagenomic 
approach in investigating changes of a range of microbiota in faecal water from patients 
with Crohn's disease or ulcerative colitis, revealing a reduced diversity in Firmicutes 
and Bacteroidetes phylum (Manichanh et al., 2006; Frank et al., 2007). Bridging the 
findings from metagenomics and metabonomics is a key step to understand the 
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interactions between the gut microbiota and the host. Scanlan et al. found an increase in 
diversity of the Clostridium leptum and C. coccoides subgroups in faecal water from 
subjects with colorectal cancer or polyposis compared with matched controls, and 
parallel metabolic profiling of faecal water showed higher levels of several amino acids 
(e.g. glutamate, leucine, isoleucine and valine) and lower levels of methylamine in the 
diseased subjects (Scanlan et al., 2008). As multivariate statistical analysis methods 
progress, so the capacity for statistically correlating these two types of dataset (e.g. 
DGGE fingerprints and NMR profiles) in order to determine the positive/negative 
correlation between bacterial species and metabolite changes, which has recently been 
demonstrated by a study on microbial structures of a Chinese family and American 
volunteers (Li et al., 2008). 
6.2.6 Metabolic profiling on microbial studies 
Metabolic profiling has been employed to characterise the cross-talk between gut 
microbiota and disease intervention at the molecular level. For example, a previous 
study on 113D showed the perturbation of microbiota-related metabolites, such as 
methylamine, trimethylamine and short chain fatty acids including acetate and butyrate, 
in faecal water from patients with Crohn's disease, which indicated a substantial 
destruction of microbiota in the gut (Marchesi et al., 2007). Additionally, diet, drug 
intervention, environment and some parasitic infection such as T. brucei brucei and S. 
mansoni-induced effects on aromatic metabolites such as hippurate and/or 3-
hydroxyphenylpropionic acid, which are known to be produced or co-metabolised by 
gut microbiota, have been characterised together with those involved in bile acid 
catabolism, choline metabolism and utilisation of short chain fatty acids (Phipps et al., 
1998; Williams et al., 2002; Nicholls et al., 2003; Wang et al., 2004; Holmes and 
Nicholson, 2005; Robosky et al., 2005; Dumas et al., 2006; Martin et al., 2007; Wang et 
al., 2008a). Further evidence of the direct contribution of microbiota to host metabolism 
has been obtained using metabolic profiling methods to characterise germ-free and 
antibiotic-rodent models (Williams et al., 2002; Nicholls et al., 2003; Martin et al., 
2006). 
Germ-free models provide valuable information on microbial-mammalian co-
metabolism, but they are not an optimal model for monitoring microbiota-mammalian 
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metabolic interaction in 'normal' animals since the gut of such animals remains 
underdeveloped and they fail to mimic a true picture of normal mammalian physiology. 
An alternative approach is to employ conventional animals, with normal gut physiology, 
combined with antimicrobial treatment, which offers a more realistic window onto gut 
colonisation. 
As part of ongoing studies to determine the effect of the gut microbiota on host 
metabolic phenotypes and the interaction between the host (mouse) and the parasite (S. 
mansoni), an antibiotic-based model was employed here to directly probe the dynamic 
effect of the microbial contribution to urinary and faecal composition and provide a 
baseline for the therapeutic studies on parasitic diseases. Vancomycin was chosen to 
reduce the Gram-positive bacteria in the gut without overtly modifying the Gram-
negative bacteria, in order to target one particular aspect of the microbial influence on 
host metabolism. Additionally, vancomycin is poorly absorbed by the mammalian 
gastrointestinal mucosa, so it should not directly alter host biochemistry (Pultz et al., 
2005). 
6.3 Methods and materials 
Animal maintenance, experimental design, sample collection and preparation for 1H 
NMR spectroscopy analysis have been described in Chapter 2. 
6.3.1 Multivariate data analysis on 1H NMR spectral data 
Multivariate data analysis was performed based on the pre-processed NMR data set. 1H 
NMR spectra obtained from urine and faecal water were automatically phased, 
calibrated and baseline-corrected using a MATLAB script developed by Dr. Ebbels at 
Imperial College. The resulting NMR spectra (81H 0-10) were imported to MATLAB 
software and digitised into 20 k data points with the resolution of 0.0005 ppm using a 
script developed in house (Dr. Cloarec). The water peak region 81H 4.7-6.35 in urine 
spectra and 81H 4.7-4.9 in faecal water spectra were removed in order to minimise the 
effect of the disordered baseline. Additionally, regions 81H 0-0.7 and 81H 9.5-10.0 in 
urine spectra, and regions 61H 0-0.5 and 61H 9.0-10.0 in faecal water spectra containing 
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only noise were removed, followed by normalisation to the entire sum of the remaining 
spectra in order to perform further analysis. Principal component analysis and a 
supervised multivariate data analysis tool, O-PLS-DA (Trygg and Wold, 2002), were 
carried out based on the resulting NMR spectral data set in SIMCA (P+11.5) and 
MATLAB software, separately. 
O-PLS regression analysis was performed using pre-processed faecal extract spectral 
data as the X matrix and the integrated hippurate resonance (61H 7.818-7.855) or the 
integrated phenylacetylglycine resonance (61H 7.4-7.446) as the Y matrix. 
6.3.2 Microbiological analysis 
6.3.2.1 DNA extraction 
Approximately 0.2 g of faecal sample was placed into a 2 ml Eppendorf tube and rinsed 
with 500 µI of phosphate buffer saline twice in order to expel alcohol from the 
reservation solution of the original sample. The pre-processed faecal sample, mixed 
with 1.4 ml of Buffer ASL, was transferred into a plastic tube containing 0.5 g of 0.1 
mm diameter glass beads and 0.5 g of 1.0 mm diameter zirconia beads and vortexed for 
1 min to ensure that the sample was thoroughly homogenised. DNA extraction was 
carried out using QIAamp DNA Stool Mini Kit (Qiagen, Dublin) according to the 
protocol provided in the handbook. 
6.3.2.2 PCR protocol 
PCR products for DGGE analysis were obtained using a two-stage PCR strategy. For 
the first PCR amplification, the forward primer 27f (5' GAG1 	GATCMTGGCTCAG 
3') and the reverse primer 1492r (5' GGYTACCTTGTTACGACTT 3') were used to 
amplify the near-full-length of 16S rRNA gene. The 25 µI of reaction mixture consisted 
of 15 µI of H2O, 2.5 µI of 10x PCR buffer (160 mM of (NH4)2SO4, 670 mM of Tris-HC1 
[0-1=8.8 at 25°C], 0.1% stabiliser), 1.5 mM of Mg2+, 5 µI of a 10 mM of each 
deoxynucleoside triphosphate mixture, 50 pmol of each primer, 7.5 lig of bovine serum 
albumin (New England Biolabs), 0.25 µI of Taq DNA polymerase (5 U/µ1, Bioline) and 
1 µI of extracted bacterial DNA. The reaction was performed on a PTC-200 thermal 
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cycler (MJ Research, USA) using the following conditions: initial denaturation at 94 °C 
for 2 min, followed by 35 cycles consisting of 92 °C for 30 sec, 55 °C for 30 sec and 
72°C for 30 sec, and the final extension at 72 °C for 5 min. The resulting PCR products 
were used as templates in the second round of PCR. The second PCR was performed 
with 341f-GC (5' CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGT-
ACGGGAGGCAGCAG 3') and 519r (5' GTATTACCGCGGCTGGCTG 3') primers 
in a total reaction volume of 50 µ1 containing all reagents mentioned above with the 
doubled concentrations (Vanhoutte et al., 2004). The PCR programme started with a 
denaturation temperature of 95 °C for 5 min and the cycle (95°C for 30 sec, 56 °C for 
40 sec and 72 °C for 1 min) run 30 times, followed by a final extension temperature of 
72 °C for 5 min. PCR products from each step were tested on 1.5% agarose gels and 
visualised by staining with ethidium bromide and exposure to UV light. 
6.3.2.3 DGGE analyses 
The DGGE analysis of PCR 16S rRNA gene products was carried out using a DCode 
universal mutation detection system (Bio Rad, UK). Polyacrylamide gels (200 x 200 x 1 
mm) consisted of 8% (v/v) polyacrylamide (37.5:1 acrylamide-bisacrylamide) and 0.5x 
TAE using a denaturing gradient of 30-55% where denaturing acrylamide of 100% was 
defined as 7 M urea and 40% (v/v) formamide. A total of 20 µI of PCR product from 
the second PCR for each sample was loaded and 500 ng per lane of a DNA ladder 
(Invitrogen 100 bp ladder) was selected added as a reference. Electrophoresis was 
performed in 0.5x TAE buffer at 60 °C for 10 min at 200 V and further 16 h at 85 V. 
The gels were stained for 40 min in 100 ml of 0.5x TAE buffer containing 10 µI of Sybr 
Gold (Invitrogen), visualised under UV light and photographed. 
6.3.2.4 Sequencing of DGGE fragment 
A number of strong bands were excised with sterile pipette tips and placed into 
microcentrifuge tubes containing 10 µI of sterile water. The PCR fragments were 
passively diffused into water at 4 °C for 24 h. An aliquot (1 µI) of eluted DNA was used 
as the template for PCR with the same primers (341f-GC and 519r) and conditions (see 
previous description). The PCR products were re-run using DGGE in order to confirm 
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that the single and correct positioned band appeared on the gel. Subsequently, 4 ill of 
the eluted DNA was used in a PCR with 341f (5' TACGGGAGGCAGCAG3') and 519r 
primers in a total of reaction volume of 100 IL These PCR products were cleaned and 
concentrated into 30 ill using QIAquick PCR Purification Kit (Qiagen, Dublin). 
Sequencing of the 16S rRNA partial gene product was performed by GATC (Germany) 
and phylogenetic analysis was performed using the RDP classifier tool (Wang et al., 
2007a). 
6.4 Results 
6.4.1 111 NMR spectroscopic profiles of vancomycin and drug vehicle 
ili NMR spectra of vancomycin and drug vehicle containing 7% Tween 80 and 3% 
ethanol (Figures 6-3 and 6-4) were acquired in order to aid the following analyses of 
biofluid samples. 
Figure 6-3 The 'H NMR spectrum of vancomycin. 
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Figure 6-4 The 11-1 NMR spectrum of drug vehicle (7% Tween 80 and 3% ethanol). 
6.4.2 1H NMR spectroscopic profiles of urine samples 
Typical 600 MHz 1H NMR spectra of urine obtained from a drug vehicle-treated control 
mouse (from here on referred to as 'control mouse') and a vancomycin-treated mouse at 
1 day post-treatment are shown in Figure 6-5. Urinary spectra were dominated by a 
number of metabolites, namely, 2-oxoglutarate, 2-oxoisocaproate, 2-oxoisovalerate, 
citrate, creatine, creatinine, dimethylamine, hippurate, lactate, phenylacetylglycine, 
succinate, lysine, taurine, 3-ureidopropionate, trimethylamine and trimethylamine-N-
oxide (Table 4-2). Resonances from vancomycin and drug vehicle were not observed in 
any of these spectra. Visual inspection of the spectra revealed marked differences in 
overall metabolic composition between urines obtained from control and vancomycin-
treated mice, with the latter showing relatively lower concentrations of urinary 
hippurate, and higher levels of urinary creatine. 
6.4.3 Multivariate data analysis of 1H NMR spectroscopic profiles of urine samples 
In order to monitor the vancomycin-induced metabolic perturbation in urine over all the 
time points, a PCA strategy was employed to analyse the entire spectral data. A total of 
3 principal components were calculated for a PCA model (R2X=35.9%) using unit 
variance scaled spectral data as shown in Figure 6-6. There was clear separation 
between urine samples obtained from control mice and mice given vancomycin 1-3 days 
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after the dosing. At days 5 and 7 post-treatment, samples from treated mice were still 
differentiated from the control cluster, but much closer, finally co-mapping with the 
control cluster at days 13 and 19 post-treatment. 
To further extract the discriminatory metabolites associated with the class separation 
between control and vancomycin-treated mice, an O-PLS-DA model was utilised to 
pairwise compare the urinary spectra of vancomycin-treated mice to the control ones at 
each sampling time point. Figure 6-7 displays three O-PLS-DA coefficient plots 
selected from days 1, 3 and 7 post-treatment, showing lower concentrations of urinary 
hippurate and PAG, and higher levels of creatine, N-acetylglycoprotein fragments, 3-
methyl-2-oxovalerate and 2-oxoisovalerate in the vancomycin-treated mice. The model 
parameters for urine samples are given in Table 6-1 together with the O-PLS-DA 
correlation coefficient values (indicating the relative contributions of metabolites 
contributing to the separation between two classes) of discriminatory metabolites at all 
time points. 
In the urinary O-PLS-DA plots comparing control and vancomycin-treated animals for 
each of the 7 time points, 3 dominant metabolites, e.g. hippurate, PAG and creatine, 
were found to co-vary consistently during the course of the recovery from vancomycin 
treatment. One peak was chosen from each metabolite (e.g. hippurate: 61H 7.818-7.855; 
creatine: 61H 3.927-3.938; PAG: 61H 7.4-7.446) and integrated based on the normalised 
spectral data, followed by averaging these integration values from the control and 
treated mice for each time point, respectively, as shown in Figure 6-8. Urinary 
concentrations of both hippurate and PAG decreased after the vancomycin treatment. 
However, the "recovery" of hippurate towards control levels was slower (ca 19 days) 
than that of PAG (ca 7 days). Urinary creatine was increased at days 1 and 2 post-
vancomycin treatment and recovered from day 3 onwards. 
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Figure 6-6 A PCA trajectory scores plot derived from 'H NMR spectra of urine samples. 
Colour code: grey (control), black (vancomycin-treated TR,), red (TR1), green (TR2), 
yellow (TR3), blue (TR5), purple (TR7), dark blue (TR13 and TR19). 
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Figure 6-7 O-PLS-DA coefficient plots derived from the 1H NMR spectra of urine 
indicating discrimination between control and vancomycin-treated mice at days 1 (A), 3 (B) 
and 7 (C) after dosing. Key: MOV: 3-methyl-2-oxovalerate; OIV: 2-oxoisovalerate; PAG: 
phenylacetylglycine; UN: unknown. 
Table 6-1 Changes of metabolites observed in urine obtained from mice at different time 
points after vancomycin treatment, compared with the corresponding control mice at the 
same time point. `+' represents higher concentrations of metabolites in the treated mice, `-' 
presents lower levels of metabolites in the treated mice compared with controls and 'I' 
means no significant correlation observed. Q2Y of model at TR19 was <0 indicating that 
there was no significant difference between control and treated mice. 
Importance of contribution at different time points post-treatment 
(O-PLS-DA) 
Metabolites 
TR I 
= 
(Q2Y 
0.78; R2X 
= 31%) 
TR 2 
(Q2Y 
0.82; R2X 
=32%) 
TR 3 
(Q2Y= 
0.75; R2X 
=34%) 
TR 5 
(Q2Y= 
0.74; R2X 
=34%) 
TR 7 
(Q2
Y 
0.67; R2X 
=30%) 
TR 13 
(Q2
Y= 
0.54; R2X 
=29%) 
2-oxoisovalerate +0.6995 / I / / / 
3-methyl-2- 
oxovalerate +0.6552 / / / / / 
unknown -03723 -0,8406 -0.6108 -0.7725 +0.6566 / 
creatine +0.6531 +0.8030 / / / / 
hippurate -0.7965 -0.8966 -0.7095 -0.8457 -0.9514 -0.7643 
N-acetylgl yeoprotein 
fragments +0.6080 +0.6451 +0.6072 / / / 
phenylacetylglycine -0.6261 -0.6436 -0.6254 / / / 
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Figure 6-8 Integration of selected peaks from hippurate, creatine and PAG in total area-
normalised urinary spectra at all time points, demonstrating the systematic variation in 
metabolite concentrations with the time progressed. Error bars represent the standard 
error of the mean. 
6.4.4 1H NMR spectroscopic profiles of faecal extract samples 
Typical 1H NMR spectra of faecal extracts obtained from a control and a vancomycin-
treated mouse at day 1 post-treatment are shown in Figures 6-9. A range of metabolites 
such as amino acids (e.g. leucine, arginine, valine, alanine, isoleucine, aspartate, 
glutamine, glutamate, lysine, glycine, methionine, phenylalanine and tyrosine), short 
chain fatty acids (e.g. butyrate, propionate and acetate), uracil, 5-aminovalerate, 
nicotinurate, choline, succinate, glucose, Tween 80 and oligosaccharides were assigned 
with an in-house database, the assistance of previously published data and 2-D NMR 
spectra (Dumas et al., 2006; Martin et al., 2007; Saric et al., 2008a). Tween 80 was 
assigned according to the spectrum shown in Figure 6-4. Reduction in the relative 
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concentrations of faecal amino acids, short chain fatty acids and uracil, and an increase 
in faecal choline and oligosaccharide levels were observed in vancomycin-treated mice. 
6.4.5 Multivariate data analysis of 111 NMR spectroscopic profiles of faecal extract 
samples 
A PCA method was utilised to monitor the vancomycin-induced metabolic perturbation 
in faecal extracts over all the time points. A total of 3 principal components were 
calculated for a PCA model (R2X=57.1%) using unit variance scaled spectral data 
(Figure 6-10). The faecal model showed a similar metabolic movement to that observed 
for the urinary data. A marked discrimination of the faecal extract composition at days 1 
and 3 post-vancomycin treatment from the control cluster was observed. At days 5 and 
7 post-treatment, samples from the treated mice still showed difference from the 
controls, but this difference was less significant in terms of the number of perturbed 
metabolites, finally co-mapping with the control cluster at days 13 and 19 post-
treatment. 
As for the previous analysis of the urinary spectra, systematic comparison of the treated 
and control groups at each sampling time point was performed using an O-PLS-DA 
method. The O-PLS-DA coefficient plots (Figure 6-11 A) derived from spectral data of 
faecal extracts at day 1 post-treatment showed a marked depletion of a range of amino 
acids including leucine, isoleucine, valine, lysine, glutamate, methionine, taurine and 
aromatic amino acids such as tyrosine and phenylalanine, and short chain fatty acids 
(e.g. acetate, propionate and butyrate), together with other metabolites, such as 5-
aminovalerate, cytosine, nicotinurate and glucose. Moreover, elevated concentrations of 
choline and oligosaccharides were also observed in the vancomycin-treated mice. 
However, at days 3 and 5 post-treatment, the number and the significance of these 
disturbed metabolites decreased. The model parameters for faecal samples are given in 
Table 6-2, together with the O-PLS-DA correlation coefficients indicating the relative 
contributions of key metabolites contributing to the antibiotic-perturbed profiles. The 
number of changed metabolites observed in faecal extracts from the vancomycin-treated 
mice is greater than that observed in the urine samples, which indicated that 
vancomycin caused a substantial and more significant effect on the faecal composition 
as compared to the urinary changes. 
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A total of 3 dominant metabolites including butyrate, acetate and 5-aminovalerate were 
chosen to directly visualise perturbation during the whole course of the experiment. 
Following exactly the same method as previously mentioned in the urine analysis, the 
integration values of these selected peaks (e.g. butyrate: 61H 0.88-0.917; acetate: 61H 
1.904-1.941; 5-aminovalerate: 61H 5.793-5.828) were plotted in Figure 6-12. Two 
metabolites showed a similar trend of changes during the course of treatment whereas 5-
aminovalerate fluctuated and recovered to "normal" level at day 13 post-treatment. 
Compared with the perturbation in urine profiles, the faecal extract spectra showed a 
stronger initial response to the vancomycin treatment and quicker recovery. 
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Figure 6-10 A PCA trajectory scores plot derived from 	NMR spectral data of faecal 
extracts. Colour code: grey (control), black (vancomycin-treated TR,), red (TR,), yellow 
(TR3), blue (TR3), purple (TR7), dark blue (TR,3 and TR19). 
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Figure 6-11 O-PLS-DA coefficient plots derived from the III NMR spectra of faecal 
extracts indicating discrimination between control and vancomycin-treated mice at days 1 
(A), 3 (B) and 5 (C) after the dosing. Key: 5-AV: 5-aminovalerate; a-glu: a-glucose; Ala: 
alanine; Arg: arginine; 11-glu: fi-glucose; Glu: glutamate; lieu: isoleucine; Leu: leucine; 
Lys: lysine; Met: methionine; Phe: phenylalanine; Tyr: tyrosine; Val: valine. 
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Table 6-2 Changes of metabolites observed in faecal extracts obtained from mice at 
different time points after vancomycin treatment, compared with the corresponding 
control mice at the same time point. `+' represents higher concentrations of 
metabolites in the treated mice, `-' presents lower levels of metabolites in the treated 
mice compared with controls and '/' means no significant correlation observed. Q2Y 
values of models from days 13 and 19 were <0 and 0.22, respectively. 
Importance of contribution at different time points post-treatment 
Metabolites (O-PLS-DA) 
TR 
(Q2Y = 0.93; 
R2X = 0.76) 
TR 3 
(Q2Y = 0.91; 
R2X = 0.61) 
TR 5 
(Q2Y = 0.82; 
R2X = 0.35) 
TR 7 
(Q2Y = 0.39; 
R2X = 0.28) 
butyrate -0.7830 -0.7873 -0.6455 / 
valine -0.8731 -0.8064 -0.6334 / 
acetate -0.8515 -0.7971 / / 
5-aminovalerate -0.8460 / +0.8995 +0.6317 
methionine -0.8020 -0.8966 / / 
taurine -0.8246 -0.7465 / 
a-glucose -0.7904 / / / 
13-glucose -0.8197 -0.8656 / / 
uracil -0.7725 -0.6285 / / 
cytosine -0.7731 -0.7277 / / 
tyrosine -0.7893 -0.8741 / / 
phenylalanine -0.7766 -0.8596 -0.7605 / 
leucine -0.8080 -0.9168 -0.6743 / 
isoleucine -0.8330 -0.8374 -0.6727 / 
alanine -0.8176 -0.8899 / / 
glutamine -0.6741 -0.6850 / / 
propionate -0.8835 -0.8064 / / 
lysine -0.8159 -0.8880 / / 
arginine -0.8259 / / / 
glutamate -0.7236 -0.6407 / / 
nicotinurate -0.7789 / / / 
oligosaccharides +0.9650 +0.7767 / / 
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Figure 6-12 Integration of selected peaks from acetate, butyrate and 5-aminovalerate in 
total area-normalised faecal water spectra for all time points, demonstrating the 
concentrations of metabolites varied as the time progressed. Error bars represent 
standard error of the mean. 
6.4.6 O-PLS correlation of urinary hippurate and phenylacetylglycine 
concentrations with faecal metabolites 
O-PLS regression of urinary hippurate and phenylacetylglycine against the faecal 
extract profiles at day 1 and 3 post-dosing, respectively, are shown in Figure 6-13. 
Urinary hippurate generated a strong O-PLS regression model (R2X=57%, Q2Y=71% 
using 1 component model) against time-matched faecal extract spectra (Figure 6-13 A). 
Several faecal amino acids including leucine, isoleucine, valine, alanine, glutamate, 
phenylalanine and tyrosine, were positively correlated with urinary hippurate 
concentrations, together with short chain fatty acids (propionate, butyrate and acetate) 
and uracil. Conversely faecal choline and oligosaccharides were negatively correlated 
with urinary hippurate. Faecal lactate and succinate were uncorrelated with hippurate. 
The regression model for urinary phenylacetylglycine showed no correlation with faecal 
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water profiles at day 1 post-treatment, but at day 3 it showed correlations with the same 
molecules as hippurate (Figure 6-13 B) but the model and correlation coefficients were 
weaker (R2X=60%, Q2Y=37% using a 1-PLS component with 1 orthogonal component). 
Subsequent O-PLS regression analyses were carried out on all the time points (day 1-
day 19) and the characteristics of these models are summarised in Table 6-3. The 
decreasing Q2Y at later time points indicates weaker correlations between the urinary 
hippurate and phenylacetylglycine concentrations and the faecal metabolic profiles. 
These findings are consistent with the changes observed in the quantified urinary 
metabolites (Figure 6-8). 
Figure 6-13 O-PLS regression of urinary hippurate (A) and urinary phenylacetylglycine 
(B) against 1 -I NMR spectra profiles of faecal extracts obtained at day 1 and 3 post-dosing, 
respectively. Key: Ala: alanine; p-glu: n-glucose; Glu: glutamate; lieu: isoleucine; Leu: 
leucine; Lys: lysine; Met: methionine; Phe: phenylalanine; Tyr: tyrosine; Val: valine. 
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Table 6-3 O-PLS model summary of the correlations between urinary hippurate and 
phenylacetylglycine with faecal metabolites for day 1, 3, 7, 13 and 19. 
Time point 
hippurate PAG 
Q2y 
R2X 
Number of 
components Q2y R2X 
Number of 
components 
TR1  71% 57% 1 <0 
TR3  56% 64% 3 37% 60% 2 
TRH 63% 64% 5 13% 20% 
TR13  52% 38% 3 <0 
TR19 17% 22% 1 <0 
6.4.7 Microbial diversity with time and trajectory of DGGE data 
16S rRNA PCR-DGGE and sequencing, as a routine molecular approach, was applied 
to examine disturbance of the microbiota caused by vancomycin treatment in mice over 
the duration of the extensive time course (19 days) of the study. Figure 6-14 compares a 
DGGE profile from a control mouse (A) with that from a vancomycin-treated mouse 
(B). It is obvious from Figure 6-14 B that vancomycin exerted a huge impact on 
microbial community as there was increased diversity of bands observed in the 
vancomycin-treated mice. Sequences closely related to Clostridium syrnbiosum and 
Photorhabdtts luminescens were found to be impacted and were lost from the DGGE 
profiles 1 day post-treatment (Table 6-4). Bands a, b, e, and g closely related to 
Eubacteriwn desmolans, C. cocleatttm, Anaeroplasma bactoclasticum and Clostridium 
sp. BA-I respectively appeared after the vancomycin dose. 
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Figure 6-14 DGGE, profiles from a control (A) and a vancomycin-treated mouse (B) at all 
time points. Refer to Table 6-4 for keys a-g. 
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Although no band was confirmed by the PCR-DGGE-Sequence method, PCR products 
derived using specific primers of C. leptum and C. coccoides respectively were 
visualised as shown in Figures 6-15 A and B, which illustrate a recovery of these two 
species at day 2 or day 3 post-treatment following an initial disappearance. 
 
amp 
s--2501253 bpy imp at as IS 4111 	wis, 
11111.1k1- __ 
Figure 6-15 Visualisations of PCR products derived from the control (A and C) and 
vancomycin-treated mice (B and D) using C. coccoides (A and B) and C. leptum (C and D) 
primers. The sizes of C. coccoides and C. leptum products are 500 and 250 base pairs, 
respectively. 
Table 6-4 Taxonomic affiliation of the partial 16S rRNA gene sequence obtained from the 
excised DGGE bands. The rows shaded in grey are the closest hits to bacteria, which have 
been cultured. 
key 	Phyla 	 Class 	 Order 	 Family 	Genus 	Species 
Accesion Sodality 
number 
Firmicures 	Manicures 	.4naeroplasmatales Anaeroplasmaraceae .inaeroplasma 
Firmicutes 	Mollicutes 	Anaeroplasmatales Anaeroplasmataceae Anaeroplarma 
Finnicures 	Mallow 	.4naeroplasmarales Anaeroplasmataceae Anaeroplasma 
Firmicutes 	Clostridia 	Clostridiales 	Eubacteriaceae 	Eubacterizan  
Uncultured bacteniun 
Anaeroplasma 
bactoclasacion  
Uncultured bacterium 
Ettbacterium 
desmolans 
	
AY960576 	92% 
M25049 	90% 
EU006469 	92% 
L34618 	83% 
b 
Finnicures 	Clostridia 	Clostridiales 	Clostridiaceae 	Clostriditmi 	Unculuired bacterium EF406679 	97% 
F17711101185 	Clostridia 	Clostridiales 	Clostridiaceve 	Clostriditan 	Clostridium 	AF028350 	97% cocleaunn 
Firmicures 	Clostridia 	Closindiales 	Clostridiaceae 	Clostridium 	Uncultured bacterium EF603657 	97% 
Firmicutes 	Clostridia 	Closaidiales 	Clostridiaceae 	Clostridium 	Clostridium sp. BA-i AB196728 	83% 
linincutes 	Clostridia 	Closindiales 	Lachnospiraceae 	Incertae sedis Uncultured bacterium EF704431 	96% 
Ftnnicutes 	Clostridia 	Clastricitales 	Closoldiaceae 	Closodu 	Closaldiuman EF442669 	95% sImbiosum 
Firmicutes 	Clostridia 	Clostridiales 	Clostridiacome 	Ruminococcus Uncultured bactenum AY976513 	58% 
Finnicutes 	Clostridia 	Clostridiales Lachnosprracecre Anaerostipes butyrate-producmg  AY305319 6CP4i bacterium SS2Y1 
Proteobacteria 	Gornmaproieobacteria 	Enterobacteriaies 	Enterobacreriacece 	Eschenclna 	Uncultured bacterium EF674507 	94% 
d 	 Photorhabdus Proteobactena Gammaproteobacterra Enterobacteriales Enterobacterzaceae Pitotorhabdus 	haninescens DQ518589 93°. 
f 
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6.5 Discussion 
It is well known that antibiotics exert a great impact on the composition of the gut 
microbiota (De La Cochetiere et al., 2005). In addition to treating bacterial infection, the 
use of antibiotics is associated with several other consequences on the structures and/or 
activities of the gut microbes. For example, antibiotics play a central role in the 
development of C. diffici/e-associated colitis (Wilcox, 2003). Moreover, the gut 
microbiota is resilient and once the antibiotic source has been removed, it is thought to 
substantially recover to its original composition and diversity (De La Cochetiere et al., 
2005). Microbial activity influences host biology and has implications for host health. 
Previous studies have shown the contribution of gut microbiota to mammalian host 
metabolism by measuring specific groups of compounds such as amino acids, bile acids, 
short chain fatty acids, monitoring changes in faecal ammonia and host physiological 
descriptors such as those related to energy expenditure, lipoprotein profile and recovery 
from gut dysbiosis (Coldham et al., 2002; Gonthier et al., 2003). 
Application of an 1H NMR-based metabonomic approach and a PCR-DGGE-based 
microbiological method is demonstrated in this study to investigate the effects of 
vancomycin on gut microbial community in conventional mice during a time course of 
19 days. All animals were fed with the same food, kept in the same environment and 
given the drug vehicle, thus it was unlikely that metabolic variation observed were due 
to environmental conditions. 
6.5.1 Effects of the drug vehicle on metabolic profiles 
Neither vancomycin nor its metabolites were detected in either urine as vancomycin is 
not absorbable by the small intestine, or faecal extract since it is probably excreted 
within 24 hours after treatment. Drug vehicle was found in faecal extract profiles on day 
1 post-treatment from both groups but not in urine and was eliminated within 48 hours. 
The pairwise comparison carried out between the vancomycin-treated and the control 
mice which received an equivalent amount of drug vehicles compromised the Tween 
80-induced metabolic perturbations. The presence of drug vehicle signals at 61H 3.7 in 
faecal extract profiles at 1 day post-treatment showed no contribution to the class 
discrimination (Figure 6-11). From DGGE profiles (Figure 6-14), no changes were 
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observed in control mice, which indicates little or no effect on microbial composition 
induced by the drug vehicle Tween 80. 
6.5.2 Effects of vancomycin on urinary metabolite profiles 
Vancomycin administration caused a great diversity of microorganisms in colonic 
ecology within 24 hours post treatment according to the DGGE profiles. Additionally, 
marked perturbations in metabolite profiles were also observed in 1H NMR urinary 
spectra, with a prominent reduction in the levels of hippurate and phenylacetylglycine in 
the vancomycin-treated mice. Hippurate is formed either by benzoate conjugation with 
glycine in liver mitochondria or by intestinal flora in the presence of quinic acid 
(1,3,4,5-tetrahydroxycyclohexanecarboxylic acid) via a complicated process (Satoor, 
1965). Previous studies on germ-free animals (Nicholls et al., 2003) and rats treated 
with antibiotics (Williams et al., 2002) reported a dynamic series of changes in the 
biochemical composition of the urine observed in germ-free animals, as reflected by 
sequential excretion of phenylacetylglycine, 4-hydroxyphenylpropionic acid, 3-
hydroxyphenylpropionic acid and, finally, hippurate at around 21 days post-exposure. 
Alterations in the concentrations of these metabolites have been previously reported in 
many studies, such as ingestion of cephaloridine (Murgatroyd et al., 1992; Halligan et 
al., 1995), gentamicin (Lenz et al., 2005), neomycin, tetracycline hydrochloride and 
bacitracin mixture (Williams et al., 2002), and also in P. berghei-infected mice (Chapter 
3), S. mansoni-infected mice (Chapter 4) and T. brucei brucei (Wang et al., 2008a), 
where these metabolites were believed to be associated with parasitic pathogen-induced 
disturbance of gut microbial composition and/or activities. Gut microbiota also 
extensively catabolise proteins and aromatic amino acids, including phenylalanine, 
tyrosine and tryptophan (Diaz et al., 2001). Faecal amino acids, including tyrosine and 
phenylalanine, were noted to be directly correlated with urinary hippurate and 
phenylacetylglycine, consistent with decreased catabolism of these amino acids by the 
microbiota. 
In the current study vancomycin had a strong impact on the region of the spectrum 
representing phenolic molecules with particular effect on reduction of signals from 
hippurate and phenylacetylglycine. Both PAG and hippurate were observed to be 
decreased after administration of vancomycin; however, urinary concentrations of PAG 
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were restored to those of controls at day 5, while recovery of urinary hippurate was not 
manifested until the end of the experiment at day 19 post-treatment. This suggests that 
establishment of a stable gut microbiota requires a similar time frame in both 
conventionalisation of germ-free rats and in conventional mice after vancomycin 
treatment. Such a 19-day recovery of hippurate may reflect a delayed re-population of 
hippurate-producing microbiota compared with other microbiota. Recovery from 
vancomycin treatment with individual metabolites showing differential recovery rates 
has been demonstrated here. 
6.5.3 Effects of vancomycin on short chain fatty acid metabolism 
Another prominent finding from this study was the reduction in the concentrations of 
short chain fatty acids (SCFAs) including propionate, acetate and butyrate, together 
with increased concentrations of oligosaccharides in faecal water from vancomycin-
treated mice compared with that from control mice on TR1, 3, 5 and 7. This was 
consistent with Bender et al.'s study where an in vitro model for the semi-continuous 
incubation of defined colon contents was employed to examine the effect of 
vancomycin on composition of SCFAs (Bender et al., 2001). These SCFAs are derived 
from the fermentation of non-gastric-digestible starches and oligosaccharides by 
saccharolytic bacteria. The composition of fermentation end-products is dependent on 
the bacteria species, substrates and chemical environment, such as pH (Walker et al., 
2005). For example, butyrate concentrations were higher at pH 5.5 than at pH 6.5 which 
is correlated with a high population of the butyrate-producing bacteria Roseburia group 
at pH 5.5 (Walker et al., 2005). Galacto-oligosaccharides were found to generate high 
levels of SCFAs and decreased the numbers of clostridia (Rycroft et al., 2001). Among 
these SCFAs, butyrate is known to be most beneficial to colon cellular functions, such 
as proliferation, membrane synthesis and sodium absorption growth and has also been 
shown to have anti-colon carcinogenesis and anti-tumour activity (Archer et al., 1998; 
Zampa et al., 2004). In the current study, antibiotic-induced altered levels of SCFAs 
lasted for more than 7 days, which suggested a large proportion of the microbiota 
experienced a long dormancy period with reduced activities. However, C. coccoides and 
C. leptum were found to recover from day 2 post-treatment onward. Thus from the 
microbiological observations, there was an increase in species diversity in the 
vancomycin treated group supported by the increased number of DNA bands appearing 
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on the DGGE gels. Unfortunately these DNA bands could not be directly attributed to 
particular species possibly due to the impurity of the DNA bands or lack of suitable 
matches in bacterial databases. However, this increase in bacterial diversity was in 
agreement with a previous human study where a marked elevation in total numbers of 
Clostridium bacteria including C. bifennentans, C. clostridioforme, C. sordellii and C. 
malenominatum, and an increased species diversity for elderly people treated with 
antibiotics (Woodmansey et al., 2004) was reported. 
6.5.4 Effects of vancomycin on amino acid metabolism 
A broad range of amino acids was observed to be decreased in faecal extracts after 
vancomycin treatment, which may result from either excessive absorption by the small 
intestine under the less competitive circumstance, or reduced bacterial population that 
are responsible for protein digestion. As to the former hypothesis, although 
vancomycin-induced reduction in bacterial population compromised the nutrient 
competition between the small intestine and bacteria, the absorption function of the gut 
could in the meantime be affected due to less availability of short chain fatty acids 
which benefit intestinal epithelial function. Intestines of germ-free animals show 
alteration of atypical epithelial structure, less efficient nutrient usage and intestinal 
inflammation (Gordon et al., 1997; Cebra, 1999; Shanahan, 2002). Thus it is unlikely 
that the first hypothesis played a major role leading to such an observation. In terms of 
the second hypothesis, gastrointestinal digestion of some dietary proteins is incomplete 
with about 2-5% escaping small intestinal digestion/absorption. These protein residuals 
could be metabolised by the gut microbiota and produce faecal amino acids. It has been 
reported that unabsorbed or partially digested proteins are an important source of faecal 
amino acids in patients with cystic fibrosis (Seakins et al., 1970). In the present study, 
vancomycin may inhibit the activity of these bacteria which are capable of synthesising 
peptidases and proteinases, consequently leading to a reduction of amino acids in faecal 
extracts from vancomycin-treated mice. 
5-aminovalerate was found to fluctuate after vancomycin treatment and it was reported 
that it can be biosynthesised from proline by certain groups of bacteria such as 
Clostridium sticklandii (Kenklies et al., 1999). The observed fluctuation of 5-
aminovalerate levels may indicate that 5-aminovalerate related bacteria were affected by 
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vancomycin at day 1 post-treatment, followed by an immediate recovery and an over 
growth. 
6.6 Summary 
This study demonstrated a platform for the investigation of microbial disturbances by 
antibiotics in conventional mice using both metabonomic techniques and routine 
molecular microbiological methods. Such a combination of these two powerful 
approaches and multivariate data analysis provided a novel manner in which to 
investigate the association between host, microbiota and antibiotic intervention. This 
conventional mouse model offered a 'real' condition in gut microbial environment 
which enabled an overview of the disturbance of entire microbial populations by the 
antibiotic treatment to be gained. The metabolic-profiling approach showed 
vancomycin-induced changes in host amino acids and SCFA metabolism as well as in 
host metabolism of phenolics. Urinary hippurate and phenylacetylglycine levels 
correlated closely with the amino acid and SCFA profiles in the faeces. In terms of the 
microbiological study, although the DNA bands on DGGE profiles were not 
unambiguously determined, the 16S rRNA PCR-DGGE method has shown capability 
for generating an overview of the gut microbiome disturbances caused by the antibiotic 
intervention. Future studies will be focused on the identification of key species which 
are responsible for the metabolic alteration in the NMR profiles. 
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Chapter 7 Summary and future work 
7.1 Summary and general discussion 
The application of an NMR spectroscopy-based metabolic profiling approach in 
parasitology has been proven to promote the characterisation of host-parasite 
interactions to a systems biology level (Wang et al., 2004; Wang et al., 2006; Wang et 
al., 2008a). Multivariate statistical data analyses have been applied in this thesis to aid 
the analysis of spectral data and to extract direct/indirect biological markers of infection 
or infection degree. This thesis has focussed on two typical rodent-parasite models, a 
protozoan infection of P. berghei in mice (Chapter 3) and a helminthic infection of S. 
mansoni in mice (Chapters 4 and 5), which provided a convenient platform for their 
comparison as the same host strain of mouse was used. One of the key characteristics of 
both host-parasite models was the initiation of a host microbial disturbance. A separate 
study on microbial ecology was therefore conducted as part of this thesis forming 
Chapter 6 in order to generate a baseline of microbial alteration induced by an oral 
treatment of vancomycin in uninfected control mice for further microbial study in 
diseased animals. 
7.1.1 Summary of current histological studies on P. berghei- and S. mansoni-
infected mice 
The spleen and kidney from P. berghei- and S. mansoni-infected mice were analysed 
via histological examination and the spleen tissues from both infections showed 
pronounced lymphofollicular hyperplasia, but no disease-related structural changes 
were observed in the kidney. These structural changes in the spleen reflect the immune 
responses of the host to the infections as the spleen is one of the major sites of the 
immune system. 
7.1.2 Summary of reducing physiological variations on metabolic profiles 
Physiological variations associated with a range of environmental factors such as age, 
diet and stress can influence the metabolic profile of biofluids, thus randomised housing 
of mice, consistent environmental conditions, and strict sampling protocals were 
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employed in order to minimise these environmental variation-induced effects of data 
analysis. 
Acclimatisation: In the P. berghei-mouse model, all animals were acclimatised for a 
week, whilst in the S. mansoni-mouse and Vancomycin-mouse models, mice were 
acclimatised for two weeks in order to minimise the variation introduced by the change 
of environment. In retrospect, with more time available the optimal strategy would be to 
evaluate the length of time required for acclimatisation by collecting samples 
throughout a prolonged acclimatisation period. 
Ageing: The parasitic infections and drug intervention were carried out on mature mice 
in order to avoid growth- and maturation-induced variations which are known to be 
particularly significant in the phase transitioning to sexual maturity. Although the effect 
of age on the NMR profile of endogenous metabolites including increased levels of 
hippurate and amino acids was shown in a previous study on rat urine, they were more 
profound during the early age such as 4-8 weeks (Williams et al., 2005). In the 
vancomycin-mouse model, vancomycin-treated mice were one week older than the 
controls, but the study was conducted when mice were approximately 14 weeks old so 
this 1-week difference should be negligible. In addition, O-PLS-DA models were 
constructed for urine and faecal extract samples from control and vancomycin-treated 
mice at the pre-treatment time point and they failed to separate the two groups 
indicating that the baseline metabolic profiles were comparable. 
Stress: Animal manipulation can cause stress and consequently introduce variations into 
the metabolic profiles. Plasma spectral data were not included in the vancomycin 
intervention study as a metabolic difference was observed between control and 
vancomycin-treated mice pre-treatment. This metabolic difference is likely to be 
contributed by manipulation-induced stress as the animals in the vancomycin-treated 
group were not manipulated until 1 day pre-treatment, while the control mice, which 
were simultaneously used as a control group for S. mansoni-mouse model, had been 
manipulated for 8 weeks prior to the drug vehicle treatment. 
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7.1.3 Summary of energy, ketogenesis and microbial metabolism 
Figures 7-1, 7-2 and 7-3 illustrate global network pictures of observed urinary, plasma 
and faecal extract biomarkers in several parasitic infection-animal models including P. 
berghei-mouse, T. brucei brucei-mouse (Wang et al., 2008a), S. mansoni-mouse, S. 
japonicum-hamster (Wang et al., 2006), T. spiralis-mouse (Martin et al., 2006) and E. 
caproni-mouse (Saric et al., 2008b), and these metabolites are involved in energy 
metabolism, ketogenesis, amino acid metabolism, microbial activities and other 
metabolic pathways. With the exception of S. japonicum which was carried out in 
hamsters, these models are comparable as they (not T. spiralis) were carried out in 
NMRI out-bred female mice and T. spiralis infection was carried out in female NIH 
Swiss mice. The line-sphere networks shown in Figures 7-1, 7-2 and 7-3 summarise the 
metabolic information gained from these models. For example, each ellipsoid represents 
a metabolite and the number of arrows connected to the ellipsoid indicates the 
universality of the metabolite, that is, how many models this metabolite involves. Each 
sphere represents a parasite-animal model and the number of lines linked to it 
demonstrates the number of disturbed metabolites observed with the line style 
indicating the trend of changes, dashed line indicating lower levels of metabolites 
observed in the infected animals and solid line indicating higher levels of metabolites in 
the infected animals. 
Enemy metabolism: All parasites studied had an impact on host energy-related 
metabolites such as glucose, lactate and creatine in the plasma and taurine in the urine. 
Glycolysis provides energy for parasite survival, especially in protozoan infections as 
the more significant changes in concentrations of glucose and lactate were observed 
compared with that in helminthic infections. This could be due to the great number of 
protozoa in the blood, which consume considerably large amounts of glucose. Altered 
lipid fractions in the plasma were only found in helminths-infected mice, which may be 
explained by the influence of the parasites on gut motility and reabsorption ability. 
Membrane metabolism: Glycerophosphorylcholine and choline were the main 
membrane phospholipid metabolites to be found involved in all parasite-host models. 
As explained in Chapters 3 and 4, these metabolites may be taken up into the parasites 
for their membrane synthesis. 
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Amino acids and ketogenesis metabolism: A broad range of amino acids were observed 
to be increased in the plasma from T. spiralis-infected mice, but not in other models. 
Levels of BCAAs were found decreased in T. brucei brucei-, T. spiralis- and E. 
caproni-infected mice but fluctuated in S. mansoni-infected mice. Concentrations of the 
keto acids observed in the urine were elevated in protozoan infected mice whilst 
depleted in helminthic infected mice. However, the reason for lower levels of keto acids 
in S. mansoni-infected mice at early time point is not clear. Observations of decreased 
BCAAs and increased keto acids in T. brucei brucei infected-mice indicate a ketogenic 
status of the diseased animals. 
Immune related protein metabolism:  O-acetylglycoprotein fragments are believed to 
act as important mediators in immunological modification and signal transduction 
(Grootveld et al., 1993). It is known that T. brucei brucei induces TH1 immune response 
which may be associated with the observed elevation in levels of O-acetylglycoprotein 
in the plasma in the infected mice (Wang et al., 2008a). N-acetylglycoprotein fragments 
were found in T. spiralis-infected mice, which may indicate an acute-phase protein 
response (Martin et al., 2006). 
Microbiota-related metabolism: Urinary hippurate, PAG and TMA were the most 
disturbed metabolites related to microbial activities in most of the host-parasite models. 
Decreased levels of hippurate and increased levels of TMA were found in all models 
except in the P. berghei-infected mice due to the absence of hippurate in both P. 
berghei-infected and control mice. Due to the fact that the experimental animals were 
out-bred, batch-to-batch variations among all models were found to be obvious. 
Elevated levels of PAG were observed in all models but not in T. brucei brucei-infected 
mice, which may suggest that T. brucei brucei induce a different pattern of microbial 
disturbance in the host. Higher concentrations of p-cresol glucuronide were only 
observed in helminths infected-animals, which may be specific for worm-induced 
microbial changes. Vancomycin was administrated in order to identify the urinary and 
faecal metabolites which are related to microbial activities. In contrast to parasite-
induced microbial ecology disturbance, vancomycin exerted a different impact on 
metabolite profiles of the urine and faecal extract with the exception of the decreased 
hippurate level. Although the alterations in levels of propionate and 5-aminovalerate 
were observed in both S. mansoni-infected and vancomycin-treated mice, the trends of 
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changes in the infected mice are opposite to those observed in the antibiotic-treated 
mice or fluctuated. However, E. caproni shared similarities with vancomycin 
intervention in that the faecal profiles demonstrated decreased levels of butyrate and 
propionate. Due to the extreme complexity of host microbial ecology, the direct 
correlation between individual species of gut flora and metabolites remains to be fully 
elucidated and is an exciting new line of research to follow. 
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Figure 7-2 Net mapping of observed plasma biomarkers in P. berghei (P. b), T. brucei 
brucei (T. bb), S. mansoni (S. m), E. caproni (E. c) and T. spiralis (T. s)-infected mice. The 
dashed line represents a negative correlation with the infection, a solid line represents 
positive correlation with the infection and uneven dashed line represents fluctuated 
correlation. 
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Figure 7-3 Net mapping of observed faecal biomarkers in S. mansoni (S. m) and E. caproni 
(E. c)-infected mice. The dashed line represents a negative correlation with the infection, 
whilst a solid line represents positive correlation with the infection. 
7.1.4 Specificity of biological markers in biofluids 
With regard to disease diagnosis, the extracted biological markers or the pattern of a 
range of biomarkers is required to be unique to the disease. Comparisons of protozoan 
infections P. berghei and T. brucei brucei, and helminthic infections S. mansoni and E. 
caproni have been discussed in Chapter 3 and 4, separately. Hence, a global comparison 
is illustrated here in order to gain an overall idea on different genus of parasites-induced 
metabolic alteration in the host. 
Figure 7-4 demonstrates unique patterns of biomarkers in different biofluids and models 
using a colour bar code manner. They indicate that each parasitic infection induces a 
unique pattern of biomarkers, which could be potentially used for diagnosis. However, 
it is difficult to compare S. mansoni and S. japonicum due to the different hosts, thus 
these two biomarker patterns might be caused by either different hosts/parasites or both. 
Thus further work is required to compare the infection in the same host. 
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Figure 7-4 Patterns of biomarkers in urine (A), plasma (B) and faecal extracts (C) from P. 
berghei (P. b), T. brucei brucei (T. bb), S. mansoni (S. m), S. japonicum (S. j), E. caproni (E. 
c) and T. spiralis (T. s) models are represented by a colour bar code illustration. The 
numerical value in each box represents a metabolite coded in Figures 7-1, 7-2 and 7-3. 
Red-filled boxes represent increased concentrations of metabolites in the infected animals; 
blue-filled ones represent decreased concentrations of the metabolites in the infected 
animals; grey-filled ones represent fluctuated concentrations of the metabolites during the 
course of the experiments. 
7.1.5 Transferability of biomarkers from the animal model to human disease 
Transferability of biomarkers is a key issue for all studies carried out in animal models. 
Indeed, human metabolite profiles are different from those of animals and much more 
complex. However, human studies on parasitic infections are difficult to perform owing 
to many environmental factors such as diet, lifestyle, drug use, pollutant exposure and 
social culture, which can obscure the parasitic infection-specific biomarker. For 
example, a trial study on human parasitic diseases in Zanzibar using metabolic profiling 
of urine samples indicated that diet and lifestyle-related metabolites dominate the 
separation between people from different villages (in-house unpublished data). 
Additionally, paracetamol and its derived metabolites were found in several urine 
samples, which also influenced data analysis. More importantly, co-parasitic infections 
are common in endemic areas and it brings more difficulties to the study, especially 
without any preliminary database. Therefore, moving back from the field to the 
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laboratory is necessary for pure potential biomarker extraction in parasitic infections in 
order to provide preliminary knowledge on target biomarkers so that the future studies 
will be more focused. 
Infection intensity is another important issue as natural infection in humans is less 
intensive than laboratory models. Moreover, in human cases, the infection intensity 
varies and re-infection is common as well. Therefore, in animal models, the higher 
infection intensity helps to generate a successful model and a series of time points can 
deliver important information on the degree of infection and stages of the disease. In 
terms of practical aspects, this higher infection intensity can reasonably shorten the 
experiment time-course which could accelerate the research steps. 
7.2 Future work 
Future work should focus on the follow 4 aspects: (1) Parasitic co-infection. Co-
infection is common in endemic areas and it may influence the host immune response, 
induce drug resistance, or metabolic interactions among host and parasites. Hence, 
future studies should move into investigation of co-infection in order to more closely 
mimic the situation occurring in human populations. (2) Confirmation of the suggested 
metabolic pathways elucidated in this thesis. A great number of metabolites were 
observed to be altered in different biofluids and tissues in response to the various host-
parasite models and many hypotheses on metabolic pathways have been suggested. A 
subsequent step would be to confirm them experimentally by measuring the enzyme 
activity, cell culture and/or labelling substances in vivo. (3) Metagenomic studies on 
host gut microbial composition and disturbance. These aforementioned studies showed 
signs of disturbance in host gut colonisation. However, the detailed and direct 
correlation between specific flora species and metabolites remain uncharted. Therefore, 
this aspect should be addressed in future studies using microbiological culture 
techniques to culture the bacteria candidates extracted from statistical data analysis 
based on the metagenomic and metabonomic data. (4) Human population studies on the 
evaluation of potential biomarkers identified in animal models. This is the ultimate aim 
to apply metabolic profiling on parasitic diseases in human populations and hopefully to 
develop a novel and robust method for parasitic disease diagnosis. 
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Appendix I 
Appendix I Buffer and solution 
1. Sodium phosphate buffer (pH=7.4) 
Dissolve 2.885 g of Na2HPO4, 0.525 g of NaH2PO4, 0.01 g of TSP and 19 mg of Na-
azide into 100 ml of water (H20: D20=1:9, v:v). 
2. Saline solution 
Dissolve 0.9 g of NaC1 into 100 ml of water (H20: D20=1:9, v:v). 
3. 50x TAE buffer 
Mix 242 g of Tris base, 57.1 ml of glacial acetic acid and 100 ml of 0.5 M EDTA 
(pH=8.0) and then top up with H2O to 1 Litre. 
4. 100% denaturing polyacrylamide solution 
Take 105.4 g of urea, 50 ml of 40% acrylamide:bisacrylamide (37.5:1), 100 ml of 
formamide and 2.5 ml 50x TAE buffer, and then top up with H2O to 250 ml. 
5. 0% denaturing polyacrylamide solution 
Take 50 ml of 40% acrylamide:bisacrylamide (37.5:1) and 2.5 ml 50x TAE buffer, and 
then top up with H2O to 250 ml. 
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resonance spectroscopy-based analysis of commercially available 
praziquantel tablets 
Li J, Wang Y, Fenwick A, Clayton TA, Lau YY, Legido-Quigley C, 
Lindon JC, Utzinger J, Holmes E (2007). Journal of pharmaceutical and 
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Abstract 
The amount of active ingredient in 20 commercially sourced batches of praziquantel (PZQ) tablets was determined using a high-performance 
liquid chromatography—ultraviolet (HPLC—UV) assay in conjunction with an anthentic, lot of PZQ powder. The general composition of each batch of 
tablets was also examined by means of 1  H nuclear magnetic resonance (NMR) spectroscopy and the NMR data were subjected to pattern recognition 
analysis by means of principal component analysis. The HPLC—UV results showed that each batch of PZQ tablets contained approximately the 
required amount of PZQ (600 mg per tablet). The NMR analysis showed a high degree of compositional variation between manufacturers, which 
caused by variation in excipients, along with some batch-to-batch variation in the tablets from a single manufacturer. Additionally, the PZQ tablets 
from one manufacturer were found to have an extra component (methyl-4-hydroxybenzoate) that was not detected in the other preparations. 
© 2007 Elsevier B.V. All rights reserved. 
Keywords: High-performance liquid chromatography; Nuclear magnetic resonance spectroscopy; Praziquantel; Principal component analysis; Quality control; 
Schistosomiasis 
1. Introduction 
Praziquantel (PZQ) is the current drug of choice for the 
treatment and control of schistosomiasis [1-4] and the major-
ity of the food-borne trematode infections [5,6]. PZQ has a 
good safety and therapeutic profile and has been widely used 
in community-based schistosomiasis control programmes. For 
example, in China and Egypt alone, more than 100 million doses 
have been administered over the past two decades [4,7]. The 
price of PZQ has plummeted since 1990 and a 2001 World 
Health Assembly resolution urges member states to regularly 
administer PZQ to school-aged children and other high-risk 
* Corresponding author. Tel.: +44 207 594 3220; fax: +44 207 594 3226. 
E-mail address: elaine.holmes@imperial.ac.uk (E. Holmes). 
0731-7085/$ — see front matter © 2007 Elsevier B.V. All rights reserved. 
doi:10.1016/j.jpba.2007.06.017 
groups in areas that are highly endemic for schistosomiasis [1]. 
A global partnership has been created and the Schistosomiasis 
Control Initiative (SCI) is supporting several countries in sub-
Saharan Africa with national control programmes emphasising 
PZQ-based chemotherapy [2,8]. 
These developments are welcomed but the price of PZQ still 
varies between schistosome-endemic countries and concern has 
been raised with regard to the PZQ content of tablets, lack of 
information on shelf life, and inter-manufacturer variation in 
physico-chemical properties and excipients [9]. Since the use 
of PZQ preparations with lower efficacy may contribute to the 
development of drug resistance, a 'Concerted Action on Prazi-
quantel' initiative was launched in the late 1990s to collect and 
perform quantitative and qualitative analysis on PZQ from dif-
ferent endemic settings and to monitor trends over time [9-11]. 
Findings reported at the 4th meeting of the 'Concerted Action 
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Fig. I. Chemical structure of PZQ. 
on Praziquantel' in 2001 also indicated that, although products 
from 3 of the 19 manufacturers investigated were slightly less 
than optimal in terms of solubility and impurities, the quality of 
all 19 products was acceptable in terms of purity and amount of 
active ingredient in each tablet tested [12]. In contrast, two sam-
ples of one brand of tablet collected previously in the Sudan were 
found to be counterfeit and to contain no active ingredient [13]. 
The purity of a sample of PZQ drug material (Fig. 1) can 
be assessed using a high performance liquid chromatography—
ultraviolet (HPLC—UV) absorbance assay as described in the rel-
evant European Pharmacopoeia 2005 official monograph [14]. 
According to the European Pharmacopoeia, the total peak area 
at 210 nm from all impurities should not exceed 0.5% of the 
area of the PZQ peak at that wavelength. However, the Euro-
pean Pharmacopoeia does not specify a method for PZQ tablets 
and it appears that at least some workers analysing PZQ tablets 
have based their approach on the drug material method. Whilst 
that is a perfectly reasonable approach, it must be recognised 
that some of the additional formulated tablet components might 
show up in the HPLC analysis and care must be taken that they 
are not wrongly identified as impurities. 
In the present work, we have used an adaptation of the Euro-
pean Pharmacopoeia HPLC—UV method for PZQ drug material 
to estimate the PZQ content of 20 batches of PZQ tablets sup-
plied by four different manufacturers. 11-1 nuclear magnetic 
resonance (NMR) spectroscopy, together with multivariate data 
analysis techniques, has previously been used to assess inter-
batch variations in the chemical composition of drugs and tradi-
tional herbal medicines including feverfew, chamomile flowers, 
St John's Wort, ginseng and artemisinin derivatives [15-19]. We 
have also used high-resolution 1 H NMR spectroscopy in com-
bination with pattern recognition analysis to examine variation 
in the overall composition of the PZQ tablets. Whilst the 1H 
NMR method employed is, like the HPLC method, only suit-
able for analysing soluble components, it has the advantage that 
it is an almost universal detector for organic compounds and also 
provides structural information on the compounds detected. 
2. Materials and methods 
2.1. PZQ tablets 
The 20 PZQ batches were obtained from four different com-
panies. Batches 1-9 were supplied by Pharmchem International 
Ltd. (Harrow Middlesex, UK; nos. 102, 106, 40719, 40720, 
40723, 40770, 40793a, 40793b and 40806). Batches 10-18 were 
from Med Pharm and supplied by Cipla Ltd. (Patalganga, India; 
nos. K40769, K40794, K40831, K41052, K41080, K41082, 
K41099, K41100 and G54020). Batch 19 was obtained from 
Tanzania Pharmaceutical Industries Ltd. (Arusha, Tanzania; no. 
RJ02), and batch 20 from Shelys Pharmaceutical Ltd. (Dar es 
Salaam, Tanzania; no. B.N. RD 001). 
2.2. Determination of PZQ content of tablets by HPLC—UV 
The column used was a TMC-Pack FL-ODS, 50 mm x 
4.6 mm x 5 vim C18 column (Yamamura Chemicals Lab Co., 
Europe GmbH), which was maintained at an oven temperature 
of 30 °C. A mobile phase gradient (acetonitrile: water from 40:60 
to 80:20 v/v) was applied over a 10 min run with a flow rate 
of 1.0 ml/min and UV detection at 262.5 nm. Here a slightly 
different wavelength was used compared to the European Phar-
macopoeia since highest absorption for PZQ was at 262.5 nm. 
Authentic PZQ (98.9%), purchased from Sigma was used for 
the response calibration with six calibration solutions, having 
PZQ concentrations in the range of 0.5-5 mg/ml in 50:50 (v/v) 
mixture of water and acetonitrile and a 100 µ1 aliquot of each 
solution manually injected onto the column. 
For each batch, 10 PZQ tablets were taken at random and 
weighed as one lot prior to crushing and homogenisation. Then, 
three accurately measured amounts, in the range of 15-20 mg, 
of the ground powder were each dissolved as far as possible 
in 4.5 ml of a water—acetonitrile mixture (50:50 v/v) with any 
volume change assumed to be insignificant. Following agitation, 
1 ml of each suspension was removed and centrifuged in a 1.5 ml 
microcentrifuge tube at 10,000 rpm for 2 min. The clear super-
natant was removed for HPLC analysis (three replicate 100 µ1 
injections) and its PZQ content determined by reference to the 
absorbance values obtained for the calibration standards. The 
average PZQ content of the relevant tablets was then calculated. 
2.3. 1 H NMR spectroscopic analysis and pattern 
recognition of overall tablet composition 
Three samples were analysed for each batch of tablets. In each 
case, 20 mg of the powdered material was mixed with 700 µ1 
D20:acetonitrile-d3 solvent (5:1 v/v) containing 0.05% (w/v) 
sodium 3-(trimethylsilyl) 2,2,3,3-d4 propionate (TSP). The sus-
pension was centrifuged at 10,000 rpm for 2 min and the clear 
supernatant transferred to a 5 mm NMR tube. 
1H NMR spectra were recorded on a Bruker DRX 600 NMR 
spectrometer (Bruker; Rheinstetten, Germany), equipped with a 
Bruker 5 mm TXI probe, operating at 600.13 MHz for 1H NMR. 
A standard 1-dimensional (1D) presaturation pulse sequence 
(D1-90-4 -904.-90-acq) was employed to achieve water sup-
pression [20]. The inter-pulse delay ti was 3 ps and the mixing 
time tm was 100 ms. A weak irradiation was applied at the water 
resonance frequency during both the mixing time and the recycle 
delay, D1, of 2 s. The 90° pulse length was 10.5 vis and a total of 
32 scans were collected into 32k data points with a spectral width 
of 20 ppm. The free induction decays were multiplied by an 
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exponential function corresponding to a 0.3 Hz line-broadening 
prior to Fourier transformation and the resulting spectra were 
manually corrected for phase and baseline distortions in XWIN-
NMR (version 3.6 Bruker Analytik; Rheinstetten, Germany). 
The spectra, over the range 3 0.2-10.0 ppm were reduced using 
AMIX (Bruker Analytik) to 245 consecutive 0.04 ppm-wide 
regions and the signal intensity in each region integrated. The 
region 3 4.30-4.86 containing the residual water signals was 
removed and the remainder of each spectrum normalized to a 
constant total integral prior to pattern recognition analysis. 
Principal component analysis (PCA) of the mean-centred 
intensity data values was performed in the Simca-P software 
(version 10.0, Umetrics; lima Sweden). PCA is mathematic 
way to reduce complexity of multivariate datasets to facilitate 
visualization of inherent patterns in the data. Each principal com-
ponent (PC) is a linear combination of variables whereby each 
successive PC explains the maximum amount of variance pos-
sible, not accounted for by the previous PCs and each PC is 
orthogonal to the other PCs. Data were visualised by plotting 
the PC scores, where each point on the scores plot represents an 
individual sample, and the PC loadings, where each point rep-
resents one spectral region. The scores and loadings plots are 
complementary. Differences between samples can be detected 
in the score plots whereas spectral regions responsible for the dif-
ferences can be viewed in the corresponding loading plots [211. 
2.4. Identification of the para-disubstituted aromatic 
compound in the Shelys product 
This compound was isolated by flash chromatography (ace-
tonitrile, silica) and examined by 11-1 NMR spectroscopy and 
by ultra-performance liquid chromatography-mass spectrom-
etry (UPLC-MS). Candidate compounds (4-methoxybenzoic 
acid and methyl-4-hydroxybenzoate) were then separately 
600 
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Fig. 2. HPLC-UV chromatograms for an authentic sample of PZQ drug mate-
rial (dotted line) and for extracts of PZQ tablets from various manufacturers 
[Pharmchem International Ltd. (dotted-dashed line), Tanzania Pharmaceutical 
Industries Ltd. (thin line) and Shelys Pharmaceutical Ltd. (solid line)]. M4HB 
denotes methyl-4-hydroxybenzoate. 
added to the isolate and further t H NMR spectra recorded. 
Having, thereby, identified the isolated compound as methyl-4-
hydroxybenzoate, this compound was then added to an extract 
of the Shelys product and a further tH NMR spectrum recorded. 
HPLC-UV chromatograms were also recorded from an extract 
of the Shelys product before and after addition of methyl-4-
hydroxybenzoate. 
3. Results and discussion 
3.1. HPLC-UV analysis of PZQ batches 
The chromatograms generated for each of the 20 batches of 
PZQ investigated here contained several impurities, which was 
to be expected since pharmaceutical grade PZQ is known to 
contain three impurities, as mentioned earlier and as depicted in 
0 
too 
PZQ 
4 	5 	6 	7 
Retention time (min) 
1\ 
Table 1 
Quantitative results obtained from HPLC-UV analysis of 20 batches of PZQ tablets obtained from four different manufacturers 
Lot Manufacturer Mean tablet mass (mg) Estimated mass of PZQ per tablet in mg ± standard deviations 
1 Pharmchem International Ltd. 935.9 582.9 ± 6.2 
2 Pharmchem International Ltd. 974.6 611.6 ± 6.2 
3 Pharmchem International Ltd. 950.4 593.5 ± 17.0 
4 Pharmchem International Ltd. 955.4 594.3 ± 2.8 
5 Pharmchem International Ltd. 975.5 596.0 ± 3.1 
6 Pharmchem International Ltd. 974.7 609.4 ± 4.9 
7 Pharmchem International Ltd. 964.5 614.7 ± 10.1 
8 Pharmchem International Ltd. 970.1 604.0 ± 8.4 
9 Pharmchem International Ltd. 968.8 607.9 ± 4.3 
10 Med Pharm 950.6 597.5 ± 4.8 
11 Med Pharm 950.0 589.9 ± 4.3 
12 Med Pharm 952.9 590.9 ± 11.1 
13 Med Pharm 946.9 597.8 ± 2.5 
14 Med Pharm 947.6 589.2 ± 14.1 
15 Med Pharm 961.4 584.5 ± 18.5 
16 Med Pharm 956.1 598.4 ± 8.0 
17 Med Pharm 963.7 617.0 ± 9.7 
18 Med Pharm 966.2 617.5 ± 3.8 
19 Tanzania Pharmaceutical Industries Ltd. 904.5 619.3 ± 1.6 
20 Shelys Pharmaceutical Ltd. 944.4 606.5 ± 7.8 
a The standard deviation is based on three samples per batch and three injections per sample. 
0 0 a. 
-1 
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Fig. 2. Peaks at retention times 5.3 and 6.2 min are unidentified 
impurities and present in all the batches of tablets as well as PZQ 
drug material. However, our analysis revealed that the PZQ batch 
supplied by Shelys Pharmaceutical Ltd. contained an extra com-
ponent that was not observed in the samples from the other man-
ufacturers (Fig. 2) with the integration for that component being 
22% of the integral of the PZQ peak. This is consistent with pre-
vious analyses of products from this source, as discussed during 
the 4th meeting of the 'Concerted Action on Praziquantel' [12]. 
The calibration for PZQ was found to be linear over the range 
of 0.54-4.92 mg/ml (R2 = 0.99) and Table 1 shows the estimated 
PZQ content of each batch of the tablet. Our analysis indicates 
that all 20 batches investigated were broadly consistent with 
the declared amount of active ingredient (i.e. 600 mg per tablet) 
[12]. In fact, in all batches the error margin on the declared PZQ 
content appeared to be within 5% and in 15 batches (75% of 
all samples) the PZQ content appeared to be within 2.5% of the 
declared amount. 
,6(102) 
	Lk_ 
3.2. t H NMR spectroscopy and PCA of NMR data 
PCA was performed on the 1 H NMR spectra acquired from 
the 20 batches of PZQ and a scores plot generated from the 
PCA is shown in Fig. 3. The plot demonstrates acceptable ana-
lytical performance with the three replicate samples for each 
batch being clustered together. As can be seen, six main clus-
ters were observed in the scores plot of the first two PCs, which 
contained 98% of the total variance in the mean-centred data 
set. Three of these clusters correspond to batches obtained from 
Pharmchem International Ltd. with the remaining three clus-
ters attributable to samples from the other three manufacturers. 
Thus, the tablets obtained from Med Pharm (and provided by 
Cipla Ltd.) showed greater batch-to-batch consistency than the 
tablets from Pharmchem International Ltd. where the observed 
batch-to-batch variation is assumed to be due to changes in drug 
excipients. The variation along the first PC was mainly due to 
resonances in the 45 3.5-3.9 region. 
• 
4 
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Fig. 3. Scores plot from PCA of I II NMR spectra of extracts of powdered 
PZQ tablets with three separate NMR analyses for each lot. Dot: Med Pharm; 
Box: Pharmchem International Ltd.; diamond: Shelys Pharmaceutical Ltd.; star: 
Tanzania Pharmaceutical Industries Ltd. 
\ 6 (40719) 
A (40769) 
7 	6 	5 	4 	3 	2 	ppm 
Fig. 4. 600 MHz I II NMR spectra representative of each of the clusters in 
Fig. 3. Key: (A) Med Pharm; (B) Pharmchem International Ltd.; (C) Shelys 
Pharmaceutical Ltd.; (D) Tanzania Pharmaceutical Industries Ltd.; (E) authentic 
PZQ. Batch numbers given in parentheses. The aromatic peaks from methyl-4-
hydroxybenzoate are highlighted by the * symbol. 
Examples of the 1 H NMR spectra in each cluster are shown 
in Fig. 4 and it is noticeable that only the Shelys product 
generated resonances at 45 6.95 (doublet), and 45 7.95 (dou-
blet), which indicated the presence of a compound having a 
para-disubstituted aromatic ring structure. This molecule was 
predominantly responsible for the deviation of the Shelys prod-
uct from the rest of the samples in the second PC. 
3.3. Identification of the para-disubstituted aromatic 
compound in the Shelys formulation 
Examination of the isolated compound by UPLC-MS (in 
negative ion mode) indicated a molecular weight of 152 
whilst examination by 111 NMR spectroscopy indicated pos-
session of a methoxy group. These findings suggested two 
possible candidates, 4-methoxybenzoic acid and methyl-4-
hydroxybenzoate, with the latter identity being confirmed by 
1H NMR spectroscopy following addition of standard samples 
of each compound obtained from Sigma—Aldrich (Fig. 5). 
Further analysis confirmed that methyl-4-hydroxybenzoate 
also accounted for the unusual extra component seen in the 
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terfeit or substandard anti-infective drugs [22] and has already 
been applied to assess batch-to-batch variation in traditional 
herbal remedies (chamomile, feverfew and artemisinin deriva-
tives) [15-17], drugs (ecstasy) [23] and polysorbates [24]. While 
the proposed analytical strategy is currently out of reach for the 
majority of settings where PZQ is needed most - due to its 
high-technology approach, expensive equipment and required 
expertise - this strategy could become an integral part within 
sentinel surveillance sites for monitoring the quality of PZQ 
and other drugs used for the treatment and control of parasitic 
diseases that are pervasive in the developing world. 
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Fig. 5. 1 H NMR spectra of para-disubstituted aromatic compound isolated from 
Shelys PZQ tablet formulation before (A) and after consecutive additions of 
4-methoxybenzoic acid (B) and methyl-4-hydroxybenzoate (C). 
HPLC-UV chromatogram of the Shelys product. Methyl-4-
hydroxybenzoate (methyl paraben) is a known preservative. 
Therefore, we would assume that it has been deliberately 
included in the Shelys formulation. 
4. Conclusions 
Compositional profiling of PZQ tablets by NMR spec-
troscopy may prove useful in comparing products from different 
manufacturers or in assessing batch-to-batch variation from a 
single manufacturer. Additionally, such comparisons could be 
facilitated by the use of pattern recognition methods such as 
PCA. In the present study, such analysis revealed significant 
compositional differences in batches of PZQ tablets from four 
different manufacturers and, in particular, one formulation was 
found to contain a preservative, methyl-4-hydroxybenzoate, that 
was not detected in the other formulations. 
Each of the tested batches appeared adequate in regard to the 
amount of PZQ per tablet as determined by HPLC. However, 
it should be recognised that the HPLC method for PZQ drug 
material described in the 2005 edition of the European Pharma-
copoeia is not directly transferable to the assessment of PZQ 
tablets since such tablets may contain additional components 
that could confuse the analysis. Thus, other tablet components 
might be wrongly identified as impurities or even mistaken for 
PZQ. 
The approach described here could be readily extended for 
quality control of other pharmaceuticals, and for detecting coun- 
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Global Metabolic Responses of NMRI Mice to an Experimental 
Plasmodium berghei Infection 
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We present a metabolism-driven top-down systems biology approach to characterize metabolic changes 
in the mouse resulting from an infection with Plasmodium berghei, using high-resolution 1H NMR 
spectroscopy and multivariate data analysis techniques. Twelve female NMRI mice were infected 
intravenously with —20 million P. berghei-parasitized erythrocytes. Urine and plasma samples were 
collected 4-6 h before infection, and at days 1, 2, 3, and 4 postinfection. Multivariate analysis of spectral 
data showed differentiation between samples collected before and after infection, with growing 
metabolic distinction as the time postinfection progressed. Our analysis of plasma from P. berghei-
infected mice showed marked increases in lactate and pyruvate levels, and decreased glucose, creatine, 
and glycerophosphoryl choline compared with preinfection, indicating glycolytic upregulation, and 
increased energy demand due to P. berghei infection. The dominant changes in the urinary metabolite 
profiles included increased levels of pipecolic acid, phenylacetylglycine, and dimethylamine, and 
decreased concentrations of taurine and trimethylamine-N-oxide, which may, among other factors, 
indicate a disturbance of the gut microbial community caused by the parasite. Although several of the 
observed metabolic changes are also associated with other parasitic infections, the combination of 
metabolic changes and, in particular, the occurrence of pipecolic acid in mouse urine postinfection are 
unique to a P. berghei infection. Hence, metabolic profiling may provide a sensitive diagnostic tool of 
Plasmodium infection and the control of malaria more generally. 
Keywords: malaria • Plasmodium berghei • mouse • metabonomics • metabolomics • 11-I NMR 
spectroscopy • multivariate data analysis • urine • plasma 
Introduction 
Malaria, which is caused by an infection of a protozoan of 
the genus Plasmodium, is the most severe and widespread 
parasitic disease in the tropics and subtropics. Indeed, malaria 
due to Plasmodium falciparum accounted for >500 million 
clinical disease episodes in 2002,' and >1 million deaths were 
attributed to the disease in 2001.2 Malaria is particularly 
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rampant in sub-Saharan Africa, with children under the age of 
5 years and pregnant women at highest risk of disease-
associated morbidity and mortality.3A The global burden of 
malaria is currently estimated at —40 million disability-adjusted 
life years (DALYs).2 Among more than 100 species of Plasmo-
dium, four infect humans, that is, P. falciparum, Plasmodium 
malariae, Plasmodium ovale, and Plasmodium vivax.4 The 
molecular mechanisms of infection and response to therapeutic 
interventions have been studied extensively in rodent models 
using murine malaria parasites, including Plasmodium berghei, 
Plasmodium chabaudi, Plasmodium vinckei, and Plasmodium 
There is a new global emphasis on the eradication of malaria, 
but the challenges ahead to control, let alone local elimination 
or eradication of the disease, are formidable.9 A particularly 
vexing problem is the large number of asymptomatic carriers19.11 
for whom detection of parasitemia with conventional methods 
is difficult. Hence, there is a need to discover, develop, and 
10.1021/pr800209d CCC: $40.75 	© 2008 American Chemical Society 
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deploy novel tools and strategies for biomarker discovery to 
aid diagnosis, interventions and integrated control packages. 
Access to prompt diagnosis and efficacious antimalarial drugs, 
for example, is one of the current pillars of malaria control. 
Microscopic detection of parasites in finger prick blood samples 
remains the most widely used diagnostic test in malaria-
endemic settings. This approach allows determination of the 
degree of infection (parasitemia) at relatively low cost, but 
requires experienced microscopists, and lacks sensitivity at low 
levels of parasitemia. A number of rapid malaria diagnostic tests 
have been developed over the past decade. They are based on 
immunochromatographic dipstick assays and find increasing 
use for self-diagnosis, but are costly and have imperfect 
sensitivity, particularly when parasitemia is low.' The issue 
of diagnosis is just one example to illustrate the need for new 
and improved tools that can be utilized for individual diagnosis 
of malaria and for monitoring disease control programs and, 
hence, measuring progress toward local elimination and eradi-
cation. Various technological approaches, including transcrip-
tomics, have been utilized to characterize malaria infection and 
to further our understanding of the difference between parasite 
strains." 
The combination of high-resolution 1H NMR spectroscopy 
of biofluids and tissue samples with multivariate statistical 
analysis has been shown to be useful in biomarker discovery 
and, hence, may facilitate development of new diagnostic tools, 
drug targets, and vaccines.14-16 Here, we explore further the 
characteristics of malarial infection by applying a metabolism-
driven top-down systems biology strategy that has proved 
effective in studying transgenomic interactions in mammalian 
symbiotic systems, for example, the gut microbiota.17'" Similar 
approaches have also been successfully applied to characterize 
the systemic metabolic fingerprints of Schistosoma spp. and 
Trypanosoma spp. infections in rodent models."-21 To establish 
the metabolic consequences of a P. berghei infection, we focus 
on a mouse model and compare urinary and plasma metabolite 
profiles from host animals prior to infection with profiles 
generated from biofluids obtained 1-4 days postinfection. The 
ultimate goal is to enhance our understanding of the metabolic 
response to a Plasmodium infection and to identify candidate 
biomarkers that may be translatable to diagnosis and prognosis 
in human populations. Our investigation is complemented with 
a histological examination of kidney, liver, and spleen obtained 
from P. berghei-infected mice upon dissection, that is, at day 
4 postinfection. 
Materials and Methods 
P. berghei-Mouse Model. The animal experiments described 
here were carried out at the Swiss Tropical Institute (Basel, 
Switzerland), adhering to local and national regulations of 
laboratory animal welfare in Switzerland (permission no. 2081). 
A total of 12 out-bred NMRI strain female mice, aged —3 weeks, 
were purchased from RCC (Fiillinsdorf, Switzerland) and ac-
climatized for 4 days. Mice were randomly allocated to 1 of 3 
cages, marked with individual identifiers, and group-housed 
in batches of 4 throughout the study. Mice were kept in stable 
environmental conditions (temperature, 22 °C; relative humid-
ity, 60-70%; 12-h light/12-h dark cycle) and had free access to 
community tap water and special pellet diet (9009 PAB-45, 
purchased from Provimi Kliba AG; Kaiseraugst, Switzerland). 
At the onset of the experiment, mice weighed between 22.7 
and 26.5 g (mean = 23.8 g; standard deviation (SD) = 1.2 g). 
research articles 
Each mouse was infected intravenously with '-20 million 
parasitized erythrocytes (GFP-transfected P. berghei strain 
ANICA22), as follows: heparinized blood from a donor mouse 
with —30% parasitemia was taken, diluted in physiological 
saline to —100 million parasitized erythrocytes per mL of blood, 
and an aliquot of 0.2 mL of this suspension (containing —20 
million P. berghei-parasitized erythrocytes) was then used for 
injection.23 
Biofluid Collection. Samples of urine and blood were 
collected at 5 time points, that is, 4-6 h before infection, and 
at days 1, 2, 3, and 4 postinfection. Following sample collection, 
the body weights of mice were measured using a Mettler 
balance (model K7T; Greifensee, Switzerland). 
Sample collection was always carried out between 08:00 and 
11:00 to minimize diurnal variations in urinary and plasma 
metabolite concentrations. At least 20 1.2L of urine was collected 
into a Petri dish by gently rubbing the abdomen of the mouse. 
Mice that failed to generate sufficient quantities of urine were 
placed individually into empty cages and observed until they 
released a few drops of urine which was immediately collected 
with a micropipette. Urine was transferred into 1.5 mL Eppen-
dorf tubes, placed on dry ice, and transferred to a freezer at 
—80 °C. 
Between 40 and 50 /IL of blood was collected into a Sodium-
heparin hematocrit capillary (Brand GMBH ± CO KG; Wer-
theim, Germany) from the tail of the mouse by cutting off its 
tip. Subsequently, plasma was separated from red blood cells 
by centrifugation (model 1-15, Sigma; Osterode am Harz, 
Germany) at 4000g for 5 min. The ratio of plasma to red blood 
cells was measured and the packed cell volume (PCV) deter-
mined and expressed as a percentage. The plasma was then 
transferred into a 1.5 mL Eppendorf tube, placed on dry ice, 
and transferred to a freezer at —80 °C. Parasitemia was 
determined with a FACScan (Becton Dickinson; Basel, Swit-
zerland) by counting 100 000 red blood cells, as previously 
des cribed.22 
Histology. On day 4 postinfection, after the final sampling 
of biofluids, mice were killed using the standard CO, method. 
The right kidney and small portions of the liver and spleen were 
removed and transferred in Eppendorf tubes containing 10% 
formalin. Sections of these organs were cut and stained with 
hematoxylin and eosin prior to examination under a micro-
scope. The results were compared with those obtained from a 
satellite group of noninfected control mice of the same age and 
sex, maintained under the same environmental conditions and 
killed at the same time point. 
Sample Preparation and 'H NMR Spectroscopic Analysis. 
Urine and plasma samples were forwarded on dry ice to 
Imperial College (London, U.K.) for subsequent Ili NMR 
analyses. Individual urine samples (20 pL) were mixed with 
equal amounts of phosphate buffer (1320/H20 (vlv), 1:1; pH 
7.4), containing sodium 3- (trimethylsily1) propionate-2,2,3,3-
d4 (TSP, 0.05%) for a chemical shift reference, and 3 mM Na 
azide was transferred into a 1.7 mm micro-NMR tube. A 
standard one-dimensional (1D) 1H NMR spectrum was ac-
quired for each urine sample with a pulse (recycle delay (RD)-
90°- tl -90°- tm-90°-acquire free induction decay (FID)) on a 
Bruker DRX 600 MHz spectrometer (Rheinstetten, Germany), 
using a 5 mm triple resonance with inversion detection (TXI) 
probe operating at 600.13 MHz. The field frequency was locked 
on D20 solvent. The water peak was suppressed by irradiation 
during the RD of 2 s and mixing time (tm ) of 100 ms. The t1  
was fixed to 3 ps. The 90° pulse length was adjusted to —10 ps. 
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Table 1. Mean PCV, Parasitemia and Body Weight in a Group of 12 Female NMRI Mice Before and at Different Time Points after 
Inoculation with -20 Million P. berghei-Infected Erythrocytes 
time point 
mean (SD) 
PCV in %' parasitemia in % body weight in g 
4-6 h preinfection 55 (4) 23.8 (1.2) 
day 1 postinfection 49 (3)* 0.4 (0.1) 23.5 (1.5) 
day 2 postinfection 47 (4)* 4.1 (0.2) 23.9 (1.6) 
day 3 postinfection 44 (4)* 16.3 (2.0) 23.9 (1.7) 
day 4 postinfection 33 (3)*  34.4 (5.2) 23.9 (1.6) 
Asterisk (*) indicates p < 0.001. 
For each sample, 64 scans were recorded into -32 000 data 
points with a spectral width of 20 ppm. An exponential line 
broadening function of 0.3 Hz was applied to FID prior to 
Fourier transformation. Additionally, two-dimensional (2D) 
NMR experiments, using 1H-1H correlation spectroscopy 
(COSY) and total correlation spectroscopy (TOCSY) to assist 
metabolite identification, were also carried out on selected 
urine samples utilizing standard acquisition parameters.19 A 
total of 128 increments with 80 scans were accumulated into 
2000 data points with a spectral width of 10 ppm for each 
dimension. 
Individual plasma samples were prepared by mixing 20 µL 
of plasma with an equal amount of saline (D20/H20 (v/v), 1:1, 
0.9% NaCI). Subsequently, this mixture was placed into 1.7 mm 
micro-NMR tubes. A 1D 1FINMR experiment with Carr-Purcell-
Meiboom-Gill (CPMG) pulse (RD-90°-(r-180°-r)n-acquire FID) 
was acquired for each sample using a spectral width of 20 ppm 
and 256 transients collected into -32 000 data points. Water 
suppression was achieved as described previously for urine 
samples. 
Data Reduction and Multivariate Analysis. '1-1 NMR spectra 
obtained from urine and plasma were automatically phased 
and baseline-corrected, using an in-house developed MATLAB 
script (T. Ebbels, Imperial College London). Urine spectra were 
referenced to the TSP resonance at 6 0.00, whereas plasma 
spectra were referenced to the anomeric proton signal from 
a-glucose at 6 5.23. The complete spectra (6 0.0-10.0) were 
each digitized into -40 000 data points using another in-house 
developed MATLAB script (0. Cloarec, Imperial College Lon-
don). The regions between 6 4.20 and 6 6.24 in urine spectra, 
and between 6 4.50 and 6 5.10 in plasma spectra were removed 
in order to minimize the effect of the baseline distortion caused 
by imperfect water suppression. Additionally, the regions 
6 0.0-0.85 and 6 8.5-10.0 in urine spectra, and the regions 
6 0.0-0.8 and 6 8.5-10.0 in plasma spectra containing only 
noise were also removed. 
For each spectrum, normalization to the entire remaining 
spectrum was performed before multivariate data analysis was 
carried out. A supervised multivariate data analysis tool, 
orthogonal-projection to latent structure-discriminant analysis 
(O-PLS-DA),24 was applied to the analysis of 11-1 NMR spectral 
data scaled to unit variance in a MATLAB environment, using 
in-house developed scripts. This method employed back-scaled 
transformation of the variables to the covariance matrix in 
order to facilitate interpretation of the results. 
Results 
P. berghei Infection and Histological Observations. Table 
1 shows the mean PCV, parasitemia and body weight in a group 
of 12 female NMRI mice 4-6 h before, and at days 1, 2, 3, and 
4 after animals were inoculated with -20 million P. berghei- 
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infected erythrocytes each. The mean PCV dropped from 55% 
preinfection to 33% by the end of experiment. Using a t-test 
allowing for unequal variance revealed that the difference 
between the mean PCV values preinfection and postinfection 
was highly significant, already at day 1 postinfection (p < 0.001). 
Parasitemia increased exponentially from day 1 to day 4 
postinfection, reaching a mean value of 34.4% at the final 
observation 4 days postinfection. The mean body weight of the 
group of mice stayed constant over the 4-day period of the 
experiment. 
Histological examination of the spleen obtained from 
P. berghei-infected mice on termination of the experiment (i.e., 
day 4 postinfection) showed signs of a response to a systemic 
infection. In particular, there was an impressive reactive 
follicular hyperplasia of white pulp nodules that was ac-
companied by red pulp congestion with abundant hemozoin 
in cordal macrophages in all infected animals (Figure 1). 
Cellular architecture in both liver and kidney appeared normal, 
although there was a tendency of a higher quantity of tubular 
cell damage in the kidney. 
111 NMR Spectroscopy of Mouse Urine. Typical 11-1 NMR 
spectra of urine obtained from mice 4-6 h preinfection, and 4 
days after infection with P. berghei are shown in Figure 2, 
panels A and B, respectively. Metabolite identification was 
assisted by our in-house database, coupled with 2D COSY and 
TOCSY (results not shown). Metabolites identified from urine 
of both pre- and postinfected mice included 2- oxoisovalerate, 
3-methyl-2-oxovalerate, 3-carboxy-2-methyl-3-oxopropanamine, 
acetate, citrate, succinate, dimethylamine, trimethylamine, 
2-oxoglutarate, creatine, creatinine, trimethylamine-N-oxide 
(TMAO), taurine, phenylacetylglycine (PAG), 2-oxoisocaproate, 
3-ureidopropanoic acid, lactate, pyruvate, p-cresol-glucuronide, 
and formate, as shown in Figure 2. Additionally, pipecolic acid 
was found, however, only in urine samples obtained from mice 
after infection with P. berghei. In order to focus on the 
metabolite changes with infection, we systematically employed 
an O-PLS-DA strategy.24 
Multivariate Analysis of 111 NMR Spectra of Urine. The 
O-PLS-DA models comparing pre- and postinfection spectral 
data were built using NMR data as the X-matrix and class 
information (i.e., pre- or postinfection) as the Y-matrix. For 
each sample collection time, a model was constructed in which 
one PIS component and one orthogonal component was 
calculated, using spectral data scaled to unit variance (Figure 
3). The color of the variables or signals in the O-PLS-DA 
coefficient plots indicates significance of metabolites contribut-
ing to group separation, that is, between pre- and postinfection 
time points. The significance level increases from blue (no 
correlation with class) to red (highly significant in discriminat-
ing between classes), which is shown in the color bar on the 
right-hand side of the O-PLS-DA coefficient plots. The orienta- 
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Figure 1. Section of a spleen obtained from a P. berghei-infected mouse 4 days postinfection showing a marked reactive follicular 
hyperplasia with large, nearly confluent germinal centers consisting of centroblasts and immunoblasts. In addition, there was red pulp 
congestion with abundant hemozoin in cordal macrophages (A). For comparison, a section of a spleen from a healthy control mouse 
(same strain, age- and sex-matched) is also shown. Note the small nonstimulated primary follicle and the lack of malarial hemozoin 
pigment (B). 
Figure 2. Typical 600 MHz 1H NMR spectra of urine obtained from a preinfected mouse (A) and a mouse 4 days after a P. berghei 
infection (B). Keys: 1, lysine; 2, 2-oxoisovalerate; 3, pyruvate; 4, 2-oxoisocaproate; 5, alanine; 6, succinate; 7, trimethylamine-N-oxide 
(TMAO); 8, phenylacetylglycine (PAG); 9, 2-oxoglutarate; 10, citrate; 11, 3-methyl-2-oxovalerate; 12, creatinine; 13, creatine; 14, tau rine; 
15, dimethylamine; 16, 3-ureidopropanoic acid; 17, acetate; 18, 3-carboxy-2-methyl-3-oxopropanamine; 19, p-cresol-glucuronide; 20, 
trimethylamine; 21, cytosine; 22, formate; 23, lactate; 24, pipecolic acid; 25, allantoin; 26, alanine. 
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Figure 3. O-PLS coefficient plots derived from 1H NMR spectra of urine individually collected from mice prior to a P. berghei infection 
and daily postinfection, illustrating the metabolic discrimination between the pre- and postinfection stages. The respective Q2 Yvalues 
for days 1 and 4 postinfection were 0.25 and 0.57 in those two O-PLS coefficient plots. 
tion of peaks in the plot describes the trend of changes of 
metabolites; upward orientation reflecting a relatively increased 
level of metabolite postinfection in comparison to the prein-
fection time point and vice versa. 
The main metabolites contributing to the differentiation 
between NMR spectral data obtained from mouse urine before 
and after mice were infected with P. berghei are summarized 
in Table 2. In addition, goodness of fit (expressed as .112.X) and 
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Table 2. Changes of Metabolites Observed in Urine Obtained from Mice at Different Time Points after Infection with P. berghei, 
Compared with Preinfection Time Point 
importance of contribution at different time points postinfection 
chemical shift (1:51H) 
day 1 
(Q2Y= 0.25; 
IFX = 0.27) 
day 2 
(Q2Y= 0.23; 
R2X = 0.22) 
day 3 
(Q2Y= 0.45; 
1FX = 0.31) 
day 4 
(Q2 Y= 0.57; 
1FX =-- 0.35) 
0.93(d), 2.09(m), 2.62(d) 
1.13(d), 3.02(m) 
0.90(t), 1.10(d) 
+0.57 
+0.68 
+0.67 
3.05(s), 4.06(s) +0.58 +0.66 
1.93(s) +0.62 +0.56 
2.72(s) +0.65 +0.58 
3.27(s) -0.71 -0.58 
3.68(s), 3.77(d), 7.43(t), 7.37(t) +0.70 +0.66 
3.27(t), 3.43(t) -0.58 
8.47(s) +0.64 
1.66(m), 1.88(m), 2.22(m), +0.77 +0.78 
3.04(m), 3.44(d), 3.61(dd) 
1.20(d), 1.24(d), 3.67(m), +0.85 +0.83 
3.81(m), 4.05(m) 
6.27(d), 6.30(d) +0.94 +0.90 
metabolite (key') 
2-oxoisocaproate (4) 
2-oxoisovalerate (2) 
3-methyl-2-oxovalerate (11) 
creatinine (12) 
acetate (17) 
dimethylamine (15) 
trimethylamine-N-oxide (TMAO) (7) 
phenylacetylglycine (8) 
taurine (14) 
formate (22) 
pipecolic acid (24) 
unknown no. 1 (33) 
unknown no. 2 (34) 
° The key is consistent with the metabolite numbers shown in Figure 2 (s = singlet, d = doublet, t = triplet, m = multiplet). 
goodness of prediction (expressed as Q2  }1  values are given for 
each of the postinfection collection time points. Increasing 
strength of Q2Y over time from day 2 to 4 postinfection 
corresponds to an increase in severity of infection, underscored 
by the declining PCV and the elevated parasitemia level. 
Although many of the changes associated with increasing 
severity were quantitative, the number of perturbed metabolites 
also altered and increased as a result of infection severity. This 
is a property of the failure of systemic homeostatic control that 
results in the enhanced use of minor pathways increasing the 
metabolic complexity (and entropy) of the system; analogous 
situations have been observed in drug metabolism studies 25.26 
Within the first 2 days postinfection, concentrations of urinary 
2-oxoisocaproate, 2-oxoisovalerate, 3-methyl-2-oxovalerate, PAG, 
acetate and formate showed higher levels in the postinfected 
mice when compared to the preinfection time point. Addition-
ally, PAG and dimethylamine were observed in urine obtained 
from P. berghei-infected mice at later time points, when 
compared to preinfection. Pipecolic acid was found to be one 
of the most discriminatory metabolites and was present only 
in the P. berghei-infected urine samples. 
'H NMR Spectroscopy of Mouse Plasma. Representative 1D 
NMR CPMG spectra of plasma samples obtained from mice 
4-6 h before and 4 days after infection with P. berghei are 
shown in Figure 4. This experiment results in the attenuation 
of signals from fast relaxing protons from macromolecules and 
motionally constrained metabolites due to protein binding." 
A number of low molecular weight metabolites, such as leucine, 
valine, lactate, alanine, acetate, pyruvate, citrate, creatine, 
choline, glycerophosphoryl choline (GPC), and glucose were 
identified in these plasma spectra as expected from previous 
studies.27 
Multivariate Analysis of 	NMR CPMG Spectra of 
Plasma. O-PLS-DA models were constructed with one PLS 
component and one orthogonal component utilizing unit 
variance scaling applied to the 'H NMR CPMG plasma spectra. 
The discrimination between mouse plasma samples obtained 
prior to and after P. berghei infection was evident, especially 
on days 3 and 4 postinfection (Figure 5). Q2 Yvalues 3 and 4 
days postinfection were 0.76 and 0.64, respectively. The coef- 
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ficient plots showed that the increase of the relative concentra-
tion of lactate became more significant from day 2 after 
infection with P. berghei onward, whereas glucose levels 
decreased at days 3 and 4 postinfection, together with de-
creased levels of creatine and GPC. 
Table 3 summarizes the plasma metabolites that significantly 
contributed to separation between pre- and postinfection time 
points. 
Discussion 
Experimental infection of female NMRI mice with P. berghei 
induced a range of systemic metabolic perturbations in the 
urine and plasma of the host as early as 1 day postinfection, 
and these changes increased as the time to infection pro-
gressed. Although a satellite group of control mice were not 
given a sham injection of uninfected erythrocytes, the meta-
bolic changes observed were not consistent with those associ-
ated with acute stress,28'29 and hence, the findings of the 
current study are almost certainly associated with a direct 
metabolic response to the infection. A prominent finding in 
the analysis of plasma spectra was the marked depletion of 
glucose, and an increase in lactate and pyruvate on days 2-4 
postinfection when compared with the preinfection time point. 
This finding conforms to previous observations that Plasmo-
dium-parasitized erythrocytes utilize higher amounts of glu-
cose, compared to normal erythrocytes 3031 Malaria parasites 
experience an intraerythrocytic asexual stage where the para-
sites require energy from the host, primarily via anaerobic 
glycolysis due to the lack of a functional tricarboxylic acid cycle 
in this stage.32'33 Our results are consistent with the increased 
glycolysis-related enzyme activities in P. berghei-infected eryth-
rocytes of mice reported already in the early 1980s.3° With 
regard to anaerobic glycolysis, the accumulation of lactate may 
cause lactic acidosis, which can cause cardiac impairment and, 
indeed, has been identified as a significant biochemical predic-
tor of death in patients with severe P. falciparum malaria 34'35 
In a recent study, Daily and colleagues have shown that 
significant changes occur in the gene expression profiles of 
malaria parasites obtained from the blood of humans carrying 
P. falciparum.' Three distinct transcriptional states of the 
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Figure 4. Representative 600 MHz 'H NMR CPMG spectra of plasma samples collected from an uninfected mouse (A) and a mouse 4 
days after a P. berghei infection (B). Key: 3, pyruvate; 5, alanine; 10, citrate; 13, creatine; 17, acetate; 23, lactate; 26, choline; 27, o-3-
hydroxybutyrate; 28, valine; 29, leucine; 30, isoleucine; 31, glycerophosphoryl choline (GPC); 32, glucose. 
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Figure 5. 0-PLS-DA coefficient plots derived from 'H NMR CPMG 
spectra of plasma obtained 4-6 h before infection (D_,), and at 
days 1(D,) and 4(D4) postinfection revealing the metabolic 
fingerprint of a P. berghei infection and changes over time as 
the disease progressed. Resonances pointing upward indicated 
the increase of metabolic concentration in the infected mice. The 
model-derived Q2 Y values were 0.45 and 0.64 for days 1 and 4 
postinfection, respectively. 
parasite were reported, namely, (i) growth with glycolysis-
provided energy, (ii) a starvation response of the parasite, and 
(iii) an environmental stress response. The observation of the 
first stage is consistent with our own metabolic findings 
obtained in female NMRI mice. 
GPC in plasma was lower in P. berghei-infected mice at days 
2-4 postinfection when compared to the preinfection time 
point. A report showing the presence of a high concentration 
of GPC in the adult filarial parasite Brugia malayi indicates that 
GPC is important for nutrient acquisition.36 GPC also regulates 
phospholipid composition by inhibiting the enzyme lysoleci- 
thinase, and the disturbance of GPC may also suggest mem-
brane abnormalities, as seen in the muscles of patients with 
Duchenne muscular dystrophy.37 Another possibility is that the 
breakdown of GPC provides free choline to Plasmodium, since 
choline is taken up into parasite-infected erythrocyte, and 
phosphorylated by choline kinase.38.39 Decreased levels of 
creatine were found in plasma of postinfected mice, which 
might be associated with the elevated concentration of plasma 
creatine phosphokinase (CPK). Indeed, increased levels of CPK 
is one of the biological indications of severe malaria.' 
To our knowledge, we report—for the first time in a parasitic 
infection using a metabolic profiling strategy—elevated levels 
of pipecolic acid in urine of P. berghei-infected mice. Pipecolic 
acid is derived from either diet (e.g., dairy products, and 
fermented beverages) or catabolism of lysine by intestinal 
microbiota as depicted in Figure 6. In terms of the origin of 
pipecolic acid in mammalian urine, Fujita and colleagues found 
that it is mainly derived from lysine degradation rather than 
food intake.' In our study, all animals were fed on the same 
diet and maintained under the same environmental conditions, 
and hence, food intake seems unlikely to have contributed to 
the increased pipecolic acid, especially since there was no 
difference in the mean body weight of animals over the course 
of our experiment. It is interesting to note that elevated levels 
of pipecolic acid in plasma are recorded in patients with 
chronic liver disease, Dyggve-Melchior-Clausen syndrome, 
pyridoxine-dependent epilepsy, and Zellweger syndrome.42-16 
Pipecolic acid is known to act as a neuromodulator in the 
central nervous system, since it has been found to inhibit the 
initial gamma-aminobutyric acid (GABA; an inhibitory neu-
rotransmitter) uptake, and to increase a high K i -induced 
release of GABA.47 The biological role of increased pipecolic 
acid in a Plasmodium infection is still unclear, since distur- 
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Table 3. Changes of Metabolites Observed in Plasma Obtained from Mice at Different Time Points after Infection with P. berghei, 
Compared with Preinfection Time Point 
chemical shift (641) importance of contribution at different time points postinfection 
day 1 	 day 2 
(Q2 Y= 0.45; 	(Q2 Y= 0.35; 
132 )( = 0.24) R2 X = 0.29) 
day 3 
(Q2Y= 0.76; 
R2 X = 0.33) 
day 4 
(Q2Y= 0.64; 
R2 X = 0.31) 
1.91(s) -0.66 -0.62 -0.55 -0.65 
3.03(s), 3.92(s) -0.62 -0.69 -0.73 
3.22(s), 3.67(m), 4.31(m) +0.72 -0.61 -0.76 -0.80 
1.31(d), 4.11(q) +0.73 +0.74 +0.71 
2.36(s) +0.68 +0.77 +0.85 
2.53(d), 2.66(d) +0.65 
5.22(d)" -0.72 -0.67 
metabolite (key") 
acetate (17) 
creatine (13) 
glycerophosphoryl choline (GPC) (31) 
lactate (23) 
pyruvate (3) 
citrate (10) 
a-glucose 
The key Is consistent with the metabolite numbers shown in Figure 4(s = singlet, d = doublet, q = quadruplet, m = multiplet). b a-Anomeric proton 
only reported as being representative of multiple a- and /3-glucose resonances. 
Al 2-piperideine 
lysine 	 keto-lysine 	carboxylic acid 	pipecolic acid 
Figure 6. Biosynthesis of pipecolic acid from lysine. 
bance of microbial community, liver dysfunction, and neuro-
logical damage are all known consequences of malaria infection. 
Severe malaria is known to cause renal dysfunction." The 
perturbation in levels of urinary dimethylamine and TMAO 
have been associated with renal cortex and papillary damage 
in methanol intoxication patients, and in proximal tubular 
toxins separately."”' An increase of dimethylamine was found 
in the urine samples from mice at days 3 and 4 postinfection, 
which may be suggestive of renal dysfunction. However, 
histological examination of kidney removed from P. berghei-
infected mice on termination of the experiment (after the final 
urine and plasma samples had been collected on day 4 
postinfection) showed no clear evidence of pathological alter-
ations in this organ (Figure 1). Importantly, altered excretion 
of dimethylamine and TMAO, which originate from choline, 
can also reflect a disturbance of the gut microbiota.51  PAG, 
dimethylamine, and TMAO showed marked increases in urine 
samples obtained from postinfected mice. These metabolites 
are known to vary with changes in gut microbiota.19 Therefore, 
the elevated excretion of PAG, dimethylamine, and TMAO 
observed in the current study may have resulted from the 
disturbance of microbial community by the P. berghei infection. 
One of the clinical symptoms of malaria is the high fever which 
could be responsible for the change of gut microbiota. How-
ever, little is known about the disturbance of the gut microbial 
ecosystem associated with malaria. Hence, further studies are 
warranted to investigate whether changes occur in gut micro-
biota over the course of a P. berghei infection. 
In conclusion, we found changes in the urinary and plasma 
metabolic profiles of mice in response to a P. berghei infection, 
indicative of global changes in metabolic regulation and 
homeostasis. Hence, our findings underscore the extensive 
metabolic cross-talk between the host (i.e., NMRI mouse) and 
the parasite (i.e., P. berghei ANKA strain) in vivo and demon-
strate the potential of a global metabolic profiling strategy 
based on 1H NMR spectroscopy in conjunction with multivari- 
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ate data analysis. Our strategy holds promise for extraction of 
biomarker information. Recently, the same NMR-based meta-
bonomic approach has been employed to characterize the 
responses in female NMRI mice to a Trypanosoma brucei brucei 
infection.' Interestingly, an upregulation of glycolysis was 
found in both studies. Although both Plasmodium and Trypa-
nosoma are protozoan parasites, the perturbation of observed 
amino acids in plasma were different with an increased level 
of creatine in T. brucei brucei, and a decreased level in 
P. berghei. Our analytical strategy presented here can be utilized 
for the development of novel, rapid, and noninvasive diagnostic 
methods. We conjecture that further development of 1H NMR 
spectroscopy/mass spectrometry and pattern recognition-
based techniques will provide the backbone for innovation, 
validation, and application of new diagnostic tools, drug targets 
and, eventually, vaccines against malaria and other parasitic 
diseases. One of the most useful applications of this technology 
could be the identification of asymptomatic cases, an important 
obstacle for contemporary malaria control efforts.1° 
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magic angle spinning-nuclear magnetic resonance spectroscopy 
Jia V. Li, Elaine Holmes, Jasmina Saric, Jennifer Keiser, Stephan Dirnhofer, Jiirg 
Utzinger, Yulan Wang 
Accepted by the International Journal for Parasitology, October 2008. 
Abstract: In order to enhance our understanding of physiological and pathological 
consequences of a patent Schistosoma mansoni infection in the mouse, we examined the 
metabolic responses of different tissue samples recovered from the host animal using a 
metabolic profiling strategy. Ten female NMRI mice were infected with —80 S. mansoni 
cercariae each, and 10 uninfected age- and sex-matched animals served as controls. At 
day 74 post-infection, mice were killed and jejunum, ileum, colon, liver, spleen and 
kidney samples removed. We employed 111 magic angle spinning-nuclear magnetic 
resonance spectroscopy to generate tissue-specific metabolic profiles. The spectral data 
were analysed using multivariate modelling methods including an orthogonal signal 
corrected-projection to latent structure analysis and hierarchical principal components 
analysis to assess the differences and/or similarities in metabolic responses between 
infected and non-infected control mice. Most tissues obtained from S. mansoni-infected 
mice were characterized by high levels of amino acids, such as leucine, isoleucine, 
lysine, glutamine and asparagine. High levels of membrane phospholipid metabolites, 
including glycerophosphoryl choline and phosphorylcholine were found in the ileum, 
colon, liver and spleen of infected mice. Additionally, low levels of energy-related 
metabolites, including lipids, glucose and glycogen were observed in ileum, spleen and 
liver samples of infected mice. Energy-related metabolites in the jejunum, liver and 
renal medulla were found to be positively correlated with S. mansoni worm burden upon 
dissection. These findings show that a patent S. mansoni infection causes clear 
disruption of metabolism in a range of tissues at a molecular level, which can be 
interpreted in relation to the previously reported signature of the biofluid in urine giving 
further evidence of the global effect of the infection. 
252 
Appendix V 
Appendix V 
Published paper 4: 
Metabonomic and microbiological analysis of the dynamic effect of 
vancomycin-induced gut microbiota modification in the mouse 
Yap, IKS,* Li JV,* Saric J, Martin FP, Davies H, Wang Y, Wilson ID, 
Nicholson JK, Utzinger J, Marchesi JR, Holmes E (2008). Journal of 
Proteome Research 7(9): 3718-3728. (* equal contribution) 
253 
Journal of 
research articles proteome 
oresearch 
Metabonomic and Microbiological Analysis of the Dynamic Effect of 
Vancomycin-Induced Gut Microbiota Modification in the Mouse 
Ivan K. S. Yap," Jia V. 1.1,t4'1 Jasmina Saric,t4 Francois-Pierre Martin," Huw Davies,t 
Yulan Wang,t Ian D. Wilson,''' Jeremy K. Nicholson,t Jiirg Utzinger,t Julian R. Marchesi,i'' and 
Elaine Hohnee't 
Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, 
Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, 
London SW7 2AZ, United Kingdom, Department of Public Health and Epidemiology, Swiss Tropical Institute, 
P.O. Box, CH-4002 Basel, Switzerland, Nestle Research Center, P.O. Box 44, Vers-chez-les-Blanc, 
CH-1000 Lausanne 26, Switzerland, Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, 
Mereside, Macclesfield, Cheshire SK10 4TG, United Kingdom, Alimentary Pharmabiotic Centre and Department 
of Microbiology, University College Cork, Western Road, Cork, Ireland, and School of Biosciences, Cardiff 
University, Cardiff CFI° 3TL, Wales, United Kingdom 
Received December 20, 2007 
The effects of the antibiotic vancomycin (2 x 100 mg/kg/day) on the gut microbiota of female mice 
(outbred NMRI strain) were studied, in order to assess the relative contribution of the gut microbiome 
to host metabolism. The host's metabolic phenotype was characterized using 1H NMR spectroscopy of 
urine and fecal extract samples. Time-course changes in the gut microbiotal community after 
administration of vancomycin were monitored using 16S rRNA gene PCR and denaturing gradient gel 
electrophoresis (PCR-DGGE) analysis and showed a strong effect on several species, mostly within the 
Firmicutes. Vancomycin treatment was associated with fecal excretion of uracil, amino acids and short 
chain fatty acids (SCFAs), highlighting the contribution of the gut microbiota to the production and 
metabolism of these dietary compounds. Clear differences in gut microbial communities between control 
and antibiotic-treated mice were observed in the current study. Reduced urinary excretion of gut 
microbial co-metabolites phenylacetylglycine and hippurate was also observed. Regression of urinary 
hippurate and phenylacetylglycine concentrations against the fecal metabolite profile showed a strong 
association between these urinary metabolites and a wide range of fecal metabolites, including amino 
acids and SCFAs. Fecal choline was inversely correlated with urinary hippurate. Metabolic profiling, 
coupled with the metagenomic study of this antibiotic model, illustrates the close inter-relationship 
between the host and microbial "metabotypes", and will provide a basis for further experiments probing 
the understanding of the microbial-mammalian metabolic axis. 
Keywords: Butyrate • Co-metabolism • Feces • Metabolomlcs • Metabonomics • Microbiota • Mouse • 
NMR • Pattern Recognition • Propionate • Urine • Vancomycin 
Introduction 
The mammalian gut contains hundreds of species of com-
mensal and symbiotic microbes, which mainly reside in the 
large intestine, and the cecum for rodents, where they con-
tribute to —60% of the total fecal mass produced."" It is widely 
acknowledged that the presence of the gut microbiota is a key 
factor in gut development, structure and function.' Intestinal 
microbiota may also play a major role in the etiology of many 
* Correspondence should be addressed to Prof. E. Holmes (e-mail: 
elaine.holmes@imperiaLac.u1c). Tel: +44 (0)20 7594 3220. 
Imperial College London. 
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gut disorders, such as irritable bowel disease (IBD) and colon 
cancer.6•7 Moreover, the microbiome has recently been re-
ported to vary significantly between obese individuals (human 
and animals) and normal individuals, and it is known to 
provide refined control mechanisms on energy recovery through 
catabolism of otherwise poorly digestible nutrients, that is, 
resistant starch and other polysaccharides.'m Since the mi-
crobiota are extremely metabolically active and co-metabolize 
many endogenous and xenobiotic compounds, they clearly 
have the potential to affect the biochemical composition of the 
tissues and biofluids of the host.11•12 
Previous research revealed the influence of the gut micro-
biota on the urinary metabolite composition in rodent studies 
using metabolic profiling methods based on 1I-1 nuclear mag-
netic resonance (NMR) spectroscopy.'" In particular, diet, 
medication and other environmental-induced effects on aro- 
10.1021/pr700864x CCC: $40.75 	© 2008 American Chemical Society 
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matic components such as hippurate and 3-hydroxyphenyl-
propionic acid (HPPA), which are known to be generated or 
co-metabolized by gut microbiota, are well-documented in 
conjunction with a variety of other metabolic pathways such 
as those involved with bile acid catabolism, choline metabolism 
and utilization of short chain fatty acids (SCFAs).11-17 Further 
evidence of the direct contribution of the microbiota to host 
metabolism has been obtained using metabolic profiling 
methods to characterize germ-free and antibiotic-rodent 
models.12,13,18,19 
Although germ-free models provide valuable information on 
microbial—mammalian co-metabolism, acting in some respects 
as a "knock out", it could be argued that, since the gut of such 
animals remains underdeveloped, they do not offer a true 
picture of 'normal' mammalian physiology and as such are not 
an optimal model for characterizing microbiota—mammalian 
metabolic interaction in 'normal' animals. An alternative 
approach is to employ conventional animals, with normal gut 
physiology, combined with antimicrobial treatment, which 
mimics more closely the actual environment of the host gut 
and its commensals. Indeed, from studies aimed at the deliber-
ate reduction of the gut microbiota, as well as on the investiga-
tion of antibiotic-induced nephrotoxicity of pharmacological 
effects on the gut microbiota, a reduction in the urinary 
excretion of hippurate and other phenolic metabolites was 
evident.13,20,21 
As part of ongoing studies to determine the effect of the gut 
microbiota on host metabolic phenotypes, we employ here an 
antibiotic-based model to directly probe the dynamic effect of 
the microbiotal contribution to urinary and fecal composition. 
Additionally, we monitor time-course changes in the gut 
microbiota community during the course of the recovery using 
16S rRNA gene polymerase chain reaction (PCR) and denatur-
ing gradient gel electrophoresis (DGGE) analysis. For this, we 
have used vancomycin (a glycopeptide antibiotic,22 with broad 
activity against Gram-positive bacteria), which causes marked 
decrease in gut microbiotal populations in mice.23 Vancomycin 
was chosen as a means of reducing the Gram-positive bacteria 
in the gut without overtly modifying the Gram-negative mi-
crobes, in order to target one particular aspect of the microbial 
influence on host metabolism. Additionally, vancomycin is 
known to be poorly partitioned across the mammalian gas-
trointestinal mucosa, and since it does not have systemic 
absorption, should not perturb host biochemistry directly.23 
Methods 
Two studies were initiated to assess effects of antibiotic 
treatments on host—gut metabolism. The initial exploratory 
study was used to monitor metabolic changes in the mouse at 
a single time point. A second study, hereafter referred to as 
the extension study, was carried out to ascertain the dynamic 
metabolic effects of antibiotic treatments in mice. 
Exploratory Study Design. This study was carried out at the 
animal care facilities of the Swiss Tropical Institute (Basel, 
Switzerland), and complied with Swiss local and national 
regulations on animal welfare (permission no. 2081). Twelve 
female (age, —3 weeks; weight, 20-25 g) outbred NMRI strain 
mice were purchased from RCC (Ffillinsdorf, Switzerland). The 
animals were kept in groups of 3 in macrolon cages, and 
acclimatized for 7 days prior to the study under controlled 
environmental conditions (temperature, -'-22 °C; relative hu-
midity, 60-70%; day/night cycle, 12-12 h). Mice were fed 
commercial rodent feed with water ad libitum. Six of the mice  
were dosed with vancomycin hydrochloride (2 x 100 mg/kg/ 
day) on day 0 of the study for 2 successive days. Mice were 
treated orally by gastric intubation with vancomycin suspended 
in 7% Tween-80 and 3% ethanol (volume 10 mL/kg body 
weight; serving as vehicle). The remaining six mice were given 
the vehicle only (10 mL/kg body weight), and hence served as 
controls. 
Fecal and urine sample collection was carried out 2 days after 
the initial dosing (i.e., day 2) between 09.00 and 11.00 h. From 
each mouse, urine (at least 20 uL) and fecal samples (1-2 
pellets) were collected into Petri dishes by gently stretching the 
mice or rubbing their abdomen. Samples were transferred into 
small microcentrifuge tubes, immediately frozen over dry ice 
and stored at —80 °C. 
Extension Time-Course Study Design. A total of 20 NMRI 
female mice were purchased from RCC and divided into the 
control and vancomycin-treated groups with 10 mice each. 
Each mouse from the vancomycin treatment group was treated 
in the same way as the first study at 15-week-old, while mice 
from the control group were administered 3 doses of drug 
vehicle only (age: 14 weeks). The 1-week difference in the age 
at the start of the experiment between this and the exploratory 
study can be ignored since mice are fully mature at this age 
and thus their microbial community would be fully established. 
Urine and stool samples for NMR experiments were collected 
from both groups at 1 day predosing and days 1, 2, 3, 5, 7, 13, 
and 19 after the final dosing and stored at —40 °C. Stool 
samples for microbiological investigation were also collected 
at the same time points, fixed in 0.5 mL of 4% formalin, to 
which 9.5 mL of 70% (v/v) ethanol was added and stored at 
—20 °C. 
Sample Preparation. Urine samples were prepared by 
mixing 20 uL of urine with 30 uL of a phosphate buffer 
containing 90% D20 and 0.25 mM 3-trimethylsily1-1- [2,2,3,3-
2H4) propionate (TSP) and left to stand for 10 min. The 
resulting mixtures were then transferred into 1.7 mm (outer 
diameter) NMR capillary tubes. 
Each fecal sample was homogenized with buffer (1 mL, 0.2 
M sodium phosphate, pH 7.4). Homogenates were sonicated 
at ambient temperature (25 °C) for 30 min and centrifuged at 
11 000g for 10 min. The supernatants (460 ML) were aliquoted 
and a final volume of 700 uL was made by the addition of 240 
uL of TSP in 90% D20. These were further centrifuged at 11 000g 
for 10 min and 600 uL of the supernatant was pipetted into 5 
mm (outer diameter) NMR tubes. 
'II NMR Spectroscopy. Spectra were obtained on a Bruker 
DRX 600 spectrometer (Bruker Biospin; Rheinstetten, Germany) 
at 600.13 MHz (ambient probe temperature 27 °C). A standard 
1-dimensional (1D) pulse sequence was used [recycle delay 
(RD)-90°-4-90°- tm-90°-acquire free induction decay (FID)]. The 
water signal was suppressed by irradiation during RD of 2 s, 
and mixing time (4„) of 150 ms. 4 was set to 3 us and the 90° 
pulse length was adjusted to —10 us. For each sample, a total 
of 64 transients (in exploratory study) and 256 transients (in 
the extension study) were accumulated into —32 000 data 
points using a spectral width of 20 ppm. Prior to Fourier 
transformation, all FIDs were multiplied by an exponential 
function equivalent to a line broadening of 0.3 Hz. The 
assignment of the peaks to specific metabolites was based on 
2-dimensional (2D) 1H-1H correlation spectroscopy (COSY) 
and 1H-1H total correlation spectroscopy (TOCSY) NMR, 
published literature,24'25  and statistical total correlation spec-
troscopy (STOCSY).26 
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Data Processing and Analysis. 11-I NMR spectra of fecal 
extract and urine samples were manually phased and baseline 
corrected using XwinNMR 3.5 (Balker Biospin; Rheinstetten, 
Germany). The 11-1 NMR spectra were referenced to the TSP 
resonance at 6 0.0. The spectra were digitized using a MATLAB 
(version 7, The Mathworks, Inc.; Natwick, MA) script developed 
in-house. The region containing the water resonance was 
removed from each spectrum to eliminate baseline effects of 
imperfect water saturation. For each spectrum, normalization 
to the total sum of the residual spectrum was carried out prior 
to pattern recognition analyses followed by scaling of the data 
to unit variance. 
Principal component analysis (PCA) was applied to the 
processed spectral data to reveal intrinsic treatment-related 
patterns within data, as well as monitoring the dynamic 
response of the mice to vancomycin intervention. Interanimal 
variation can confound data interpretation, particularly in 
multivariate data of high dimensionality. Therefore, orthogonal-
projection to latent structure discriminant analysis (O-PLS-
DA)27 was performed in a MATLAB environment to optimally 
model class differences and to systematically identify metabo-
lites contributing to the differences between the vancomycin-
treated and control groups. The O-PLS-DA method decomposes 
the variation in X (NMR data) into 3 parts; the first being the 
variation in X related to Y (the class variable), and the last 2 
containing the specific systemic variation in X and residual, 
respectively. The contribution of each metabolite to sample 
classification is interpreted using the O-PLS coefficients with 
back-scaling transformation, indicating the variable contribu-
tions to the antibiotic-induced discrimination in the models.' 
Here, the colors projected onto the spectrum indicate the 
correlation of the metabolites discriminating vancomycin-
treated mice from the corresponding controls. Red indicates a 
high correlation and dark blue denotes no correlation with 
sample class. The direction and magnitude of the signals relate 
to the covariation of the metabolites with the classes in the 
model. A coefficient of 0.71, corresponding to 5% significance 
level, was used as a cutoff value to select variables that had a 
significant correlation with class and the model predictive 
performance (robustness) was evaluated using a 7-fold cross 
validation method.' 
Two of the 3 urinary metabolites that were most highly 
correlated with antibiotic ingestion, namely, hippurate and 
phenylacetylglycine, were regressed against the total fecal 
metabolite profiles using O-PLS analysis based on the inte-
grated hippurate resonance at 61 7.84 ppm, or the integrated 
phenylacetylglycine resonance at 61 7.43 ppm, as the Y 
(response) matrix. The third metabolite, guanidinoacetate, was 
not integrated due to substantial peak overlap, which would 
lead to inaccuracy in the calculation. 
Microbiological Analysis (PCR-DGGE Experiment) and 
DNA Extraction. Approximately 0.2 g of stool sample was 
processed to remove preservation solution (2 washes with 0.5 
mL of PBS) and mixed with 1.4 mL of buffer ASL; the 
suspension was transferred into a plastic tube containing 1 g 
of 0.1 mm diameter zirconium/glass beads and vortexed for 1 
min at maximum speed to ensure the sample was thoroughly 
homogenized. The DNA extraction was carried out using 
QIAamp DNA Stool Mini Kit (Qiagen, Dublin, Ireland) accord-
ing to the manufacturer's instructions. The 16S rRNA gene was 
amplified using a nested approach; the first PCR used primers 
27f (5' GAGTTTGATCMTGGCTCAG 3') and 1492r (5' GGYTAC-
CTTGTTACGACTT 3') and the second PCR was performed with 
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341fGC primers (5' CGCCCGCCGCGCGCGGCGGGCGGGGC-
GGGGGCACGGGGGTACG-GGAGGCAGCAG 3') and 519r prim-
ers (5' GTATTACCGCGGCTGGCTG 3'). DGGE analysis was 
performed as described elsewhere.3° A number of strong 
discriminatory DGGE bands were excised with a sterile pipet 
tip into sterile water, amplified and cleaned (QIAquick PCR 
Purification Kit, Qiagen, Dublin, Ireland) for the sequencing. 
The amplicon was purified (QIAquick PCR Purification Kit, 
Dublin, Ireland) and sequenced by GATC (Konstanz, Germany), 
phylogenetic analysis was performed using the RDP classifier 
tool." Additional PCR was performed using specific primers 
(Clostridium leptum subgroup or the Clostridium coccoides 
subgroup) based on the extracted DNA and the PCR products 
were visualized on agarose gels by staining with ethidium 
bromide.' 
Results 
Data obtained from both the exploratory and extension 
studies revealed consistent changes in the urinary and fecal 
metabolic profiles with the time course study generating further 
information on recovery of individual metabolites and the 
global profile after antibiotic intervention. The control and 
treated groups excreted drug vehicle (7% Tween-80 and 3% 
ethanol) in their feces on day 1 but this was totally eliminated 
within 48 h. No significant endogenous changes in metabolite 
profile were observed in the first 3 principal components (PCs). 
Vancomycin-Induced Effects on the NMR Spectroscopic 
Profiles of Urine Samples. Typical examples of the 1HNMR 
spectra of urine obtained from an untreated and a vancomycin-
treated mouse are shown in Figures IA and 1B. Spectra from 
control mice were dominated by a number of metabolites, 
namely, a-ketoglutarate, a-ketoisocaproate, a-ketoisovalerate, 
n-butyrate, citrate, creatine, creatinine, dimethylamine, fuma-
rate, glycine, hippurate, lactate, N-acetyl glycoprotein frag-
ments, phenylacetylglycine, succinate, taurine, trimethylamine, 
and trimethylamine-N-oxide. Visual inspection of the spectra 
revealed marked differences in overall metabolic composition 
between urines obtained from untreated and vancomycin-
treated mice, with the latter showing relatively lower concen-
trations of urinary phenylacetylglycine, hippurate and fumarate, 
and higher levels of urinary creatine, a-ketoisocaproate and 
a-ketoisovalerate. To examine the metabolic disturbance re-
sulting from vancomycin in urine over all the time points, a 
PCA strategy was applied to the entire data set. A total of 3 
PCs were calculated for a PCA model using unit variance scaled 
spectral data shown in Figure 1C. There was clear separation 
between urine samples obtained from control mice and mice 
given vancomycin 1-3 days after the final dosing. At days 5 
and 7 post-treatment, samples from treated mice were still 
differentiated but moved closer to the control duster, finally 
co-mapping with the control cluster by day 13 post-treatment. 
In addition to visually identified metabolites, O-PLS-DA 
(Figure 2) highlighted further discriminatory metabolites for 
the antibiotic-treated group, with vancomycin-treated mice 
showing lower levels of urinary trimethylamine and trimethy-
lamine-N-oxide, and the higher levels of urinary n-butyrate, 
guanidinoacetic acid and N-acetyl glycoprotein fragments. 
However, Student's t-tests of the urinary NMR data revealed 
that only guanidino acetic acid and hippurate showed statistical 
significance at a 5% significance level. The model parameters 
for urine samples are given in Table 1 together with the O-PLS- 
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Figure 1. Typical 600 MHz 1H NMR spectra of urine obtained from untreated mice (A) and vancomycin-treated mice (B) 2 days after the 
final dosing. (C) PCA trajectory plots of urine. Color code: gray (control), black (vancomycin-treated d-1), red (d1), green (d2), yellow 
(d3), blue (d5), purple (d7), dark blue (d13 and d19). Key: 5, lactate; 7, acetate; 14, succinate; 17, taurine; 18, glycine; 22, a-ketoisocaproate; 
23, butyrate; 24, a-ketoisovalerate; 25, N-acetyl glycoproteins (NAG); 26, pyruvate; 27, a-ketoglutarate; 28, dimethylglycine; 29, 
dimethylamine; 30, trimethylamine; 31, creatine; 32, creatinine; 33, trimethylamine-N-oxide (TMAO); 34, guanidoacetic acid (GAA); 35, 
hippurate; 36, fumarate; 37, phenylacetylglycine; 38, citrate. 
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DA correlation coefficients indicating the relative contributions 
of key metabolites contributing to the antibiotic-perturbed 
profiles. 
In urinary O-PLS-DA plots comparing control and treated 
animals for each of the 7 time points, 3 dominant metabolites, 
that is, hippurate, phenalactyglycine (PAG) and creatine, were 
found to co-vary consistently during the course of the recovery 
from vancomycin treatment. The mean integrated signals for 
these metabolites relative to the total spectrum were calculated 
and plotted (Figure 2B). Urinary concentrations of both hip-
purate and PAG decreased after the vancomycin treatment. 
However, the "recovery" of hippurate toward control levels was 
slower (ca. 19 days) than that of PAG (ca. 7 days). Urinary 
creatine was increased at days 1 and 2 post-vancomycin 
treatment and recovered from day 3 onward. 
Vancomycin-Induced Effects on the Fecal Metabolite 
Profiles. Typical examples of the 1H NMR spectra of fecal 
extracts obtained from an untreated and a vancomycin-treated 
mouse are shown in Figures 3A and 3B. A range of metabolites 
such as amino acids, SCFAs, uracil and succinate were also 
directly assigned in spectra from control and vancomycin-
treated mice consistent with previously published data.16,17,24,25 
Reduction in the relative concentrations of fecal amino acids, 
SCFAs and uracil, and an increase in fecal choline and 
oligosaccharide levels were observed in vancomycin-treated 
mice. The PCA plot of fecal samples collected over the entire 
study duration (Figure 3C) showed a similar metabolic move- 
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Table 1. Metabolic Effects of Vancomycin Treatment on Urine 
of Mice 
metabolites chemical shift 
untreated vs vancomycin-treated 
(correlation coefficient) 
urine 
QZ =0.75 
R2 = 0.98 
a-ketoisovalerate 1.13 (d) —0.64" 
n-butyrate 0.90 (t) —0.58" 
creatine 3.93 (s) —0.60" 
creatinine 4.06 (s) —0.45" 
GAA 3.80 (s) —0.75 
glycine 3.56 (s) —0.47" 
hippurate 7.84 (d) +0.86 
NAG 2.06 (s) —0.64" 
phenylacetylglycine 7.43 (m) +0.67" 
taurine 3.46 (t) +0.49" 
TMA 2.89 (s) +0.55" 
TMAO 3.27 (s) +0.50" 
Shows trend but not significant at the level of P < 0.05; GAA, 
guanidoacetic acid; NAG, N-acetyl glycoproteins; TMA, trimethylamine; 
TMAO, trimethyl-N-oxide; s, singlet; d, doublet; t, triplet; m, multiplets; 
relatively higher in control mice; -, relatively lower in control mice. 
ment to that observed for the urinary data. At days 1 and 3 
post-vancomycin dosing, the fecal water composition was 
markedly different from that of controls. In terms of the 
number of perturbed metabolites, vancomycin showed a 
greater effect in fecal water than in urine. 
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Figure 3. Typical 600 MHz 1H NMR spectra of fecal extracts obtained from untreated mice (A) and vancomycin-treated mice (B) 2 days 
after the final dosing. (C) PCA trajectory plots of fecal water. Color code: gray (control), black (vancomycin-treated d-1), red (dl), yellow 
(d3), blue (d5), purple (d7), dark blue (d13 and d19). Keys: 1, isoleucine; 2, leucine; 3, valine; 4, propionate; 5, lactate; 6, alanine; 7, 
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taurine; 18, glycine; 19, uracil; 20, tyrosine; 21, phenylalanine; 23, butyrate; 39, 5-aminovalerate. 
Systematic comparison of the treated and control groups 
using O-PLS generated strong models with goodness of fit, 
R2 , of 98.3% and goodness of prediction,272B  c12, of 92.3%, 
and showed good discrimination in the scores plot (Figure 
2), indicating that vancomycin caused a substantial and 
significant effect on the fecal composition as compared to 
the urinary changes. The O-PLS coefficients plot (Figure 4) 
confirmed the observed metabolic changes and also identi-
fied decreased levels of fecal lactate and succinate as 
significant discriminators of vancomycin treatment. The 
model parameters for fecal samples are given in Table 2, 
together with the O-PLS-DA correlation coefficients indicat- 
ing the relative contributions of key metabolites contributing 
to the antibiotic-perturbed profiles. 
The O-PLS-DA coefficient plot derived from spectra data of 
fecal water at day 1 post-treatment (data not shown) showed 
a marked depletion of a range of amino acids including leucine, 
isoleucine, valine, lysine, glutamate, methionine, taurine and 
aromatic amino acids such as tyrosine, phenylalanine and 
cytosine, and SCFAs (acetate, butyrate), together with other 
metabolites, such as 5-aminovalerate, succinate, nicotinurate 
and glucose. Moreover, increased concentrations of choline, 
oligossacharides and fumarate were also observed in the 
vancomycin-treated mice. All metabolites showed a similar 
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trend of changes during the course of treatment except 
5-aminovalerate, which fluctuated and recovered back to 
"normal" level at day 7 post-treatment. The relative concentra-
tions of selected metabolites were calculated based on the 
integration of peaks, shown in Figure 4B. 
0-PIS Correlation of Urinary Hippurate and Phenylacetylg-
lycine Concentrations with Fecal Metabolites. O-PLS regres-
sion of urinary hippurate against the fecal extract profiles 
(Figure 5A) generated a strong model (R2 = 92.9%, Q2 = 67.8% 
using a 1-component model with 1 orthogonal component). 
Several fecal amino acids were highly correlated with urinary 
hippurate concentrations,while SCFAs (propionate, n-butyrate 
and acetate) and uracil were also significantly positively cor-
related with urinary hippurate, albeit to a lesser extent. 
Conversely, fecal choline and sugars were inversely correlated 
with urinary hippurate. Lactate and succinate were uncorre-
lated with hippurate. The regression model for urinary phe-
nylacetylglycine (Figure 5B) showed correlations with the same 
molecules as hippurate, but the model and correlation coef-
ficients were weaker (R2 = 86.2%, Q2 = 41.1% using a 
1-component model with 1 orthogonal component). Subse-
quent O-PLS regression analyses were carried out on all the 
time points (day 1—day 19) and the characteristics of these 
models are summarized in Table 3. The pattern of changes 
observed in these models were consistent, with decreasing Q2 
at later time points, indicating weaker correlations between the 
fecal metabolic profiles and urinary hippurate and pheny- 
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lacetylglycine concentrations. These findings are consistent 
with the changes observed in the quantified urinary metabolites 
(Figure 2B). 
Microbial Diversity with Time and Trajectory of DGGE 
Data. 16S rRNA PCR-DGGE and sequencing, as a routine 
molecular approach, was applied to examine disturbance of 
the microbiota caused by vancomycin treatment in mice over 
the duration of the extension study time course (19 days). 
Sequences closely related to C. leptum, C. coccoides, Clostridium 
symbiosum and Photorhabdus luminescens were found to be 
impacted and were lost from the DGGE profiles 1 day post-
treatment (Table 4). However, bands which were shown to be 
closely related to C. leptum and C coccoides recovered at day 
2 or day 3 post-treatment. 
Discussion 
Antibiotics alter the composition of the gut microbiota' and 
play a central role in the development of Clostridium difficile-
associated colitis.33 Moreover, the gut microbiota is resilient, 
and once the antibiotic source has been removed, it is thought 
to substantially recover to its original composition and diver-
sity.' However, no work to date has shown how a major 
perturbation of the gut microbiota manifests itself in the host's 
systemic metabolic phenotype, which is known to be partially 
under inicrobiome control.' Metabolites synthesized via mi-
crobiome activity influence host biology and any dysbiosis in 
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Table 2. Metabolic Effects of Vancomycin Treatment on Feces 
of Mice 
metabolites 
chemical shift of 
discriminating 
signals 
untreated vs vancomycin-treated 
(correlation coefficient) 
Feces 
Q2 = 0.92 
R2 = 0.98 
5-aminovalerate 3.02 (t) +0.95 
acetate 1.92 (s) +0.88 
alanine 1.48 (d) +0.97 
arginine 1.63 (m) +0.96 
asparagine 2.94 (m) +0.82 
aspartate 2.79 (m) +0.90 
n-butyrate 0.90 (t) +0.86 
choline 3.23 (s) -0.69a 
glutamate 2.08 (m) +0.91 
glycine 3.56 (s) +0.65=a 
isoleucine 1.02 (d) +0.95 
lactate 1.32 (d) +0.48a 
leucine 0.96 (t) +0.94 
lysine 1.72 (m) +0.95 
methionine 2.13 (s) +0.93 
oligosaccharides 3.5 - 4.0 -0.90 
phenylalanine 7.40 (t) +0.95 
propionate 2.19 (q) +0.90 
taurine 3.46 (t) +0.81 
tyrosine 6.87 (dd) +0.89 
uracil 5.81 (d) +0.91 
valine 1.04 (d) +0.94 
"Shows trend but not significant at the level of P > 0.05; s, singlet; d, 
doublet; dd, doublet of doublets; t, triplet; m, multiplets; +, relatively 
higher in control mice; -, relatively lower in control mice. 
this virtual organ has implications for the host health. We 
undertook to correlate changes in the gut microbiota, induced 
by exposure to vancomycin, with the host's metabonome35 and 
determine to what extent they are associated. 
Results obtained from the exploratory and extension studies 
revealed consistent changes in the urine and fecal metabolic 
profiles of mice after vancomycin treatment indicating that the 
vancomycin-induced effect on the microbiotal community was 
robust and reproducible. In the extension study, we demon-
strated recovery from vancomycin treatment with individual 
metabolites showing differential recovery rates. We also showed 
clear differences in gut microbial communities between control 
and antibiotic-treated mice using PCR-DGGE-based microbio-
logical methods. Since all animals were fed with the same food, 
kept in the same environment and given drug vehicle, it was 
unlikely that metabolic variation observed were due to envi-
ronmental conditions. Neither vancomycin nor its metabolites 
were detected in any of the urine samples. This was expected 
since vancomycin does not cross through the intestinal lining, 
and since feces are excreted within 24 h after treatment. 
However, drug vehicle was detected in the fecal profiles on day 
1 from both groups and was eliminated within 48 h. Certain 
drug vehicles have been shown to effect urinary biochemical 
profiles. However, in a study conducted by Beckwith-Hall et 
al.36 Tween exerted the smallest effect on the metabolic profiles 
after saline consistent with the present study.36 The spectral 
regions affected by the vehicle were removed from the data 
set prior to mathematical modeling to minimize its effect on 
data analyses and interpretation of the metabolic data. 
Previous studies have highlighted the reduction in the 
urinary excretion of hippurate in both germ-free animals' and 
in rats treated with antibiotics." After exposure to a standard  
laboratory environment, a dynamic series of changes in the 
biochemical composition of the urine was observed in germ-
free animals, as reflected by sequential excretion of pheny-
lacetylglycine, 4-hydroxyphenylpropionic acid, 3-hydroxyphe-
nylpropionic acid and, finally, hippurate at around 21 days 
postexposure. Hippurate is a well-described mammalian-
microbial co-metabolite17•37 formed by glycine conjugation of 
benzoate (predominantly in the liver), which is produced from 
bacterial metabolism of plant phenols,' or by intestinal 
microbiota in the presence of quinic acid (1,3,4,5-tetrahydroxy-
cyclohexanecarboxylic acid)." Depletion of hippurate has been 
previously reported after ingestion of antibiotics such as 
cephaloridine,19.2° gentamicin,21 neomycin, tetracycline hy-
drochloride and bacitracin mixture.13 Gut microbiota also 
extensively catabolize protein and aromatic amino acids, 
including phenylalanine, tyrosine and tryptophan4°  Fecal 
amino acids, including tyrosine and phenylalanine, were noted 
to be directly correlated with urinary hippurate and pheny-
lacetylglycine, consistent with decreased catabolism of these 
amino acids by the microbiota. In the current study, vanco-
mycin had a strong impact on the region of the spectrum 
representing phenolic molecules with particular effect on 
reduction of signals from hippurate and phenylacetylglycine. 
Both PAG and hippurate were observed to be decreased after 
administration of vancomycin; however, urinary concentrations 
of PAG were restored to those of controls at day 5, while 
recovery of urinary hippurate was not experienced until the 
end of the experiment at day 19 post-treatment. This suggests 
that establishment of a stable gut microbiota requires a similar 
time frame in both conventionalisation of germ-free rats and 
in conventional mice after vancomycin treatment. Such a 19-
day recovery of hippurate may reflect a delayed repopulation 
of hippurate-producing microbiota compared with other 
microbiota. 
Other urinary indicators of vancomycin-perturbed micro-
biota included relative decrease in the concentrations of 
trimethylamine (TMA), a gut bacterial product of the choline 
metabolism, and trimethylamine-N-oxide (TMAO), a product 
of its hepatic detoxification.41•42 Choline metabolism is a 
complex host-symbiont molecular interaction which involves 
both mammalian and symxenobiotic (metabolite with dietary 
and/or gut microbiota origin) metabolic pathways.16 Although 
vancomycin treatment did not significantly alter the choline 
and methylamine content of fecal extracts, a trend towards 
decreased levels of choline in fecal water from vancomycin-
treated mice was observed at day 1 postdosing. The variations 
of TMA and choline concentration were not observed from day 
3 onward. This might indicate that choline metabolism is 
influenced by both vancomycin and nonvancomycin sensitive 
bacteria. In addition, methylamines are known to be co-
metabolized by the host and the gut microbiota in the large 
intestine 42  
Bacterial fermentation of carbohydrates in the cecum and 
the large intestine leads to the production of SCFAs and lactic 
acid depending on the bacterial strains involved.'" We 
observed lower amounts of fecal acetate, n-butyrate, propionate 
and lactate, and increased quantities of fecal oligosaccharides 
in mice treated with vancomycin compared to controls (Table 
1), suggesting disruption in carbohydrate fermentation due to 
vancomycin-induced changes in gut microbial populations. Our 
observations are consistent with previous in vitro experiments 
using porcine cecal contents to create an in vitro model of gut 
microbial metabolism which showed marked decrease of fecal 
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Table 3. O-PLS Model Summary of the Correlations Between 
Urinary Hippurate and Phenylacetylglycine with Fecal 
Metabolites for Day 1 (DO, Day 3 (D3), Day 7 (DO, Day 13 (D13) 
and Day 19 (D19) 
time 
point 
hippurate 
Q2  R2 
number of 
components 
PAG 
Q2  R2 
number of 
components 
D1  71% 57% 1 <0 — — 
D3 56% 64% 3 37% 60% 2 
D7 63% 64% 5 13% 20% 1 
D13 52% 38% 3 <0 — — 
D19 17% 22% 1 <0 — — 
SCFAs following vancomycin intervention.' In particular, 
fermentation of carbohydrates by the Bifidobacteria normally 
induces a decrease in the pH of the cecal content associated 
quantitatively with different SCFA profiles of treated animals 
as compared to control animals, which inhibits the growth of 
pathogens."'" The disruption of the microbial production of 
SCFAs after vancomycin administration might thus be expected 
to profoundly disturb the gut microbial environment and alter 
relative amounts, and composition of colonic bacterial spe-
cies.' Given that most of the SCFAs are rapidly absorbed in 
the ascending part of the colon and represent potential 
substrates for the liver and various tissues, such antibiotic-
induced effects might have significant nutritional consequences 
for the host :15.'5° The disruption of the SCFA bacterial 
metabolism results in a loss of bioavailability of these metabo-
lites for the host metabolism, possibly related to the observed 
reduction in urinary elimination of n-butyrate and a-ketois-
ovalerate (Table 2). In addition, the reduction in n-butyrate 
production might have physiological consequences for indi-
vidual animals because bacterial n-butyrate has a 'trophic' 
effect on colonocytes.4" Previous studies have shown the 
contribution of gut microbiota to mammalian host metabolism 
by measuring specific groups of compounds such as amino 
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acids, bile acids, SCFAs, monitoring changes in fecal ammonia 
and host physiological descriptors such as those related to 
energy expenditure, lipoprotein profile and recovery from gut 
dysbiosis.' Interestingly, fecal lactate did not correlate with 
urinary hippurate (Figure 5A) and may reflect the fact that 
urinary lactate contains both the D- and L-enantiomers, of 
mixed host and microbial sources, whereas fecal lactate is 
predominantly produce by bacteria and therefore is mainly in 
the o-form. 
Another prominent finding is the reduction in the concen-
trations of SCFAs including acetate and butyrate, together with 
increased concentrations of oligosaccharides in fecal water 
from vancomycin-treated mice compared with that from 
control mice on days 1, 3, 5, and 7. This is consistent with a 
previous study where Bender et al.' employed an in vitro 
model for the semicontinuous incubation of defined colon 
contents to examine the effect of vancomycin on SCFAs 
composition." These SCFAs are derived from the fermentation 
of nongastric-digestible starches and oligosaccharides by sac-
charolytic bacteria. The composition of fermentation end-
products is dependent on the bacteria species, substrates and 
chemical environment, such as pH.48 Rycroft et al.54 reported 
that galacto-oligosaccharides generated high levels of SCFAs 
and decreased the numbers of clostridia.' Among these SCFAs, 
n-butyrate seems to be most beneficial to colon cellular 
functions, such as proliferation, membrane synthesis and 
sodium absorption, and it also shows effect of anti-colon 
carcinogenesis and anti-tumor activity.55.56 In the present 
study, the 'abnormal' levels of SCFAs, which lasted for 13 days, 
indicated a large amount of microbiota experienced reduced 
activities, unlike C. coccoides and C. leptum which recovered 
from day 2 onward. Interestingly, there was an increase in 
species diversity in the vancomycin-treated group supported 
by the increased number of DNA bands appearing on the 
DGGE. Although those species could not be unequivocally 
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Table 4. Taxonomic Affiliation of the Partial 16S rRNA Gene Sequence Obtained from the Excised DGGE Bands 
Phyla Class Order Family Genus Species Accesion number Similarity (%) 
Firmicutes Mollicutes Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Uncultured bacterium AY960576 92 
Firmicutes Mollicutes Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Anaeroplasma bactoclasticum M25049 90 
Firmicutes Mollicutes Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Uncultured bacterium E0006469 92 
Firmicutes Clostridia Clostridiales Eubacteriaceae Eubacterium Eubacterium L34618 desmolans 83 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Uncultured bacterium EF406679 97 
Firmicutes Clostridia Clostridia/es Clostridiaceae Clostridium Clostridium AF028350 cocleatum 97 
Frmicutes Clostridia Clostridiales Clostridiaceae Clostridium Uncultured bacterium EF603657 97 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Clostridium sp. BA- AB196728 83 
Firmicutes Clostridia Clostridiales Lachnospiraceae Incertae sedis Uncultured bacterium EF704431 96 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Clostridium symbiosum EF44266995 
Firmicutes Clostridia Clostridiales Clostridiaceae Ruminococcus Uncultured bacterium AY976513 58 
Firmicutes Clostridia Clostridiales Lachnospiraceae Anaerostipes Bbuat ycrtaa- pmrosdsu2ic n  g AY305319 60 
Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Escherichia Uncultured bacterium EF674507 94 
Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Photorhabdus rhesacbdenuss 
Pith motion DQ518589 93 
" The rows shaded in gray are the closest hits to bacteria, which have been cultured. 
identified here, this gross observation is in agreement with a 
previous human study,' which reported a marked elevation 
in total numbers of Clostridium bacteria including C. bifer-
mentans, C. clostridioforme, C. sordellii and C. malenominatum, 
and an increased species diversity in the elderly people under 
antibiotic treatment. 
In the current study, lower fecal concentration of amino acid 
levels were observed in vancomycin-treated mice (Table 1, 
Figure 4), which may affect the complex fluxes of amino acids 
and protein nitrogen across the intestinal mucosa.57 Although 
gastrointestinal digestion of some dietary proteins is incom-
plete, only about 2-5% escapes small intestinal digestion/ 
absorption. Immense populations of bacteria living within the 
large intestine are key contributors to the digestion and 
metabolism of amino acids and vitamins in the gut.' In 
particular, intestines in germ-free animals generally show 
changed gut morphology, including atypical epithelial struc-
ture, less efficient nutrient usage and intestinal inflammation.59-61  
The antibiotic-induced disruption of the gut bacterial ecology 
may thus promote an inflammatory disruption of absorptive 
abilities of intestinal brush border, which could lead to mal-
absorption of amino acids and SCFAs.' Additionally, since 
<50% of the fecal mass generally consists of bacteria,' it is 
conceivable that the amino acids extracted from feces might 
also be derived from the gut bacteria themselves and that the 
observed reduction in fecal amino acids reflects perturbed 
amino acids metabolism as well as reduced bacterial popula-
tion due to vancomycin treatment. 
Changes were noted in urinary a-ketoisocaproate and cre-
atine levels following antibiotic treatment. In the human gut, 
the anaerobic genus Clostridium were found to metabolize 
leucine to isocaproate and a-ketoisocaproate;" and creatine 
has also been shown to be co-metabolized in mammals and 
their gut microbiota.6a,65  Perturbed gut microbial changes 
observed in SCFAs, oligosaccharides and amino acids indicated 
vancomycin-induced changes in metabolism of these com-
pounds, which may also explain the change in the relative 
amounts of a-ketoisocaproate and creatine in the urine. 
This work has shown the potential of a metabolic profiling 
strategy for studying the effects of antibiotics on the gut 
microbiota and has provided insights into the metabolic 
changes associated with antibiotic treatment and its effect on 
gut microbiota modification. Furthermore, urinary hippurate 
levels correlated closely with the amino and SCFA profiles in 
the feces. Our metabolic profiling approach showed changes 
in host amino acids metabolism and SCFA metabolism as well 
as in host metabolism of phenolics due to antibiotic treatment. 
The methods used here were intended to look at general 
aspects of the gut microbiome and as such are not specific 
enough to determine which species are being altered and may 
be responsible for the changes in the host's metabolite profiles. 
Further studies using such methods as stable isotope probing, 
metabonomics and high-throughput sequencing of 16S rRNA 
genes are needed to start to determine the keystone species in 
the gut, which are responsible for generating the host's 
metabotype. 
Abbreviations: COSY, 'H—'H correlation spectroscopy; FID, 
free induction decay; IBS, irritable bowel syndrome; NMR, 
nuclear magnetic resonance; O-PLS-DA, orthogonal signal 
correction-projection to latent structure-discriminant analysis; 
PCR-DGGE, polymerase chain reaction-denaturing gradient gel 
electrophoresis; RD, recycle delay; SCFA, short chain fatty acid; 
STOCSY, statistical total correlation spectroscopy; TMA, trim-
ethylamine; TMAO, trimethylamine-N-oxide; TOCSY, 'H—'H 
total correlation spectroscopy; TSP, 3-trimethylsily1-1-12,2,3,3-
21-141 propionate. 
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Abstract 
Background: Metabolic profiling holds promise with regard to deepening our understanding of infection biology and 
disease states. The objectives of our study were to assess the global metabolic responses to an Echinostoma caproni 
infection in the mouse, and to compare the biomarkers extracted from different biofluids (plasma, stool, and urine) in terms 
of characterizing acute and chronic stages of this intestinal fluke infection. 
Methodology/Principal Findings:Twelve female NMRI mice were infected with 30 E. caproni metacercariae each. Plasma, 
stool, and urine samples were collected at 7 time points up to day 33 post-infection. Samples were also obtained from non-
infected control mice at the same time points and measured using 1 H nuclear magnetic resonance (NMR) spectroscopy. 
Spectral data were subjected to multivariate statistical analyses. In plasma and urine, an altered metabolic profile was 
already evident 1 day post-infection, characterized by reduced levels of plasma choline, acetate, formate, and lactate, 
coupled with increased levels of plasma glucose, and relatively lower concentrations of urinary creatine. The main changes 
in the urine metabolic profile started at day 8 post-infection, characterized by increased relative concentrations of 
trimethylamine and phenylacetylglycine and lower levels of 2-ketoisocaproate and showed differentiation over the course 
of the infection. 
Conclusion/Significance: The current investigation is part of a broader NMR-based metabonomics profiling strategy and 
confirms the utility of this approach for biomarker discovery. In the case of E. caproni, a diagnosis based on all three 
biofluids would deliver the most comprehensive fingerprint of an infection. For practical purposes, however, future 
diagnosis might aim at a single biofluid, in which case urine would be chosen for further investigation, based on quantity of 
biomarkers, ease of sampling, and the degree of differentiation from the non-infected control group. 
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Introduction 
An estimated 40 million individuals are infected with food-borne 
trematodes and, in many parts of the world, the diseases caused by 
these infections are emerging [I]. Yet, food-borne trematodiases are 
so-called neglected tropical diseases [2]. An infection with food-
borne trematodes is acquired by the consumption of the larval stage 
of the parasite, present in aquatic food products (e.g., freshwater fish, 
crustacean, and water plants). Adult flukes reside either in the 
intestine (e.g., Echinostoma spp.), the lung (e.g., ParagomMusspp.), or the 
liver (e.g., Clonorchis sinensis, Fasciola spp., Opisthorchis spp.) and can 
lead to various forms of pathology [2,3]. 
A light infection with the intestinal fluke Echinostoma spp. in 
humans causes no marked deviation from the healthy state in the 
majority of cases, whereas the clinical symptoms due to a heavy 
www.plosntds.org  
infection include abdominal pain, violent diarrhea, anorexia, easy 
fatigue, and changes in the intestinal architecture, such as 
intestinal erosions, damage of intestinal mucosa, and catarrhal 
inflammation [4]. Histopathological investigations in mice and 
humans infected with Echinostoma spp. have revealed atrophied, 
fused and eroded villi, and a crypt hyperplasia in both lightly and 
heavily infected subjects [5-7]. 
At present, the most widely used diagnosis for infections with 
Echinostoma spp. and other food-borne trematodes, is by means of 
microscopic examination of stool samples for the presence of 
parasite eggs. However, light infection intensities, particularly at 
the onset of disease are often missed by this diagnostic approach. 
In addition, the detection of echinostome eggs in stool samples 
varies greatly due to species-dependent differences in egg laying 
capacity. Other means for diagnosis of food-borne trematode 
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Author Summary 
Consumption of raw fish and other freshwater products 
can lead to unpleasant worm infections. Indeed, such 
worm infections are of growing public health and 
veterinary concern, but they are often neglected, partially 
explained by the difficulty of accurate diagnosis. In the 
present study we infected 12 mice with an intestinal worm 
(i.e., Echinostoma caproni) and collected blood, stool, and 
urine samples 7 times between 1 and 33 days after the 
infection. At the same time points, blood, stool, and urine 
were also sampled from 12 uninfected mice. These biofluid 
samples were examined with a spectrometer and data 
were analyzed with a multivariate approach. We observed 
important differences between the infected and the 
uninfected control animals. For example, we found an 
increased level of branched chain amino acids in the stool 
of infected mice and subsequent depletion in blood 
plasma. Additionally, we observed changes related to a 
disturbed intestinal bacterial composition, particularly in 
urine and stool. The combination of results from the three 
types of biofluids gave the most comprehensive charac-
terization of an E caproni infection in the mouse. Urine 
would be the biofluid of choice for diagnosis of an 
infection because the ease of sample collection and the 
high number and extent of changed metabolites. 
infections include immunological and molecular tests, such as the 
enzyme-linked immunosorbent assay (ELISA) [8] or polymerase 
chain reaction (PCR) [9], which depend on specificity of antigens 
and primers, respectively. 
In the current study we applied a combination of I H nuclear 
magnetic resonance (NMR) spectroscopy and multivariate statis-
tical analysis to identify candidate biomarkers of an E. caproni 
infection and disease states in the mouse, by metabolic profiling of 
blood plasma, stool, and urine samples. E. caproni is a suitable 
trematode model that has been widely and effectively used in the 
laboratory for drug screening, and to deepen our understanding of 
the immunology and pathology of echinostomes and other food-
borne trematodes in the vertebrate host [10-12]. NMR spectros-
copy delivers a snapshot of the metabolite composition of biofluids, 
tissues and even bone, and has found a large array of applications 
in biology and medicine, such as the detection and differentiation 
of coronary heart disease [13], and biomarker identification in 
schizophrenia patients [14]. The systemic metabolic profile of a 
biological sample is of special interest, because it can be 
characteristic of the entire organism, and hence finds increasing 
application in systems biology [15]. The use of multivariate 
statistical methods to analyze and interpret complex spectral 
datasets makes it possible to deal with large sample data banks, 
and to detect differences between physiologically or pathologically 
distinct states. Candidate biomarkers can be identified from these 
models, taking into consideration intra-group variations, sample 
preparation methods, and spectral data acquisition. Thus far, we 
have characterized the global metabolic responses to several 
parasitic infections in rodents, namely (1) Schistosoma mansoni in the 
mouse [16], (ii) Schistasoma japonicum in the hamster [17], (iii) 
Trichinella spiralis in the mouse [18], (iv) Tgpanosoma brucei brucei in 
the mouse [19], and (v) Plasmodium berghei in the mouse [56] mainly 
based on the urine and/or blood plasma metabolite profiles. Here 
we extend these initial host-parasite models to consider the relative 
merit of using biomarkers derived from a combined biological 
sample profile, and apply a metabolic profiling strategy for the first 
time to a food-borne trematode. 
Materials and Methods 
E. caproni-mouse model and animal husbandry 
Our experiments were carried out in accordance with Swiss 
cantonal and national regulations on animal welfare (permission 
no. 2081). Female NMRI mice (n = 24) were purchased from RCC 
(Itingen, Switzerland), and housed in groups of 4 in macrolon 
cages under environmentally-controlled conditions (temperature: 
—25°C; humidity: —70%; light-dark cycle: 12-12 h). Mice had 
free access to commercially available rodent food from Nafag 
(Gossau, Switzerland) and community tap water supply. 
Mice were 5 to 6-week-old at the onset of the experiments and 
had an average weight of 25.5 g (standard deviation (SD) = 0.9 g). 
Half of the mice remained uninfected throughout the study and 
served as controls. The other 12 mice were orally infected with 30 
E. caproni metacercariae each (provided by B. Fried; Lafayette 
College, Easton, PA, United States of America) [20] on designated 
study day 0, which took place I week after arrival of animals to 
provide sufficient acclimatization time, and hence minimize stress-
related impact on the metabolic profiles. Upon dissection of mice 
at the end of the experiment, however it was found that no 
infection had been established in 4 animals. Therefore these 4 
mice were excluded from any further analysis. 
Collection of biofluids 
Blood plasma, stool and urine samples were collected over a 33-
day time course at 7 distinct sampling points (days 1, 5, 8, 12, 19, 26, 
and 33 post-infection), representative of different stages in the life of 
the E. caproni fluke, including acute and chronic infection stages. 
Collection was carried out between 08:00 and 10:00 hours in order 
to avoid potential variation of metabolite concentrations due to 
diurnal fluctuations. Stool and urine samples were collected into 
Petri dishes by gently rubbing the abdomen of the mice, and were 
immediately transferred into separate Eppendorf tubes and kept at 
—40°C. Blood samples (40-50 pi) were collected from the tail tip of 
each mouse into haematocrit tubes with sodium [Na] heparin-coat. 
Tubes were placed in a centrifuge (model 1-15, Sigma; Osterode am 
Harz, Germany) operated at 4,000 g for 4 min in order to separate 
plasma from red blood cells. The packed cell volume (PCV), i.e., 
length of red blood cells column in the microcapillary versus total 
length of blood sample column, was determined and expressed as 
percentage. Subsequently, the plasma fraction (-20 pl) was 
transferred into a separate Eppendorf tube and kept at —40°C. 
Animals were weighed at each sampling point, using a Mettler 
balance (model K7T; Greifensee, Switzerland). 
Mice were killed 36 days post-infection, using CO2. The small 
intestine was removed, and adult worms recovered from the ileum 
and jejunum and counted. Biological samples and an E caproni 
specimen were forwarded to Imperial College London (United 
Kingdom) on dry ice and stored at —40°C prior to processing for 
1H NMR spectroscopic data acquisition. 
Preparation of biofluids and E. caproni homogenate 
Urine samples were prepared with a phosphate buffer (pH 7.4) 
containing 50% D20 (Goss Scientific Instruments; Chelmsford, 
United Kingdom) as a field frequency lock and 0.01% sodium 3-
(trimethylsilyl) [2,2,3,3-2H4] propionate (TSP) (Cambridge Isotope 
Laboratories Inc.; Andover, MA, United States of America), as a 
chemical shift reference (8 0.0). An aliquot of 25 pl of urine was 
added to 25 pl phosphate buffer. Plasma samples were prepared 
by adding 30 Al of 0.9% saline made up in 50% D20 into the 
Eppendorf tubes containing —20 pl of plasma. Because of the 
limited volumes of urine and plasma, samples were transferred 
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Figure 1. Aliphatic regions of representative 600 MHz 1 H-NMR 1D spectra of biological samples obtained from an uninfected control 
mouse, aged 7-8 weeks. Spectra of urine (A), plasma (B) and fecal water (C) are shown. Additionally, the same region of a 600 MHz 1 H NMR 1D 
spectrum of an E. caproni extract is depicted (D). Key: 2-og, 2-oxoglutarate; 3-hb, 3-hydroxybutyrate; 2-kic, 2-ketoisocaproate; 2-kiv, 2-ketoisovalerate; 
13-glu, (3-glucose; aa, amino acids; ace, acetate; ala, alanine; arg, arginine; asn, asparagine; asp, aspartate; bcaa, branched chain amino acids; bet, 
betaine; but, butyrate; cit, citrate; cho, choline; cre, creatine; crt, creatinine; dht, dihydroxythymlne; dma, dimethylamine; dmg, dimethyiglycine; glc, 
glycolate; gln, glutamine; glu, glutamate; gly, glycine; gpc, glycerophosphocholine; gua, guanidinoacetate; hip, hippurate; lac, lactate; leu, leucine; lys, 
lysine; mea, methylamine; meg, methylguanidine; mel, methanol; met, methionine; nmna, N-methyl-nicotinamide; phe, phenylalanine; pip, 
pipecolate; pro, proline; p5p, pyridoxamine-5-phosphate; pyr, pyruvate; scy, scyllo-inositol; suc, succinate; tau, taurine; thr, threonine; tma, 
trimethylamine; tmao, trimethylamine-N-oxide; ure, ureidopropanoate. 
doi:10.1371/journal.pntd.0000254.g 001 
into 1.7 mm diameter micro NMR-tubes (CortecNet; Paris, 
France) using a micro-syringe. 
Stool samples were prepared with the same buffer as for urine 
but using 90% D20 to reduce the water content. Two pellets of 
stool were mashed with 700 µI buffer and sonicated for 30 min to 
inactivate gut bacteria and achieve biochemical stability in the 
sample. The samples were then centrifuged at 10,000 g for 2 min, 
and 550-600 µI of the supernatant was transferred into a new 
Eppendorf tube and stored at -40°C. Shortly before data 
acquisition, the stool supernatant was defrosted, centrifuged and 
transferred into NMR tubes of 5 mm outer diameter. 
A tissue extraction was performed on the E. caproni specimen for 
1H NMR spectroscopic analysis. The adult E. caproni fluke was 
mashed in 1 ml of chloroform with a glass mortar and pestle. A total 
of 1 ml of methanol and 1 ml of water were added, and this mixture 
was transferred into a glass tube. Another 0.5 ml of each liquid was 
used to rinse the mortar and transferred into the same glass tube. 
The mixture was centrifuged at 2,500 g for 30 min. The aqueous 
and the chloroform phases were transferred into a new glass tube 
each, chloroform was evaporated over night and the aqueous phase 
was lyophilized. Prior to 'H NMR data acquisition, the powder 
obtained from the aqueous phase was resolved in 550 µI phosphate 
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Figure 2. Aromatic regions of representative 600 MHz 1H-NMR 
1D spectra of biological samples obtained from an uninfected 
control mouse, aged 7-8 weeks. Spectra of urine (A), plasma (B) and 
fecal water (C) are shown. Additionally, the same region of a 600 MHz 
'H NMR 10 spectrum of an E. caproni extract is depicted (D). Key: a-glu, 
a-glucose; alt, alantoin; for, formate; fum, fumarate; hip, hippurate; his, 
histidine; horn, homocarnosine; ind, indoxylsulfate; nmna, N-methyl-
nicotinamide; pag, phenylacetylglycine; phe, phenylalanine; trp, tryp-
tophan; tyr, tyrosine; ura, uracil; uri, uridine; uro, urocanate. 
dokl 0.1371/journal.pntd.0000254.g002 
buffer (90% D20), whereas the dry mass of the chloroform fraction 
was dissolved in detiterated chloroform (CDC13). 
Acquisition of spectral data 
IH NMR spectra from plasma, stool, and urine samples, and 
the E. caproni extract were recorded on a Bruker DRX 600 NMR 
spectrometer, operating at 600.13 MHz for proton frequency 
(Bruker; Rheinstetten, Germany). A Bruker 5 mm triple resonance 
probe with inverse detection was used, employing a standard 
NMR 1-dimensional (1D) experiment with pulse sequence [recycle 
delay (RD)-90'-t /-90'-4„-90'-ACQ], setting II to 3 us, and using a 
mixing time (t„,) of 150 ms. Water suppression was achieved with 
irradiation of the water peak during the RD set to 2 s and mixing 
time. The 90' pulse length was adjusted to —10 us. A total of 256 
transients were collected into —32,000 data points for each spectrum 
with a spectra] width of 20 ppm. For plasma, two additional pulse 
programs were applied, namely Carr-Purcell-Meihoom-Gill 
(CPMG), and diffusion edited spectroscopy [21] to focus on the 
low and high molecular weight components of the plasma profile, 
respectively. All free induction decays (FIDs) were multiplied by an  
exponential function equivalent to a 0.3 Hz line-broadening factor 
prior to Fourier transformation. 
Assignments of the spectral peaks were made from literature 
values [22-25] and confirmed via statistical total correlation 
spectroscopy (STOCSY) in MATLAB [26] and via standard 2-
dimensional (2D) NMR experiments conducted on selected samples, 
including correlation spectroscopy (COSY), total correlation spec-
troscopy (TOCSY), and J-resolved NMR spectra [27,28]. 
Figure 3. PCA trajectory plot of urine (A), plasma (6) and fecal 
water spectra (C) obtained from the mean PC1 and PC2 values 
for the E. caproni-infected mice over a 33-day period. The 
collection of the biofluids was performed at days 1, 5, 8, 12, 19, 26, and 
33 post-infection. The ellipses in the 3D plots (Figures 3B and C) are for 
illustration purposes only to denote time points which become distinct 
from controls in 3D but are not clearly resolved in two dimensions, and 
are not based on statistical boundaries. 
do1:10.1371/journal.pntd.0000254.9003 
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Table 1. List of main metabolites found in urine over a 33-day study period in NMRI female mice. 
Maximal time of 
Metabolite 	 metabolic change 	Chemical moiety Chemical shift in ppm and multiplicity 
(d1): 1 (d12)*  
2-hydroxyisobutyrate 
2-ketoisocaproate 
2-oxoglutarate 
acetate 
alanine 
allantoin 
citrate 
creatine 
creatinine 
dimethylamine 
dimethylglycine 
formate 
fumarate 
cc-glucose  
2xCH3 
	 1.36(s) 
CH2, CH, 2xCH3 	 2.61(d), 2.10(m), 0.94(d) 
13-0-12, y-CH2 	 3.02(t), 2.50(t) 
CH3 	 1.91(s) 
cc-CH, 13-CH3 	 3.81(g), 1.48(d) 
CH 
	
5.40(s) 
1-CH2, 3-CH2 	 2.69(d), 2.54(d) 
CH3, CH2 
	 3.04(5), 3.93(s) 
CH3, CH2 	 3.05(s), 4.06(s) 
2 x CH3 	 2,71(s) 
2 x CH3, CH2 	 2.89(5), 3.71(s) 
CH 	 8.45(s) 
CH 	 6.53(s) 
1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-0-12, half 6-0-12 
	5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd 
.1, (d12) 
(d8) 
(d8) 
(d1); 1 (d12)* 
.1, (d33) 
(d12) 
ft-glucose 
glycolate 
guanidinoacetate 
hippurate 
indoxylsulfate 
lactate 
mannitol 
methylcrotonate 
methylamine 
methylguanidine 
N-methyl-nicotinamide 
p-cresolglucuronide 
phenylacetylglycine 
pyridoxa mine-5-phosphate 
succinate 
taurine 
trimethylamine 
trimethylamine-N-oxide 
ureidopropanoate 
urocanate 
1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-0-12, half 6-CH2  
CH2 
CH2 
CH2, 2,6-CH, 3,5-CH, 4-CH 
5-CH, 6-CH, 4-CH, 7-CH 
CH, CH3 
2xcc-CH2, 2x13-CH, 2xy-CH 
8-CH, 7-CH3, 7'-CH3 
CH3 
CH3 
CH3, 6-CH, 2-CH, 5-0-1, 4-CH 
2,6-04, 3,5-CH, CH3 
2,6-CH, 3,5-CH, Ph-CH2, N-CH2 
0CH2, CH2N, CH3 
2xCH2 
CH2N, CH25 
3xCH3 
3 x CH3 
7-012, 13-CH2 
cc-CH, 	5-CH, 2-CH  
3.85(m) 
4.65(d), 3.25(dd), 3.47(t), 3.40(t), 3A7(ddd), 
3.78(dd), 3.90(dd) 
3.94(s) 
3.80(s) 
3.97(d), 7.84(d), 7.55(t), 7.64(t) 
7.20(t), 7.27(t), 7.51(d), 7.70(d) 
4.12(g), 1.33(d) 
3.78(m), 3.88(dd), 3.68(dd) 
1.66(s), 1.70(s), 1.71(s) 
2.61(s) 
2.83(s) 
4.48(s), 8.97(d), 9.28(s), 8.19(t), 8.90(d) 
7.06(d), 7.23(d), 2.30(s) 
7.43(m), 7.37(m), 3.75(d), 3.68(s) 
7.67(s), 4.34(5), 2.48(s) 
2.41(5) 
3.27(t), 3.43(t) 
2.88(s) 
3.27(s) 
2.38(t), 33(0 
6.40(d), 7.13(d), 7.41(s), 7.89(s) 
(d12) 
(d26) 
(d33) 
(dig) 
(d12) 
(d12) 
The arrows show whether the metabolic change, associated with an E. caproni infection, is significantly increased ( ) or decreased (j) in infected mice compared to 
non-infected control mice and the numbers, next to the arrows indicate the day of maximum significance. The p-values for the changing metabolites were assessed 
using a non-parametric 1-way analysis of variance (Mann-Whitney U) test in MATLAB, based on the integrals of the selected peaks and were all in the range of 0.001 to 
0.05. 
doll 0.1371 /journal.p ntd.0000254.t001 
Data processing and analysis 
Data processing was as follows. First, spectra were corrected for 
phase and baseline distortions with an in-house developed 
MATLAB script. Second, the region containing the water/urea 
resonances (i.e., 5 4.2-6.3 in urine, 5 4.4-5.2 in plasma, and 5 4.7-
5.5 in stool extracts) was excluded. Third, the spectra were 
normalized over the total sum of the remaining spectral area. 
Analysis of the spectral data was performed with principal 
component analysis (PCA) [29], projection to latent structure 
discriminant analysis (PLS-DA) and orthogonal (0)-PLS-DA [30].  
PCA was used to explore any intrinsic similarity between samples. 
PCA models cannot be over-fitted since no prior information on 
infection status is included in the model. PLS-DA was then used to 
apply knowledge of infection status to optimize separation of classes 
and recovery of candidate biomarkers [30]. O-PLS-DA includes an 
orthogonal data filter in the PLS-DA and was used to further 
improve the extraction of infection-related biomarkers by removing 
the influence of systematic variation not related to infection status. 
The weight of contribution of the peaks is indicated by the color 
scale, whereby red symbolizes relatively high correlation with 
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Table 2. List of main plasma metabolites found in mice over a 33-day study period. 
Metabolite 
Maximal time of 
metabolic change Chemical moiety Chemical shift in ppm and multiplicity 
2-ketoisovalerate CH, 2 xCI-13 3.02(m), 1.13(d) 
3-hydroxybutyrate half a-CH2, half a-CH2, --CH, 	-CH3 2.32(m), 2.42(m), 4.16(m), 1.21(d) 
acetate (d12) CH3 1.91(s) 
acetoacetate a-CH2, y-CH3 2.29(s), 3.45(s) 
alanine a-CH, p-CH3 3.81(q), 1.48(d) 
allantoin CH 5.40(s) 
choline I (d33) 3 xCH3, a-CH2, 13-CH2 3.21(s), 4.07(m), 352(m) 
citrate 1-CH2, 3-CH2 2.69(d), 2.54(d) 
creatine , 	(d12) CH3, CH2 3.04(s), 3.93(s) 
dihydroxythymine CH2, CH, CH3 3.17(m), 2.47(m), 1.07(d) 
formate (d12) CH 8.45(s) 
a-glucose (dl); 	I 	(d12)* 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 
3.85(m) 
1-glucose T 	(d1); 	. 	(dl 2). 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 4.65(d), 3.25(dd), 3.47(t), 3.40(t), 3.47(ddd), 
3.78(dd), 3.90(dd) 
glycerophosphocholine 1 	(d12) 3 xCH3, half tx-CH2, half a-CH2, half 0-CH2, half --CH2, -CH2 3.23(s), 4.32(t), 3.60(dd), 3.68(t), 3.89(m), 3.72(dd) 
isoleucine I (d33) a-CH, --CH, half 7-CH2, half y-CH2, 8-CH3, P-CH3 3.68(d), 1.93(m), 1.25(m), 1.47(m), 0.99(d), 1.02(d) 
lactate CH, CH3 4.12(q), 1.33(d) 
leucine J. 	(d33) a-CH, 	-CH2, y-CH, 8-CH3, 8-CH3 3.72(t), 1.63(m), 1.69(m), 0.91(d), 0.94(d) 
methionine a-CH, 	y-CH2, CH3 3.87(m), 2.10(m), 2.65(dd), 2.15(s) 
scyllo-inositol 6 xCH 3.35(s) 
valine 1 (d33) a-CH, --CH, y-CH3, 	'-CH3 3.62(d), 2.28(m), 0.98(d), 1.03(d) 
lipid fraction CH3 0.84(t) 
lipid fraction (CH2)n 1.25(m) 
lipid fraction ii-CH2CH2C0 1.57(m) 
lipid fraction CH2C=C 1.97(m), 2.00(m) 
lipid fraction CH2CO 2.23(m) 
lipid fraction C=CCH2C=C 2.69(m), 2.71(m), 2.72(m) 
lipid fraction CH =CH 5.23(m), 5.26(m), 5.29(m) 
Arrows indicate significantly changing substances comparing plasma of E. caproni-infected mice with non-infected control mice ( , increased; I, decreased in infected 
animals) and the numbers in brackets indicate the day of maximum significance. glucose was the only metabolite found, which changed its directionality with time, i.e., 
it increased significantly after one day of infection and at day 12 post-infection was present in significantly lower concentrations, compared to uninfected control mice. 
The p-values for the changing metabolites were assessed using a non-parametric 1-way analysis of variance (Mann-Whitney U) test in MATLAB, based on the integrals of 
the selected peaks and were all in the range of 0.001 to 0.05. 
doi:10.1371 /journal.pntd.0000254.t002 
infection and blue indicates relatively low or no correlation. The 
metabolites which contributed the greatest weight to the O-PLS-DA 
coefficient plot were identified (Tables 1-3). 
The NMR spectral data were used as the X-matrix and class 
information (infected or non-infected control) as the 2'-matrix to 
build the O-PLS-DA models. A model consisting of one PLS 
component and one orthogonal component was generated using 
7-fold cross validation. 
Finally, in order to more accurately profile the temporal 
behavior of the discriminatory metabolites characterizing an 
E. caproni infection, computational integration was performed on 
selected resonances. Resonances from several of the metabolites in 
each sample, which showed infection-dependent variations, were 
integrated using an automated curve fitting program. The relative 
concentration in relation to the total spectral integral, subsequent 
to removal of the water resonance, was determined. This was 
performed in MATLAB using a previously published method [31], 
. www.plosntds.org  
and further modified by a colleague (K. Veselkov; Imperial 
College London, UK). The p-values for the metabolites were 
assessed using a non-parametric 1-way analysis of variance (Mann-
Whitney U) test in MATLAB. 
Results 
Physiological monitoring of mice 
E. caproni-infected mice showed no visible sign of ill-health over 
the course of the experiment. The mean weight and mean PCV of 
E. caproni-infected (n = 8) and non-infected control mice (n = 12) 
did not differ at any of the time points investigated. The PCV 
values maintained a constant level throughout the experiment 
(49.6-55.1%). Upon dissection and worm count, an infection was 
confirmed in 8 out of the 12 mice (average worm count 26.5, 
SD = 12.0, range: 10-44 worms). The 4 animals with no 
established infection were excluded from further analyses. 
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Table 3. Main metabolites found in fecal water of mice over a 33-day study period. 
Metabolite 
Maximal time of 
metabolic change Chemical moiety 	 Chemical shift In ppm and multiplicity 
2-hydroxyisovalerate 	 a-CH, p-CH, y-CH,, y'-CH, 	 3.85(d), 2.02(m), 0.79(d), 0.84c1) 
2-ketoisocaproate 	 CH2, CH, 2xCH3 	 2.61(d), 2.10(m), 0.94(d) 
2-ketolsovalerate 	 CH, 2xCH3 	 3.02(m), 1.13(d) 
3-aminopropionic acid 	 a-CH2, P-CH2 	 2.56(t), 3.19(t) 
3-hydroxyphenylpropionate 	 a-CH2, (3-CH2, 2-CH 	 2.85(t), 2.47(m), 6.80(m) 
2-oxoisoleucine 	 CH, half y-CH2, half y-CH2, 5-CH3, (3-CH-CH, 	2.93(m), 1.70(m), 1.46(m), 0.90(t), 1.10(d) 
5-aminovalerate 	 i (d26) 	 5-CH2, 2-CH2, 3,4-CH2 	 3.02(t), 2.24(t), 1.65(m) 
acetate 	 (. (d12) 	 CH, 	 1.91(s) 
alanine 	 ,I. (d12) 	 a-CH, p-CH, 	 3.81(q), 1.48(d) 
arginine 	 a-CH, p-CH2, y-CH2, 5-CH2 	 3.76(t), 1.89(m), 1.59(m), 3.17(t) 
asparagine 	 a-CH, half 13-CH2, half 13-CH2 	 4.01(m), 2.87(dd), 2.96(dd) 
aspartate 	 a-CH, half P-CH2, half )3-CH2 	 3.92(m), 2.70(m), 2.81(m) 
bile acids 	 CH, 	 0.70(m) 
butyrate 	 1 (d26) 	 a-CH2, f3-CH2, y-CH3 	 2.16(t), 1.56(m), 0.90(t) 
ethanolamine 	 NH-CH2, HO-CH2 	 3.15(t), 3.78(t) 
formate 	 CH 	 8.45(s) 
fumarate 	 CH 	 6.53(s) 
a-glucose 	 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, 	5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 
half 6-CH2 	 3.85(m) 
13-glucose 	 1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, 	4.65(d), 3.25 (dd), 3A7(t), 3.40(t), 3.47(ddd), 
half 6-CH2 	 3.78(dd), 3.90(dd) 
glutamate 	 a-CH, (3-CH2, y-CH2 	 3.78(m), 2.06(m), 2.36(m) 
g lutamine 	 a-CH, (3-CH2, y-CH2 	 3.78(m), 2.15(m), 2.46(m) 
glycerol 	 half a-CH2, half rx-CH2, p-CH 	 3.56(dd), 3.64(dd), 3.87(m) 
glycine 	 ,L (d12) 	 CH2 
hypoxanthine 	 3-CH, 7-CH 
isoleucine 	 T (d26) 	 a-CH, (3-CH, half y-CH2, half y-CH2, 5-CH3, P-CH, 
lactate 	 CH, CH, 
leucine 	 I (d8) 	 a-CH, 13-CH2, y-CH, 5-CH3, 5-CH3 
lysine 	 a-CH, J3-CH2, y-CH2, 5-CH2, e-CH2 
3.55(s) 
8.10(s), 8.11(s) 
3.68(d), 1.93(m), 1.25(m), 1.47(m), 0.99(d), 1.02(d) 
4.12(q), 1.33(d) 
3.72(t), 1.63(m), 1.69(m), 0.91(d), 0.94(d) 
3.77(t), 1.92(m), 1.73(m), 1.47(m), 3.05(t) 
methionine 	 a-CH, (3-CH2, y-CH2, CH, 	 3.87(m), 2.10(m), 2.65(dd), 2.15(s) 
myo-inositol 	 13-CH, 2-CH, 5-CH, 4,6-CH 	 3.53(dd), 4.06(t), 3.28(t), 3.63(t) 
phenylacetic acid 	 CH2, 2,4,6-CH, 3,5-CH 	 3.52(s), 7.29(t), 7.36(t) 
phenylalanine 	 2,6-CH, 3,5-CH, 4-CH, half 13-CH2, half p-CH2, 
a-CH 
praline 	 a-CH, half P-CH2, half P-CH2, 7-CH2, 5-CH2 
propionate 	 i (d26) 	 CH2, CH, 	 2.19(q), 1.06(t) 
succinate 	 2x CH2 	 2.41(s) 
threonine 	 a-CH, P-CH, y-CH, 	 3.60(d), 4.26(m), 1.33(d) 
tryptophan 	 4-CH, 7-CH, 2-CH, 5-CH, 6-CH, a-CH, half p-cH2, 7.79(d), 7.56(d), 7.34(s), 7.29(t), 7.21(t), 4.06(dd), 
7.44(m), 7.39(m), 7.33(m), 3.17(dd), 3.30(dd), 
3.99(dd) 
4.15(dd), 2.05(m), 2.38(m), 2.00(m), 3,39(m) 
tyrosine 
uracil 
urocanate 
valine 
half 13-CH2 	 3.49(dd), 331(dd) 
2,6-CH, 3,5-CH, CH2, a-CH 	 7.23(d), 6.91(d), 2.93(t), 3.25(t) 
5-CH, 6-CH 
	
5.81(d), 7.59(d) 
a-CH, P-CH, 5-CH, 2-CH 
	
6.40(d), 7.13(d), 7.41(s), 7.89(s) 
a-CH, p-CH, y-CH3, r-CH, 	 3.62(d), 2.28(m), 0.98(d), 1.03(d) 
(d8) 
(d26) 
Arrows indicate differences in the spectral profiles between E. caprani-infected mice and non-infected control mice ( 	increased; i , decreased in infected animals) and 
the numbers in brackets show the day post-infection of maximum concentration difference of the respective metabolite. The p-values for the changing metabolites 
were assessed using a non-parametric 1-way analysis of variance (Mann-Whitney U) test in MATIAB, based on the integrals of the selected peaks and were all in the 
range of 0.001 to 0.05. 
doi:10.1371  
www.plosntds.org  7 	 July 2008 I Volume 2 I Issue 7 I e254 
Metabolic Profiling of an E. caprorri infection 
Table 4. List of main metabolites found in extracts of an adult E. caproni. 
Metabolite 	 Chemical moiety Chemical shift in ppm and multiplicity 
3-hydroxybutyrate 
acetate 
alanine 
betaine 
choline 
formate 
a-glucose 
0-glucose 
glutamine 
glycerophosphocholine 
glycine 
homocarnosine 
isoleucine 
lactate 
leucine 
lysine 
methionine 
phenylalanine 
pipecolate 
proline 
propionate 
scyllo-inositol 
succinate 
threonine 
tryptophan 
tyrosine 
uridine  
half a-CH, half a-CH2, (3-CH, y-CH3 	 2.32(m), 2A2(m), 4.16(m), 1.21(d) 
CH3 	 1.91(s) 
cc-CH, 13-CH3 	 3.81(q), 1.48(d) 
CH2, CH3 	 3.90(s), 327(s) 
3xCH3, a-CH2, 13-CH2 
	 321(s), 4.07(m), 3.52(m) 
CH 
	
8.45(s) 
1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 	 5.24(d), 3.56(dd), 3.70(t), 3.40(t), 3.83(m), 3.72(dd), 3.85(m) 
1-CH, 2-CH, 3-CH, 4-CH, 5-CH, half 6-CH2, half 6-CH2 
	 4.65(d), 3.25(dd), 3.47(t), 3.40(t), 3.47(ddd), 3.78(dd), 3.90(dd) 
a-CH, 0-CH2, 7-CH2 	 3.78(m), 2.15(m), 2.46(m) 
3xCH3, half a-CH2, half a-CH, half t-CH2, half 13-CH2, y-CH2 	 3.23(s), 4.32(t), 3.60(dd), 3.68(t), 3.89(m), 3.72(dd) 
CH2 	 3.55(s) 
5-CH, 3-CH, y-CH2, (3-CH, a-CH 	 7.89(s), 7.12(s), 3.85(dd), 3.67(m), 3.62(m) 
5-CH, 3-CH, half ring-CH2, half ring-CH2, N-CH, N-CH2, CO-CH2, CH2 	7.90(s), 7.01(s), 3.17(dd), 2.96(dd), 4.48(m), 2.92(m), 2.36(m), 
1.89(m) 
a-CH, (3-CH, half y-CH2, half y-CH2, 6-CH3, p-CH3 	 3.68(d), 1.93(m), 1.25(m),1.47(m), 0.99(d), 1.02(d) 
CH, CH3 	 4.12(q), 1.33(d) 
a-CH, p-CH2, y-CH, 6-CH3, 6-CH3 	 3.72(t), 1.63(m), 1.69(m), 0.91(d), 0.94(d) 
a-CH, )3-CH2, 7-CH2, 6-CH2, e-CH2 	 3.77(t), 1.92(m), 1.73(m), 1.47(m), 3.05(t) 
a-CH, 13-CH2, y-CH2,  CH3 
	
3.87(m), 2.10(m), 2.65(dd), 2.15(s) 
2,6-CH, 3,5-CH, 4-CH, half 0-CH2, half 13-cH2, a-CH 
	
7.44(m), 7.39(m), 7.33(m), 3.17(dd), 3.30(dd), 3.99(dd) 
half 3,4,5-CH2, half 4,5-CH2, half 3-CH2, half 6-CH2, half 6-CH2, 2-CH 
	
1.60-1.66(m), 1.86(m), 2.22(m), 3.02(m), 3.43(m), 3.60(m) 
a-CH, half 0-CH2, half l-CH2, 7-CH2, 8-CH2 	 4.15(dd), 2.05(m), 2.38(m), 2.00(m), 3.39(m) 
CH2, CH3 	 2.19(q), 1.06(t) 
6xCH 
	
3.35(1) 
2xCH2 
	
2.41(s) 
a-CH, 13-CH, 7-CH3 	 3.60(d), 4.26(m), 1.33(d) 
4-CH, 7-CH, 2-CH, 5-CH, 6-CH, a-CH, half 13-CH2, half t-CH2 	 7.79(d), 7.56(d), 734(s), 7.29(t), 7.21(t), 4.06(dd), 3.49(dd), 
3.31(dd) 
2,6-CH, 3,5-CH, CH2, a-CH 
	
7.23(d), 6.91(d), 2.93(t), 325(t) 
6-CH, 5-CH, 2'-CH, 3'-CH, 4'-CH, 5'-CH(d), half CH2OH, half CH2OH 
	
7.87(d), 5.90(s), 5.92(d), 4.36(t), 4.24(t), 4.14(q), 3.92(dd), 
3.81(dd) 
3.62(d), 2.28(m), 0.98(d), 1.03(d) valine 	 a-CH, t-CH, 7-CH3, y'-CH3 
do1:10.1371/journal.pntd.0000254.t004 
Composition of metabolite profiles 
Prior to assessing the metabolic effects of an E. caproni infection, 
the 1H NMR spectra of plasma, stool, and urine samples obtained 
from non-infected mice were characterized and found to be 
inherently different in composition. All three types of biofluids 
contained lactate, alanine, glucose, and acetate. Unique to the 
urine metabolic profile was the presence of hippurate, indox-
ylsulfate, urocanate, taurine, trimethylamine-N-oxide (TMAO), 2-
oxoglutarate, ureidopropanoate, and 2-ketoisocaproate, amongst 
others (Figure 1A, Figure 2A and Table 1). The plasma spectral 
profiles were characterized by the predominance of various lipids 
and lipoprotein fractions, along with resonances from creatine, 
and several amino and organic acids (Figure 1B, Figure 2B and 
Table 2). Apart from the standard 113 acquisition, applied on all 
biofluids, a CPMG and diffusion edited pulse sequence was used in 
plasma profiling, to represent low and high molecular weight 
metabolites, respectively. Characteristic metabolic features of the 
stool extracts were bile acids and short chain fatty acids (SCFAs), 
such as butyrate, and propionate. In addition, other amino acids, 
. www.plosntds.org  
such as tryptophan, lysine, argininc, and glutamine were more 
visible in stool spectra, compared to urine and plasma (Figure IC, 
Figure 2C and Table 3). 
In order to establish whether excretory products of the parasite 
itself were likely to contribute to any of the biofluids analyzed, a 
standard 1D spectrum of an adult E. caproni was acquired. The 
spectrum of the parasite differed from the biofluids obtained from 
the mouse host in content of homocarnosine, histidinol, uridine, 
pipecolate, and betaine (Figure ID, Figure 2D), although betaine 
has been observed in 1H NMR spectra of rodent urine in previous 
studies [32]. Tables 1-4 summarize key metabolites found in 
urine, plasma, and stool extracts of mice, and in the E caproni 
homogenate, respectively. 
Multivariate analysis and global metabolic trajectories 
In both PCA and PLS-DA scores plots of the urinary metabolite 
profiles, a clear separation of E. caproni-infected and non-infected 
control mice was already visible I day post-infection. This 
separation was maintained in all later time points except day 5. 
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Figure 4. Pair-wise comparison via O-PLS-DA between urine obtained from non-infected control mice (control) and E. caproni-
infected mice (infected) at 3 different sampling time points, i.e., day 8 (A), day 12 (8) and day 33 (C) post-infection. The color scale 
indicates the relative contribution of the peak/region to the strength of the differentiation model and the peak intensity is measured relative to the 
whole peak contribution in arbitrary units (am.). Note that the aromatic region (left part) is magnified by a factor 5. 
doi:10.1371  
Metabolic trajectories were constructed for each type of biofluid 
by taking the mean position in the principal component (PC) 
scores plot for each group of mice (E. caproni-infected and non-
infected controls) separately, and connecting the coordinates 
chronologically to establish any systematic change in metabolic 
composition over the time course of the experiment. The control 
group showed no significant movement over the study duration 
(data not shown), whereas in the infected group, day 19 was 
significantly separated from all other days post-infection, and the 
whole time course of infection showed a shift from the upper left to 
the lower right quadrant (Figure 3A), whereby days 1 and 5 post-
infection differed significantly from the sampling end point (day 
33). 
The plasma spectra of E. caproni-infected mice showed marked 
differences at days 1, 12, 26, and 33 post-infection, with the best 
discriminatory model at day 12 post-infection (goodness of 
prediction (Q!) according to PCA= 0.97; 0( (PLS-DA) = 0.89). 
Comparing the 3 different pulse programs applied, plasma time 
trajectories, showed similar behavior. The control trajectories were 
generally clustered, indicating stability of the metabolite compo-
sition over the study period. However, the standard 1D trajectory  
showed a slight difference between early and late time points (e.g., 
day I was separated in space from days 19 to 33). In contrast, for 
the E. caproni-infected animals, there was a significant metabolic 
movement from early (day 1) to intermediate time points post-
infection (days 5 and 12) in the first component and finally to late 
time points (days 26 and 33) in the third component (Figure 3B). 
This movement pattern was consistent across the datasets acquired 
by all three pulse programs. 
With regard to the 'H NMR spectra obtained from stool 
samples, a clear separation was found at day 5 post-infection in 
both the PCA and PLS-DA scores plot between E. caproni-infected 
and non-infected control mice, with maximum model fit for the 
PLS-DA model at day 26 post-infection (Q2 =0.79). At the final 
time point (day 33), the two groups were metabolically similar; 
there was no separation between infected and non-infected mice 
using PCA, and the PLS-DA model revealed a lower, but still 
significant Q2 value than all previous time points. By comparing 
the time trajectories of the non-infected control with the E. caproni-
infected group of mice, the controls were more tightly clustered, 
but showed a significant movement from day 8 post-infection 
onwards along PC 1. In the 2D time trajectory plot of the E. raproni- 
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infected mice, all time points were tightly clustered with the 
exception of days El and 12 post-infection, which comprised a 
separate cluster (Figure 3C). Introducing an additional PC brought 
about clear differentiation of the late time points (days 19, 26, and 
33) from day 1 post-infection caused by more subtle systematic 
variation in metabolic levels. 
Pair wise comparison of time points across different 
types of biofluids 
O-PLS-DA was used to extract information on specific 
metabolic changes induced by an E. caproni infection over the 
duration of the study. Changes in urinary, plasma and fecal 
metabolites are presented in Figures 4-6 for selected time points 
and the complete set are summarized in Figure 7. Amongst the 
most significantly changed urinary metabolites were hippurate 
(decreased at day 33), 2-ketoisocaproatc (decreased from day 
onwards), trimethylamine (TMA; increased at days 8, 12, 19, and 
33), taurine (decreased at days 8, 12, and 19), p-cresol glucuronide  
(increased at days 8, 12, 19, and 26), mannitol (increased from day 
5 onwards), TIVIA0 (increased at days 8, and 12), phenylace-
tylglycine (increased from day 12 onwards), acetate (decreased at 
days 8, and 19) and creatine (decreased at days 1, 5, 8, and 12). 
Plasma from infected mice showed changes in the relative 
concentration of acetate (increased at all time points except day 5), 
creatine (decreased from day 8 onwards), lipids (increased from day 8 
onwards), formate (decreased at days 1, 8, 12, and 19, but increased 
at day 33), lactate (decreased at days 1, 8, 12, 19, and 26), glucose 
(increased at days 1, and 33, but decreased at days 12, 19, and 26), 
glycerophosphorylcholine (GPC; decreased at days l2, 26, and 33), 
choline (decreased at days I, 12, 26, and 33) and branched chain 
amino acids (BCAAs; decreased at days 12, 26, and 33). 
The changes in stool samples from infected animals included the 
BCAAs (increased at days 8, and 26), uracil (increased at day 8), 
butyrate (decreased at days 12, 19, and 26), propionate (decreased at 
days 12, 19, and 26) and 5-aminovalerate (increased from day 5 
onwards). 
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Analysis of relative concentrations of key metabolites 
over study duration 
Figure 8 shows the relative concentration of some of these 
metabolites both for control (blue) and infected mice (colored 
according to hiofluid). The error bars signify 2 SDs of the mean. 
According to this 3x3 diagram; the selected plasma and urine 
metabolites showed a more robust pattern of group separation 
over time when compared to fecal water extracts. Whereas some 
overlap was observed in the scores plot relating to the fecal water 
samples, there was a tendency toward increasing discrimination of 
urinary metabolites with time over the course of an E. caproni 
inlixtion, whereas the discrimination became smaller toward the 
end of the experiment in the selected plasma metabolites. 
Discussion 
NMR-based metabolic profiling of hiofluids is an established 
method for deepening our understanding of host-parasite 
interactions and for investigating disease states in clinical studies 
[15,19,331. Sample preparation and spectral acquisition of a 
hiofluid takes little time, and often an overview of the metabolic  
state of the organism can be obtained by visual assessment of the 
spectra. Identification of biomarkers from different types of 
hiofluids is similarly convenient, although stool samples need 
slightly more preparation time and require sonication and an 
additional centrifugation step, due to the high amount of 
sediments in the stool-buffer mixture [341. 
A number of potential biomarkers for diagnosis of an E. caproni 
infection in the mouse were found here for each of the biofluids 
employed; 12 in plasma, 10 in urine and 7 in stool. Hence, if for 
practical purpose, a diagnosis was required based on a single 
biofluid, either plasma or urine would be the first choice for 
further development. Stool is the least suitable biological sample 
not only in terms of a lower number of potential biontarkers, but 
also because of the more difficult sample preparation, a lower 
robustness of metabolites (Figures 7 and 8), and larger inter- and 
intra-individual variation [341. The latter issue makes it difficult to 
determine if the change is related to the actual infection, or results 
from other factors, e.g., age and/or microbiotal presence or 
activity. Although the high degree of individual variation in the 
fecal metabolite profiles derived from laboratory studies can he 
overcome with parallel monitoring of metabolic time-related 
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changes in a control group, this issue needs to he addressed in 
future applications of metabonomics for diagnosis of parasitic 
infections and disease states, and hence for monitoring disease 
control programs. If the stability of the urine profiles compared to 
plasma over the study duration is taken into account, then urine 
would he the biofluid of choice on which to base a diagnostic. 
Morevoer, urine collection is less invasive than blood collection. 
Inter-group separation and trajectories 
The time trajectories allow the influence of growth and 
maturation of either host or parasite to be considered. Since very 
few of the metabolites observed in the E. caproni fluke appeared in 
any biofluid, infection-related changes are unlikely to correlate 
with maturation of the parasite. Additionally, since the urinary 
time trajectories were very different, comparing the control with 
the infected group, whereas the control trajectory did not show 
any significant movement over time; this would indicate that the 
maturation of the host organism did not markedly influence the 
metabolic profile over the 33-day time course. Hence, the systemic 
movement over time observed in the infected group is most likely 
to be related to the establishment and progression of the E. caproni 
infection. 
In stool and plasma, the time trajectories of the infected animals 
demonstrated a markedly greater magnitude from the baseline 
position than the non-infected animals. The greatest differentia- 
tion between E. caproni-infected mice and non-infected control 
animals was found in the PC scores plots based on the urine 
spectral profiles. The smallest differentiation was observed in the 
stool. From the scale of the PC scores plot axes the trajectory of the 
infected group occupied a 1.5 and 50 times larger space for stool 
and plasma, respectively than the non-infected group, whereas in 
urine, the control trajectory occupied a 106 times bigger space, 
compared to the trajectory of infection. The magnitude of 
infection-induced metabolic disturbance in the urine profile again 
clearly points to the greater suitability of urine as a diagnostic 
biological matrix. 
Intestinal re-absorption 
The considerable increase in concentration of lipids in the 
plasma, e.g., fatty acids, triaglycerols, and lipoproteins, reflects the 
action of the parasite in the hosts gut. In mice harboring a 2-week-
old E. caproni-infection, an increased breakdown of membrane 
lipids in the host intestinal tissue has been observed [35], which is 
consistent with the present findings of a maximum lipid increase 
on day 12 post-infection [36]. The excretory products of E. caproni 
in the intestinal mucosa are primarily free sterols, triaglycerols, 
and free fatty acids [37], but it is unlikely that the amounts 
excreted by the parasite make a substantial contribution to the 
host metabolic profile, given that the total parasite mass to host 
weight ration is —1:300. 
Whilst the simple diffusion of lipid micelles into mucosal cells 
seems unaffected by the parasite, the Na'-dependent active transport 
of amino acids could be impaired as the increase of the BCAAs in 
stool as the subsequent decrease in plasma supports. Depletion of the 
carrier molecules at the brush border of the mucosal cells, or a 
change of the electrochemical gradient for Na l" might explain the 
selective impact on trans-luminal gut transport [38]. 
The observed decrease of leucine in plasma, in turn, might 
induce the significant reduction in levels of 2-ketoisocaproatc in 
urine, which is a transamination product of the former [39]_ 
Taurine is mainly conjugated with cholic acid and chenodeoxy-
cholic acid in the liver to form primary bile salts, and is excreted 
via the urine after deconjugation from the bile salt or it leads into 
the sulphur- or pyruvate metabolism. Once the taurine conjugated 
bile salt has transformed the lipids into a micellar form, which is 
necessary to cross the intestinal wall, taurine is deconjugared by 
gut bacterial species and reabsorbed into the liver via blood 
circulation [40]. The decreased levels of excreted taurine in the 
urine of the infected mice may result from the higher demand for 
increased lipid digestion, resulting from the action of E. caproni in 
the gut. 
Gut microbiota 
The changes in hippurate, phenylacetylglycine, p-cresol-glucu-
ronide, and TMA in urine, and 5-aminovalerate, and the SCFA 
levels in stool, are associated with a change in gut microbiotal 
presence or activity, as all of these metabolites undergo 
modification via gut microbial species befbre excretion. For 
instance, 5-aminovalerate is formed by several different Clostridium 
species which utilize ornithine and proline as substrates, but to our 
knowledge, only C aminovalericum degrades 5-aminovalerate further 
to form mainly propionate and acetate [41-43]. 'Phis may imply 
that the presence of E. caproni in the gut disturbs the microbial 
balance resulting in depleted or inactivated C. aminovalnicum. The 
formation of p-cresol is likewise known to he performed by a 
Clostridium subspecies (i.e., C. diffirile and C. scatologenes) [44,45], 
with the bacterium-specific enzyme p-hydroxyphenylacetate. It is 
then conceivable that p-cresol is taken up by the bloodstream, 
bound to serum proteins and glucuronidated in the kidney prior to 
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excretion [46]. Increased excretion of p-cresol-glucuronide might 
be coupled with a higher activity or higher presence of this 
bacterial strain as the kidney function does not seem to be 
impaired in infected animals. PCR analyses on several different 
Clostridium sub-strains are ongoing and will be discussed in 
forthcoming publications. 
The decrease of the SCFAs in stool may also be indicative of an 
unbalanced microbiota, as dietary carbohydrates (e.g., starches and 
fibres) are fermented by colonic bacteria to mainly acetate, 
propionate, and butyrate. Whilst butyrate serves as main energy 
source for colonocytes, acetate and propionate pass through the 
intestinal wall and move via peripheral blood to the liver where they 
have antagonistic functions on the cholesterol synthesis. Whilst the 
former increases cholesterol synthesis, the latter was shown to act as 
an inhibitor. The uptake from colon by the blood system is four times 
higher in the case of acetate, than propionate, which is a possible 
explanation for depletion of the SCFA, also reflected by the observed 
decrease in levels of acetate in both urine and plasma [47,48]. 
The increased concentration of TMA and phenylacetylglycine, 
and the decrease of hippurate in urine, observed at the later time 
points of our experiment, are concomitant phenomena of the 
changed gut microbiota [49,50]. Trimethylammonitim compounds 
like choline and carnitine, which are ingested in the normal diet, are 
degraded by intestinal bacteria to TMA, and then oxidized in the  
liver to TMAO in a second step [51,52]. A microbial shift toward 
choline degrading bacteria might explain the choline/GPC 
depletion in plasma and the subsequent increase of TMAO in urine. 
Specificity of biomarkers for diagnosis 
An infection with E. caproni induces changes in the concentra-
tion of a range of metabolites in urine, plasma, and stool. To he 
useful as a 'rear biomarker, the metabolic candidate must be 
reproducible, robust, specific and, ideally, easy to measure [53]. 
From the current analyses an anomalous increase in urinary 
mannitol was noted in infected animals, Mannitol is likely to derive 
from the diet, since it is not synthesized by vertebrates. However, 
the higher amounts of urinary mannitol in K raproni-infected mice, 
may reflect the higher intestinal permeability, compared to the 
control group [54]. 
To assess the specificity of the biomarkers identified for 
potential diagnosis of infection, the obtained F. caproni fingerprint 
was compared to altered metabolite patterns, associated with other 
parasite-rodent models [16-18]. Interestingly, E. raproni seems to 
alter the gut microbiota in a similar way to the biologically-related 
blood flukes, i.e., S. mansard [16], and S. japorticum [17]. Hippurare, 
phenylacetylglycine, and TMA are modified by several gut 
microbial species before excretion in urine. In the 3 disease 
models, hippurate was found to decrease significantly, whereas 
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phenylacetylglycine, p-cresol-glucuronide and TMA showed 
increased levels in infections with all 3 parasites, which suggests 
a common trematode-inherent influence on gut microbial 
composition. The change in 2-ketoisocaproate in urine was unique 
to the infection with E. caproni and 5-aminovalerate in stool may 
also deliver an E. caproni-specific marker but, at the time being, 
cannot be compared to other disease models, as the metabonomic 
assessment of stool was applied only in the present parasite-rodent 
model. The metabolic effect of a nematode infection (T spina/is) in 
NIH Swiss mice has also been reported by Martin and colleagues 
[18]. T spiralis has a similar initial mechanism of pathogenicity 
and also induces a state of inflammation of the gut before it 
migrates from the intestine to muscle tissue and induces 
hypercontractility [55]. While comparison between the study 
conducted by Martin et al. [18] and the current study revealed a 
number of biomarkers, which were the same in both models, the 
directionality of these metabolites was different. For example, a 
decrease in choline and creatine concentrations was observed in 
E. caproni-infected mice, whereas the same metabolites were 
reported to be increased in T. spiralis-infected mice compared to 
non-infected controls. Furthermore, the lipids (e.g., triaglycerides, 
saturated and unsaturated fatty acids) which undergo a marked 
increase in E. caproni-infected animals, showed a significant 
decrease in the mice infected with T spiralis. 
Future studies evaluating additional laboratory host-parasite 
models, and applying complementary metabolic profiling meth-
ods, such as ultra performance liquid chromatography (UPLC), in 
combination with mass spectrometry (MS), will help to confirm the 
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The metabolic composition of fecal extracts provides a window for elucidating the complex metabolic 
interplay between mammals and their intestinal ecosystems, and these metabolite profiles can yield 
information on a range of gut diseases. Here, the metabolites present in aqueous fecal extracts of 
humans, mice and rats were characterized using high-resolution 1H NMR spectroscopy coupled with 
multivariate pattern recognition techniques. Additionally, the effects of sample storage and preparation 
methods were evaluated in order to assess the stability of fecal metabolite profiles, and to optimize 
information recovery from fecal samples. Finally, variations in metabolite profiles were investigated in 
healthy mice as a function of time. Interspecies variation was found to be greater than the variation 
due to either time or sample preparation. Although many fecal metabolites were common to the three 
species, such as short chain fatty acids and branched chain amino acids, each species generated a 
unique profile. Relatively higher levels of uracil, hypoxanthine, phenylacetic acid, glucose, glycine, and 
tyrosine amino acids were present in the rat, with j3-alanine being unique to the rat, and glycerol and 
malonate being unique to the human. Human fecal extracts showed a greater interindividual variation 
than the two rodent species, reflecting the natural genetic and environmental diversity in human 
populations. Fecal composition in healthy mice was found to change over time, which might be 
explained by altered gut microbial presence or activity. The systematic characterization of fecal 
composition across humans, mice, and rats, together with the evaluation of inherent variation, provides 
a benchmark for future studies seeking to determine fecal biomarkers of disease and/or response to 
dietary or therapeutic interventions. 
Keywords: fecal extracts • gut microbiota • 'H NMR spectroscopy • multivariate statistical analysis • 
metabonomics • metabolomics • metabolite profiling 
Introduction 
There is growing awareness both of the beneficial role the 
gut microbiota can play in maintaining homeostasis in human 
health and of the adverse association of certain microbial 
species with diseases as diverse as cardiovascular diseases and 
autism.' This link has led to renewed interest in the charac-
terization of the microbial content in the mammalian intestine. 
Several studies have used fecal material as a medium for 
assessing the presence of diseases, such as chronic pancreatitis, 
inflammatory bowel disease (IBD), and colon cancer.'-It  
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Moreover, the potential anticarcinogenic activity of microbial 
metabolites present in feces, particularly short chain fatty acids 
(SCFAs), has been investigated by exposing cultured cells to 
fecal extracts.12 
High-resolution rHNMR spectroscopy of biofluids such as 
urine and plasma can be used to generate diagnostic informa-
tion relating to many physiological and pathological conditions, 
particularly when used in conjunction with pattern recognition 
methods.'17 Recent studies have shown that rHNMR spectral 
profiles of fecal extracts carry diagnostic information for 
diseases, including Crohn's disease and ulcerative colitis.' 
However, unlike urine and plasma which are relatively well-
characterized in terms of their metabolite composition and 
extent of interspecies variation,'" temporal variation and the 
effect of sample preparation in the fecal metabolite profile have 
not yet been assessed. 
Here, we characterize interspecies differences between 
humans, mice, and rats in the content and temporal stability 
10.1021/pr070340k CCC: $40.75 	© 2008 American Chemical Society 
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Human African trypanosomiasis (HAT) is transmitted by tsetse flies 
and, If untreated, is fatal. Treatment depends on infection stage, 
and early diagnosis is crucial for effective disease management. 
The systemic host biochemical changes induced by HAT that enable 
biomarker discovery or relate to therapeutic outcome are largely 
unknown. We have characterized the multivariate temporal re-
sponses of mice to Trypanosoma brucei brucei infection, using 1 H 
nuclear magnetic resonance (NMR) spectroscopic metabolic phe-
notyping of urine and plasma. Marked alterations in plasma 
metabolic profiles were detected already 1 day postinfection. 
Elevated plasma concentrations of lactate, branched chain amino 
acids, and acetylglycoprotein fragments were noted. T. brucei 
brucei-infected mice also had an imbalance of plasma alanine and 
valine, consistent with differential gluconeogenesis (parasite)-
ketogenesis (host) pathway counterflux, involving stimulated host 
glycolysis, ketogenesis, and enhanced lipid oxidation in the host. 
Histopathologic evidence of T. brucei brucei-induced extramedul-
lary hepatic hemopoiesis, renal interstitial nephritis, and a pro-
voked inflammatory response was also noted. Metabolic distur-
bance of gut microbiotal activity was associated with infection, as 
indicated by changes in the urinary concentrations of the microbial 
co-metabolites, including hippurate. Concluding, parasite infection 
results in multiple systemic biochemical effects in the host and 
disturbance of the symbiotic gut microbial metabolic interactions. 
Investigation of these transgenomic metabolic alterations may 
underpin the development of new diagnostic criteria and metrics 
of therapeutic efficacy. 
diagnosis I metabonomics I NMR spectroscopy I trypanosomiasis 
U uman African trypanosomiasis (HAT), also known as sleeping 
II II sickness, is a so-called neglected tropical disease (1). It is 
caused by two subspecies of the protozoan parasite Trypanosoma 
brucei: Trypanosoma brucei gambiense occurs in western and central 
Africa, and Trypanosoma brucei rhodesiense is endemic in the 
eastern and southern parts of Africa (2, 3). The route of transmis-
sion is through the bite of infected tsetse flies (3). T. brucei brucei 
represents the third subspecies; it is not infectious to humans but 
can cause disease in cattle, goats, and sheep (i.e., nagana), and 
therefore contributes to the societal impact of these diseases. In the 
1980s and 1990s, there was a major reemergence of HAT, due to 
war, migration, environmental deterioration, increasing parasite 
drug resistance, and lack of surveillance (4, 5). It is currently 
estimated that 60 million people are at risk of HAT, with an average 
annual incidence of 30,000 cases (2). 
The infection evolves in two stages: first the hemolymphatic stage 
(usually occurring 1-3 weeks after the bite of an infectious tsetse 
fly), followed by the meningo-encephalitic stage. During the he-
molymphatic stage, trypanosomes enter the bloodstream and cause 
nonspecific symptoms, including malaise, headache, weakness, and 
joint pain. The meningo-encephalitic stage is marked once trypano-
somes have crossed the blood—brain barrier, and therefore pene-
trate the central nervous system (CNS). The onset is insidious and 
www.pnas.org/cgi/doi/10.1073/pnas.0801777105  
evokes a wide clinical phenotype, causing an array of neurological 
disorders, including motor, psychiatric, and sensory abnormalities, 
and disturbed sleep cycles, thus the term "sleeping sickness." An 
infection eventually leads to seizures, coma, and death if untreated. 
Treatment is tailored to the stages of the disease, but is generally 
unsatisfactory. 
There is a need to adopt effective diagnosis, which is able to give 
not only clear indication of trypanosome infection, but also an 
accurate staging of HAT, because failure to treat patients with CNS 
involvement will ultimately always lead to death. The current lack 
of early diagnostic tools and the absence of safe and efficacious 
drugs remain major bottlenecks for sound disease surveillance and 
control (3, 6, 7). Specific diagnosis at the early stage of disease 
involves the demonstration of the parasite in the peripheral blood 
or lymph node aspirates, which is, however, unreliable at low 
parasitemia. Serological tests play an important role: e.g., antibody-
detecting card agglutination trypanosomiasis test (CATT) and latex 
agglutination test (LATEX/Mg) (8, 9). Identification of disease 
stage invariably involves a lumbar puncture, which is invasive and 
thus unsuitable for large-scale screening purpose (10). 
Clinical manifestations of HAT are nonspecific (4); therefore, 
there is an unmet need for a reproducible biomarker or surrogate 
marker for disease presence and stage of infection. To be useful in 
the diagnosis of this disease, such a biomarker must be robust, 
exhibit high sensitivity and selectivity, and change with disease 
stage. With the advent of "omics" technologies, new approaches to 
the diagnosis of infectious diseases have been made possible. Both 
genomic and proteomic approaches have been applied to the 
diagnosis of HAT (11, 12). However, as yet no satisfactory biomar-
kers, or combination thereof, have been identified. 
Metabonomics offers an alternative approach to characterizing 
biomarkers of disease in accessible biological samples such as urine 
and blood plasma. This approach typically employs high-resolution 
spectroscopic methods, such as 1H nuclear magnetic resonance 
(NMR) spectroscopy or mass spectrometry (MS) to provide a 
fingerprint of biological samples. These fingerprints can be inter-
preted and classified according to disease status by using multivar-
iate statistical analysis (13). Although metabonomics has been 
successfully used in many fields, e.g., in the study of disease 
processes (14, 15) and dietary intervention (16, 17), the application 
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of this technology to characterize parasitic diseases is still in its 
infancy. 
Previous studies of metabolic changes in response to Schistosoma 
mansoni and Schistosoma japonicum infection in rodent models 
indicated that a characteristic metabolic fingerprint could be de-
rived for each type of infection (14, 18). In the current study, we 
evaluated the time course of systemic metabolic effects of T. brucei 
brucei exposure in mice. Our objective is to use NMR spectroscopy 
as an exploratory tool to determine a metabolic signature of the 
different stages of T. brucei brucei infection to further our under-
standing of host-parasite interactions, which could then lead to the 
development of biochemical assays. The ultimate aim is to provide 
the basis for accurate diagnosis and staging of HAT and come 
forward with new metrics for measuring the efficacy of interven-
tional therapeutics. 
Results 
Experimental Setup and Rationale. To establish metabolic changes 
associated with T. brucei brucei infection, urine and plasma were 
collected from 12 mice 2 days before infection and at a series of time 
points over a 33-day study period postinfection. Urine and plasma 
were also collected from 12 uninfected mice that served as control. 
In addition, a satellite group of mice (n = 48) was used to 
establish the time at which the parasites crossed the blood—brain 
barrier. For the GVR35 strain of T. brucei brucei in the mouse 
model, it has been reported that at day 21 postinfection parasites 
have established in the brain (4). However, because parasite strains 
maintained under laboratory conditions can alter in virulence (19), 
it was important to ascertain at which time point trypanosomes had 
crossed the blood—brain barrier in our model [for details, see 
supporting information (SI) Text]. The results indicated that 
T. brucei brucei established in the brain within 7 days. 
Parasitemia, Bodyweight, and Histology. No change in the body 
weight of the infected mice occurred and parasitemia levels were 
consistent with the literature (SI Text). On termination, control 
mice showed no abnormalities in cellular architecture in either the 
liver or kidney. All infected animals manifested marked hepatic 
extramedullary hemopoiesis and renal interstitial nephritis 
(Fig. 51). 
'H NMR Spectra of Urine and Plasma. 1H NMR spectra of urine 
obtained from a mouse at three time points, i.e., preinfection, and 
days 14 and 28 postinfection, are plotted in Fig. 1. Preinfection urine 
spectra were consistent with previously reported metabolite profiles 
for this murine strain (14). Changes in the urinary profiles were 
observed in T. brucei brucei-infected mice when compared with 
the samples taken from the same mice at preinfection stage: e.g., 
increase in concentrations of lactate, 2-oxoisocaproate, 2-
oxoisovalerate, D-3-hydroxybutyrate, and taurine. Additionally, 
three singlets not reported previously at 5 1.66, 5 1.70, and 5 1.71 
(Fig. 1) were observed in 23 of the 24 mice and were assigned as 
3-methylcrotonic acid, which disappeared or was reduced in the 
urine from both infected and control mice at later time points. 
Because these resonances are not always present in urine spectra 
from mice of the same strain, they are unreliable as markers of a 
general T. brucei brucei infection. A doublet at 5 1.08 (Fig. 1), which 
appeared only in the infected mice, was directly linked with a 
resonance at 5 2.50 in the 1H 1H  correlation spectroscopy (COSY) 
spectrum, and with 5 3.18, 5 3.55, and 5 3.72 in the total correlation 
spectroscopy (TOCSY) spectrum, and was tentatively assigned as 
3-carboxy-2-methyl-3-oxopropanamine. 
Examples of 1H standard 1-dimensional (1D) NMR spectra of 
plasma obtained from a representative mouse, i.e., preinfection, 
days 14 and 28 postinfection, are presented in Fig. 2. Several 
differences between the preinfection and postinfection states could 
be observed. For example, reduced amino acid levels were noted in 
plasma of T. brucei bnicei-infected mice. To generate an overview 
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Fig. 1. Typical 600 MHz 1H NMR spectra of urine obtained from a mouse at 
preinfection (A), at 14 days postinfection (9), and at 28 days postinfection (C). The 
spectra in the aromatic region (56.5-8.0) were magnified 4 times compared with 
the region 5 23-43, whereas the region 5 0.7-2.3 was magnified twice. Key: 1, 
2-oxoisocaproate; 2, 3-methyl-2-oxovalerate; 3, 3-carboxy-2-methyl-3-oxopro-
panamine; 4, 2-oxoisovalerate; 5, o-3-hydroxybutyrate; 6, acetate; 7. succinate; 8, 
t3-alanine; 9, 2-oxoglutarate; 10, trimethylamine; 11, citrate; 12, dimethylamine; 
13, creatine; 14, trimethylamine-N-oxide; 15, malonate; 16, taurine; 17, glycine; 
18, phenylacetylglycine; 19, tryptophan; 20, hippurate; 21, lactate; 22, 4-hydroxy-
phenylacetic acid; 23, alanine, 24, methylcrotonic acid. 
of metabolite patterns and to identify biomarkers of the temporal 
biological response to a T. brucei brucei infection, multivariate data 
analysis of 1H NMR profiles of urine and plasma from the 12 
infected mice was carried out over the seven collection times 
spanning the study duration. 
Disease Progression. To characterize the evolution of the disease 
with time, principal component analysis (PCA) was performed on 
the 1H NMR spectral data of the urine and plasma from all of the 
time points using mean centered data. For the plasma samples, the 
scores plots showed differentiation of the preinfection samples 
from all other time points with greater separation and dispersion 
between animals at the later time points (Fig. 3A). Clear separation 
of all early (days 1-14) postinfection plasma samples from pre-
infection samples was established in a further PCA model (Fig 3E). 
The scores of the first and second principal components (PCs) were 
averaged for the group of infected mice at each time point and 
plotted in Fig. 3B. The trajectory indicated that the infected mice 
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Fig. 2. Representative 600 MHz 1H NMR spectra of plasma using a standard 1D 
water presaturation pulse sequence from a mouse at preinfection (A), at 14 days 
postinfection (8), and at 28days postinfection (C). Key: 5, D-3-hydroxybutyrate; 6, 
acetate; 11, citrate; 13, creatine; 21, lactate; 23, alanine; 25, lipoprotein; 26, valine; 
27/28, leucine and isoleucine; 29, oxaloacetate; 30, glutamine; 31, choline; 32, 
phosphatidylcholine; 33, 0-acetyl-glycoprotein fragments; 34, glucose; 35, lysine. 
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Fig. 3. Pseudo three-dimensional (3D) score plots obtained 
from the PCA of 'H NMR spectra of plasma (A). and urine (C); 
Band D are the trajectory of PCA score plots of PC1 MID versus 
PC2 (t[2]) for 'H NMR spectra of plasma and urine, respectively, 
obtained at different time points with error bars representing 
two standard deviations. Black (d-2), preinfection. Red (dl), 
blue (d7), green (d14), yellow (d21), pink (d28), and dark green 
(d33) denote samples collected at day 1, 7, 14, 21, 28, and 33 
postinfection, respectively. (E) 3D score plots obtained from 
the PCA of 1 H NMR spectra of plasma obtained from d-2, dl, 
d7, and d14 showing clear differentation of preinfection and 
infection at earlytime points, which are otherwise obscured by 
the extreme variation in metabolite profiles observed at later 
time points. 
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deviated from the controls along the PC2 direction after T. hrucei 
brucei inoculation up to day 14 and subsequently moved in the PC1 
direction. In addition, 21 days postinfection, the samples were more 
dispersed in metabolic space compared with the samples obtained 
from days 1-14 postinfection, as demonstrated by the standard 
deviation bars (Fig. 3B). 
For the urine samples the scores plots showed a similar time-
related behavior to those calculated for the plasma (Fig. 3 C and D). 
To eliminate the contribution of growth and maturation in the mice 
to the differentiation of later time points from the preinfection 
samples, the same PCA strategy was applied to the 'H NMR data 
obtained from the control mice. No significant time-related move-
ment of the metabolic profiles was found. An orthogonal signal 
correction-partial least square-discriminant analysis (O-PLS-DA), 
performed on spectra obtained from each time point postinfection 
(i.e., days 1, 7,14, 21, 28, and 33) in pairwise comparison with those 
obtained from the preinfection control mice, showed systematic 
metabolic changes for both urine and plasma. 
Characterization of Sequential Urinary Metabolic Changes Associated 
with T. brucei brucei Infection. Potential urinary biomarkers of a 
trypanosome infection and stage were identified by using an 
O-PLS-DA method. One PLS component was calculated for each 
model by using unit variance scaled data with one orthogonal  
component to remove the variables in NMR spectra unrelated to 
the variation between the two classes. The total explained variation 
for the X-matrix (NMR data) was indicated by the 1122 value 
(0.88-0.91 for all time points except day 1 postinfection; Table 1) 
and the corresponding cross-validation parameter indicating the 
predictive performance of the model (Q2) reflected a high predic-
tive ability (i.e., >0.73 for all time points except day 1 postinfection; 
Table 1). Model outcomes indicated that the metabolic differen-
tiation between the preinfection and postinfection time points was 
highly significant from day 7 onwards. 
Interpretation of the differences between the 1H NMR spectra 
of urine from mice before and after infection was carried out by 
using O-PLS-DA cross-validated coefficient plots with results 
shown in Fig. S2A. Key metabolites contributing to the separation 
of preinfection data from the postinfection data, along with their 
significance values, are summarized in Table 1. A coefficient >0.53 
is considered to be significant as this coefficient corresponds to the 
critical value of a correlation coefficient with a risk of 5%. 
The urine samples obtained at day 7 postinfection deviated 
from the corresponding controls because of the increased uri-
nary excretion of 3-methyl-2-oxovalerate, trimethylamine, tryp-
tophan, and 4-hydroxyphenyl acetic acid in the infected mice. 
These changes were associated with decreased urinary excretion 
of 3-methylcrotonic acid, creatine, and hippurate in the infected 
Table 1. Metabolite changes in mouse urine induced by T. brucei brucei infection 
Metabolites* S, ppm 
Day 1 	Day 7 
R2 = 0.06 	R2 = 0.88 
Q2 = 0.78 	Q2 = 0.73 
Day 14 
R2 = 0.94 
Q2 = 0.87 
Day 21 
R2 =0.94 
Q2 = 0.87 
Day 28 
R2 = 0.90 
Q2 =0.86 
Day 33 
R2 = 0.91 
Q2 = 0.78 
3-Ca rboxy-2-methy1-3-oxopropanamine (3) 1.08 +0.71 +0.75 +0.87 +0.81 
3-Methyl-2-oxovalerate (2) 1.11 +0.50 -0.72 +0.84 +0.74 +0.77 
2-Oxoisovalerate (4) 1.14 +0.59 +0.69 
D-3-hydroxybutyrate (5) 1.20 +0.74 -0.75 +0.75 
Lactate (21) 1.33 +0.66 -0.65 +0.68 
Methylcrotonic acid (24) 1.70 -0.57 -0.48 -0.54 -0.63 
Trimethylamine (10) 2.89 +0.49 +0.62 0.51 -0.51 
Tryptophan (19) 7.30 +0.78 +0.78 +0.84 +0.74 
4-Hydroxyphenylacetic acid (22) 7.14 -0.64 [0.73 +0.73 +0.72 +0.82 
Hippurate (20) 7.83 -0.66 -0.59 -0.71 -0.70 -0.66 
*Numbers in parentheses refer to metabolites shown in Fig. 1, Fig. 2, and Fig. 52. 
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Table 2. Metabolite changes in mouse plasma induced by T. brucei brucei infection 
Metabolites* S, ppm 
Day 1 
R2 = 0.90 
Q2 = 0.61 
Day 7 
R2 = 0.94 
Q2 = 0.72 
Day 14 
R2 = 0.95 
Q2 = 0.75 
Day 21 
R2 = 0.96 
Q2 = 0.82 
Day 28 
R2 = 0.96 
Q2 = 0,74 
Day 33 
R2 = 0.94 
Q2 = 0.61 
Lactate (21) 1.33 +0.65 +0.76 +0.83 +0.76 +0.74 +0.77 
Glutamine (30) 2.30 -0.50 -0.80 -0.72 
Oxaloacetate (29) 2.36 +0.69 +0.66 +0.51 +0.51 +0.66 
Lysine (35) 1.45 +0.62 +0.79 +0.82 
Glucose (34) 5.23 +0.56 -0.58 -059 
Isoleucine (28) 0.95 -0.86 -0.82 -0.88 -0.83 -0.78 
Valine (26) 0.98 -0.81 -0.76 -0.81 -0.80 -0.83 
Leucine (27) 1.00 -0.88 -0.84 -0.81 -0.88 -0.64 
Acetate (6) 1.91 +0.68 +0.54 +0.55 
O-acetyl•glycoprotein (33) 2.07 +0.81 +0.83 +0.75 +0.80 
Choline (31) 3.18 +0.61 +0.89 +0.61 +0.67 +0.55 
Phosphatidylcholine (32) 3.21 -0.59 -0.70 -0.79 -0.84 -0.85 
Creatine (13) 3.02 +054 +0.76 +0.72 +0.82 +0.77 
Lipoprotein (25) 0.84 -0.72 -0.61 -0.75 -0.76 
Unknown 2.34 +0.50 +0.50 +0.63 +0.87 
*Numbers in parentheses refer to metabolites shown in Fig. 1, Fig. 2, and Fig. S2. 
mice. Separation between infected and preinfected mice was 
enhanced at later time points, as suggested by higher Q2 values. 
At later time points, the levels of the metabolites identified at day 
7 were further differentiated from the preinfection group and 
additional metabolites, such as 2-oxoisovalerate, 3-carboxy-2-
methyl-3-oxopropanamine, D-3-hydroxybutyrate, and lactate, 
were significantly elevated in the urine of infected mice. 
Characterization of Sequential Plasma Metabolic Changes Associated 
with T. brucei brucei Infection. O-PLS-DA indicated systematic 
differentiation of plasma obtained from the T. brucei brucei-
infected and preinfected mice. A selected O-PLS-DA coefficient 
plot, comparing plasma from a control mouse and that from day 14 
postinfection, is shown in Fig. S2B). The quality of models indicated 
by the R2 and Q2 was good for all time points postinfection and are 
listed together with the significance of metabolites contributing to 
the differentiation between the plasma obtained from the post-
infected and preinfected mice in Table 2. Plasma samples obtained 
as early as 1 day postinfection could be discriminated from those of 
preinfected mice and were typified by increased concentrations 
of lactate, oxaloacetate, and glucose, and decreased concentrations 
of glutamine, and lysine. Increasingly significant differentiation 
between preinfection and postinfection samples was achieved at 
later time points, which is consistent with the urinary metabolite 
data. Additional metabolites accounted for the separation between 
the T. brucei brucei-infected and preinfected mice at day 7 post-
infection and later on, including elevated levels of acetate, 
O-acetylglycoprotein fragment signals, choline, and creatine, de-
pleted levels of phosphatidylcholine, lipoproteins, and a range of 
amino acids, including isoleucine, valine, and leucine (Table 2). In 
addition, a plasma resonance at 5 234 from an unidentified 
metabolite was also increased in infected mice. The pattern of 
infection-induced metabolite perturbations was broadly consistent 
across all of the time points from day 7, with exception of glutamine 
and acetate, which showed a high degree of interanimal variation 
in levels after day 14. The concentration of glucose, increased at day 
1 postinfection returning to preinfection levels at day 7 postinfec-
tion. However, a significant decrease in plasma glucose concentra-
tions occurred at days 28 and 33 postinfection. 
The decreased concentration of valine in the blood plasma, and 
increased urinary excretion of ketone bodies were suggestive of 
increased ketogenesis in the infected mice and therefore the valine 
to alanine ratio was measured by integration of the valine and 
alanine resonances in the plasma spectra. A significant and endur-
ing decrease in this ratio occurred from day 7 postinfection 
(Fig. S3). 
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Discussion 
A range of systemic metabolic perturbations in response to a 
T. brucei brucei infection in the mouse was observed with the 
earliest detection limit being day 1 postinfection in plasma and day 
7 postinfection in urine. Several of the observed metabolic changes 
depended on time, and therefore stage of infection. The response 
to infection became stronger, and the degree of interanimal vari-
ability greater in the urine and plasma profiles as the time course 
evolved. Previous research has shown that T. brucei brucei parasites 
of the GVR35 strain were established in the brains of mice and rats 
at days 21 and 13 postinfection, respectively (4, 20). Our satellite 
experiment (SI Text) revealed that T. brucei brucei had already 
crossed the blood-brain barrier within 7 days of infection, therefore 
considerably earlier than we had anticipated. This early establish-
ment of parasites in the brain may reflect an increase in the 
virulence of the T. brucei brucei strain used, which might be 
explained by prolonged passages in the laboratory (19). Such 
occurrences warrant further investigation with respect to interspe-
cies differences in host-parasite behavior. 
The current method of choice for diagnosis of first-stage HAT is 
based on microscopic detection of trypanosomes in blood and 
lymph node aspirate. Examination of cerebrospinal fluid is neces-
sary in all patients to assess whether the parasites have penetrated 
into the brain (21). The obvious drawbacks of this method are that 
it is labor-intensive and invasive. In the present investigation, 
differentiation of metabolic profiles was achieved in mouse plasma 
already at day 1 postinfection onwards and in urine obtained from 
day 7 after infection. In addition, the PCA trajectory of 1H NMR 
spectra of plasma and urine samples illustrated relocations in the 
metabolic space as well as more dispersed metabolic profiles 
between days 14 and 21 postinfection. This finding suggests increas-
ing severity of disease and greater interanimal variation at later time 
points. Because the trypanosomes were already established in the 
CNS by day 7 postinfection, it seems difficult to identify a set of 
metabolic changes associated specifically with this event. 
An elevated level of lactate was observed in both the urine and 
plasma obtained from mice after infection. This observation sug-
gests an up-regulation of glycolysis in T. brucei brucei-infected mice, 
which is the likely result of parasites in the bloodstream. Previous 
research has shown that T. brucei brucei depends solely on glycolysis 
for its supply of ATP (22). In the current study, the relative 
concentration of glucose increased on the first day after infection, 
but then remained fairly constant until days 28 and 33 postinfection, 
when a marked reduction in glucose concentrations was observed. 
The observed initial rise in plasma glucose is consistent with 
previous research, which showed that T. brucei infection produced 
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a condition resembling type 2 diabetes characterized by increased 
concentrations of urinary ketogenic acids, together with decreased 
peripheral glucose utilization, which responded to insulin (23). This 
diabetes-like state was also present throughout the course of the 
disease, but was counteracted by the high rate of glucose utilization 
by T. brucei as an energy substrate. Indeed, severe hypoglycemia has 
been attributed to be the cause of death in trypanosomiasis (24, 25), 
and parenteral administration of glucose has been shown to delay, 
but not prevent death, suggesting the involvement of more than one 
pathogenic process (25). Moreover, mice chronically infected with 
T. brucei gambiense had significantly increased levels of pyruvate, 
and lactate, among other metabolites, pointing to an increased 
glycogen mobilization and increased catabolic activity (26), which 
is in line with our observations. 
We noted the depletion of plasma amino acids, including glu-
tamine, leucine, isoleucine, and valine in plasma samples obtained 
from T. brucei brucei-infected mice. Glutamine is a gluconeogenic 
amino acid and could provide a source for maintaining a normal 
level of glucose in infected animals. The depletion of other plasma 
amino acids may also reflect a compensatory mechanism for 
maintaining host energy homeostasis and ketogenesis. In addition, 
there was an associated increase in urinary concentrations of the 
keto acids, 3-methyl-2-oxovalerate and 2-oxoisovalerate. This asso-
ciation suggested that there was stimulation of ketogenesis in 
7'. brucei brucei-infected mice because ketogenic amino acids are 
capable of producing keto acids via aminotransferases (26). A 
decreasing valine to alanine ratio in plasma samples from infected, 
but not control, animals was noted from day 7 postinfection 
persisting over the study duration, which concurs with the hypoth-
esis of increased ketogenesis. Because alanine is a gluconeogenic 
amino acid, and valine (also isoleucine and leucine) is ketogenic, we 
suggest that the simple measurement of the plasma valine to alanine 
ratio from plasma NMR spectra may provide a useful window on 
the balance of ketogenesis and gluconeogenesis in vivo. 
As the disease progressed, increased levels of D-3-hydroxy-
butyrate were noted in the urine of infected mice (Table 1). This 
observation suggested that at the later stage of the infection, 
animals were in a ketotic state and lipids were metabolized as an 
energy source. Reduced levels of lipids in plasma of infected mice 
were observed, consistent with the ketotic state of the animals 
(Table 2). 
Hepatic extramedullary hemopoiesis was observed in all infected 
animals at 33 days postinfection (Fig. S1). Significantly increased 
serum levels of alanine aminotransferase and aspartate aminotrans-
ferase have been noted in infected animals (27). The reported 
increase in the levels of these enzymes is consistent with 7'. brucei 
brucei-induced liver damage. Interestingly, aspartate aminotrans-
ferases have also been cloned and expressed from 7'. brucei brucei 
(28). Another pathologic consequence of a trypanosome infection 
is renal damage, which has been found in the rat (29), and in the 
rabbit (30). In the present study, kidney pathology manifested as 
interstitial nephritis. In addition, O-acetylglycoprotein fragments 
were found in increased concentrations in the plasma of the 
infected mice, and may be reflective of tubular damage (Table 2). 
Potent inflammatory responses of the host triggered by trypano-
somes have been suggested as an underlying factor in the patho-
genesis of this infection (31). The dominant inflammatory response 
presents as an increase in Ig levels and a range of cytokines, 
including IL-6, IL-10, and the proinflammatory cytokine tumor 
necrosis factor (TNF)-a have been found to be elevated in the 
meningo-encephalitic stage (32). In the current study, increased 
intensity of 0-acetyl glycoprotein fragment resonance was observed 
in infected mice. Elevated 0-acetyl glycoprotein fragment signals 
from acute phase reactive protein in rat blood plasma was consid-
ered to be associated with inflammatory conditions, such as cancer, 
certain liver diseases, and also during surgical trauma (33, 34). 
It is known that parasitic protozoa have a membrane and a 
surface coat that has a different lipid and protein composition  
relative to the membrane of the host (35). Several reports on 
T. brucei have indicated that the parasites are capable of scavenging 
phospholipids from their host and rapidly incorporating these 
phospholipids into the membrane structure. In addition, blood-
stream stage trypanosomes are able to take up low density lipopro-
teins from the host for robust growth (36, 37). The reduced 
concentrations of phosphatidylcholine and lipoproteins were ac-
companied by elevated levels of choline in the plasma of infected 
mice. This association most likely indicates a breakdown of choline-
containing phospholipids by trypanosomes. 
In the current study, reduced concentration of hippurate and 
increased concentrations of trimethylamine, and 4-hydroxyphenyl-
acetic acid were observed in urine from infected mice. The reduced 
excretion of urinary hippurate was also observed in S. mansoni-
infected mice and in S. japonicum-infected hamsters (14, 18). 
Therefore, it has been suggested that hippurate was associated with 
the disturbance of microbial activity. Trimethylamine is also derived 
from the intestinal bacterial degradation of choline (38) that is 
present in high level in the infected mice because of breakdown of 
choline-containing fatty acids. Evidence from the investigations 
of host-parasite interactions have suggested that the introduction of 
parasites into the mammalian system could disrupt normal mam-
malian-microbial behavior, thereby causing variation in metabo-
lism. The major distinguishing consequences of a 7'. brucei brucei 
infection in the mouse were elevated levels of urinary 3-methyl-2-
oxovalerate, 3-carboxy-2-methyl-3-oxopropanamine and 4-
hydroxyphenyl acetic acid, when compared with a Schistosoma spp. 
infection in rodents. Additionally, for metabolic changes, which 
were in common; e.g., decreased excretion of hippurate, the dy-
namic progression of the infection differs (14, 18). 
The role of rodent models in the investigation of HAT has been 
debated (39). The current consensus is that, although not perfect, 
mouse models can provide a useful means of investigating both the 
mechanism of pathogenesis and response to therapeutics. The 
metabonomic strategy presented here shows diagnostic potential 
for presence of infection and stage of disease. Ongoing studies 
investigating the transferability of the differentiating biomarkers, 
together with further animal studies exploring the specificity of the 
biofluid metabolite alteration in relation to other parasitic infec-
tions, should provide evidence of the utility of metabolic profiling 
in the mouse, as a model to deepen our understanding of HAT. 
In conclusion, we have profiled the dynamic metabolic response 
of a T. brucei brucei infection in the mouse over the entire disease 
time course. We found systematic variations between T. brucei 
brucei-infected and the corresponding animals before infection in 
the metabolic profiles of plasma and urine using a NMR-based 
metabonomic strategy. The results obtained from both types of 
biofluids are consistent, underscoring evidence concerning the 
mechanisms of a trypanosome infection. The insights into biological 
response could provide vital information for targeted drug discov-
ery and novel diagnostic tools. Moreover, we have demonstrated 
that the severity of the infection could be monitored using a PCA 
trajectory, and that infection-induced alteration could be detected 
as early as 1 day postinfection. Our investigation therefore dem-
onstrates the usefulness of metabonomics as a tool for the inves-
tigation of host metabolic responses to pathogen invasion and 
for monitoring disease development and responses to control 
interventions. 
Materials and Methods 
Animal Handling and Sample Collection. The study protocol was approved by the 
institutional review boards of the Swiss Tropical Institute (Basel, Switzerland) and 
Imperial College (London, U.K.). The experiments were in compliance with can-
tonal and Swiss national regulations (permission no. 2081). For the main meta-
bolic profiling experiment, a total of 24 female mice (NMRI strain), aged —3 
weeks, weighing 20-24 g, were purchased from RCC (Fullinsdorf, Switzerland). 
Mice were housed in groups of 4 at the animal facilities of the Swiss Tropical 
Institute under environmentally controlled conditions (temperature, ,-,22°C; rel- 
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ative humidity, --70%; day-night light cycle, 12-12 h) and acclimatized for? days. 
Mice had free access to water and standard rodent diet obtained from NAFAG 
(Gossau, Switzerland). Twelve mice were infected i.p. with --20,000 T. brucei 
brucei (GVI1.35 strain) each. The remaining 12 mice were left untreated, serving as 
controls. 
Urine and blood plasma for 1H NMR spectroscopic analysis were collected from 
each mouse 2 days preinfection and on days 1, 7,14, 21, 2B, and 33 postinfection. 
Blood samples were also collected for parasitemia testing from day 7 postinfec-
tion onwards. Animals were weighed at each time point, using a Mettler balance 
(model K7T; Greifensee, Switzerland). Collection of urine and blood plasma was 
carried out according to standardized procedures (14, 18) (51 Text). 
Establishing the Time Frame at Which Trypanosomes Crossed the Blood-Brain 
Barrier. The experimental setup of this satellite study is provided in S/ Text and 
results are presented in Table 51. 
1H NMR Spectroscopy. Urine samples were prepared by mixing 20µI of urine with 
30 j21 of phosphate buffer (pH 7.4) containing 50% D20 as a field frequency lock 
and 0.05% sodium 3-(tri-methylsily1) propionate-2,2,3,3-d4 (TSP) as a chemical 
shift reference (8 0.0). Plasma samples were prepared by adding 30 j.JI of saline 
containing 50% D20 in an Eppendorf tube containing P-20 µl of plasma. Samples 
were then transferred into 1.7-mmmicroNMRtubes.Standard1DIHNmR spectra 
were recorded on a Bruker Avance 600 NMR spectrometer operating at 600.13 
MHz (14). Additionally, water-suppressed Carr-Purcell-Meiboom-G I (CPMG) (40) 
spectra were acquired for plasma, and metabolites were assigned from the 
literature (41) and from 2-dimensional (2D) NMR spectra including 1H-1H COSY, 
TOCSY, and 1H J-resolved NMR spectra acquired fora selection of plasma sample 
using parameters described in previous studies (14). 
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4. Kennedy PGE (2004) Human African trypanosomiasis of the CNS: Current issues and 
challenges. J Clin Invest 113:496-504. 
5. Stich A, Abel PM, Krishna 5 (2002) Human African trypanosomiasis. BMJ 325:203-206. 
6. Barrett MP, Boykin DW, Brun R, Tidwell RR (2007) Human African trypanosomiasis: 
Pharmacological re-engagement with a neglected disease. BriPharmacol 152:1155-1171. 
7. Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment 
of African trypanosomiasis. Annu Rev Pharmacol Toxicol 35:93-127. 
8. Magnus E, Vervoort T, Van Meirvenne N (1978) A card-agglutination test with stained 
trypanosomes (C.A.T.T.) for the serological diagnosis of T. b. gambiense trypanosomi-
asis. Ann Soc Belg Med Trop 58:169-176. 
9. Hutchinson OC, Webb H, Picozzi K, Welburn 5, Carrington M (2004) Candidate protein 
selection for diagnostic markers of African trypanosomiasis. Trends Parasitol 20:519-523. 
10. Kennedy PGE (2006) Diagnostic and neuropathogenesis issues in human African 
trypanosomiasis. Int J Parasitol 36:505-512. 
11. Agranoff D, Stich A, Abel P, Krishna 5 (2005) Proteomic fingerprinting for the diagnosis 
of human African trypanosomiasis. Trends Parasito! 21:154-157. 
12. Papadopoulos 	etal. (2004) A novel and accurate diagnostic test for human African 
trypanosomiasis. Lancet 363:1358-1363. 
13. Trygg J (2002) 02-PLS for qualitative and quantitative analysis in multivariate calibra-
tion. J Chemometr 16:283-293. 
14. Wang YL, et al. (2004) Metabonomic investigations in mice infected with Schistosoma 
mansoni: An approach for biomarker identification. Proc Nat! Acad Sci USA 
101:12676-12681. 
15. Brindle JT, etal. (2002) Rapid and noninvasive diagnosis of the presence and severity 
of coronary heart disease using 1H NMR-based meta bonomics. Nat Med 8:1439-1444. 
16. Solanky KS, et aL (2005) Biofluid 11-1 NMR-based metabonomic techniques in nutrition 
research-metabolic effects of dietary isoflavones in humans. J Nutt Biochem 16236-244. 
17. Wang YL, et al. (2005) A metabonomic strategy for the detection of the metabolic 
effects of chamomile (Matricaria recutita L) ingestion. J Agri Food Chem 53:191-196. 
18. Wang YL, et al. (2006) System level metabolic effects of a Schistosoma japonicum 
infection in the Syrian hamster. Mol Biochem Parasito! 146:1-9. 
19. Ebert D (1998) Experimental evolution of parasites. Science 282:1432-1435. 
20. Darsaud A, et al. (2003) Clinical follow-up in the rat experimental model of African 
trypanosomiasis. Exp Biol Med 228:1355-1362. 
21. Chappuis F, Loutan L, 5 imarro P, Lejon V, Buscher P (2005) Options for field diagnosis 
of human African trypanosomiasis. Clin Microbiol Rev 18:133-T46. 
22. Bakker BM, Michels PAM, Opperdoes FR, Westerhoff HV (1999) What controls glyco-
lysis in bloodstream form Trypanosoma brucei? J Biol Chem 274:14551-14559. 
23. Voorheis H (1969) The effect of T. brucei (S-42) on host carbohydrate metabolism: Liver 
production and peripheral tissue utilization of glucose. Trans R Soc Trop Med Hyg 
63:122-123. 
24. Hoppe J, Chapman C (1947) Role of glucose in acute parasitemic death of the rat 
infected with Trypanosoma equiperdum. J Parasitol 33:509-516. 
Data Reduction and Pattern Recognition. Spectra were automatically corrected 
for phase and baseline distortion by using an in-house developed MATLAB script 
(Imperial College, London, U.K.). The blood plasma spectra were referenced to 
the anomeric proton of glucose resonance at 85.223. The plasma spectra over the 
range 8 0.6-8.0 were digitized into 14,800 points by using a MATLAB script 
developed in•house (Imperial College, London, U.K.) (42). The region 84.40-5.19 
was removed to avoid the residual spectral effects of imperfect water suppres-
sion. Normalization to the sum of the spectrum was carried out on these data 
before pattern recognition analyses (42). Urine spectra were referenced to TSP at 
8 0.0 and digitized in the same way as plasma spectra. NMR regions 84.50-4.90 
and 8 5.29-6.30 were removed. Normalization to the total sum of the spectrum 
was also carried out in the same way as for plasma spectra. In the first instance, 
PCA was performed on all data by using mean-centered data with the software 
SIMCA-P 10.00 (Umetrics, lime& Sweden). A further PCA model was constructed 
for the preinfection and days 1-14 inclusive postinfection samples to clarify the 
response observed at the early stage of infection. O-PLS-DA (13) of the NMR 
spectra was &so carried out on the same data after scaling to unit variance in a 
MATLAB 7.0 environment with MATLAB script developed in-house (Imperial 
College, London, U.K.) (42). This procedure involved combining of orthogonal 
signal correction and partial least square-discriminant analysis as described by 
Trygg (13). It also incorporated back transformation of the coefficient plot with 
weight of the variable contributing to discrimination in the models and facilitat-
ing interpretation. The statistical total correlation spectroscopy (STOCSY) (43) 
method, based on the high correlation coefficient computed from signals from 
the same molecule, was also applied to aid metabolite assignment. 
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Appendix IX 
Conference abstract: 
Gordon Research Conference on Host-Parasite Interactions (Newport, US, June 2008) 
Metabolic profiling of co-infection of Trypanosoma brucei brucei strains in mice 
Jia V. Li, Jasmina Saric, Yulan Wang, Juerg Utzinger, Oliver Balmer, Elaine Holmes 
Abstract: Multiple-species and multiple-strain co-infections are common in parasitic 
infections. Co-infections have an important epidemiological and evolutionary influence 
on both host and parasite and have been shown to either increase or decrease the 
infection severity depending on the parasite species and the metabolic status of the host. 
The aim of the current study was to examine the metabolic profiles of urine and faecal 
water from mice with either a single strain of T. brucei brucei (STIB777AE-G1 or 
STIB246BA-R1).or both strains using nuclear magnetic resonance (NMR) spectroscopy 
coupled with multivariate data analysis methods and to assess the parasite-induced 
metabolic response of the mice. 1H NMR spectra were acquired from urine and faecal 
water samples collected from 5 control, 5 T. bb STIB777AE-G1 (`green')-infected, 5 T. 
bb STIB246BA-R1(`red')-infected and 5 red and green co-infected NMRI female mice 
1 day prior to the infection and 1, 3 and 4 days post infection. No changes were found in 
faecal water profile. Regardless of the strain, the T. bb infection caused a characteristic 
alteration in the spectral signatures of urine at day 4 post infection, which consisted of 
increased concentrations of 2-oxoisocaproate, D-3-hydroxybutyrate, lactate, 4-
hydroxyphenylacetic acid, phenylpyruvate and 4-hydroxyphenylpyruvate and decreased 
levels of hippurate. However, reduced levels of creatine and creatinine were only 
observed in the red strain and co-infected mice at day 4. Although there were no marked 
differences in the nature of the metabolic signature observed in the T. bb red, green or 
co-infected mice, animals infected with the T. bb green strain demonstrated slower 
metabolic response than those infected with either the red strain or the combined strains, 
which suggests that the red strain is more severe than the green one. This study 
illustrates the potential of metabolic profiling in exploring the metabolic consequences 
of co-infection in a host-parasite model. 
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